Assessing and improving the accuracy of surveillance case definitions using administrative data by Cadieux, Geneviève
  
 
 
 
 
Assessing and improving the accuracy of surveillance case definitions                        
using administrative data 
 
 
 
 
 
Geneviève Cadieux 
Department of Epidemiology, Biostatistics and Occupational Health 
McGill University, Montreal, Canada 
December 2010 
 
 
 
 
 
 
 
 
A thesis submitted to McGill University in partial fulfillment of the requirements of the 
degree of Doctor of Philosophy in epidemiology 
 
 
© Geneviève Cadieux, 2011 
   
i 
 
Abstract 
 
Background 
Monitoring infectious diseases is a continuously evolving challenge, and constant 
advances in surveillance methods and infrastructure are necessary to keep pace with 
rapidly evolving demands. A promising new surveillance methodology is syndromic 
surveillance, where health department staff, assisted by automated data acquisition and 
generation of statistical alerts, monitor human health indicators, including pre-
diagnostic and diagnostic data, in real-time or near real-time. This novel approach is 
used increasingly for detecting disease outbreaks rapidly, and, more recently, for 
‘situation awareness’ or guiding efforts to control recognized public health threats in 
real-time. There are many syndromic surveillance systems in place throughout the 
world, and several of these systems use diagnoses captured in administrative databases. 
Because diagnoses in physician claims are not audited, variations in coding are expected. 
The influence of this variation on the accuracy of surveillance case definitions is not 
known. Furthermore, in practice, high false-positive rates undermine the usefulness of 
existing syndromic surveillance systems. Attempts to reduce the false-positive rate by 
improving statistical detection algorithms have had limited success. However, almost no 
effort has been made to reduce the false-positive rate by improving the positive 
predictive value (PPV) of the diagnostic data used in syndromic surveillance. 
 
Objectives 
1) To evaluate the feasibility of identifying syndromes using diagnoses from physician 
claims. 
2) To assess the accuracy of syndrome definitions based on diagnostic codes in 
physician claims.  
3) To identify physician, billing, patient, and encounter characteristics associated with 
the PPV of syndrome definitions based on diagnoses in physician claims. 
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Methods & Results 
Study 1: We focused on a subset of diagnoses from a single syndrome (respiratory), for 
which we compared cases and non-cases identified from physician claims to medical 
charts. A convenience sample of 9 family physicians concurrently enrolled in the MOXXI 
e-Rx trial agreed to participate. 3,526 visits among 729 patients were abstracted from 
medical charts and linked to a physician claim in the Quebec provincial health insurance 
database. Episodes of common cold, influenza, laryngitis, unspecified acute upper 
respiratory infection, pharyngitis, acute bronchitis, pneumonia, otitis media, and 
sinusitis were investigated. Sensitivity and specificity estimates were adjusted for 
sampling a larger fraction of cases relative to non-cases. The sensitivity and PPV of 
physician claims for identifying episodes of respiratory infection were 0.49, 95% CI (0.45, 
0.53) and 0.93, 95% CI (0.91, 0.94). This pilot work demonstrated the feasibility of the 
proposed methods and generated estimates of sensitivity and PPV, which were crucial 
to planning and obtaining funding for a full-scale, population-based validation of several 
case definitions used in syndromic surveillance. 
Study 2: We focused on 5 syndromes (fever, gastrointestinal, neurological, rash, and 
respiratory, including influenza-like illness) because of their relevance to public health. 
We selected a random sample of 3,600 physicians who practiced in the fee-for-service 
system in the province of Quebec, Canada in 2005-2007. We randomly selected 10 visits 
per physician from their claims, stratifying on syndrome type and presence, diagnosis, 
and month. Double-blinded chart reviews were conducted by telephone with consenting 
physicians to obtain information on patient diagnoses for all sampled visits. The 
sensitivity, specificity, PPV and negative predictive value (NPV) of physician claims were 
estimated by comparison to chart review. 1,098 (30.5%) physicians completed the chart 
review. A chart entry on the date of the corresponding claim was found for 10,529 
(95.9%) visits. The sensitivity of syndrome definitions based on diagnoses in physician 
claims was low, ranging from 0.11, 95%CI (0.10, 0.13) for fever syndrome to 0.44, 95%CI 
(0.41, 0.47) for respiratory syndrome. The specificity and NPV were very high for all 
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syndromes. The PPV was moderate to high, ranging from 0.59, 95%CI (0.55, 0.64) for 
fever syndrome, to 0.85, 95%CI (0.83, 0.88) for respiratory syndrome. 
Study 3: The same syndrome definitions as in study 2 were used. We focused on the 
4,330 visits with a syndrome-positive diagnosis in the claims (i.e., the cases) of the 1,098 
physicians who participated in study 2. We estimated the association between claim-
chart agreement on syndrome and physician, patient, encounter, and billing 
characteristics using multivariate logistic regression analyses. The likelihood of the 
medical chart agreeing with the physician claim about the presence of a syndrome was 
higher when the treating physician had billed many visits for the same syndrome 
recently (RRper 10 visits for the same syndrome, 1.05; 95% CI, 1.01-1.08), had a lower workload on 
the day of the visit (RRper 10 claims, 0.93; 95% CI, 0.90-0.97), and when the patient was 
younger (RRper 5 years, 0.96; 95% CI, 0.94-0.97)  and less socially deprived (RRmost versus least 
deprived quintile, 0.76; 95% CI, 0.60-0.95). We also found that syndrome-positive physician 
claims produced by billing software that abstracted the billing diagnosis from the 
electronic medical record in an automated manner were more likely to be confirmed as 
syndrome-positive by the medical chart than claims produced by software that required 
the manual input of billing diagnoses. 
 
Conclusions 
This was the first large-scale, population-based investigation of the accuracy of 
syndrome definitions based on diagnoses in physician claims. We found that the 
sensitivity of syndrome definitions based on diagnoses in physician claims was low, the 
PPV was moderate to high, and the specificity and NPV were near-perfect. We identified 
several physician, patient, encounter, and billing characteristics associated with the PPV 
of syndrome definitions based on diagnoses in physician claims. Many of the predictors 
of syndrome definition accuracy that we identified are readily accessible to public health 
departments and other organizations that routinely perform syndromic surveillance, 
such as the US Department of Defense (ESSENCE) and some health maintenance 
organizations. These predictors could be used to reduce the false-positive rate of 
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syndromic surveillance systems, either by focusing on the diagnostic data most likely to 
be correct, or by adjusting the observed data for known biases in diagnostic coding and 
performing surveillance using the adjusted values. 
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Résumé 
 
Contexte 
La surveillance des maladies infectieuses est un défi en constante évolution, et un 
progrès continu au niveau des méthodes et des infrastructures est nécessaire pour 
répondre à la demande. Une nouvelle approche méthodologique prometteuse est la 
surveillance syndromique. La surveillance syndromique est une approche par laquelle le 
personnel des départements de santé, assisté de systèmes automatisés de collecte de 
données et de génération d’alertes statistiques, surveille des indicateurs de santé en 
temps réel ou quasi-réel. Cette nouvelle méthodologie est utilisée de façon croissante 
pour la détection rapide des épidémies, et plus récemment, pour guider, en temps réel, 
les interventions de santé publique cherchant à contrôler des menaces connues. 
Plusieurs systèmes de surveillance syndromique sont utilisés à travers le monde, et 
nombre d’entre eux s’appuient sur les codes de diagnostics enregistrés dans les bases de 
données administratives. Étant donné que ces codes ne font pas l’objet d’audits, des 
variations au niveau du codage sont probables. L’effet de ces variations sur l’exactitude 
des définitions de cas syndromiques n’est pas connu. De plus, en pratique, l’utilité des 
systèmes de surveillance syndromique existants est également réduite par leurs taux 
élevés de faux positifs. Par le passé, des chercheurs ont tenté de réduire ces taux en 
améliorant les algorithmes de détection statistiques, mais ces tentatives ont rencontré 
un succès limité. Toutefois, peu d’efforts ont été consentis afin d’améliorer le coefficient 
de prédiction positif des codes de diagnostics utilisés par les systèmes de surveillance 
syndromiques, une approche qui permettrait de réduire leurs taux de faux-positifs.  
 
Objectifs 
1) Évaluer la faisabilité d’identifier des syndromes en utilisant les codes de diagnostics 
provenant des services facturés par les médecins. 
2) Évaluer l’exactitude de définitions syndromiques basées sur les codes de diagnostics 
provenant des services facturés par les médecins.  
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3) Identifier les caractéristiques des médecins, du mode de facturation, des patients, 
et de la rencontre médecin-patient qui sont associées au coefficient de prédiction 
positif des définitions syndromiques basées sur les codes de diagnostics provenant 
des services facturés par les médecins. 
 
Méthodes & Résultats 
Étude 1: Cette étude portait sur un sous-ensemble de codes de diagnostics associés à un 
seul syndrome (respiratoire). Pour ce syndrome, nous avons comparés les cas positifs et 
négatifs, identifiés à partir des codes de diagnostics provenant des services facturés par 
les médecins (données administratives), aux données contenues dans les dossiers 
médicaux des patients. Un échantillon de convenance, composé de 9 médecins de 
famille, a été constitué à partir du groupe de médecins faisant partie de l’étude clinique 
MOXXI; une étude portant sur la prescription électronique. Les codes de diagnostics 
associés à 3 526 visites médicales, effectuées par 729 patients, ont été extraits des 
dossiers médicaux de ces patients, et reliées aux services médicaux correspondants dans 
la base de données administrative provinciale du Québec. Les épisodes de rhume, de 
grippe (influenza), de laryngite, d’infection non-précisée des voies respiratoires 
supérieures, de pharyngite, de bronchite aigue, de pneumonie, d’otite moyenne et de 
sinusite ont été examinés. La sensibilité et la spécificité ont ensuite été estimées, puis 
ajustées de façon à tenir compte du sur-échantillonnage des codes de diagnostics 
d’intérêt. La sensibilité et le coefficient de prédiction positif, associés à l’identification 
d’épisodes d’infection respiratoire à partir de codes de diagnostics issus des services 
facturés par les médecins, étaient 0.49, 95% IC (0.45, 0.53) et 0.93, 95% IC (0.91, 0.94) 
respectivement. Cette étude pilote a démontré la faisabilité des méthodes proposées, et 
a généré des estimés de la sensibilité et du coefficient de prédiction positif qui ont 
contribué à la planification et à l’obtention du financement pour une étude à grande-
échelle portant sur la validation de plusieurs définitions syndromiques.  
Étude 2: Cette étude portait sur 5 syndromes (fièvre, gastro-intestinal, neurologique, 
cutané,  et respiratoire, incluant le syndrome d’allure grippale), sélectionnés en raison 
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de leur importance pour la santé publique. Nous avons sélectionné un échantillon 
aléatoire de 3 600 médecins de première ligne ayant été rémunérés à l’acte, entre 2005 
et 2007, dans la province de Québec (Canada). Utilisant la base de données 
administrative provinciale du Québec, nous avons par la suite échantillonné 
aléatoirement 10 visites, parmi l’ensemble des services facturés par chacun de ces 
médecins, et ce en stratifiant en fonction de quatre paramètres : 1) le type de syndrome, 
2) la présence ou de l’absence de ce syndrome, 3) le code de diagnostic utilisé et, 4) le 
mois où la visite a été facturée. Pour chacune des visites échantillonnées, une révision 
de dossier à double insu a par la suite été conduite par téléphone, avec les médecins 
consentants, et ce afin d’obtenir les diagnostics notés dans les dossiers médicaux. La 
sensibilité, la spécificité et les coefficients prédictifs positif et négatif des définitions 
syndromiques basées sur des codes de diagnostics ont été estimés en comparant les 
données administratives aux données contenues dans les dossiers médicaux. Un total de 
1 098 (30.5%) médecins ont pris part aux entrevues téléphonique, et l’information 
pertinente à l’étude a été retrouvée dans le dossier médical pour 10,529 (95.3%) visites. 
La sensibilité des définitions syndromiques était faible, allant de 0.11, 95%CI (0.10, 0.13) 
pour le syndrome fièvre à 0.44, 95%CI (0.41, 0.47) pour le syndrome respiratoire. La 
spécificité et le coefficient prédictif négatif étaient très élevés pour tous les syndromes. 
Le coefficient prédictif positif variait de moyen à élevé, allant de 0.59, 95%CI (0.55, 0.64) 
pour le syndrome fièvre à 0.85, 95%CI (0.83, 0.88) pour le syndrome respiratoire. 
Étude 3: Nous avons utilisé les définitions syndromiques de l’étude 2. Nous avons 
restreint notre échantillon aux 4 330 visites avec un diagnostic positif pour l’un ou 
l’autre des syndromes à l’étude, et aux 1 098 médecins ayant participé à l’étude 2. Nous 
avons utilisé une régression logistique multi-variée afin d’estimer le degré d’association 
entre les caractéristiques du médecin traitant, du mode de facturation, du patient, et de 
la rencontre médecin-patient (variables indépendantes) et l’exactitude des données 
administratives quant à la présence de ce syndrome, telle que vérifiée par comparaison 
avec les données contenues dans le dossier médical du patient (variable dépendante). La 
probabilité que le dossier médical confirme la présence d’un syndrome, tel que suggéré 
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par les données administratives, était plus élevée lorsque le médecin traitant avait 
facturé plusieurs visites pour le même syndrome récemment (RRpar 10 visites pour le même 
syndrome, 1.05; 95% IC, 1.01-1.08), lorsque le médecin avait  une charge de travail moindre 
le jour de la visite (RRpar 10 services médicaux, 0.93; 95% IC, 0.90-0.97) et lorsque le patient 
était plus jeune (RRpar 5 ans, 0.96; 95% IC, 0.94-0.97) et provenait d’un milieu moins 
socialement défavorisé (RRquintile le plus défavorisé comparé au moins défavorisé, 0.76; 95% IC, 0.60-
0.95). Nous avons aussi découvert que les données administratives suggérant la 
présence d’un syndrome ont de meilleures chances d’être confirmées par le dossier 
médical lorsqu’un logiciel de facturation génère automatiquement les codes de 
diagnostics d’intérêt à partir d’un dossier médical informatisé, que lorsque qu’il requiert 
l’entrée manuelle de ces codes. 
 
Conclusions 
Cette étude fut la première investigation à grande-échelle à examiner l’exactitude de 
définitions syndromiques qui sont basées sur des codes de diagnostics provenant des 
services facturés par les médecins. Nous avons découvert que la sensibilité de ces 
définitions était faible, que le coefficient prédictif positif variait de moyen à élevé et que 
la spécificité et le coefficient prédictif négatif étaient près de 100%. Nous avons 
identifiés plusieurs caractéristiques du médecin, du mode de facturation, du patient et 
de la rencontre médecin-patient associées au coefficient de prédiction positif des 
définitions syndromiques. Plusieurs de ces caractéristiques peuvent être facilement 
obtenues par les départements de santé publique et les organisations qui font de la 
surveillance syndromique, dont le Département de la Défense des États-Unis (ESSENCE) 
et certains organismes d’assurance maladie. Ces caractéristiques pourraient être 
utilisées afin de réduire les taux de faux-positifs des systèmes de surveillance 
syndromique; soit en identifiant les données ayant le meilleur coefficient prédictif 
positif; soit en ajustant, dans un premier temps, les données observées de façon à tenir 
compte des principaux biais de codification des diagnostics, et en s’appuyant, dans un 
deuxième temps, sur les données ajustées afin de faire la surveillance.  
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Statement of originality 
 
Syndromic surveillance systems are currently being used around the world to monitor 
population health. However, existing systems are plagued by high false-alert rates that 
limit their usefulness. The work contained in this thesis is an original and important 
contribution to the improvement of public health surveillance methods. First, it assesses 
the accuracy of case definitions used in syndromic surveillance. Whereas a few other 
studies also attempted to do this, they suffered from important methodological 
limitations. The present research was the first to assess the accuracy of syndrome 
definitions in a large representative sample of community healthcare settings; a larger 
volume of syndrome cases present to community healthcare settings than to emergency 
departments, and some studies suggest that monitoring visits to community healthcare 
settings enables timelier influenza detection than monitoring emergency department 
visits. This work was also the first to correct for verification bias introduced at the 
sampling stage; to date, all other published estimates of syndrome definition sensitivity 
are highly inaccurate due verification bias induced by sampling a larger fraction of cases 
relative to non-cases. Additionally, we were the first to provide estimates of positive 
predictive value at the level of the individual ICD-9 code, which lends empirical support 
to ongoing work to modify syndrome definitions; others have only reported accuracy at 
the syndrome level. Finally, to our knowledge, the present research was the first to 
attempt to remedy the high false-alert rate of existing syndromic surveillance systems by 
identifying physician, billing, patient, and encounter characteristics associated with the 
positive predictive value of case definitions used in syndromic surveillance. 
 
With the help and guidance of my thesis supervisors and committee members, I 
generated the research questions, reviewed the relevant literature, developed the 
methods, performed the statistical analyses, and wrote each manuscript. The medical 
chart data used in this thesis was collected by me with the help of others, using a 
methodology I developed, specifically for the purpose of answering the research 
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questions posed in this thesis. The physician claims data used in this thesis was obtained 
from the Régie de l’assurance maladie du Québec (RAMQ); however, the predictor 
variables used in this thesis were operationalized and produced by me, using RAMQ 
data.  
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Chapter 1. Introduction 
 
Monitoring infectious diseases: a continuously evolving challenge 
 
Since the US Surgeon General declared victory over infectious diseases in 1967 (1), we 
have witnessed the emergence of many new pathogens (e.g., Legionella, HIV, Borrelia) 
(2;3), and the re-emergence, fuelled in part by antimicrobial drug resistance, of 
infections previously thought to be under control (e.g., tuberculosis, cholera, dengue 
fever) (3;4). Infectious diseases continue to be a leading cause of healthcare expenditure 
in North America, accounting for about one fifth (5) to one quarter (6) of all outpatient 
visits in the US each year, and with annual direct and indirect costs totalling more than 
$120 billion dollars in the US (6). The healthcare burden of infectious disease increases 
sharply during epidemics; for example, the direct and indirect costs of the 2003 
epidemic of severe acute respiratory syndrome (SARS) were estimated at approximately 
$2 billion in Canada alone (7).  
 
Recent outbreaks of SARS in Toronto (8;9), West Nile Virus in New York City (10), 
Clostridium difficile in Quebec (11;12), and influenza A (H1N1) in Mexico and around the 
world (13;14) have brought infectious diseases back to the forefront of public 
consciousness in North America, and exposed shortcomings in surveillance and control. 
In the current context of increasing globalization and converging disease ecologies (3), 
tracking emerging infectious diseases presents a continuously evolving challenge. Public 
health agencies recognize that traditional surveillance methods and infrastructure are 
insufficient to meet rapidly evolving demands.  
 
Traditional surveillance relies on routine or ad hoc reporting of counts or individual 
cases of disease by clinicians and laboratories to local health departments, where staff 
aggregate and examine reported data for unusual patterns of occurrence. Because most 
traditional approaches monitor previously known diseases, outbreaks of emerging 
infections are almost always recognized by astute clinicians, who notice and report 
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suspicious clusters of cases to health departments (15;16). For example, the 1993 Four 
Corners outbreak of hantavirus pulmonary syndrome was first recognized by medical 
personnel at the Indian Health Service, and the SARS outbreak was first reported by 
physicians in Asia (15). Even when used to monitor previously known diseases, the 
usefulness of the traditional disease surveillance approach for the detection of 
outbreaks is severely limited by delays in obtaining data. Delays occur because case 
reporting is still done by mail or fax in many jurisdictions, and because of delays inherent 
to laboratory confirmation of a suspected diagnosis. As a result, public health agencies 
are generally not aware of cases from an outbreak until days or weeks after cases occur 
(17-19), especially in situations where outbreaks involve cases spread over a wide area 
(20). For example, a retrospective analysis of hospital admissions and emergency 
department  visits for gastroenteritis suggested that the drinking water caused 
significant waterborne cryptosporidiosis in Milwaukee well before the massive 
documented outbreak of April 1993, and that earlier identification of these cases of 
infection could have prevented the larger outbreak (21). 
 
Timely surveillance information is essential for effective public health action. Early 
detection of outbreaks is important to hasten public health response to limit 
transmission, thereby reducing outbreak size and incidence of infection in high-risk 
individuals. Providing timely and accurate surveillance information to public health 
practitioners requires novel surveillance methods enabling outbreak detection on a time 
scale consistent with incubation periods, and allowing the characterization of ongoing 
outbreaks to guide focussed and effective interventions (22). 
 
Syndromic surveillance: a promising new approach 
 
One promising approach for improving public health surveillance is syndromic 
surveillance. Syndromic surveillance is a surveillance methodology where health 
department staff, assisted by automated data acquisition and generation of statistical 
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alerts, monitor human health indicators, including pre-diagnostic and diagnostic data, in 
real-time or near real-time. This novel approach is used increasingly for detecting 
disease outbreaks rapidly (23), and, more recently, for ‘situation awareness’ or guiding 
efforts to control recognized public health threats in real-time (24). Health indicators 
monitored by syndromic surveillance systems reflect either health services utilization, 
such as visits to clinics and emergency departments with a chief complaint or diagnosis 
corresponding to a syndrome under surveillance (e.g., influenza-like illness), or health-
related behaviours, such as purchase of over-the-counter medications for respiratory or 
gastrointestinal symptom relief (e.g., oral rehydration salts), and school/work 
absenteeism (25). 
 
To provide a more timely and accurate description of population health, syndromic 
surveillance systems use pre-diagnostic data that are available electronically, and rely on 
automated data transfer, processing, and analysis. Pre-diagnostic data are data 
generated before laboratory confirmation of a suspected diagnosis (26). These data may 
reveal anomalous patterns earlier in the course of an outbreak than laboratory-
confirmed diagnoses, and therefore provide more timely results than traditional 
surveillance systems. For example, assuming a population of infected persons (Figure 1), 
a majority of cases are expected to self-treat (27-29), at least initially, and some may 
purchase over-the-counter symptom-relief medication. A smaller proportion of cases are 
expected to present to primary care walk-in clinics (27), likely later in the course of the 
illness, and an even smaller number may find their way to a hospital emergency 
department. Laboratory testing may be requested for a small number of those who 
presented to a clinic or an emergency department. For most infections (except 
hemorrhagic fevers and other rare infections with fulminant onset), monitoring clinic 
visits will yield a greater volume of cases and may yield more timely detection than 
monitoring emergency department visits. 
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Figure 1. Opportunities for case detection 
 
Data used in syndromic surveillance are also expected to reflect changes in population 
health due to conditions that are not under routine surveillance, such as newly emerging 
infectious diseases. This is because syndromic surveillance monitors groups of related 
clinical presentations, which are more sensitive and less specific than laboratory-
confirmed diagnoses because they aggregate many similar clinical presentations into 
syndromes. For example, surveillance for respiratory syndrome would have been 
expected to identify cases of SARS, even before its etiology was discovered, because its 
clinical presentation overlapped with the case definition for respiratory syndrome. 
 
Secondary use of existing data for surveillance purposes 
 
Surveillance systems that require healthcare providers to enter additional data to report 
a suspicious case using a parallel system, independent and unrelated to care delivery, 
are becoming less common due to the many limitations of this approach (Table 1). 
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Parallel reporting of suspicious cases by healthcare professionals requires extra time and 
offers little incentive for timely and exhaustive reporting. For this reason, the 
information obtained from parallel reporting is likely to present a dated and biased 
account of a developing outbreak, thereby limiting the use of surveillance systems that  
 
Table 1. Data sources used in surveillance: parallel reporting versus secondary use of existing data 
 Parallel reporting of cases Case identification from existing data 
 Notifiable diseases 
surveillance  
Sentinel surveillance  Administrative data Electronic medical 
record data 
Diseases 
under 
surveillance 
 Typically 50-100 
diseases 
 Previously known 
diseases only 
 Typically one or a few 
case definitions 
 Previously established 
case definitions only 
 Unlimited number of 
case definitions 
 Data can be queried for 
any case definition 
 Unlimited number of 
case definitions 
 Data can be queried for 
any case definition 
Data type  Individual cases 
 Potential for detailed 
clinical information 
 Usually, weekly counts 
of cases 
 Potential for detailed 
clinical information 
 Diagnostic codes 
 Procedure codes 
 Characteristics of the 
insured (e.g., age, sex, 
area of residence) 
 Triage chief complaint  
 Physician diagnosis 
 Full clinical notes 
 Laboratory and 
imaging reports 
Data entry  Parallel data entry 
system with associated 
implementation and 
maintenance costs 
 Transmission is 
typically done by 
telephone, fax, mail, or, 
in some jurisdictions, 
electronically 
 Parallel data entry 
system with associated 
implementation and 
maintenance costs 
 Transmission  is 
typically done 
electronically 
 Existing computerized 
billing system 
 Centralized data 
repository (payer) 
 Requires pre-existing 
electronic medical 
record system in local 
clinical settings (e.g., 
community clinics)  
 Issues associated with 
meaningful aggregation 
of data from different 
sites and systems 
Timeliness  Poor, because lack of 
incentive for timely 
reporting  and delay 
inherent to method of 
reporting 
 Poor, because lack of 
incentive for timely 
reporting and delay 
inherent to method of 
reporting (e.g., weekly) 
 Timely, because 
information is tied to 
physician payment 
cycle 
 Timely, because 
information is tied to 
patient care 
Population 
coverage 
 Population coverage 
tends to be poor 
 Sentinel sites only  Complete population 
coverage 
 To date, few sites 
(mostly hospitals, few 
community clinics) 
Validity  Sporadic and selective 
reporting, because 
reporting increases 
physician workload 
 Sporadic and selective 
reporting, because 
reporting increases 
physician workload 
 Avoids reporting biases 
when information is 
tied to physician 
payment 
 Avoids reporting biases 
when information is 
tied to patient care 
Examples  Treating physicians 
report diagnosed cases 
of notifiable diseases to 
their local public health 
agency by telephone, 
fax, or mail 
 Laboratories report 
positive tests for 
notifiable diseases to 
their local public health 
agency electronically. 
 Volunteer sentinel 
physicians report 
weekly counts of 
patients that met the 
case definition for 
influenza-like illness 
(ILI) to public health 
(US Influenza Sentinel 
Provider 
Surveillance Network). 
 Physicians practicing in 
49 sentinel travel 
health clinics report 
individual cases of 
travel-related morbidity 
to the GeoSentinel 
system electronically. 
 Physician billing data 
from a health 
maintenance 
organisation is queried 
for ICD-9 coded 
diagnoses that may 
reflect measles-like 
illness (30). 
 Electronic medical 
records from a network 
of community health 
centers are queried for 
chief complaints, 
diagnoses, and  
laboratory testing 
results that meet the 
criteria for ILI or 
infectious 
gastroenteritis (31). 
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rely on this type of information (32). Also, surveillance systems that rely on parallel 
reporting of suspicious cases by healthcare professionals typically have poor population 
coverage. For example, a review of previous evaluations of US notifiable disease 
surveillance found that the completeness of reporting was as low as 9% for some 
diseases (33). Despite these many limitations of parallel reporting, its main advantage is 
the potential for collecting detailed information (e.g., symptoms, contacts, exposures). 
 
In contrast, making secondary use of existing data for surveillance does not add to the 
healthcare provider’s burden. Furthermore, when electronic documentation of the 
reason for a medical visit is tied to provider payment or patient care, timely and 
complete capture of cases is ensured, thereby avoiding biases inherent to parallel 
reporting (34). Administrative data offer the broadest population coverage, i.e., the 
large territory served by the health administrative authority. To date, surveillance 
systems that rely on electronic medical record data offer variable population coverage, 
depending on the number of hospitals and clinics that share information with public 
health, and their respective catchment areas. Broader population coverage and greater 
representativeness are expected to increase the sensitivity of surveillance and outbreak 
detection systems by enabling more cases to be captured, as opposed to capturing only 
cases that seek care at sentinel sites. Systems with broad population coverage that 
monitor populations across geo-political boundaries (e.g., health administrative regions) 
are more likely to detect outbreaks involving a few cases spread over a wide area (20), 
such as outbreaks associated with foods not produced locally. Whereas, at present, 
administrative data offer the broadest population coverage, they contain the least 
clinical detail: most administrative health databases are limited to one primary diagnosis 
or symptom, usually represented by an International Classification of Disease, 9th 
revision (ICD-9) code. 
 
Because administrative data offer broader population coverage than parallel sentinel 
reporting and electronic medical records, many syndromic surveillance systems 
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currently in place in North America use diagnoses from administrative data, including 
the Electronic Surveillance System for the Early Notification of Community-based 
Epidemics (ESSENCE) of the US Department of Defense (DoD) and ESSENCE II (35). These 
syndromic surveillance systems use groups of ICD-9 diagnostic codes to define 
syndromes of interest for surveillance. Using groups of codes, instead of individual 
codes, is expected to increase the sensitivity of detection, and is motivated by the 
concern that individual codes are too fine-grained for outbreak detection. Many 
diseases can initially present with overlapping symptoms that may not raise clinical 
suspicion; therefore grouping cases into syndromes is expected to provide earlier 
evidence of an outbreak. Grouping similar ICD-9 codes into syndromes is also expected 
to improve coding accuracy by minimizing inter-coder variability and within-coder 
variability over time. For example, pneumonias (ICD-9 codes 480-486), and influenza 
(487) are grouped under respiratory syndrome. 
 
Whereas administrative data offer great promise for population surveillance by allowing 
access to diagnostic information from many geographically-dispersed community 
healthcare settings, concerns about administrative data quality arise because, unlike 
procedure codes, diagnostic codes are not audited by health administrative authorities. 
This is expected to result in differences in diagnostic coding practices between 
physicians and between institutions. Therefore, before we evaluate how accurately 
syndrome definitions based on diagnostic codes in physician claims can detect 
outbreaks, we should first determine how accurately these codes capture the reason for 
the clinical encounter. 
 
The development of syndromic surveillance case definitions based on diagnoses in 
administrative data 
 
To harness the potential of administrative data for syndromic surveillance, clinical case 
definitions must be mapped to diagnostic codes. To this end, a multi-agency working 
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group under the auspices of the US Centers for Disease Control and Prevention (CDC) 
was given the mandate of developing case definitions for the syndromic surveillance of 
diseases associated with critical bioterrorism-associated agents, which were published in 
2003. The expert panel settled on 11 syndromes (Table 2). For each syndrome, the 
experts first articulated a conceptual definition, taking care to exclude any chronic 
conditions with similar clinical presentations. Then, the experts selected the 
International Classification of Disease, 9th revision, Clinical Modification (ICD-9-CM) 
codes that most closely corresponded to the conceptual definition. Each ICD-9-CM code 
was ranked based on expert consensus, from 1 (highest consensus) to 3 (lowest 
consensus). These definitions were later adopted by the US Department of Defense 
(DoD) for use in their syndromic surveillance system. 
 
Table 2. Eleven syndrome definitions developed and published by the US Center for Disease Control and 
Prevention in 2003 
 
Syndrome Conceptual definition Examples of corresponding  
ICD-9-CM codes 
Botulism-like ACUTE condition that may represent exposure to botulinum toxin  
ACUTE paralytic conditions consistent with botulism: cranial nerve 
VI (lateral rectus) palsy, ptosis, dilated pupils, decreased gag 
reflex, media rectus palsy.  
ACUTE descending motor paralysis (including muscles of 
respiration)  
ACUTE symptoms consistent with botulism: diplopia, dry 
mouth, dysphagia, difficulty focusing to a near point.  
005.1  Botulism 
344.9  Paralysis 
368.2  Diplopia 
342.9  Hemiparesis/hemiplegia, 
           unspecified 
784.3  Aphasia 
784.5  Speech disturbance 
037     Tetanus 
Fever ACUTE potentially febrile illness of origin not specified  
INCLUDES fever and septicemia not otherwise specified  
INCLUDES unspecified viral illness even though unknown if fever 
is present  
EXCLUDE entry in this syndrome category if more specific 
diagnostic code is present allowing same patient visit to be 
categorized as respiratory, neurological or gastrointestinal 
illness syndrome  
020.2  Plague, septicemic 
020.8  Plague, other 
020.9  Plague, unspecified 
038.9  Septicemia, unspecified 
780.6  Fever 
790.7  Bacteremia 
790.8  Viremia, unspecified 
Gastro-
intestinal 
ACUTE infection of the upper and/ or lower gastrointestinal (GI) 
tract  
SPECIFIC diagnosis of acute GI distress such as Salmonella 
gastroenteritis  
ACUTE non-specific symptoms of GI distress such as nausea, 
vomiting, or diarrhea  
EXCLUDES any chronic conditions such as inflammatory 
bowel syndrome 
005.9  Food poisoning, unspecified 
008.5  Bacterial enteritis, other 
008.8  Viral enteritis, unspecified 
535.0  Acute gastritis 
787.91  Diarrhea 
787.01  Nausea and vomiting 
Hemorrhagic 
illness 
SPECIFIC diagnosis of any virus that causes viral hemorrhagic 
fever (VHF): yellow fever, dengue, Rift Valley fever, Crimean-
Congo HF, Kyasanur Forest disease, Omsk HF, Hantaan, Junin, 
Machupo, Lassa, Marburg, Ebola  
ACUTE condition with multiple organ involvement that may be 
consistent with exposure to any virus that causes VHF  
ACUTE blood abnormalities consistent with VHF: leucopenia, 
neutropenia, thrombocytopenia, decreased clotting factors, 
albuminuria  
287.1  Platelet disorder 
287.2  Nonthrombocytopenic  
           purpura 
287.9  Hemorrhagic condition,  
           unspecified 
511.8  Hemothorax 
459.0  Hemorrhage, unspecified 
578.0  Hematemesis 
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Table 2 (continued). Eleven syndrome definitions developed and published by the US Center for Disease Control 
and Prevention in 2003 
Syndrome Conceptual definition Examples of corresponding 
ICD-9-CM codes 
Lymphadenitis ACUTE regional lymph node swelling and/ or infection (painful 
bubo- particularly in groin, axilla or neck)  
020.0  Plague, bubonic 
075     Mononucleosis 
289.3  Lymphadenitis, unspecified 
785.6  Lymph node enlargement 
Localized 
cutaneous 
lesion 
SPECIFIC diagnosis of localized cutaneous lesion/ ulcer 
consistent with cutaneous anthrax or tularemia  
ACUTE localized edema and/ or cutaneous lesion/ vesicle, ulcer, 
eschar that may be consistent with cutaneous anthrax or tularemia  
INCLUDES insect bites  
EXCLUDES any lesion disseminated over the body or generalized 
rash  
EXCLUDES diabetic ulcer and ulcer associated with peripheral 
vascular disease  
020.0  Plague, bubonic 
022.0  Anthrax, cutaneous 
680.9  Boil, unspecified 
682.9  Cellulitis, unspecified 
919.4  Insect bite, non-venomous, 
           unspecified site 
078.3  Cat-scratch disease 
Neurological ACUTE neurological infection of the central nervous system 
(CNS)  
SPECIFIC diagnosis of acute CNS infection such as 
pneumococcal meningitis, viral encephalitis  
ACUTE non-specific diagnosis of CNS infection such as 
meningitis not otherwise specified (NOS), encephalitis NOS, 
encephalopathy NOS  
ACUTE non-specific symptoms of CNS infection such as 
meningismus, delirium  
EXCLUDES any chronic, hereditary or degenerative conditions 
of the CNS such as obstructive hydrocephalus, Parkinson‟s, 
Alzheimer‟s  
047.9  Viral meningitis, unspecified 
320.9  Bacterial meningitis,  
           unspecified 
322.9  Meningitis, unspecified 
348.3  Encephalopathy,  
           unspecified 
323.9  Encephalitis, unspecified 
781.6  Meningismus 
784.0  Headache 
784.3  Aphasia 
Rash ACUTE condition that may present as consistent with smallpox 
(macules, papules, vesicles predominantly of face/arms/legs)  
SPECIFIC diagnosis of acute rash such as chicken pox in person 
> XX years of age (base age cut-off on data interpretation) or 
smallpox  
ACUTE non-specific diagnosis of rash compatible with infectious 
disease, such as viral exanthem  
EXCLUDES allergic or inflammatory skin conditions such as 
contact or seborrheic dermatitis, rosacea  
EXCLUDES rash NOS, rash due to poison ivy, sunburn, and 
eczema  
050.9  Smallpox, unspecified 
052.9  Varicella, unspecified 
057.9  Viral exanthema,  
           unspecified 
695.9  Erythematous condition,  
           unspecified 
692.9  Dermatitis, unspecified 
782.1  Rash/nonspecific skin  
           eruption 
Respiratory ACUTE infection of the upper and/ or lower respiratory tract (from 
the oropharynx to the lungs, includes otitis media)  
SPECIFIC diagnosis of acute respiratory tract infection (RTI) such 
as pneumonia due to parainfluenza virus  
ACUTE non-specific diagnosis of RTI such as sinusitis, 
pharyngitis, laryngitis  
ACUTE non-specific symptoms of RTI such as cough, stridor, 
shortness of breath, throat pain  
EXCLUDES chronic conditions such as chronic bronchitis, 
asthma without acute exacerbation, chronic sinusitis, allergic 
conditions (Note: INCLUDE acute exacerbation of chronic 
illnesses.)  
460     Acute nasopharyngitis 
462     Acute pharyngitis 
463     Acute tonsilitis 
464.0  Acute laryngitis, without  
           obstruction 
465.9  Acute upper respiratory  
           infection, unspecified 
466.0  Acute bronchitis 
480.9  Viral pneumonia,  
           unspecified 
486     Pneumonia, organism  
           unspecified 
Severe illness 
or death 
potentially due 
to infectious 
disease  
ACUTE onset of shock or coma from potentially infectious causes  
EXCLUDES shock from trauma  
INCLUDES SUDDEN death, death in emergency room, 
intrauterine deaths, fetal death, spontaneous abortion, and still 
births  
EXCLUDES induced fetal abortions, deaths of unknown 
cause, and unattended deaths  
780.01  Coma 
780.50  Shock, unspecified 
780.59  Shock, unspecified,  
             without trauma 
799.9    Mortality, cause unknown 
Specific 
infection 
ACUTE infection of known cause not covered in other syndrome 
groups, usually has more generalized symptoms (i.e., not just 
respiratory or gastrointestinal)  
INCLUDES septicemia from known bacteria  
INCLUDES other febrile illnesses such as scarlet fever  
Not specified 
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There have been few attempts to validate these syndrome definitions, which were 
developed based on expert consensus, using diagnostic data from medical visits. 
Published validations have focused on the syndromes with the highest prevalence, have 
involved small convenience samples of one or a few healthcare sites, and have suffered 
from several methodological limitations. As a result, prior estimates of the accuracy of 
these syndrome case definitions vary widely. A thorough discussion of these studies is 
found in the next chapter. 
 
More recently, investigators involved with the US DoD’s ESSENCE system developed a 
definition for another syndrome of great importance for population surveillance: 
influenza-like illness (ILI). A set of 29 ICD-9-CM diagnostic codes potentially 
corresponding to ILI was first identified by experts, and then pruned using empirical 
methods in a 2-step process. In the first step, using a sample of 6,236 medical visits with 
a diagnostic code included in the ILI set and where a respiratory specimen was collected 
and tested for influenza, the investigators calculated, for each ICD-9-CM diagnostic code, 
the proportion of medical visits in which the patient tested positive for influenza virus A 
or B. In the next step, in a DoD-wide sample, investigators evaluated the correlation 
between a time-series of weekly counts of positive influenza isolates and a time-series 
of weekly counts of medical visits with a diagnostic code included in the ILI set, for each 
diagnostic code individually. Combining results from these two assessments, 
investigators then selected the ICD-9-CM diagnostic codes most likely to reflect ‘true’ 
cases of ILI, yielding a sensitive ‘large-group’ definition of ILI (14 codes) and a specific 
‘small-group’ definition of ILI (4 codes). 
 
Limitations of existing systems and the expanding uses of syndromic surveillance 
 
Syndromic surveillance systems were adopted rapidly in the wake of the terrorist attacks 
of September 11, 2001 to address concerns of bioterrorism. The primary purpose of 
these systems was to detect disease outbreaks and bioterrorism events rapidly. To 
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ensure that no outbreak would be missed, syndromic surveillance systems were initially 
designed to generate alerts at very low thresholds. A consequence of this design was 
high rates of false-positive alerts (36), which have limited syndromic surveillance 
systems’ ability to correctly identify outbreaks. Indeed, because of the prohibitive cost 
of investigating every alert, many public health practitioners have adopted a ‘wait-and-
see’ response to alerts, thereby detracting from a main advantage of syndromic 
surveillance systems over traditional public health surveillance systems, namely the 
ability to provide a timelier portrait of population health. Attempts to reduce false-
positive rates by improving statistical detection algorithms used in syndromic 
surveillance (37-39) have had limited success. Partly because of these limitations, and 
partly because of the absence of bioterrorist attacks since 2001 (40), the focus of 
syndromic surveillance has begun to shift away from outbreak detection towards 
population health monitoring or situation awareness (24). Syndromic surveillance 
systems are now being used to describe the course of seasonal illnesses (e.g., influenza) 
as they sweep across communities, and to monitor unintentional disease outbreaks 
(e.g., food contamination), adverse health effects of natural and other disasters (e.g., 
wild fires, heat waves), and non-infectious conditions (e.g., exposures to toxic chemicals) 
(24). 
 
Syndromic surveillance systems are now being tailored to suit these novel uses. Whereas 
outbreak detection sought to identify and alert on every suspicious increase in the 
incidence of cases, maintaining situation awareness entails gathering data about the 
current state of population health, analyzing and interpreting these data, and projecting 
the likely evolution of the current state (41). Accurate case definitions are critical for 
monitoring population health and maintaining situation awareness, but to date, almost 
no attempts have been made to improve the accuracy of the case definitions used in 
syndromic surveillance (42-44). Identifying properties of surveillance data associated 
with higher positive predictive value of case definitions used in syndromic surveillance 
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will improve individual case detection and situation awareness, and will likely also lead 
to improved outbreak detection. 
 
Improving the accuracy of syndromic surveillance case definitions using covariates 
 
Several properties of surveillance data, such as who generated them (healthcare 
provider characteristics), how they were reported (reporting/billing system 
characteristics), who they describe (patient characteristics), and where and in what 
context they arose (clinical encounter characteristics), are likely to influence case 
definition accuracy. Characteristics of the healthcare provider that are associated with 
practice style or coding accuracy may influence the positive predictive value of 
diagnostic data. For example, two studies have found that greater experience was 
associated  with lower diagnostic coding accuracy (45) and lower billing diagnosis 
accuracy (46). Reporting/billing practices, including who enters the diagnosis in the 
system and how the diagnosis is entered (e.g., direct entry of diagnostic codes, 
searchable list of diagnoses that the software then maps to codes, automated 
abstraction of the billing diagnosis from an electronic medical record) are likely to 
influence the positive predictive value of diagnostic data. The context for the clinical 
encounter, which influences how much time and what resources are available for 
reporting/billing, is also likely to impact diagnostic data accuracy. For example, higher 
physician workloads were associated with lower billing diagnosis accuracy in one study 
(46). Treating more complex patients likely requires more working memory and 
increases physician cognitive load (47), therefore diagnostic coding errors may be more 
likely to occur for complex patients. For this reason, indicators of patient complexity, 
such as age, comorbidity, socioeconomic status, and health services utilization (48), may 
impact the positive predictive value of diagnostic data. 
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Research objectives 
 
The purpose of my thesis work was to evaluate the accuracy of administrative data for 
use in population-based syndromic surveillance. The specific objectives were: 
 
1) To evaluate the feasibility of identifying syndromes using diagnoses from 
physician claims. 
2) To assess the accuracy of syndrome definitions based on diagnostic codes in 
physician claims from community healthcare settings.  
3) To identify predictors of accuracy of syndrome definitions based on diagnostic 
codes in physician claims from community healthcare settings. 
 
Organization of the dissertation 
 
This thesis is organized around three core research manuscripts. The next chapter 
provides further background for these manuscripts by reviewing published validations of 
syndrome case definition accuracy, relevant methodological issues, and studies that 
sought to identify covariates associated with the accuracy of case definitions based on 
diagnoses in administrative data. Chapter 3 describes the data sources, sampling 
strategy, and data collection methods used in manuscripts 2 and 3, as well as the 
statistical methods used to account for the complex sampling strategy in manuscript 2. 
The core chapters (4-6) present research that directly addresses each specific thesis 
objective, respectively. Chapter 4 describes an evaluation of the feasibility of identifying 
syndromes using diagnoses from physician claims, and was published in Health Services 
Research under the title “Accuracy of physician billing claims for identifying acute 
respiratory infections in primary care.” Chapter 5 presents an assessment of the 
accuracy of syndrome definitions based on diagnostic codes in physician claims; this 
manuscript was published in BMC Public Health under the title “Accuracy of syndrome 
definitions based on diagnoses in physician claims.” Chapter 6 identifies physician, 
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billing, patient, and encounter characteristics associated with the positive predictive 
value of syndrome definitions based on diagnoses in physician claims in a manuscript 
titled “Predictors of accuracy of syndrome definitions based on diagnoses in physician 
claims.” Finally, the last chapter summarizes the most important findings from the three 
studies, highlights their strengths and limitations, discusses the public health 
implications of the findings, and suggests potential research avenues for improving 
infectious disease monitoring through syndromic surveillance. 
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Chapter 2. Background 
 
In the previous chapter, we advocated that syndromic surveillance is a promising new 
approach for detecting disease outbreaks rapidly and for guiding efforts to control 
recognized public health threats in real-time. We also argued that the most useful 
surveillance systems are those that make use of pre-diagnostic data that are already 
available electronically, gather data from many healthcare sites that cover a large 
representative sample of the population, and rely on automated data transfer, 
processing, and analysis. We briefly mentioned that there have been numerous efforts 
to develop surveillance case definitions based on administrative data, and that attempts 
to validate these case definitions had been plagued with methodological limitations that 
impeded the interpretation of their results. Finally, we suggested that the accuracy of 
surveillance case definitions may be improved by taking into account other variables 
that are associated with case definition accuracy and that are readily accessible to public 
health departments. 
 
In this chapter, we provide a more thorough critique of the published validations of 
syndromic surveillance case definitions based on administrative data. Because several of 
these published validations suffered from verification bias, we provide a detailed 
discussion of how this bias arises, what effect it has on the results, and how to correct 
for it. Finally, we look to studies outside the realm of syndromic surveillance for 
evidence that case definitions based on diagnoses in administrative data are associated 
with, and can be improved by the addition of, covariates. 
 
Validity of syndromic surveillance case definitions based on administrative data 
 
Many syndromic surveillance systems rely on health-related data collected for 
administrative purposes because of the advantages of using existing data for 
surveillance, compared to implementing parallel case reporting. However, because 
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administrative data are not collected for surveillance purposes, public health users need 
to assess the accuracy of these data for use in syndromic surveillance. Studies to assess 
the accuracy of administrative data for syndromic surveillance can be grouped in two 
large categories based on methodology: ecological studies and ‘direct’ validation of 
individual cases. 
 
Many validation studies of administrative data used in syndromic surveillance have 
relied on an ecological (correlation) approach. In this approach, a time-series of (daily or 
weekly) counts of cases identified from administrative data is compared to a time-series 
of counts of cases identified using another data source. The two time-series are 
compared using some statistical method (e.g., cross-correlations at different lags), and a 
judgement is made about how closely the time-series obtained from administrative data 
resembles the time-series obtained from the other data source. Several validation 
studies of syndrome case definitions published in the literature have used this approach 
(Table 3).  
 
Whereas the ecological validation approach can provide some general assurance that 
case counts based on administrative data yield similar seasonal variation as case counts 
from another data source, the accuracy of the data source being used as a comparison 
often has not been convincingly established. Also, by virtue of this approach being 
ecological, it does not enable us to examine whether a given individual case identified 
from administrative data is indeed a case, based on other information. Furthermore, the 
ecological approach does not permit the estimation of the sensitivity, specificity, positive 
predictive value, and negative predictive value of the case definition, which are very 
important parameters for public health to consider when implementing a syndromic 
surveillance system and when interpreting alerts from an existing syndromic surveillance 
system.
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Table 3. Studies that have assessed the validity of syndromic surveillance case definitions based on administrative data using an ecological approach 
Study Syndrome under 
surveillance 
Administrative data being 
validated (format) 
Data used as comparison 
(format) 
Study population and validation 
methodology 
Findings 
Hripcsak et al., 
2009 (31) 
Influenza-like 
illness 
Gastrointestinal 
Electronic health record  (EHR) 
from 13 community health centers 
in NYC: 
1) Structured EHR data: 
diagnoses (ICD-9 codes), coded 
reason for visit, temperature, and 
respiratory rate  
2) Narrative EHR data: Outpatient 
internal medicine notes (free text) 
1) ED chief complaint recorded by 
triage nurse (free text) from 47 
EDs throughout NYC 
2) Laboratory tests positive for 
influenza A or B (daily counts) 
from the US WHO collaborating 
laboratories in NYC 
July 1, 2004 to June 30, 2005  
(1 year of data) 
Manhattan and the Bronx 
124,568 visits to the 13 community 
health centers with a temperature 
recording 
3.4 million ED chief complaints 
Lagged (daily) cross-correlations 
between time-series 
For influenza-like illness:  
Structured EHR data: 
0.89 correlation with lab data  
0.84 correlation with ED data 
Narrative EHR data: 
0.93 correlation with lab data 
0.89 correlation with ED data 
For gastrointestinal syndrome:  
Structured EHR data: 
0.81 correlation with ED data 
Narrative EHR data: 
0.47 correlation with ED data 
Marsden-Haug 
et al., 2007 
(49) 
Influenza-like 
illness 
Outpatient visit diagnoses (ICD-9 
code) from all US military 
treatment facilities in the US and 
abroad 
Laboratory tests positive for 
influenza A or B, or any viral 
respiratory pathogen (weekly 
counts) from all US military 
treatment facilities in the US and 
abroad 
October 2000 to December 2004 
(almost 4 years) 
All US military treatment facilities 
(in the US and abroad) 
Lagged (weekly) cross-
correlations between time-series 
and signal-to-noise analysis for 
each ICD-9 code separately 
Influenza-like illness, small-group 
definition (ICD-9 codes with a 
significant correlation and a high 
signal-to-noise ratio): 465.9, 487.0, 
487.1, 487.8. 
Influenza-like illness, large-group 
definition (ICD-9 codes with a 
significant correlation but a lower 
signal-to-noise ratio): 79.99, 382.9, 
460, 461.9, 465.9, 466.0, 486, 
490, 780.6, 786.2. 
May et al., 
2010 (50) 
Upper respiratory 
infection (URI) 
URI and sinusitis 
Viral illness 
Pneumonia 
 
From a single academic hospital in 
Washington, DC: 
1) ED chief complaint (free text or 
pull-down menu) 
2) ED discharge diagnoses (ICD-9 
codes) 
Cases (weekly counts) reported by 
sentinel physicians and 
laboratories from the US CDC 
Influenza Sentinel Provider 
Surveillance Network for the South 
Atlantic region 
June 2005 to May 2006 (1 year) 
Washington, DC 
Time-series modeling 
No cross-correlations computed 
ED complaints of URI peaked at 
week 10 of the influenza season, 
whereas the CDC data peaked at 
week 7. ED chief complaints of 
URI began to rise earlier than ED 
diagnoses of URI. 
Lemay et al., 
2008 (51) 
Influenza-like 
illness 
ED chief complaint recorded by 
triage nurse (free text) from 3 
hospitals in the Ottawa region, 
Canada 
Laboratory tests positive for 
influenza A or B (weekly counts) 
from the provincial Reporting 
Disease Information System 
1998-2003 (5 influenza seasons) 
Ottawa region, Canada 
892,674 ED visits 
Data were stratified by age group  
and aggregated by week 
Time-series modeling 
Box-Jenkins lagged (weekly) 
cross-correlations 
194,816 (21%) visits for influenza-
like illness 
For children aged 5 and under: 
Cross-correlation of ED chief 
complaint data and laboratory data 
were statistically significant in 
each influenza season (except 
2002-2003), but at different lags 
ED: emergency department. ICD: International Classification of Disease. NYC: New York City. WHO: World Health Organisation. US DoD: US Department of Defense. US CDC: US 
Centers for Disease Control and Prevention.
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Table 3 (continued). Studies that have assessed the validity of syndromic surveillance case definitions based on administrative data using an ecological approach 
Study Syndrome under 
surveillance 
Administrative data being 
validated (format) 
Data used as comparison 
(format) 
Study population and validation 
methodology 
Findings 
Caudle et al., 
2009 (52) 
Gastrointestinal ED discharge diagnoses (ICD-10-
CA code) from the National 
Ambulatory Care Reporting 
System (NACRS), which receives 
data from all hospitals in Ontario, 
Canada 
Patient disposition from calls to 
Telehealth Ontario (nurse-
assigned syndrome groups) 
June 1, 2004 to March 31, 2006 
(almost 2 years of data) 
Ontario province, Canada 
184,904 calls and 34,499 ED visits 
for gastrointestinal illness 
Lagged (weekly) cross-
correlations between time-series  
Spearman rank tests 
0.90 (p<0.0001) correlation 
coefficient at lag 0 between ED 
discharge diagnoses from NACRS 
and Telehealth Ontario calls 
Van Dijk et al., 
2008 (53) 
Respiratory Patient disposition from calls to 
Telehealth Ontario (nurse-
assigned syndrome group) 
ED discharge diagnosis (ICD-10-
CA codes) from the from the 
National Ambulatory Care 
Reporting System (NACRS), 
which receives data from all 
hospitals in Ontario, Canada  
 
July 4, 2004 to March 31, 2006 
(almost 2 years of data) 
Ontario province, Canada 
216,105 Telehealth Ontario calls 
for respiratory complaints 
819,832 ED discharge diagnoses 
of respiratory illness 
Lagged (weekly) cross-
correlations between time-series  
Spearman rank tests 
0.97 (p<0.0001) correlation  
coefficient at lag 0 between 
Telehealth Ontario calls and ED 
discharge diagnoses from NACRS 
Van Dijk et al., 
2009 (54) 
Respiratory ED chief complaint recorded by 
triage nurse (free text) from the 
Emergency Department 
Surveillance System (EDSS), 
which receives data from 7 
hospitals in Southeastern Ontario, 
Canada 
1) ED discharge diagnosis (ICD-
10-CA codes) from the from the 
National Ambulatory Care 
Reporting System (NACRS), 
which receives data from all 
hospitals in Ontario, Canada  
2) Patient disposition from calls to 
Telehealth Ontario (nurse-
assigned syndrome group) 
July 4, 2004 to March 31, 2006 
(almost 2 years of data) 
Southeastern region of Ontario 
province, Canada 
29,668 ED chief complaints of 
respiratory disease 
19,315 ED discharge diagnoses of 
respiratory disease 
4,247 Telehealth Ontario calls 
about respiratory disease 
Lagged (weekly) cross-
correlations between time-series  
Spearman rank tests 
0.98 (p<0.0001) correlation 
coefficient at lag 0 between ED 
chief complaints from EDSS and 
ED discharge diagnoses from 
NACRS 
0.91 (p<0.0001) correlation 
coefficient at lag 0 between ED 
chief complaints from EDSS and 
Telehealth Ontario calls 
Brabazon et 
al., 2010 (55) 
Influenza-like 
illness 
Patient self-reported reason for 
call (free text) to the general 
practitioner out-of-hours (GP 
OOH) telehealth system  in 
Ireland, UK (7-9.5% population 
coverage) 
Cases (weekly counts) reported by 
sentinel physicians to the Irish 
Sentinel GP influenza surveillance 
system (54 GPs, 5% population 
coverage) 
2003-2009 (6 influenza seasons) 
Ireland, UK 
539,732 calls to the GP OOH, of 
which 17,062 (3.2%) were for 
influenza-like illness 
Time-series modeling 
Spearman‟s rank correlation 
Correlation between GP OOH 
calls for influenza-like illness and 
visits to sentinel physicians for 
influenza-like illness ranged from 
0.68 to 0.90 over the 6 influenza 
seasons, and all were statistically 
significant 
ED: emergency department. ICD: International Classification of Disease.
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Table 3 (continued). Studies that have assessed the validity of syndromic surveillance case definitions based on administrative data using an ecological approach 
Study Syndrome under 
surveillance 
Administrative data being 
validated (format) 
Data used as comparison 
(format) 
Study population and validation 
methodology 
Findings 
Cooper et al., 
2007 (56) 
Respiratory Patient disposition from calls to 
NHS Direct health information 
telephone line (nurse-assigned 
syndrome group), available in 
England and Wales 
Laboratory tests positive for 
respiratory viruses and Strep. 
pneumoniae (weekly counts) from 
the Health Protection Agency 
Centre for Infections, which 
collects reports from about 400 
laboratories in England, Wales, 
and Northern Ireland 
October 2002 to October 2004 
(2 years of data) 
England and Wales, UK 
601,454 NHS Direct calls for 
respiratory syndrome 
49,652 laboratory reports  positive 
for respiratory pathogens 
Looked at different ages 
categories: all ages vs. 0-4 years 
Multiple linear regression models 
to estimate the weekly proportion 
of NHS Direct calls (dependent 
variable) attributable to respiratory 
pathogens in laboratory reports 
(independent variable) 
Respiratory viruses, notably 
influenza and respiratory syncytial 
virus (RSV) were responsible for 
at least 50% of the seasonal 
variation in NHS Direct calls.  
During the 2 influenza seasons, 
influenza was estimated to 
account for 25-51% of cold/flu 
calls (all ages), and 17-41% of 
fever calls (0-4 years). 
Yih et al., 2009 
(57) 
Influenza-like 
illness 
Patient disposition (nurse-
assigned syndrome group) from 
calls to the Optum national 
managed-care nurse telephone 
triage service   
From the US CDC Influenza 
Sentinel Provider Surveillance 
Network: 
1) Laboratory tests positive for 
respiratory viruses and Strep. 
pneumoniae (weekly counts)  
2) Cases reported by sentinel 
physicians (weekly counts) 
October 3, 2004 to April 16, 2005 
(1 influenza season) 
17 US states with at least 500,000 
residents eligible to use the nurse 
telephone triage service by virtue 
of their health insurance plan 
Analyses stratified by US state 
Pairwise lagged (weekly) 
correlations 
Pearson correlation test 
For the 17 states, the median 
correlation coefficient between 
Optum calls and laboratory 
isolates was 0.65 (range 0.35-
0.83) at lag 0; only 4 states had a 
correlation coefficient ≥0.75. 
For the 17 states, the median 
correlation coefficient between 
Optum calls and visits to sentinel 
physicians was 0.74 (range 0.34-
0.83) at lag 0; and 8 states had a 
correlation coefficient ≥0.75. 
Lazarus et al., 
2001 (58) 
Lower respiratory Ambulatory care visit diagnoses 
(ICD-9 codes)  and temperature 
from the electronic medical record 
used by Harvard Vanguard 
Medical Associates (10% 
population coverage of Eastern 
Massachusetts) 
Mortality due to pneumonia or 
influenza (ICD-10 codes) in 122 
US cities obtained from the US 
CDC 
October 1996 to October 1999  
(3 years of data) 
Eastern Massachusetts 
152,435 visits for lower respiratory 
illness in the electronic medical 
record 
Time-series modeling 
Visual inspection only 
Seasonal variation in visits for 
lower respiratory illness in the 
electronic medical record was 
similar to seasonal variation in 
mortality due to pneumonia or 
influenza. For most winters the 
counts of lower respiratory illness 
rise shortly before the peaks in 
mortality. 
ED: emergency department. ICD: International Classification of Disease. US CDC: US Centers for Disease Control and Prevention. 
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Table 3 (continued). Studies that have assessed the validity of syndromic surveillance case definitions based on administrative data using an ecological approach 
Study Syndrome under 
surveillance 
Administrative data being 
validated (format) 
Data used as comparison 
(format) 
Study population and validation 
methodology 
Findings 
Lazarus et al., 
2002 (59) 
Lower respiratory Ambulatory care visit diagnoses 
(ICD-9 codes)  and temperature 
from the electronic medical record 
used by Harvard Vanguard 
Medical Associates (10% 
population coverage of Eastern 
Massachusetts) 
Hospitalisation discharge 
diagnoses (ICD-9 codes) from the 
Massachusetts Division of 
Healthcare Finance and Policy 
October 1996 to October 1999  
(3 years of data) 
Eastern Massachusetts 
Time-series modeling 
Spearman rank lagged (weekly) 
correlations 
Correlation between the hospital 
discharge data and the ambulatory 
care data was: 
0.89 at lag 0 
0.90 at lag -1 week 
0.92 at lag -2 weeks 
0.89 at lag -3 weeks 
0.85 at lag -4 weeks 
0.85 at lag -5 weeks 
0.80 at lag -6 weeks 
These results suggests that the 
hospital discharge data lagged 
behind the ambulatory care data 
Van den 
Wijngaard et 
al., 2008 (60) 
Respiratory 1) Hospitalisation discharge 
diagnoses (ICD-9-CM codes) from 
the Dutch National Medical 
Register (99% population 
coverage) 
2) Mortality due to respiratory 
causes (ICD-10 codes) from 
Statistics Netherlands (100% 
population coverage) 
3) Electronic medical record 
diagnoses for visits to general 
practitioners  (IPCP
 
codes) from 
the Netherlands Information 
Network of General Practice (1-
2% population coverage) 
4) Work absenteeism from 
Statistics Netherlands (80% 
coverage of the working 
population) 
5) Laboratory test requests from 
the Dutch National Infectious 
Diseases Information System 
(16% coverage) 
1) Laboratory tests positive for 
respiratory viruses (weekly counts) 
from the Weekly Sentinel 
Surveillance System of the Dutch 
Working Group in Clinical Virology 
(38-73% population coverage)  
2) Laboratory tests positive for 
Strep. pneumoniae from  6 
regional public health laboratories 
(24% population coverage) 
3) Reports of pertussis to the 
national notifiable disease 
surveillance system 
1999-2004 (5 years), or less for 
some data sources 
The Netherlands 
All data were aggregated by week 
Time-series modeling 
Pearson correlation coefficients 
Linear regression analyses with 
the number of syndrome cases as 
the dependent variable and the 
number of positive laboratory 
isolates as the independent 
variable, with lags of -5 to +5 
weeks 
Earliest syndrome elevations were 
observed in absenteeism data, 
followed by hospital data (+1 
week), visits to general 
practitioners (+2 weeks), and 
mortality/laboratory test requests 
(+3 weeks). 
86% of variation in syndrome 
counts was explained by the 
number of positive laboratory 
isolates. 
ED: emergency department. ICD: International Classification of Disease. ICPC: International Classification of Primary Care.
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Rigorous attempts to validate individual syndrome cases identified using diagnostic 
codes in administrative data against information on the same case from another data 
source have been few (Table 4). All have relied on small convenience samples of one or a 
few healthcare sites, bringing into question the generalizability of their findings. With 
the possible exception of Marsden-Haug et al. (49), all of these validation studies 
focused exclusively on emergency departments visits, yet there is evidence to suggest 
that visits to community healthcare settings offer potential for earlier outbreak 
detection (43;44). Also, many of these studies suffered from methodological limitations, 
which may explain the large differences in sensitivity estimates for the same syndromes 
in different studies; the specificity and negative predictive value of syndrome definitions 
were high in a majority of the studies.  
 
In the next paragraphs, I review validation studies of case definitions from two large 
syndromic surveillance systems currently in use in North America: the University of 
Pittsburgh’s Real-time Outbreak and Disease Surveillance System (RODS) and the US 
DoD’s ESSENCE system. I provide a detailed discussion of the methodological limitations 
of these two studies, and I explain how these limitations may have biased the results.  
 
Chapman et al. (61) performed a validation study of the syndrome case definitions used 
by the RODS system (Appendix B). They validated 7 syndrome case definitions (botulinic, 
constitutional, gastrointestinal, hemorrhagic, neurological, rash, and respiratory) 
consisting of ICD-9 coded diagnoses from hospital emergency department reports. They 
sampled only one site, the University of Pittsburgh Medical Center Presbyterian Hospital 
emergency department. A total of 1,557 hospital charts were reviewed by trained 
internists for the presence of none, one, or many of the syndromes under study, and the 
syndrome(s) abstracted from the chart were compared to the syndrome(s) obtained 
from the ICD-9 coded diagnosis in the emergency department report. Whereas the 
RODS study findings challenged some of the scepticism about using administrative data 
for surveillance purposes, the sampling of only 1 hospital emergency department 
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Table 4. Studies that have assessed the validity of syndrome definitions based on diagnostic codes through direct comparison of data on individual cases 
Study Syndrome 
under 
surveillance 
Administrative 
data being 
validated (format) 
Data used as 
comparison 
(format) 
Study population and 
sampling 
Accuracy of syndrome 
definitions based on ICD-9 
codes 
Limitations 
Espino et al., 
2001 (62) 
Acute 
respiratory 
illness 
1) ED chief 
complaint recorded 
by triage nurse 
(ICD-9 code) 
2) ED discharge 
diagnoses (ICD-9 
code) 
Chart review of ED 
reports 
University of Pittsburgh Medical 
Center Health System 
9 hospital EDs 
Simple random sample of 800 
visits  
July-October 2000 (4 months) 
Prevalence based on chart 
review: 4.9% 
Chief complaint: 
Sn: 0.44 ± 0.15 
Sp: 0.97 ± 0.01 
PPV: 0.44 ± 0.15 
NPV: 0.97 ± 0.01 
Discharge diagnosis: 
Sn: 0.43 ± 0.15 
Sp: 0.97 ± 0.01 
PPV: 0.45 ± 0.16 
NPV: 0.97 ± 0.04 
Excluded 131 (16.4%) ED visit 
due to missing discharge 
diagnosis or chief complaint, 
therefore agreement may have 
been overestimated. 
Bourgeois et 
al., 2007 (63) 
7 syndromes, 
including: 
Fever 
Respiratory 
Gastrointestinal 
Dermatologic 
Neurological 
 
1) ED chief 
complaint recorded 
by triage nurse (free 
text) 
2) ED discharge 
diagnoses (ICD-9 
code) 
3) Patient/parent 
self-report survey 
(free text) 
Chart review of ED 
reports 
Children‟s Hospital Boston 
1 hospital ED 
Patients aged 22 years or 
younger eligible 
February 2004-March 2005 (1 
year) 
85% participation rate during 
„recruitment periods‟ 
936 patients enrolled 
Discharge diagnosis: 
Fever: 
Sn: 0.21, Sp: 0.99 
Respiratory: 
Sn: 0.52, Sp: 99 
Gastrointestinal: 
Sn: 0.75, Sp: 99 
Dermatologic: 
Sn: 0.41, Sp: 0.99 
Neurological: 
Sn: 0.67, Sp: 0.99 
No description of „recruitment 
periods‟, and annual census for 
that ED is approx. 51,000 
patients, therefore difficult to 
assess the sampling strategy 
and population coverage. 
No estimates of PPV or NPV, 
and no confidence intervals 
provided. 
Guasticchi et 
al., 2009 (64) 
13 syndromes, 
including: 
Respiratory 
infection with 
fever 
Gastroenteritis 
Febrile illness 
with rash 
Meningitis-like 
ED chief complaint 
recorded by triage 
nurse (syndrome 
category) and ED 
discharge 
diagnoses (ICD-9-
CM code) 
 
To estimate PPV, 
chart review of ED 
reports 
To estimate 
sensitivity, free-text 
physician diagnosis 
from ED report, 
present in only 40% 
of all ED reports 
34 hospital EDs (of 61 in the 
Lazio region of Italy) 
All ED visits in 2004 (1 year) 
were eligible 
To estimate PPV, random 
sample of 300 cases for each of 
the 13 syndromes selected 
based on chief complaint and 
discharge diagnosis (jointly). 
To estimate sensitivity, used 
capture-recapture method 
Chief complaint and discharge 
diagnosis (jointly): 
Respiratory infection with fever: 
PPV: 0.99, 95% CI (0.98, 1.00) 
Sn: 0.79, 95% CI (0.77, 0.81) 
Gastroenteritis: 
PPV: 0.94, 95% CI (0.92, 96.3) 
Sn: 0.76, 95% CI (0.74, 0.78) 
Febrile illness with rash: 
PPV: 0.98, 95% CI (0.97, 1.00) 
Sn: 0.77, 95% CI (0.76, 0.78) 
Meningitis-like : 
PPV: 0.37, 95% CI (0.32, 0.41) 
Sn: 0.32, 95% CI (0.26, 0.40) 
Agreement overestimated 
because used a modified version 
of the capture-recapture 
methodology, but with two 
different data fields from the 
same data source (i.e., the data 
sources were not independent). 
 ED: emergency department. ICD: International Classification of Disease. Sn: sensitivity. Sp: specificity. PPV: positive predictive value. NPV: negative predictive value. ICPC: 
International Classification of Primary Care. 
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Table 4 (continued). Studies that have assessed the validity of syndrome definitions based on diagnostic codes through direct comparison of data on individual cases 
Study Syndrome 
under 
surveillance 
Administrative 
data being 
validated (format) 
Data used as 
comparison 
(format) 
Study population  
and sampling 
Accuracy of syndrome 
definitions based on ICD-9 
codes 
Limitations 
May et al., 
2010 (50) 
Influenza-like 
illness 
Gastrointestinal 
Viral illness 
ED discharge 
diagnoses (ICD-9 
code) 
ED chief complaint 
recorded by triage 
nurse (free text or 
pull-down menu) 
1 hospital ED in Washington, DC 
June 2005-May 2006 (1 year) 
Sampled all visits with either an 
ED chief complaint or an ED 
discharge diagnosis 
corresponding to one of the 
syndrome definitions 
5,682 ED visits sampled 
Influenza-like illness: 
% agreement: 71% 
Gastrointestinal: 
% agreement: 61% 
Viral illness: 
% agreement: 76% 
Cannot estimate Sn or PPV 
because no „syndrome-negative‟ 
ED visits (based on either 
source of information) were 
sampled. 
Betancourt et 
al., 2007 (65) 
CDC-
ESSENCE 
syndrome 
definitions (66): 
Fever 
Gastrointestinal 
Respiratory 
 
ED discharge 
diagnoses (ICD-9 
code) 
Chart review of ED 
reports 
3 military hospital EDs 
September 1999-August 2000 (1 
year) 
Random sample of ED visits, 
stratified on syndrome status 
based on ED discharge 
diagnosis (case to non-case 
ratio of 1:2) 
Fever (N=465):  
Sn: 0.69, Sp: 0.96, PPV: 0.81,  
NPV: 0.92 
Gastrointestinal (N=875):  
Sn: 0.89, Sp: 0.96, PPV: 0.93, 
NPV: 0.94 
Respiratory (N=454):  
Sn: 0.66, Sp: 0.96, PPV: 0.81, 
NPV: 0.91 
Sensitivity overestimated and 
specificity underestimated due to 
verification bias introduced by 
sampling strategy stratified on 
syndrome status based on ED 
discharge diagnosis. 
No 95% confidence intervals 
provided for the estimates. 
Marsden-
Haug et al., 
2007 (49) 
Influenza-like 
illness 
Military treatment 
facility outpatient 
visit diagnoses 
(ICD-9 code) 
Laboratory tests 
positive for 
influenza A or B 
US Air Force military treatment 
facilities 
June 2002-June 2004 (2 years) 
All 6,236 outpatient visits where 
a respiratory specimen was 
collected and tested for viral 
pathogens 
% visits with a test positive for 
influenza A or B is reported for 
each ICD-9 code separately, 
with the highest (75%) being for 
influenza with pneumonia (ICD-9 
487.0), and the lowest (0%) for 
acute tonsilitis (ICD-9 463) 
Collection of respiratory 
specimens at the discretion of 
the treating physician 
(convenience sample). 
Whereas definitions of influenza-
like illness consisting of ICD-9 
codes are suggested based on 
viral positivity, their Sn, Sp, PPV, 
and NPV are not estimated. 
Chapman et 
al., 2005 (61) 
7 syndromes, 
including : 
Constitutional 
Respiratory 
Gastrointestinal 
Neurological 
Rash 
ED discharge 
diagnoses (ICD-9 
code) 
Chart review of ED 
reports 
University of Pittsburgh Medical 
Center Presbyterian Hospital (1 
hospital ED) 
December1990-September 2003 
(14 years) 
Random sample of 1,557 ED 
visits, stratified on syndrome 
type (7) and ICD-9 code within 
syndrome 
Constitutional:  
Sn: 0.24, PPV: 0.43 
Respiratory: 
Sn: 0.38, PPV: 0.74 
Gastrointestinal: 
Sn: 0.30, PPV: 0.86 
Neurological: 
Sn: 0.29, PPV: 0.79 
Rash:  
Sn: 0.66, PPV: 0.48 
PPV likely underestimated 
because of sampling strategy 
(i.e., the stratification on ICD-9 
code within syndrome) was not 
taken into account. 
Sensitivity affected by sampling 
strategy as above, and also 
subject to verification bias. 
ED: emergency department. ICD: International Classification of Disease. Sn: sensitivity. Sp: specificity. PPV: positive predictive value. NPV: negative predictive value. ICPC: 
International Classification of Primary Care. 
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raises concerns about the generalizability of results. Also, the investigators sampled 
equal numbers of charts for each ICD-9 diagnostic code that comprise the 7 syndrome 
definitions. Consequently, the final chart review sample did not reflect the true 
frequency distribution of diagnostic codes. Because infrequent diagnostic codes are 
more likely to result from coding errors (67;68), the reported sensitivity and positive 
predictive value estimates were likely biased downward. Also, the analysis did not adjust 
for the verification bias induced by the relative difference in the sampling fraction for 
cases (ED visits with a diagnosis corresponding to the syndrome of interest) and non-
cases (ED visits with a diagnosis corresponding to any other syndrome); verification bias 
results in an over-estimation of sensitivity and underestimation of specificity (69). The 
use of ED visits with a diagnosis corresponding to any other syndrome as ‘non-cases’ is 
also problematic, because, as the authors themselves report, fever (ICD-9 code: 780.6), 
which is included in the case definition of constitutional syndrome, is often present 
among cases of other syndromes as well (e.g., gastrointestinal, respiratory, 
neurological). The use of cases of other syndromes as controls may have led to an 
underestimation of sensitivity: due to overlapping case definitions, chart review would 
have shown that a portion of the ED visits originally classified as non-cases for a given 
syndrome were really cases of that syndrome. 
 
Two years later, Betancourt et al. (65) published a validation of the syndrome definitions 
developed by the US CDC (66) and used by the US DoD’s ESSENCE system. In that study, 
the accuracy of ICD-9 codes in ED reports for identifying 3 syndromes (fever, 
gastrointestinal, and respiratory) was assessed as compared to hospital chart diagnoses. 
The investigators sampled only 3 military treatments facilities, and they reported 
substantial variation in sensitivity and positive predictive value between sites, which 
raises questions about the generalizability of their results. For greater data collection 
efficiency, the fraction of syndrome-positive ED reports sampled was larger than the 
fraction of syndrome-negative ED reports sampled. However, analyses were not 
adjusted for this sampling strategy, which resulted in verification bias (69;70), and led to 
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a large overestimation of sensitivity and underestimation of specificity. Furthermore, 
syndrome-negative ED visits were not matched to syndrome-positive ED visits on 
season. Because most syndromes follow seasonal variation, this sampling strategy may 
have resulted in seasonal bias if the seasonal distribution of the syndrome-negative ED 
visits was different from that of the syndrome-positive ED visits. For example, if 
respiratory syndrome cases occurred predominantly in winter, and non-cases were 
sampled predominantly from the summer months, then sensitivity would be 
overestimated because, due to the lower prevalence of respiratory syndrome in 
summer, fewer summer non-cases than winter non-cases would turn out to be false-
negatives after chart review. 
 
In summary, a majority of validation studies of syndrome case definitions based on 
administrative data have relied on an ecological approach, whereby two time-series of 
case counts are compared using cross-correlations. Fewer studies involved a ‘direct’ 
validation of individual syndrome cases identified from administrative data against a 
‘gold standard’, most often medical chart review. Of those studies that validated 
individual syndrome cases, a majority relied on small convenience samples of one or a 
few healthcare sites, and all suffered from methodological limitations that impeded the 
interpretation and comparison of their findings. A common methodological limitation 
was verification bias, which resulted from the use of a stratified sampling strategy 
whereby the proportion of cases validated was higher relative to the proportion of non-
cases validated. We provide a detailed explanation of how verification bias arises, its 
impact on results, and how to correct for it in the next section of this chapter. 
 
Verification bias: source, effect, and correction 
 
Verification bias was first described in relation to diagnostic test evaluation (69). It 
referred to the situation in which patients are first tested with test A (e.g., fecal occult 
blood test), and then, based on the clinician’s interpretation of the results from test A in 
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the context of other relevant factors (e.g., other signs, symptoms, family history), some 
patient are selected to undergo test B (e.g., colonoscopy). Verification bias arises in the 
estimation of the sensitivity and specificity of test A when a non-representative sample 
of patients who underwent test A are selected to undergo test B. For example, for a 
screening test, a larger fraction of patients who tested positive on the screening test A 
will typically be selected to undergo the diagnostic test B, as compared to the fraction of 
patient who tested negative on test A who may be asked to undergo the diagnostic test 
B (based on the full clinical picture available at the time). Failure to account for the 
mechanism whereby patients are selected to undergo test B (i.e., the ‘verification’ test) 
when estimating the sensitivity and specificity of test A results in verification bias, the 
consequence of which is that the sensitivity of test A is overestimated and the specificity 
of test A is underestimated.  
 
Verification bias in diagnostic testing 
 
  Diagnostic 
Test B 
  
  Positive Negative   
S
c
re
e
n
in
g
  
T
e
s
t 
A
 Positive TP FP 
 Typically, a larger fraction of patients who tested positive on the screening 
test will be asked to undergo the diagnostic test, as compared to patients 
who tested negative on the screening test. 
Negative FN TN 
 
Some patients who tested negative on the screening test may still be asked 
to undergo the diagnostic test, based on other relevant information. 
      
 
Whereas verification bias was first described for diagnostic tests, it also arises in any 
validation study based on a stratified random sample where the sampling fractions differ 
between the ‘positive’ (cases) and ‘negative’ (non-cases) strata. This stratified sampling 
strategy is often used to validate case definitions of diseases that have low population 
prevalence, because the alternative – validating a simple random sample large enough 
to include a sufficient number of cases – is often infeasible. Therefore, for diseases that 
have low population prevalence, investigators usually sample a larger fraction of the 
cases than the non-cases, i.e., they select a relatively larger random sample in the case 
stratum than in the non-case stratum.  
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Syndromes monitored by syndromic surveillance systems typically have a low population 
prevalence; for example, one study (62) reported a prevalence of 4.9% for respiratory  
syndrome. For this reason, validation studies of case definitions used by two large 
syndromic surveillance systems in North America, RODS (61) and ESSENCE (65), both 
used such a stratified random sampling strategy. However, neither corrected their 
sensitivity and specificity estimates for the verification bias caused by their sampling 
strategy. The example below, based on the validation study of ESSENCE case definitions 
by Betancourt et al. (65), illustrates how verification bias arises from the use of this type 
of stratified random sampling. 
 
Stratified random sample of ESSENCE reports 
 
  Chart review 
(gold standard) 
 
  Fever-
positive 
Fever-
negative 
Total 
E
S
S
E
N
C
E
 
re
p
o
rt
s
 
Fever-
positive 
378 87 465 
Fever-
negative 
167 1,842 2,009 
 Total 545 1,929 2,474 
 
Sensitivity = 0.69 (overestimated) 
Specificity = 0.95 (underestimated) 
Positive predictive value = 0.81 
Negative predictive value = 0.92 
Prevalence of fever-positive ESSENCE reports in this 
study sample = 0.19 
 
Simple random sample of ESSENCE reports 
 
  Chart review  
(gold standard) 
 
  Fever-
positive 
Fever-
negative 
Total 
E
S
S
E
N
C
E
 
re
p
o
rt
s
 
Fever-
positive 
378 87 465 
Fever-
negative 
3,683 42,352 46,035 
 Total 4,061 42,439 46,500 
 
Sensitivity = 0.09 
Specificity = 1.00 
Positive predictive value = 0.81 
Negative predictive value= 0.92 
Prevalence of fever-positive ESSENCE reports in the 
entire system= 0.01
In this example, there were 465 fever-positive and 2,009 fever-negative ESSENCE reports 
sampled, for a sample prevalence of fever-positive ESSENCE reports of 19%. Assuming 
that the prevalence of fever syndrome in ESSENCE reports is similar to the prevalence of 
fever syndrome in billing claims from primary care physicians practicing in the province 
of Quebec (71), the true prevalence of fever-positive reports in ESSENCE should be 
about 10 per 1,000 reports or 1%. Because estimating sensitivity and specificity involves 
summing fever-positive and fever-negative ESSENCE reports (i.e., summing numbers 
from different sampling strata), failure to adjust for the different sampling fractions in 
28 
 
each stratum leads to verification bias. Verification bias does not affect the positive 
predictive value or the negative predictive value because positive predictive value is 
estimated within the sampling stratum of fever-positive ESSENCE reports, and negative 
predictive value is estimated within the sampling stratum of fever-negative ESSENCE 
reports (i.e., each is estimated within its own sampling stratum, not across sampling 
strata). 
 
Another way of explaining verification bias is to compare the ratio of fever-positive to 
fever-negative ESSENCE reports in the study sample, which is 465 to 2,009 (about 1:4), 
to the same ratio for the entire population of ESSENCE reports, which is 465 to 46,035 
(about 1:99). Verification bias arises because the ratio of fever-positive to fever-negative 
ESSENCE reports is not the same in the sample and in the population. By manipulating 
the ratio of fever-positive to fever-negative ESSENCE reports in the sample (and not 
adjusting for the resulting verification bias), sensitivity is artificially inflated and 
specificity is underestimated. 
 
A method for correcting for verification bias was published by Begg and Greenes (69). It 
involves taking into account the relative difference in sampling fractions between the 
syndrome-positive stratum and the syndrome-negative stratum in the estimation of 
sensitivity and specificity. The larger the relative difference in sampling fractions 
between strata, the bigger the change in sensitivity and specificity when the verification 
bias correction is applied. For syndrome definitions based on diagnoses in administrative 
data, which usually have low prevalence and very high specificity, the impact of the 
verification bias correction is usually greater for sensitivity estimates, as compared to 
specificity estimates. In the example above, the sensitivity is reduced drastically, from 
0.69 to 0.09, and the specificity is slightly increased, from 0.95 to 1.00. 
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Predictors of accuracy of case definitions based on administrative data 
 
There have been a few attempts to improve the accuracy of syndromic surveillance 
systems by modifying statistical outbreak detection algorithms (37-39) or by using 
different data sources (42;72). Only one study has attempted to improve the accuracy of 
a case definition used in syndromic surveillance by taking into account covariates. 
DeLisle et al. (73), sought to improve the accuracy of a case definition of acute 
respiratory infection based on ICD-9 diagnostic codes from the Veteran’s Affairs  
Healthcare system by also considering  other structured data from the electronic 
medical record (vital signs, test orders, imaging requests, and symptom-relief or 
antimicrobial drug prescriptions) and respiratory symptoms (e.g., cough) extracted from 
the free-text clinical notes. They found that algorithms including ICD-9 diagnostic codes 
performed significantly better than those that did not include them, suggesting that ICD-
9 diagnostic codes represent an invaluable source of data for syndromic surveillance 
systems. They also found that adding prescriptions for cough remedies and elevations in 
body temperature to the case definition based on ICD-9 codes significantly improved its 
sensitivity, but decreased its specificity and positive predictive value. Adding symptoms 
extracted from free-text analysis further increased sensitivity, but caused a large decline 
in positive predictive value. 
 
In areas outside syndromic surveillance, diagnostic codes in administrative data are 
commonly used to identify disease cases. Many studies have attempted to identify 
covariates associated with the accuracy of case definitions based on diagnostic codes in 
administrative data. Most of these studies have focused on improving the identification 
of chronic disease cases using diagnoses in administrative databases. 
 
In order to identify potential covariates that may influence the accuracy of case 
definitions based on diagnostic codes in administrative data, an understanding of the 
mechanism whereby diagnostic codes are entered on physician claims is necessary.  
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Figure 2 illustrates the steps commonly involved in physician billing for outpatient visits 
in a fee-for-service healthcare system. First, the physician meets with the patient, takes 
the patient’s medical history and performs the relevant physical examination(s). Then, 
the physician documents his observations in the medical chart and fills out a billing slip. 
Figure 3 is an example of the physician billing slip used in the province of Quebec; of 
note, only one 4-digit ICD-9 diagnostic code can be entered per billing slip. The 
information on the billing slip is then entered into billing software; this step may be 
accomplished by the physician, a secretary or clerk at the clinic, or by an off-site billing 
agency. The claim is then submitted to the Quebec provincial health agency 
electronically. Fax or mail submission of paper billing slips is rare, because a penalty of 
$0.50 is levied on each billing slip not submitted electronically. Although physicians have 
up to 3 months from the date of the visit to submit a claim to the Quebec provincial 
health agency, claims submission generally follows the biweekly physician 
reimbursement cycle.  
 
 
Figure 2. Typical process of physician billing for outpatient visits in fee-for-service healthcare system 
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Figure 3. Physician billing slip used in the province of Quebec; only one 4-digit ICD-9 diagnostic code can be 
entered per billing slip 
 
In keeping with what is known about the physician billing process, previous attempts to 
improve the identification of chronic disease cases using diagnoses in administrative 
databases have investigated the effect of covariates such as the characteristics of the 
physician, patient, encounter or hospitalisation, and healthcare site (Table 5). 
 
Whereas diagnoses in administrative databases are often assigned by physicians, 
especially for visits to community clinics, few studies have investigated the impact of 
physician characteristics on the accuracy of diagnostic codes in administrative data. 
Studney et al. (46) reported that physician workload, as measured by both gross income 
and the number of patients seen per day, was significantly and negatively associated 
with billing diagnosis accuracy. A study by Farzandipour et al. (45) reported that errors in 
ICD-10 principal diagnosis coding were more common among coders with more years of 
experience and among those who coded from memory instead of using reference 
materials. Whereas the Farzandipour et al.  study involved hospitalisations for which 
ICD-10 coding was performed by professional medical records coders, its findings are 
likely to also apply to physicians, when working in clinical settings where they perform 
their own diagnostic coding. Finally, a study by Peabody et al. (74) reported that the 
physician error rate in primary diagnosis varied by healthcare site and by condition, with 
32 
 
Table 5. Studies that have identified covariates associated with the accuracy of case definitions based on diagnoses in administrative data 
 
Study Disease(s) 
under study 
Administrative 
data being 
validated (format) 
Data used as 
comparison 
(format) 
Covariate data 
source 
Study population  
and sampling 
Statistical 
analysis 
Findings 
Farzandipour 
et al., 2010 
(45) 
No specific 
disease 
targeted 
Hospital discharge 
diagnoses (ICD-10 
codes) 
Blinded expert 
recoding of 
discharge 
diagnoses (ICD-10 
codes) 
Original coder‟s 
experience and 
education were 
obtained from 
personnel files 
Coding practice was 
assessed through 
direct observation 
Stratified random sample of 
370 hospitalisations to 4 
teaching hospitals in 
Kashan, Iran in 2007-2008 
 
Outcome: errors 
in principal 
diagnosis coding 
Bivariate analyses 
Chi-squared tests 
Errors were present in principal 
diagnosis coding in 84 (22.7%) 
medical records. 
Less experienced coders made 
fewer errors (p <0.0001) 
As compared to memory-based 
coding, using reference 
materials was associated with 
fewer coding errors (p<0.0001). 
Studney et 
al., 1981 (46) 
No specific 
disease 
targeted 
Billing diagnoses on 
account cards (in 
words, not coded) 
Medical record 
review 
Average patients 
seen per day was 
computed from day 
sheets for the study 
period 
Gross income was 
based on gross 
billing for the study 
period 
Sample of 1,215 visits to 12 
physicians from 1 clinic 
located in British Columbia, 
Canada over a 3-month 
period in 1976 
Outcome: % 
agreement 
between billing  
diagnosis and 
medical record 
diagnosis 
Bivariate analyses 
Pearson‟s 
correlation 
coefficients 
Disagreement on principal 
diagnosis was present in 40% of 
visits. 
Agreement was significantly 
(p<0.01) and negatively 
associated with physician 
workload, as measured by both 
average patients seen per day 
(r = -0.73) and gross income 
(r=-0.75). 
Peabody et 
al., 2004 (74) 
Diabetes, 
COPD, 
vascular 
disease, 
depression 
1) Diagnoses in 
computerized 
administrative 
records (format not 
described) 
2) Diagnoses on 
administrative 
encounter forms 
Medical record 
review 
 
Disease was 
assigned to each 
standardized patient 
Training was 
categorized as 2
nd
 
year resident, 3
rd
 
year resident, or 
attending physician 
348 visits by 45 
standardized patients at 3 
outpatient clinics in San 
Francisco, CA between 
March-July 2002 
Outcome: % 
agreement 
between 
diagnoses in 
administrative 
data and medical 
record diagnoses 
Bivariate analyses 
Chi-squared tests 
Administrative data contained 
the correct diagnosis in 57% of 
visits. 
Agreement was significantly 
(p<0.05) different for different 
diseases and clinics. 
Agreement was not significantly 
associated with physician 
training (R2, R3, or attending). 
Kostylova et 
al., 2005 (75) 
Head injury, 
probable 
head injury, 
orthopedic 
injury 
Physician claims 
diagnoses  from the 
Régie de 
l’assurance maladie 
du Québec (ICD-9 
codes) 
Canadian Hospitals 
Injury research and 
Prevention Program 
(CHIRPP) database 
Patient age and sex 
was obtained from 
the CHIRPP 
database 
3,145 children aged 1-18 
years who sought care for 
an injury in 2000-2001 at 
either of the two Montreal 
pediatric hospitals 
emergency departments 
Outcome: 
agreement 
between 
physician claims 
diagnosis and 
CHIRPP data 
Bivariate analyses 
Good agreement (Kappa, 0.66)  
Mean age of children whose 
claim diagnosis disagreed with 
CHIRPP diagnosis (6.6 years) 
was significantly lower than that 
of children whose claim 
diagnosis agreed with the 
CHIRPP diagnosis (8.5 years) 
(p<0.001). 
ICD: International Classification of Disease. COPD: chronic obstructive pulmonary disease. 
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Table 5 (continued). Studies that have identified covariates associated with the accuracy of case definitions based on diagnoses in administrative data 
 
Study Disease(s) 
under study 
Administrative 
data being 
validated (format) 
Data used as 
comparison 
(format) 
Covariate data 
source 
Study population  
and sampling 
Statistical 
analysis 
Findings 
Andrade et 
al., 2002 (76) 
Peptic ulcer, 
upper gastro-
intestinal 
bleeding 
Hospital discharge 
diagnoses (ICD-9-
CM codes) 
Diagnosis 
confirmed by 
surgery, endoscopy, 
x-ray or autopsy 
documented in the 
hospital chart 
Patient age and 
gender were 
obtained from the 
health maintenance 
organization 
database 
8 large US health 
maintenance organizations 
1,152 hospitalisations with a 
hospital discharge diagnosis 
of peptic ulcer or upper 
gastrointestinal bleeding in 
1994-1997 
The hospital chart was 
located for 884 (76.7%) 
hospitalisations 
Outcome: PPV of 
hospital discharge 
diagnoses 
Bivariate analyses 
Chi-squared test 
 
The discharge diagnosis was 
confirmed for 207 (23.4%) 
hospitalisations. 
The proportion of confirmed 
discharge diagnoses was higher 
among patients aged less than 
60 years (32%) as compared to 
those 80 years and older (19%) 
(p = 0.01).  
Site-specific diagnostic codes 
had higher positive predictive 
values than nonspecific codes. 
Losina et al., 
2003 (77) 
Rheumatoid 
arthritis, 
avascular 
necrosis, 
osteoathritis 
Hospital and 
surgeons‟ Medicare 
claim diagnoses 
(ICD-9-CM codes) 
Medical record 
review 
Hospitals were 
categorized as low- 
and high-volume 
based on a cut-off 
of 25 total hip 
replacements per 
year (median of the 
sample) 
A stratified random sample 
of 922 Medicare 
beneficiaries who received 
total hip replacement in 
1995 in Ohio, Pennsylvania, 
and Colorado 
Outcomes: 
sensitivity and 
PPV of the 
Medicare claim 
diagnoses 
Bivariate analyses 
Chi-squared test 
(p<0.05) 
 
Sensitivity ranged from  
0.54 (95% CI, 0.42-0.66) for 
avascular necrosis to 0.96 (95% 
CI, 0.95-0.98) for osteoathritis. 
PPV did not differ by disease 
(range, 0.86-0.89).  
Sensitivity was higher for 
rheumatoid arthritis and lower 
for avascular necrosis in low-
volume hospitals as compared 
to high-volume ones. 
No relationship between PPV 
and hospital volume. 
Jollis et al., 
1993 (78) 
12 prognostic 
factors in 
patients with 
ischemic 
heart disease  
Medicare claims 
diagnoses (ICD-9-
CM codes) 
Hospital clinical 
information system  
Patient age and sex 
were obtained from 
the hospital clinical 
information system 
All 12,937 Medicare 
patients who underwent 
inpatient cardiac 
catheterization at Duke 
Medical Center in 1985-
1990 
Outcome: 
Sensitivity of 
Medicare claims 
diagnoses 
Bivariate analyses 
Chi-squared test 
The sensitivity of Medicare 
claims diagnoses ranged from 
0.83 for diabetes to 0.14 for 
unstable angina and tobacco 
use.  
Sensitivity of Medicare claims 
diagnoses was significantly 
higher for patients aged less 
than 65 years as compared to 
patients aged 65 years and 
older. 
ICD: International Classification of Disease. PPV: positive predictive value. 
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Table 5 (continued). Studies that have identified covariates associated with the accuracy of case definitions based on diagnoses in administrative data 
 
Study Disease(s) 
under study 
Administrative 
data being 
validated (format) 
Data used as 
comparison 
(format) 
Covariate data 
source 
Study population  
and sampling 
Statistical 
analysis 
Findings 
Katzman-
McClish et 
al., 1997 (79) 
Breast, 
colorectal, 
lung, and 
prostate 
cancers 
Medicare claims 
diagnoses (ICD-9-
CM codes) 
Virginia Cancer 
Registry 
Patient age, gender, 
and comorbidity 
were obtained from 
the Medicare 
database 
Income and 
education were 
obtained from the 
1990 Census  
Cancer stage was 
obtained from the 
Virginia Cancer 
Registry  
All Virginia residents aged 
65 years and older with a 
breast (N=3,690), colorectal 
(N=4,690), lung (N=5,781), 
or prostate (N=4,495) 
cancer diagnosis in the 
Virginia Cancer Registry in 
1986-1989 
Outcome: case 
not identified by 
Medicare claims 
(yes/no) 
Multivariate 
logistic regression 
analyses stratified 
by type of cancer 
 
Medicare claims diagnoses 
identified between 73% 
(prostate cancer) and 83% 
(breast and lung cancers) of 
cases in the registry.  
Patient characteristics 
associated with Medicare claims 
data missing a case included 
age 65-75 years (vs. 75+ 
years), male gender, urban area 
of residence, higher education 
and income, in situ disease, and 
lack of comorbidity. 
Ostbye et al., 
2008 (80) 
Dementia Medicare claims 
diagnoses (ICD-9-
CM codes) 
Self- or proxy-
reported cognitive 
status from the 
Asset and Health 
Dynamics among 
the Oldest Old 
(AHEAD) national 
survey 
Patient age, gender, 
and education (data 
source not 
described) 
7,974 cases of dementia 
were identified from the 
AHEAD study 
Of those, 80% consented to 
share their Medicare claims 
data with the researchers 
Outcome: 
agreement 
(yes/no) 
Multivariate 
logistic regression 
analyses with  
Agreement between Medicare 
claims and survey data was 
poor (Cohen‟s Kappa, 0.23; 
95% CI, 0.17-0.30).  
Agreement between Medicare 
claims and survey data was 
more likely among older (ORper 
year of age, 0.94; 95% CI, 0.93-
0.96) and more educated 
respondents (ORper year od education  
1.05; 95% CI, 1.02-1.07). 
Muhajarine 
et al., 1997 
(34) 
Hypertension Physician claims 
data from the 
Manitoba Health 
Insurance Plan 
(ICD-9-CM codes) 
Manitoba Heart 
Health Survey: 
1) patient self-report 
2) clinical 
measurement of 
blood pressure 
Patient sex, age, 
education, income, 
employment, and 
marital status, 
smoking, obesity, 
cholesterol levels, 
physical activity, 
diabetes, and 
cardiac medications 
were obtained from 
the survey 
Stratified random sample of 
2,792 non-institutionalized 
adults aged 18-74 years 
residing in Manitoba 
2,339 (84%) completed the 
clinical visit 
2,275 (97.3%) had a 
physician claim in the 2 
years before the survey 
Outcome: 
Disagreement 
(yes/no)  
Multivariate 
logistic regression 
analyses 
 
Disagreement between claims 
and clinical measurement was 
more likely among homemakers 
(OR, 1.78; 95% CI, 1.11-2.84), 
1.62-2.79), obese patients (OR, 
2.13; 95% CI, 1.62-2.79), older 
patients (OR 55+ vs. 18-34 y.o., 2.92; 
95% CI, 1.84-4.61), patients 
with hypercholesterolemia (OR, 
1.35; 95% CI 1.02-1.79), and 
patients on medication for heart 
disease (OR, 1.66; 95% CI 
1.13-2.43). 
ICD: International Classification of Disease.  
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Table 5 (continued). Studies that have identified covariates associated with the accuracy of case definitions based on diagnoses in administrative data 
 
Study Disease(s) 
under study 
Administrative 
data being 
validated (format) 
Data used as 
comparison 
(format) 
Covariate data 
source 
Study population  
and sampling 
Statistical 
analysis 
Findings 
MacIntyre et 
al., 1997 (67) 
Australian 
national 
diagnosis-
related 
groups 
(ANDRG) 
Victorian In-Patient 
Minimum Database 
(ICD-9-CM codes) 
Medical record audit Hospital location 
(rural or urban), 
admission type 
(emergency  or 
other), length of 
stay, death, 
ANDRG frequency, 
and type of ANDRG 
(medical or other)  
were obtained from 
the Victorian In-
Patient Minimum 
Database 
7,013 cases from 63 (54%) 
Victorian hospitals in the 
year 1993-1994 were 
randomly selected and 
audited 
Outcome: 
disagreement on 
principal 
diagnosis 
Multivariate 
logistic regression 
analyses 
Disagreement was present in 
1,565 (22%) cases.  
Disagreement was more likely 
among hospitalizations longer 
than 5 days (OR, 1.95; 95% CI, 
1.69-2.25), involving emergency 
admission (OR, 1.14; (% CI, 
1.02-1.28), and resulting in 
death (OR, 1.90; 95% CI 1.19-
3.00). 
Likelihood of discrepancy 
increased with increasing rarity 
of ANDRG. 
Taylor et al., 
2002 (81) 
Alzheimer‟s 
disease 
ICD-9 codes in 
Medicare claims 
(ICD-9 codes) 
Clinical diagnosis of 
Alzheimer‟s disease 
in the Consortium to 
Establish a Registry 
for Alzheimer‟s 
Disease (CERAD) 
Patient age, 
education, marital 
status, and 
Alzheimer‟s disease 
severity,  were 
obtained from 
CERAD 
Number of visits 
was ascertained 
from Medicare 
claims 
417 patients with a clinical 
diagnosis of Alzheimer‟s 
disease in CERAD 
Outcome: 
Alzheimer‟s 
disease diagnosis 
in Medicare 
claims (among 
patient so 
diagnosed in 
CERAD)  
Multivariate Cox 
proportional 
hazards analyses 
A diagnosis of Alzheimer‟s in 
Medicare claims was more likely 
among males (HR, 1.27; 
p<0.05), younger patients (HRper 
year, 0.97; p<0.05), patients with 
less severe disease (HRstage, 
0.65; p<0.01). 
The likelihood of a diagnosis of 
Alzheimer‟s in Medicare claims 
increased with the number of 
visits (HRper visit, 1.09; p<0.001). 
Singh et al., 
2009 (82) 
Arthritis Diagnosis in the 
Veteran‟s Affairs 
administrative data 
(ICD-9 -CM codes) 
Patient self-reported 
physician diagnosis 
from the Prior 
Veterans‟ Quality of 
Life (Vet-QoL) 
survey 
Patient sex, 
education, 
comorbidity, activity 
limitation, tobacco 
use, and health 
status (SF-36) were 
obtained from the 
survey database 
Of 70,334 veterans 
contacted for the survey, 
34,440 (49.0%) answered 
the question on arthritis 
 
Outcome: 
Discordance 
between 
administrative and 
survey data 
Multivariate 
logistic regression 
analyses 
Poor agreement (Kappa, 0.25) 
Discordance more likely among 
infrequent healthcare users 
(ORlowest vs. highest tertile, 1.11; 95% 
CI, 1.03-1.19), with no prior 
hospitalization (OR1+ vs. 0, 0.88; 
95% CI, 0.80-0.96), older  
veterans (OR65+ vs. <50 y.o., 1.38; 
95% CI, 1.26-1.52), with more 
comorbidities (OR3+ vs. 0, 1.54; 
95% CI, 1.40-1.69), and worse 
physical health (ORhighest vs. lowest 
PCS score tertile, 0.83; 95% CI, 0.76-
0.91). 
ICD: International Classification of Disease.  
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Table 5 (continued). Studies that have identified covariates associated with the accuracy of case definitions based on diagnoses in administrative data 
 
Study Disease(s) 
under study 
Administrative 
data being 
validated (format) 
Data used as 
comparison 
(format) 
Covariate data 
source 
Study population  
and sampling 
Statistical 
analysis 
Findings 
Lix et al., 
2008 (83) 
Osteoporosis Physician claims 
diagnoses from the 
Manitoba Health 
Insurance Plan 
(ICD-9-CM codes) 
BMD test results in 
the Manitoba Bone 
Density Program 
database 
Patient age, region 
of residence, 
income quintile, 
comorbidity, 
osteoporosis 
prescriptions were 
obtained from 
administrative 
databases 
5,527 patients with at least 
one BMD test in the 
Manitoba Bone Density 
Program database during 
the fiscal year 2000-2001 
Outcome: 
osteoporosis 
based on BMD 
test result 
Multivariate 
logistic regression 
analyses 
Likelihood of osteoporosis 
based on BMD test increased 
with an ICD-9 diagnostic code 
for osteoporosis in physician 
claims (OR, 2.74; p <0.0001), a 
prescription for an osteoporosis-
specific medication (OR, 5.13; 
p<0.0001), and older age (ORper 
year of age: 1.06; p<0.0001). 
Gabriel et al., 
1996 (84) 
Osteoarthritis Diagnoses from the 
Olmsted County, 
Minnesota 
computerized 
database (ICD-9 
code) 
Medical record 
review 
Patient age and sex 
were obtained from 
the computerized 
database 
Random sample of 400 
patients with a diagnosis of 
osteoarthritis in the 
computerized database 
in1975-1987 
The medical record was 
available for 387 (96.8%) 
patients 
Outcome: positive 
predictive value of 
the computerized 
database 
Recursive 
partitioning 
analysis 
 
Positive predictive value of the 
computerized database: 60% 
(232/387). 
Older patients were more likely 
to be true-positives. 
Love et al., 
2010 (85) 
Psoriatic 
arthritis 
Physician billing 
diagnostic codes 
(ICD-9) in the 
Research Patient 
Data Registry 
(RDPR) 
Rheumatologist-
diagnosed psoriatic 
arthritis ascertained 
by a review of the 
RDPR 
Coded data from 
the RDPR 
Information 
extracted from the 
full text visit notes 
from the RDPR 
Laboratory values 
from the RDPR 
2,318 patients with a 
physician billing diagnostic 
code for psoriatic arthritis in 
1995-2007 were identified 
from the RDPR of the 
Brigham and Women‟s 
Hospital and its outpatient 
clinics (Boston, MA) 
A random sample of 550 
(23.7%) patient records 
were reviewed 
Outcome: 
rheumatologist-
diagnosed 
psoriatic arthritis  
Random forest 
analysis (an 
extension of 
recursive 
partitioning) 
The sensitivity of coded data 
(e.g., number of psoriatic 
arthritis diagnostic codes) for 
identifying rheumatologist-
diagnosed psoriatic arthritis was 
improved by the addition of 
variables extracted from the 
medical record using natural 
language processing (e.g., the 
number of rheumatology and 
clinic notes mentioning psoriatic 
arthritis) and laboratory values 
(e.g., highest erythrocyte 
sedimentation rate). 
ICD: International Classification of Disease. BMD: bone mineral density. 
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Table 5 (continued). Studies that have identified covariates associated with the accuracy of case definitions based on diagnoses in administrative data 
 
Study Disease(s) 
under study 
Administrative 
data being 
validated (format) 
Data used as 
comparison 
(format) 
Covariate data 
source 
Study population  
and sampling 
Statistical 
analysis 
Findings 
Szumski et 
al., 2009 (86) 
Parkinson‟s 
disease 
Diagnoses from 
Veteran‟s Affairs 
administrative data 
(ICD-9-CM codes) 
Medical record 
review 
Patient age, sex, 
number of 
diagnostic codes for  
Parkinson‟s 
disease, number of 
visits to neurology 
clinic, and number 
of visits to 
movement disorder 
clinic were obtained 
from the Veteran‟s 
Affairs database 
577 patients with a 
diagnosis of Parkinson‟s 
disease in the Veteran‟s 
Affairs administrative 
database between October 
1, 2001 and September 30, 
2002 
Outcome: 
sensitivity, 
specificity, PPV 
and NPV of 
administrative 
data as compared 
to the chart 
Two-sample test 
of proportion 
(α=0.05) used to 
compare outcome 
estimates across 
algorithms 
Medical record review 
determined 436 (75.6%) 
patients to have Parkinson‟s 
disease.  
PPV of administrative data was 
improved by giving greater 
weight to diagnostic codes from 
specialists over non-specialists, 
and by taking into account 
prescriptions for Parkinson‟s 
disease-related medications. 
Van 
Walraven et 
al., 2010 (87) 
Kidney 
disease 
Diagnoses in the 
Ottawa Hospital 
Data Warehouse 
(ICD-10) 
Serum creatinine 
measurements from 
the from the Ottawa 
Hospital Data 
Warehouse 
Patient age, sex, 
and comorbidity 
were obtained from 
the Ottawa Hospital 
Data Warehouse 
Hospitalization-level 
characteristics: 
admission urgency, 
admitting service, 
ICU stay, surgical 
procedures, hospital 
survival, and length 
of stay were 
obtained from the 
Ottawa Hospital 
Data Warehouse  
A random sample of 
100,000 adult admissions to 
the Ottawa Hospital in 
2002-2008 was selected 
from the Ottawa Hospital 
Data Warehouse 
Outcome: kidney 
disease based on 
serum creatinine 
measurements 
Multivariate 
logistic regression  
Kidney disease was confirmed 
by serum creatinine in 20,713 
(20.7%) patients.  
The most powerful predictor of 
kidney disease based on serum 
creatinine was a diagnostic 
code for kidney disease (RR: 
34.4).  
Other variables were associated 
with kidney disease based on 
serum creatinine, including 
patient characteristics (e.g., 
age, gender, comorbidities) and 
hospitalization characteristics 
(e.g., length of stay, ICU stay, 
dialysis). 
 ICD: International Classification of Disease. ICU: intensive care unit. PPV: positive predictive value. NPV: negative predictive value.  
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errors being less common for diabetes and more common for chronic obstructive 
pulmonary disease and vascular disease. That study found no association between 
physician experience and diagnostic coding errors, but a very uninformative measure of 
experience was used: physicians were categorized as 2nd year resident, 3rd year resident, 
or attending physician, with the latter category likely encompassing a wide range of 
years of experience. 
 
Several studies have attempted to identify patient characteristics associated with the 
accuracy of case definitions based on diagnoses in administrative data. For chronic 
diseases that are typically first diagnosed among the elderly (e.g., dementia, 
osteoporosis, osteoarthritis, renal failure), accuracy of case definitions based on 
diagnoses in administrative data was higher among older patients (79;80;83;84;87). 
Patient comorbidity was negatively associated with accuracy of case definitions based 
on diagnoses in administrative data (34;82;87); a likely explanation for this finding is that 
the selection of a single principal diagnosis for a medical encounter is complicated by 
the presence of concurrent illness(es). The studies reviewed in Table 5 do not show a 
clear trend between accuracy of case definitions based on diagnoses in administrative 
data and patient income, education, or geographic area of residence. 
 
Few studies have assessed the impact of visit- or site-specific characteristics on the 
accuracy of case definitions based on diagnoses in administrative data. Losina et al. (77) 
reported that the sensitivity of case definitions based on diagnoses in Medicare claims 
was higher among low-volume hospitals than high-volume hospitals; this finding is 
similar to that of a study by Studney et al. (46), in which diagnostic coding accuracy was 
higher among physicians with lower workloads, as compared to those with higher 
workloads. Two studies (67;87) have assessed the impact of length of stay and 
emergency admission on the accuracy of case definitions based on hospital discharge 
diagnoses, and they report opposite findings. 
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To summarize, we found only one published study (73) in which the investigators 
attempted to improve the accuracy of syndrome definitions based on diagnoses in 
administrative data by taking into account covariates, and the covariates investigated 
were limited to characteristics of the presentation and medical management of the 
illness itself, i.e., symptoms, signs, laboratory test orders, imaging requests, and 
medications prescribed. In contrast, in areas outside syndromic surveillance, many 
studies have identified covariates associated with the accuracy of case definitions based 
on diagnoses in administrative data (67;74-78;81;82;87), and a few studies have even 
shown that the accuracy of case definitions can be improved substantially by taking into 
account such covariates (83-86). Whereas some of the covariates identified by these 
studies may be disease-specific (e.g., older age in identifying diseases more prevalent 
among the elderly), and therefore may not be directly applicable to syndromic 
surveillance, these studies nonetheless provide clues as to what type of covariates may 
influence the accuracy of syndrome case definitions. Specifically, based on findings from 
these studies, we should investigate the impact of physician, patient, encounter, and 
healthcare site characteristics on the accuracy of syndrome case definitions based on 
diagnoses in administrative data. 
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Chapter 3. Methods 
 
In the previous chapter, we discussed the methodological limitations of published 
validations of syndrome case definitions based on diagnoses in administrative data. In 
particular, we drew attention to the fact that most published validations were based on 
a convenience sample of one or a few healthcare sites, and we showed how verification 
bias led to a large overestimation of sensitivity in some of these studies. We also 
described findings from studies outside the realm of syndromic surveillance that 
suggested types of covariates that may be associated with case definition accuracy, 
namely physician, patient, encounter, and healthcare site characteristics.  
 
In this chapter, we provide a detailed explanation of the methodology we used to obtain 
data for our large-scale, population-based validation of syndrome case definitions based 
on diagnostic codes in physician claims (manuscript 2), and our study on the predictors 
of syndrome definition accuracy (manuscript 3). (Of note, our approach to the 
methodology used in manuscripts 2 and 3 was guided by our pilot work experience and 
the findings published in manuscript 1). We first describe the administrative data used in 
this thesis, including the physician claims whose diagnoses were validated in manuscript 
2, and the various data sources used to generate many of the potential predictors of 
syndrome case definition accuracy investigated in manuscript 3. We then provide a 
detailed explanation of the sampling strategy we used to select physician claims for 
validation in manuscript 2, and how this strategy insured population representativeness 
and guarded against biases. Next, we describe how we collected data from the medical 
chart (i.e., the ‘gold standard’), and the various safeguards that were put in place to 
ensure high data quality. Finally, we explain the statistical analyses we used to estimate 
the accuracy of syndrome case definitions based on diagnostic codes in RAMQ physician 
claims, taking into account our complex stratified sampling strategy. 
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Administrative databases used in this thesis 
 
The work contained in this thesis was conducted in the province of Quebec, Canada, 
where universal health coverage is provided through the provincial health insurance 
plan. Each Canadian province maintains a population-based registry of insured persons 
and claims for all physician visits remunerated on a fee-for-service basis. All claims 
record unique physician and patient identifiers that can be used to create longitudinal 
histories of healthcare use. In the province of Quebec, 99% of residents have provincial 
health insurance and 85-95% of medical visits are remunerated on a fee-for-service basis 
(88). In 2006, there were more than 7.6 million inhabitants in Quebec (89), and 18,908 
active registered physicians (90). The availability of diagnostic information for nearly all 
medical visits to Quebec physicians represented an invaluable opportunity for assessing 
the validity of using diagnostic codes in physician claims for population-based 
surveillance. 
 
Three databases from the provincial healthcare agency, the Régie de l’assurance maladie 
du Québec (RAMQ), were used in this thesis. Patient age and gender, as well as an 
anonymized unique patient identifier, were obtained from the beneficiary database. The 
physician claims database provided the treating physician identifier, patient identifier, 
date of visit, medical procedure code, ICD-9 diagnostic code, type of clinic (private clinic, 
community health center, ambulatory hospital-based clinic), and geographic location of 
clinic (urban, rural) for all visits billed on a fee-for-service basis. The physician 
demographics database provided the physician identifier and the physician gender, 
language (French or English), and specialty. The Quebec medical regulatory authority, 
the Collège des Médecins du Québec (CMQ), provided physicians’ year of licensure. 
 
Statistics Canada’s 2006 census data for the province of Quebec was mapped to 6-digit 
postal codes by the research team; a high degree of spatial precision was achieved by 
mapping the 6-digit postal code centroids (i.e., geometric centers) to the corresponding 
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census dissemination area, which was the smallest available census area. The RAMQ 
then linked the census data to the beneficiary database using the patient’s 6-digit 
residential postal code. Census variables provided to the research team included 
geographic location of residence (urban, rural), average household income in the 6-digit 
postal code area (in thousands of dollars), and proportion of persons with a university 
degree in the 6-digit postal code area. Material and social deprivation indices developed 
by the Quebec National Public Health Institute (91;92) were computed by the RAMQ for 
each patient using Statistics Canada’s 2006 census data. The material deprivation index 
summarizes information on the proportion of persons who have no high school diploma, 
the proportion of persons employed, and the average income in the patient’s 6-digit 
postal code area of residence. The social deprivation index summarizes information on 
the proportion of single-parent families, the proportion of persons living alone, and the 
proportion of persons separated, divorced, or widowed in the patient’s 6-digit postal 
code area of residence. 
 
Sampling of physician claims to be validated (for manuscripts 2 and 3) 
 
The accuracy of case definitions based on diagnoses in physician claims for identifying 
syndromes was assessed by comparison to clinical information in the corresponding 
medical chart. To ensure representativeness, we used a population-based, 3-stage 
stratified random sample of 36,000 visits (Figure 4), for which we made the necessary 
statistical adjustments in the analyses so as to avoid verification bias. In the first stage 
(Figure 4, Stage 1), the RAMQ identified all physicians who were eligible to be included 
in our study. To be eligible, physicians had to be a general practitioner, pediatrician, 
internist, geriatrician or general surgeon who practiced in the fee-for-service system in a 
private clinic, community health center, or hospital-based ambulatory care clinic during 
the 2-year study period (October 1, 2005 to September 30, 2007). Internists and general 
surgeons were included in our sample because, especially in rural-remote and 
underserved areas, these physicians may provide first-contact care and act as patients’ 
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family physician. From the 8,700 eligible physicians identified, the provincial health 
insurance agency selected a random sample of 3,600 (41.4%) physicians.  
 
 
Figure 4. Population-based, 3-stage stratified random sample of ambulatory visits to all physicians working in 
community healthcare settings in the province of Quebec in 2005-2007 
 
In the second stage (Figure 4, Stage 2), to facilitate chart retrieval for review, the RAMQ 
randomly selected one eligible community practice location for each physician. The 
RAMQ then sent the research team an anonymized file containing all physician claims 
billed by the 3,600 physicians from their respective selected community practice 
location during the 2-year study period.  
 
In the third stage (Figure 4, Stage 3), the research team randomly selected 5 syndrome-
positive visits, i.e., 1 visit for each of fever, gastrointestinal, neurological, rash, and 
 
8,700 eligible physicians 
Stage 1: simple random sample of 3,600 (41.4%) eligible physicians 
 
3,600 sampled physicians 
Stage 2: simple random sample of 1 eligible practice location per physician 
 
3,600 physician practice locations 
Stage 3: random sample of 10 visits per physician practice location:  
 5 visits negative for all syndromes 
 1 visit positive for each of the 5 syndromes (fever, gastrointestinal, neurological, 
rash, and respiratory including influenza-like illness). 
 For each syndrome, the sample of syndrome-positive visits was further 
stratified by ICD-9 code. 
Exclusion was used to ensure each patient was sampled only once. 
Syndrome-negative visits were frequency-matched on month to syndrome positive 
visits to avoid seasonal bias. 
 
36,000 visits to be verified 
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respiratory syndrome (including influenza-like illness), and 5 visits negative for all 
syndromes. A visit was considered syndrome-positive if the ICD-9 code on the physician 
claim for the visit was included in the syndrome definition. Because syndromes have low 
population prevalence, to maximize data collection efficiency (69;70), syndrome-positive 
visits were over-sampled relative to syndrome-negative ones, so as to yield 5 syndrome-
positive visits and 5 syndrome-negative visits per physician.  When sampling syndrome-
positive claims, to maximize the number of syndrome-positive ICD-9 codes verified, we 
further stratified on ICD-9 code. Because two or more syndromes can occur concurrently 
in the same patient (61), syndrome-negative visits were negative for all syndromes. 
Syndrome-negative visits were also frequency-matched to syndrome-positive visits on 
calendar month to avoid bias due to syndrome seasonality (Figure 5). To avoid bias due 
to visits being clustered within patients, restriction was used to ensure that each patient 
was only sampled once. The number of syndrome-positive visits, per syndrome, in the 
sampling frame and in the final sample of 36,000 visits is shown in Table 6.  
 
 
Figure 5. Weekly counts of syndrome-positive claims (CDC syndrome definitions) among all physician claims 
billed by the 3,600 physicians from their selected practice location from October1, 2005 to September 30, 2007 
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Table 6. Number and prevalence of syndrome-positive visits, per syndrome, among all physician claims billed by 
the 3,600 physicians from their selected practice location from October1, 2005 to September 30, 2007,  and 
number of syndrome-positive visits, per syndrome, in the sample of 36,000 visits to be validated 
 
 In the sampling frame In the sample 
Syndrome No. visits 
Prevalence
1
 
(per 1,000 visits) No. visits 
CDC-DoD ESSENCE definitions (66) :    
   Fever 241,705 11.9 1,966 
   Gastrointestinal 471,491 23.2 2,868 
   Neurological 114,046 5.6 3,172 
   Rash 351,270 17.3 2,991 
   Respiratory 2,555,164 125.7 3,600 
ESSENCE definitions
3
 (49) :    
   Influenza-like illness, large group 1,751,828 86.2 2,218 
   Influenza-like illness, small group 93,300 4.6 160 
RODS definitions
4
 (61) :    
   Fever 453,990 22.3 2,817 
   Gastrointestinal 429,933 21.2 2,347 
   Neurological 103,688 5.1 2,876 
   Rash 158,949 7.8 2,698 
   Respiratory 1,355,757 66.7 2,263 
None of the syndromes above 16,469,389 810.2 19,557 
 
1
 There were a total of 20,326,404 visits among all physician claims billed by the 3,600 physicians from their selected 
practice location between October1, 2005 and September 30, 2007. 
2
 A total of 36,000 visits (10 visits per physician x 3,600 physicians) were sampled for validation. 
3
 Each of the diagnostic codes in the influenza-like illness definitions are included in the respiratory and/or fever syndrome 
definitions; influenza-like illness did not required separate sampling. 
4 
For the same syndrome, there is some overlap between the diagnostic codes included in the CDC-DoD ESSENCE 
definitions and the RODS definition. When we selected the sample of 36,000 visits to validate, we pooled the CDC-DoD 
ESSENCE and RODS definitions by syndrome, and attempted to select 3,600 syndrome-positive visits per syndrome. 
 
The list of 10 sampled visits was enumerated for each of the 3,600 physicians, and an 
anonymized unique identifier, the study number, was assigned to each sampled visit by 
the research team. 
 
Medical chart data retrieval (for manuscripts 2 and 3) 
 
Medical chart data retrieval methodology 
The accuracy of syndrome case definitions based on diagnoses in physician claims was 
assessed by comparison to clinical information from medical charts. Because we used a 
province-wide sampling frame, physician-facilitated chart reviews were deemed 
47 
 
superior to both in-office chart abstraction and mail or web-based self-report. Chart 
abstraction would have involved prohibitive travel costs and required patient consent, 
the latter increasing the complexity of recruitment and further contributing to non-
response bias. Alternatively, mail or web-based self-report would have yielded poorer 
data quality (93), and increased the potential for measurement error by having as many 
raters as physicians. 
 
Validation of the medical chart data retrieval methodology 
To avoid biasing responses in a particular direction, the interview was semi-structured 
and questions were open-ended. The questionnaire was pre-tested to ensure accurate 
capture of all relevant information in the patient medical record by comparing physician-
facilitated chart review to chart abstraction (by the thesis author). A convenience 
sample of 6 physicians concurrently enrolled in the MOXXI electronic prescribing trial 
(94) was used, and 8 visits were validated per physician. After consent was obtained, I 
telephoned each physician and performed the physician-facilitated chart review. 
Physicians then faxed me a copy of the medical chart entry corresponding to each 
sampled visit; to preserve patient anonymity, the physician was asked to black-out any 
patient identifiers and add a visit number to the medical chart copy before faxing it. 
Agreement between the physician-facilitated chart review and the medical chart was 
very high for 5 of the 6 physicians: 50 diagnoses were common to the physician-
facilitated chart review and the paper chart abstraction, 2 diagnoses were obtained only 
from the physician-facilitated chart review (not found verbatim in the paper chart), and 
1 diagnosis was found in the paper chart but not mentioned during the physician-
facilitated chart review. One physician’s charts were almost entirely illegible, which 
highlighted the advantage of having the physician interpret his own writing. 
 
Overview of the data collection procedure 
Figure 6 provides an overview of how the medical chart data was collected. To preserve 
physician and patient anonymity, the health insurance agency sent the list of physicians 
and visits sampled by the research team to the medical regulatory authority (Figure 6, 
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Step 3). The medical regulatory authority has the legal right to access confidential 
physician and patient information, therefore the list it received included physicians’ 
name and mailing address, as well as patients’ name, insurance number, sex, and date of 
birth. The medical regulatory authority acted as a trusted third party and recruited 
physicians to the study on behalf of the research team; it also sent each physician the 
list of 10 sampled visits (Figure 6, Step 4). Lists sent to physicians included patients’ first 
and last names, sex, date of birth, health insurance number, date of the visit to be 
verified, and the ‘study number’ assigned to each visit. 
 
 
 
 
Because the lists sent to physicians contained both patient information and study 
numbers, it enabled physicians to retrieve the relevant medical charts, and researchers 
to link the information collected through chart review to the anonymized physician 
claims file. Interested physicians mailed their written consent and contact information to 
the research team (Figure 6, Step 5). Non-responding physicians were sent up to five 
reminders. To maximize participation, physicians were offered $50 compensation for 
Figure 6. Overview of data collection 
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health 
insurance 
agency 
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research 
team 
 
 Physicians in 
community 
settings 
 
Quebec 
medical 
regulatory 
authority 
Step 1: Health insurance agency sends 
anonymized physician claims from 3,600 
randomly-sampled physicians to research team 
Step 4: Medical regulatory authority recruits 
physicians to study, sends info on 10 
sampled visits to each physician 
Step 5: 
Physicians 
provide written 
consent to 
research team 
Step 6: 
Physician-
facilitated 
medical 
chart review 
Step 3: Health 
insurance agency 
sends info on 3,600 
physicians and 36,000 
visits to medical 
regulatory authority 
Step 2: Research team samples 10 
visits per physician, sends them to 
health insurance agency 
49 
 
their participation and a summary of study findings. Using a previously published 
methodology (95), trained interviewers contacted consenting physicians by telephone to 
perform the chart review (Figure 6, Step 6). During the chart review, interviewers and 
physicians referred to each visit using only the study number and visit date, thereby 
preserving patient anonymity. 
 
Physician recruitment and participation 
Efforts to recruit physicians to our study began in September 2008 and ended in August 
2009. The Quebec medical regulatory authority made up to 5 attempts to recruit each 
physician, for a total of 13,840 recruitment packages mailed. Physician response after 
each mailing is shown in Table 7. On average, obtaining physician consent required 2 
mailings (median, 2; range, 1-5). 
 
Table 7. Physician response after each mailing 
 Mailings 
Total 
 1st 2nd 3rd 4th 5th 
No. letters sent 3,600 2,863 2,556 2,434 2,387 13,840 
No. physicians with incorrect addresses 172 0 0 0 0 172 
No. physicians who refused 29 37 105 36 11 218 
No. physicians who consented 536  270  201 86 36 1,129 
% physicians who consented
1
 14.9 9.4 7.9 3.5 1.5 8.2 
 
1
 The % consent was calculated as the (no. physicians who consented * 100) / no. letters sent. 
 
Figure 7 provides a detailed breakdown of physician eligibility and participation. The 
Quebec provincial health agency had an inaccurate billing address for 172 (5%) 
physicians, which suggests that these physicians were not being reimbursed on a fee- 
for-service basis; we considered these physicians to be ineligible to participate in the 
study. Another 170 (5%) physicians contacted the research team but were determined 
to be ineligible to participate, most often because they were no longer working in an 
eligible community-based practice setting, had retired, were on sick/maternity leave, or 
had moved their practice to another Canadian province. Of the remaining 3,258 (90%) 
potentially eligible physicians, 218 (7%) refused to participate in the study; the two most 
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Figure 7. Physician eligibility and participation 
 
common reasons for refusal were lack of time to participate and lack of interest in the 
study. Of 1,129 physicians who consented to participate in our study, 31 (3%) later 
refused or were not reached. A total of 1,098 physicians participated in the study, for a 
participation rate of 33.7% (1,098/3,258). After the research team received physicians’ 
written consent via business-reply mail, it took an average of 5.4 (median, 4; range, 1-
35) telephone calls to schedule and complete the physician-facilitated chart review. An 
average of 20 days (median, 13; range, 0-326) elapsed between the date when the 
physician’s consent form was received and the date when the physician-facilitated chart 
review was completed. Of the 1,129 physicians who consented to participate in the 
study, 100 (8.9%) physicians were not available to complete the telephone chart review 
at the scheduled time at least once, for a total of 138 missed/rescheduled telephone 
chart reviews. 
 
Physician-facilitated chart reviews 
Physician-facilitated medical chart reviews began in September 2008 and ended in 
December 2009. For each of the 10 sampled visits, the interviewer asked the physician 
3,258 (90%) 
potentially  
eligible 
3,600 
physicians 
sampled 
 
172 (5%) 
wrong address 
 
170 (5%) 
not eligible 
 
218 (7%) 
refused 
 
1,129 (35%) 
consented 
31 (3%) 
unreachable or 
later refused 
 
1,098 (97%) 
participated 
 
1,911 (59%) 
did not respond 
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to list all diagnoses. For each diagnosis corresponding to a syndrome definition, the 
interviewer asked the physician about the signs, symptoms, and key findings recorded in 
the medical chart, as well as the most likely etiology for the diagnosis (based solely on 
information available at the time of the visit). The interviewer entered physician 
responses directly into an Oracle database using an Access data entry form (Figures 8-
11). Diagnoses were selected from a searchable list of diagnoses (mapped to ICD-9 
codes) or, if the physician had recorded the ICD-9 code in the medical chart, the ICD-9 
code was entered directly. For each syndrome-positive diagnosis, a list of syndrome-
specific signs and symptoms (Table 8) was elicited, and the interviewer selected from a 
drop-down list whether the symptom had been present, absent, or not recorded in the 
medical chart. Symptoms or signs not in the list and other key findings, such as contacts 
with other diagnosed cases (e.g., siblings or children with diagnosed Strep throat) or 
links to known outbreaks (e.g., salmonella outbreak among employees on a chicken 
farm), were recorded as free text in separate fields. The data collection tool was 
translated to French for use with French-speaking physicians, and back-translated to 
English to ensure comparability of data collection. To minimize data entry errors, the 
database was pre-populated with the physician identifier, visit identifier and visit date. 
Logical limits were placed on date fields (e.g., physician consent date) to insure that 
dates entered manually fell within a reasonable time interval. 
 
At the time of the chart review, the physician and the interviewer were both blinded to 
the ICD-9 code in the physician claim and the syndrome-positive or syndrome-negative 
status of the visit. To minimize measurement error due to inter-rater differences, 
interviewers were trained to use the data collection tool. Inter-rater reliability was 
assessed at baseline by having interviewers perform 2 simulated physician interviews of 
10 visits each (for a total of 20 visits). To maintain data quality, interviewers underwent 
quality assurance monitoring every 3 months. Each assessment was comprised of 2 
simulated physician interviews of 10 visits each (for a total of 20 visits). Agreement 
between interviewers was perfect (ICC=1.00) on all assessments of inter-rater reliability; 
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all interviewers agreed on all items on the first two assessments (at baseline and 3 
months later), one interviewer recorded 1 item incorrectly on the third assessment (6 
months after baseline), and two interviewers recorded 1 and 2 items incorrectly on the 
last assessment (9 months after baseline). Of note, only the author of this thesis 
performed physician-facilitated chart reviews during the first 1.5 months of data 
collection (i.e., gradual roll-out period, before the interviewers were hired and trained) 
and the last 4.5 months of the study (i.e., winding-down period, after attempts to recruit 
physicians had stopped). 
 
Table 8. Signs and symptoms recorded during the physician-facilitated chart review 
Syndrome
1
 Signs and symptoms
2
 
Fever Fever 
Chills 
Rapid breathing 
Increased heart rate 
Low blood pressure 
Altered level of consciousness 
Gastrointestinal Fever 
Nausea 
Vomiting 
Diarrhea 
Bloody diarrhea 
Neurological Fever 
Headache 
Nuchal rigidity / stiff neck  
Vomiting 
Altered level of consciousness 
Rash Fever 
Pruritis 
What type of rash was it predominantly? (drop-down list) 
   Macular/papular 
   Vesicular 
   Nodular 
   Ulcerating 
   Hives 
   Other (free text entry) 
   Not recorded 
Respiratory Fever 
Throat pain 
Cough 
Increased sputum production 
Abnormal lung sounds on auscultation 
Shortness of breath 
 
1
 The pooled RODS and CDC-DoD ESSENCE definitions were applied to the „diagnosis‟ and „potential cause‟ ICD-9 
codes entered during the physician-assisted chart review to determine which list(s) of symptoms needed to be asked by 
the interviewer. 
2
 The question asked by the interviewer was “Based on your notes for this visit only, did the patient have or report...‟ The 
physician‟s answer was recorded as „present‟, „absent‟, or „not recorded‟ (unless otherwise specified). 
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Figure 8. Screenshot of the Access data entry form used during the physician-facilitated chart review: physician contact information and call tracking / interview 
scheduling 
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Figure 9. Screenshot of the Access data entry form used during the physician-facilitated chart review: questions about physician billing practices 
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Figure 10. Screenshot of the Access data entry form used during the physician-facilitated chart review: questions about date agreement between the claims and the 
medical chart 
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Figure 11. Screenshot of the Access data entry form used during the physician-facilitated chart review: questions about the diagnosis, suspected cause, signs, 
symptoms, and other key findings for the visit (1 form per diagnosis, unlimited number of diagnoses per visit)
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Ethics 
 
The research described in manuscript 1 was included in the MOXXI III research program; 
copies of ethics certificates from the McGill Institutional Review Board and the provincial 
privacy commission, the Commission d’accès à l’information du Québec (CAI), pertaining 
to the MOXXI III research program and relevant to the time period covered in 
manuscript 1 can be found in Appendix D. Data collection for manuscript 1 was 
performed in 2004-2005, among physicians and patients who had previously consented 
to participate in the MOXXI III research program.  
 
Copies of ethics certificates pertaining to the research described in manuscripts 2 and 3 
from the McGill Institutional Review Board, the CAI, and the legal department of the 
RAMQ can be found in Appendix E. It should be noted that, due to issues at the CAI 
unrelated to our project, we faced an unexpected delay of several months in obtaining 
initial ethics approval for the research in manuscripts 2 and 3 (jointly). Furthermore, 
although there was approval from both the CAI and the RAMQ on the data access 
request for manuscript 3, the RAMQ later refused to honour that agreement because of 
concerns about the size of the dataset. As a result, we had to make major modifications 
to our data request to suit all concerned parties, and seek further approval from the CAI 
and from the RAMQ’s legal department, which took nearly a year. The data necessary 
for the completion of manuscript 3 was finally received in September 2010. 
 
Statistical analyses 
 
Comparison of the characteristics of participating and non-participating physicians 
The analyses in manuscripts 2 and 3 are based on visits billed by participating physicians. 
Based on other large-scale studies of primary care physicians, we expected the physician 
participation rate to be low. We tested the statistical significance at the p<0.05 level of 
any differences between participating and non-participating physicians using a 
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multivariate logistic regression model where the dependent variable was participation 
and the independent variables were all available physician and practice characteristics 
(see manuscript 2, Table 1). 
 
Statistical adjustment for our complex stratified sampling strategy 
In manuscript 2, we used a complex stratified sampling strategy (Figure 3). Because of 
the low prevalence of syndrome-positive visits, we validated a larger sampling fraction 
of syndrome-positive visits relative to syndrome-negative visits. Because of large 
variation in prevalence between individual syndrome-positive ICD-9 codes within a given 
syndrome definitions we stratified our sample of syndrome-positive visits by ICD-9 code 
to maximize the number of different diagnostic codes validated. To avoid biasing our 
results, we took into account the sampling strategy used in our estimation of sensitivity, 
specificity, positive predictive value, and negative predictive value. 
 
Re-sampling of syndrome-negative visits to avoid seasonal bias 
In our initial sample of 36,000 visits, syndrome-positive visits (based on the physician 
claim) were frequency-matched on calendar month to syndrome-negative visits (based 
on the physician claim) (Figure 4). However, low physician participation and our inability 
to validate some visits among participating physicians (e.g., because some charts were 
not accessible) led to imbalances in seasonal distribution between syndrome-positive 
and syndrome-negative visits in the final sample of 10,529 validated visits. To ensure 
that the seasonal distribution of syndrome-negative visits (based on the physician claim) 
was identical to that of the syndrome-positive visits (based on the physician claim), we 
re-sampled the syndrome-negative visits (based on the physician claim) at the analysis 
stage. To do so, for each syndrome, we calculated the proportion of all visits positive for 
that syndrome (based on the physician claim) that took place in each of the 12 calendar 
months. Then, among the 5,564 validated visits that were negative for all syndromes 
(based on the physician claim), we randomly sampled as many syndrome-negative visits 
as possible while ensuring that the proportional distribution of syndrome-negative visits 
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over the 12 months was identical to that of the syndrome-positive visits (see example in 
Table 9). 
 
Estimation of positive predictive value and negative predictive value 
The negative predictive value of each syndrome case definition was estimated directly 
from the data for that syndrome. Because we stratified syndrome-positive visits by ICD-9 
code, we had to use an adjustment based on Bayes Theorem (69) to estimate the PPV of 
each syndrome definition. The PPV was estimated as a weighted average of each ICD-9 
code’s PPV, the weight being the number of visits with a given ICD-9 code among 
participating physicians’ claims, divided by the total number of visits positive for that 
syndrome among participating physicians’ claims. 
 
Table 9. Example of the re-sampling of syndrome-negative visits at the analysis stage to avoid seasonal bias 
(respiratory syndrome, CDC definition) 
 Validated visits positive for the 
CDC’s respiratory syndrome 
based on the physician claim 
(N=1,049) 
Validated visits negative for all syndromes 
based on the physician claim 
 
Among all 10,529 validated 
visits 
In the month-matched random 
sample used in the analyses 
Month No.  % No. % No. % 
January 123 11.7 453 8.1 453 11.7 
February 100 9.5 498 9.0 368 9.5 
March 97 9.2 525 9.4 357 9.2 
April 93 8.9 461 8.3 343 8.9 
May 88 8.4 494 8.9 324 8.4 
June 80 7.6 520 9.3 295 7.6 
July 63 6.0 393 7.1 232 6.0 
August 55 5.2 442 7.9 203 5.3 
September 71 6.8 435 7.8 261 6.8 
October 75 7.1 341 6.1 276 7.1 
November 121 11.5 562 10.1 446 11.5 
December 83 7.9 440 7.9 306 7.9 
Total 1,049 100.0 5,564 100.0 3,864 100.0 
 
 
Estimation of sensitivity and specificity and the correction for verification bias 
Because we validated a larger fraction of syndrome-positive visits than syndrome-
negative ones, direct estimation of the sensitivity and specificity of syndrome case 
definitions using our data would lead to verification bias: sensitivity would be 
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overestimated, and specificity underestimated (69). However, because validated claims 
were randomly sampled within syndrome-positive and syndrome-negative strata, 
unbiased estimation of these parameters was achieved by re-weighting for the different 
sampling fractions (69). Therefore, to estimate the sensitivity and specificity of each 
syndrome definition from the PPV and NPV (96), while correcting for verification bias 
(69), we used the following equations (where  is the prevalence of syndrome-positive 
visits in the physician claims):   
 
We estimated the 95% confidence intervals (CI) for the bias-corrected sensitivity and 
specificity using the methods described by Begg and Greenes (69). 
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Chapter 4. Accuracy of diagnoses in physician billing claims for identifying acute 
respiratory infections in primary care 
 
Preamble to Manuscript 1 
 
The purpose of the pilot work described in manuscript 1 was to demonstrate the 
feasibility of using groups of ICD-9 diagnostic codes in RAMQ physician claims to identify 
episodes of acute respiratory infection. The impetus for manuscript 1 was to assess 
whether diagnoses in physician claims accurately reflected treatment indication, for the 
purpose of evaluating antibiotic prescribing for acute respiratory infections. The 
respiratory infection diagnoses validated in manuscript 1 (Table 10) overlap with the 
definitions of respiratory syndrome developed by the CDC (66) and RODS (61) syndromic 
surveillance systems.  
 
Table 10. Respiratory infection diagnoses and their corresponding ICD-9 diagnostic codes 
Diagnoses Corresponding ICD-9 diagnostic codes 
Infections of likely viral etiology:  
   Acute unspecified upper respiratory infection 465-465.9 
   Common cold 460-460.9 
   Laryngitis 464-464.9, 476-476.9 
   Influenza 487-487.9 
Infections of potentially bacterial etiology:  
   Pharyngitis 34.0, 462-462.9, 463-463.9, 472-472.9 
   Otitis media 381-381.9, 382-382.9 
   Sinusitis 461-461.9, 473-473.9 
   Bronchitis 466-466.9, 490-490.9 
   Pneumonia 481-481.9, 482-482.9, 483-483.9, 485-485.9, 486-486.9 
 
 
The pilot work described in manuscript 1 allowed us to generate estimates of sensitivity 
and positive predictive value for acute respiratory infections, and these estimates were 
crucial to planning and obtaining funding for a full-scale, population-based validation of 
definitions of respiratory and other syndromes. However, the respiratory infection 
diagnoses validated in manuscript 1, as a group, would be expected to have higher 
specificity than either the CDC’s or the RODS system’s definition of respiratory 
62 
 
syndrome, because the definitions of respiratory syndrome also include many ICD-9 
codes for respiratory symptoms not specific to respiratory infection (e.g., cough, 
dyspnea).  
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Abstract 
 
Objective: To assess the accuracy of physician billing claims for identifying acute 
respiratory infections in primary care. 
 
Study setting: Nine primary care physician practices in Montreal, Canada (2002-2005). 
 
Study design: A validation study was carried out to compare diagnoses in 3,526 
physician billing claims to diagnoses documented in the corresponding patient medical 
records. 
 
Data collection: In-office medical record abstraction. 
 
Principal findings: Claims had a high PPV, NPV, and specificity for identifying respiratory 
infections; however, their sensitivity was below 50%. Large variation in sensitivity and 
PPV was observed among physicians. 
 
Conclusions: Because claims data are now routinely used to monitor antibiotic 
prescribing in primary care, future research should determine if acute respiratory 
infections diagnoses are missing from claims at random, or if bias is present. 
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Introduction 
 
Several randomized, placebo-controlled trials of antibiotic use have shown that 
antibiotics do not provide clinical benefit to children or adults with upper respiratory 
tract infections (97-103), and fail to prevent complicated bacterial infections (104;105). 
Yet 75% of oral antibiotics prescribed to ambulatory patients are for pharyngitis, otitis 
media, sinusitis, bronchitis, common cold, and unspecified upper respiratory tract 
infection of likely viral etiology (106), and 22-49% are estimated to be unnecessary 
(107;108). Inappropriate use of antibiotics for respiratory infections promotes antibiotic 
resistance (109-111), increases health services utilization and costs (112), and increases 
the risk of preventable drug-related adverse events (113). To enable the development of 
effective interventions to reduce inappropriate antibiotic use in primary care, 
determinants of inappropriate antibiotic prescribing and accurate methods for 
monitoring antibiotic use need to be identified. 
 
Monitoring antibiotic prescribing in primary care is challenging because well developed 
measures of antibiotic prescribing are scarce, often inaccurate, and may not reflect real 
prescribing practices. Studies of antibiotic prescribing in primary care have relied on 
physician self-reported prescribing (114-116), chart review or audit (117-119), or 
prescription claims (107;108;120-124). Self-reported antibiotic prescribing was shown to 
underestimate actual antibiotic prescribing by about 30% (117) and the cost of chart 
review is too high for wide scale use. Prescription claims data avoid self-report bias, do 
not require additional data collection, and because they involve financial transactions, 
prescription claims are carefully audited by payers and have been found to be highly 
accurate (125). Due to these advantages, prescription claims are now used routinely to 
monitor antibiotic prescribing for respiratory infections in primary care (107;108;120-
124;126). 
 
  
66 
 
However, an important limitation of using prescription claims to monitor antibiotic 
prescribing is that treatment indication is not recorded on prescription claims. 
Treatment indication is required to determine the appropriateness of antibiotic 
prescribing; therefore it must be inferred from other sources of information, such as 
physician billing claims for patient visits. If prescription claims are to be used to monitor 
antibiotic prescribing, then the accuracy of using diagnostic information in physician 
billing claims to infer the indication for antibiotic treatment needs to be assessed. 
 
Two previous studies have assessed the accuracy of physician billing claims for 
identifying respiratory infection diagnoses, and both have shown promising results. The 
first was a study of administrative claims data from 7 health insurance providers in 
Colorado, and it found that 79% of bronchitis diagnoses and 83% of pharyngitis 
diagnoses in administrative claims had a corresponding diagnosis in the written medical 
record (PPV) (127). However, this study did not investigate what proportion of bronchitis 
and pharyngitis diagnoses documented in patient medical records were accurately 
documented in physician billing claims (sensitivity and specificity). The second study 
assessed the accuracy of Research Patient Data Repository (RPDR) claims from 9 primary 
care clinics in the Brigham and Women’s Primary Care Practice-Based Research Network 
in Boston, and reported that 86% of respiratory infection diagnoses in RPDR claims had a 
corresponding diagnosis in the electronic health record (128). However, sensitivity and 
specificity estimates were not corrected for the verification bias introduced by over-
sampling claims with a diagnosis of respiratory infection relative to claims without such 
a diagnosis (i.e., the study design inflated the prevalence of respiratory infection in the 
sample, relative to the true population prevalence) (69;70). 
 
The objective of this study was to assess the accuracy of physician billing claims for 
identifying episodes of acute respiratory infection in primary care. In particular, we 
sought to estimate the sensitivity, specificity, positive predictive value (PPV), and 
negative predictive value (NPV) of physician billing claims.  
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Methods 
 
Study design and population 
 
A validation study was carried out to assess the sensitivity, specificity, positive predictive 
value, and negative predictive value of physician billing claims for identifying episodes of 
respiratory infection, as compared to the patient medical record. The study population 
was comprised of 34 Montreal-region family physicians and 17,002 of their patients who 
were participating in the MOXXI electronic medication management trial (129) in 2002-
2005. All patients participating in the MOXXI trial had previously consented to share 
their medical records and provincial health insurance (RAMQ) data with researchers. 
These data were available for a period starting 1 year prior to patient enrolment date 
(2001 or later) until 2005, when the present study was conducted. From the available 
physician billing claims, we identified those with a diagnostic code (International 
Classification of Disease, 9th Revision, or ICD-9) for laryngitis/tracheitis (464), common 
cold (460), influenza (480, 487), acute unspecified upper respiratory infection (465), 
pharyngitis/tonsillitis (462, 463, 034), otitis media (381, 382), sinusitis (461), acute 
bronchitis (466), or bacterial pneumonia (481-486) (all decimal place suffixes of these 
ICD-9 codes were included). We purposefully selected 10 physicians who had been 
enrolled in the MOXXI trial for at least 2 years and had the most MOXXI-consenting 
patients (and therefore also had the most physician billing claims available for research 
purposes), and requested their consent. 
 
Sample of physician billing claims 
 
Among the 10 physicians selected, we identified all MOXXI-consenting patients who had 
at least one physician billing claim with a diagnosis of acute respiratory infection during 
the study period, and randomly sampled 635 of those patients. We also identified all 
patients without any physician billing claim with a diagnosis of acute respiratory 
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infection during the study period, and randomly sampled 94 of those patients. To 
improve the efficiency of data collection, we over-sampled patients with at least one 
diagnosis of acute respiratory infection, relative to those with no diagnosis of acute 
respiratory infection (69;70). For each of the 729 patients sampled, we identified all 
physician billing claims generated during the study period (i.e., from 2001 or later, 
depending on enrolment date, until 2005) and validated each one against the paper-
based patient medical record. Information available in the physician billing claims 
included the patient’s lifelong RAMQ personal identifier, physician license number, visit 
date, and ICD-9 diagnostic code. 
 
Medical record abstraction 
 
Once the physician billing claims had been sampled, a list of sampled patients’ names 
and RAMQ personal identifiers was generated and faxed to each consenting physician’s 
office. The selected patients’ paper-based medical records were retrieved by office staff, 
and reviewed by one of the authors (GC). For each sampled physician billing claim, the 
corresponding visit was identified in the medical record, the date of the visit was 
recorded, and the presence or absence of all acute respiratory infections under study 
was ascertained from the clinical notes. At the time of the medical record abstraction, 
the reviewer was blinded to the ICD-9 code in the corresponding physician billing claim. 
Information abstracted from patient medical records was entered directly in an 
electronic, structured chart abstraction form and stored in a MS Access database, which 
had been pre-populated with participating physicians’ license numbers, sampled 
patients’ RAMQ identifiers, and visit dates according to physician billing claims. Intra-
rater reliability was measured on 25 randomly selected visits that were reviewed a 
second time, and the percent agreement between the first and second review was 
100%. 
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Linkage of physician billing claims and data abstracted from medical records 
 
Data retrieved from patient medical records were linked directly to physician billing 
claims using the patient’s lifelong RAMQ personal identifier, physician license number, 
and visit date +/- one day.  
 
Analyses 
 
For each type of acute respiratory infection under study, a 2x2 table of diagnoses 
abstracted from patient medical records versus diagnoses obtained from the 
corresponding physician billing claims was generated using SAS statistical software 
(Version 9.3, SAS Institute Inc., Cary, NC). Information retrieved from the patient medical 
record was treated as a gold standard. The prevalence, PPV, and NPV of physician billing 
claims for identifying acute respiratory infections were estimated. Sensitivity and 
specificity estimates were corrected for the over-sampling of claims with a diagnosis of 
acute respiratory infection relative to claims without such a diagnosis (69) using MS 
Excel 2003 (Version 5.1). To investigate between-physician variation in physician billing 
claim diagnosis accuracy, these analyses were repeated for each physician individually, 
combining all 9 types of acute respiratory infection under study (because each physician 
contributed too few of each type of acute respiratory infection to analyze each type 
individually). 
 
Because we sampled several claims (and medical record visits) per patient, we 
conducted a sensitivity analysis to assess the effect of clustering of claims within 
patients on our estimates of sensitivity, specificity, PPV, and NPV. We did this by 
generating 100 random samples of 1 claim per patient (n= 729 claims) from our total 
sample of 3,526 claims, and averaging the estimates of sensitivity, specificity, PPV, and 
NPV over all 100 random samples, which is similar to bootstrapping methodology (130). 
 
70 
 
Results 
 
Ten physicians participating in the MOXXI trial were purposefully selected for this study, 
and 9 agreed to participate. Among these 9 physicians’ patients enrolled in the MOXXI 
trial, we randomly selected 635 patients who had at least one claim with a diagnosis of 
acute respiratory infection, and 94 patients without any claims with a diagnosis of acute 
respiratory infection. These 729 patients made 3,526 visits to their respective MOXXI 
physician during the study period (duration of 1-5 years, depending on the date of 
enrolment), for an average of 4.8 visits per patient. The medical records of all 729 
sampled patients were abstracted, and written documentation for each of the 3,526 
visits identified from physician billing claims was found in the corresponding patient’s 
medical record. In all, 1,173 (33.3%) of sampled claims were positive for respiratory 
infection. Sixty-six percent of sampled patients were women, and the mean age of 
sampled patients was 47.6 (SD 21.0, range <1 to 90 years). The characteristics of 
patients enrolled in the MOXXI trial, as compared to those of the general population, 
have been discussed previously (131). 
 
The agreement between the diagnosis in the medical record and the ICD-9 code in the 
physician billing claim is shown in Table 1, where shaded areas indicate concordant 
diagnoses. For example, there were 63 physician billing claims with a diagnosis of 
laryngitis, and for all 63 claims, a diagnosis of laryngitis was also documented in the 
medical record at the corresponding date; however an additional 16 diagnoses of 
laryngitis were documented in medical records that were not documented in physician 
billing claims. The overall percent agreement for the presence of any acute respiratory 
infection was 72.5%, which is the sum of all diagnoses of respiratory infection present in 
the physician billing claim and the corresponding medical record (969) divided by the 
sum of all diagnoses of respiratory infection documented in medical records (1,337). 
The proportion of physician billing claims with a diagnosis of acute respiratory infection 
confirmed in the patient medical record (PPV) was 0.93, 95% CI (0.91, 0.94) for all acute 
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respiratory infection combined, and 0.84, 95% CI (0.81, 0.88) for respiratory infections of 
likely viral etiology (Table 2). The PPV for acute respiratory infections of potentially 
bacterial etiology was 0.89, 95% CI (0.87, 0.92), and ranged from 0.72, 95% CI (0.67, 
0.78) for acute bronchitis to 0.91, 95% CI (0.85, 0.97) for bacterial pneumonia. Sensitivity 
of physician billing claims for all acute respiratory infections combined was 0.49, 95% CI 
(0.45, 0.53). With the exception of influenza, sensitivity was markedly lower for viral 
respiratory infections than for bacterial ones. Specificity was 0.99 or higher for all types 
of acute respiratory infection studied. 
 
The prevalence of acute respiratory infection diagnoses in physician billing claims varied 
between physicians from 19.5 to 111.4 per 1,000 claims (Table 3). Sensitivity and PPV 
varied between physicians from 1.00, 95% CI (1.00, 1.00) to 0.19, 95% CI (0.06, 0.47), 
and from 0.98, 95% CI (0.96, 1.00) to 0.70, 95% CI (0.53, 0.87), respectively. The accuracy 
of physician billing claims for identifying acute respiratory infections did not appear to 
be higher among physicians who diagnosed more acute respiratory infections. 
Our sensitivity analysis using only 1 claim per patient yielded estimates for sensitivity 
(0.55, 95% CI 0.45, 0.64), specificity (0.99, 95% CI 0.99, 1.00), PPV (0.93, 95% CI 0.90, 
0.96) and NPV (0.94, 95% CI 0.91, 0.97) that were similar to the estimates obtained 
when all visits were used. The confidence intervals from the sensitivity analysis are 
wider because the sample size is smaller: 729 claims (1 per patient) were used instead of 
all 3,526.  This shows that the effect of within-patient clustering of claims on sensitivity, 
specificity, PPV, and NPV estimates is small. 
 
Discussion 
 
The PPV of physician billing claims was high for all types of acute respiratory infection 
studied. Our study was the first to estimate the prevalence, sensitivity, and specificity of 
physician billing claims for identifying chart-documented acute respiratory infections in 
primary care. For all but one type of acute respiratory infection investigated, our 
72 
 
sensitivity estimates were below 0.50. Our study was also the first to look at between-
physician variation in physician billing claim diagnosis accuracy. We found that 
prevalence of respiratory infections in physician billing claims varied widely between 
primary care physicians. We also observed large unexplained between-physician 
variation in sensitivity and PPV of physician billing claims for identifying acute 
respiratory infections. 
 
If physician billing claims had many false-positive diagnoses of respiratory infection, they 
would not be a useful data source for monitoring antibiotic prescribing. Therefore, a 
high PPV, or a high likelihood that diagnoses of respiratory infection in physician billing 
claims are also present in the corresponding patient medical record, provides support 
for using health administrative data for monitoring antibiotic prescribing. For most of 
the acute respiratory infection diagnoses investigated, our estimates of PPV were similar 
to those previously reported in the literature (127;128). However, our PPV estimate for 
influenza (0.66, 95% CI 0.58, 0.74) was much higher than the 0.20 reported by Linder et 
al, but the latter was aberrantly low as compared to other PPV estimates in the same 
study (128). 
 
Previous studies have emphasized the high PPV of health administrative data for 
identifying episodes of respiratory infection, but have overlooked the importance of 
sensitivity (127;128). A high sensitivity is desirable because it suggests that the data 
capture a majority of visits for respiratory infections. A low sensitivity is problematic 
because it suggests that several visits for respiratory infections are not documented in 
health administrative data. Non-documentation of visits for respiratory infections may 
or may not be associated with antibiotic prescribing, which may result in bias when 
using health administrative data to monitor antibiotic prescribing.  
 
Our study estimated the sensitivity of physician billing claims for identifying acute 
respiratory infections. Our sensitivity estimates were below 0.50 for all types of acute 
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respiratory infection studied except acute bronchitis, which raises concerns about the 
potential for bias. Whereas one previous study estimated the sensitivity of claims for 
identifying respiratory infections (128), the authors did not correct their sensitivity 
estimate for the verification bias introduced by over-sampling claims with a diagnosis of 
acute respiratory infection relative to claims without such a diagnosis (69;70); 
consequently they greatly overestimated sensitivity. For example, if we had not 
corrected our estimates for verification bias, our estimate of the sensitivity of physician 
billing claims for identifying laryngitis would have been 0.80, as compared to the 
corrected sensitivity estimate of 0.20. 
 
We were first to investigate between-physician variation in physician billing claim 
diagnosis accuracy for acute respiratory infections. We found almost 6-fold variation 
between physicians in the prevalence of respiratory infection. We observed similar 
between-physician variation in the sensitivity and PPV of physician billing claims for 
identifying acute respiratory infection. We expected that claims submitted by physician 
who diagnosed more acute respiratory infections would be more accurate for identifying 
acute respiratory infections, but we found that neither frequency nor prevalence of 
acute respiratory infection seemed to be related to physician billing claim diagnosis 
accuracy. This finding suggests that other factors are likely responsible for the observed 
between-physician variation in physician billing claim diagnosis accuracy.  
 
A limitation of our study is that medical records may not represent a true gold standard 
for identifying acute respiratory infections diagnosed in primary care. The use of a single 
rater was also a limitation of our study, and systematic misclassification of acute 
respiratory infection diagnoses may have occurred as a result. Another limitation of our 
study was its small convenience sample of primary care physicians. Whereas physicians 
participating in the MOXXI trial are generally similar to other eligible physicians in the 
Montreal region, they tend to be younger than MOXXI non-participants. If physician 
billing claim diagnosis accuracy is related to physician age or practice experience, then 
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our study results may not be applicable to older or more-experienced physicians. Also, 
the MOXXI trial involves physicians practicing in urban and suburban areas, and our 
results may not be generalizable to physicians practicing in rural areas. Furthermore, 
patients enrolled in the MOXXI trial tend to differ from non-participating patients in that 
they are generally older, with more complex health status, and more visits to the MOXXI 
physician (131). Younger, healthier patients may be under-represented in our study 
sample. Future research should involve a large random sample of primary care physician 
from both urban and rural areas, and a stratified random sample of patients from each 
physician’s practice population.  
 
Because physician billing claims and prescription claims are now routinely used to 
monitor antibiotic prescribing for acute respiratory infections in primary care 
(107;108;120-124), it is important for future research to determine whether half of all 
acute respiratory infections diagnoses are missing from physician billing claims at 
random, or whether bias is present. If bias is present, future research should also focus 
on identifying determinants of physician billing claim diagnosis accuracy, so that 
appropriate corrections for the resulting bias can be developed and applied when 
physician billing claims are used to infer treatment indication for antibiotic prescribing. 
As suggested by the large between-physician variation observed in this study, physician 
characteristics may be associated with physician billing claim diagnosis accuracy. The 
effect of physician characteristics, as well as patient, encounter, practice, and billing 
characteristics, on physician billing claim diagnosis accuracy should be assessed in future 
research. 
  
75 
 
Table 1. Concordance of diagnoses in physician billing claims and patient medical records (shaded areas indicate concordance) 
 
  Number of visits in patient medical records 
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Laryngitis 63 0 0 0 0 0 0 0 0 0 63 
Common cold 1 66 1 0 2 0 0 0 0 4 74 
Influenza 2 1 85 7 1 1 6 6 5 15 129 
Unspecified acute upper respiratory infection 0 1 1 154 3 0 2 4 0 22 187 
Pharyngitis 2 1 1 2 93 1 1 0 0 6 107 
Otitis Media 0 0 0 5 1 116 1 0 1 8 132 
Sinusitis 1 1 1 0 0 0 138 3 0 9 153 
Acute bronchitis 6 3 1 11 3 3 15 173 9 15 239 
Pneumonia 0 0 0 0 0 0 2 2 81 4 89 
No respiratory infection 4 29 5 28 12 28 19 28 11 2,189 2,353 
Total 79 102 95 207 115 149 184 216 107 2,272 3,526 
 Uncorrected sensitivity* 0.80 0.65 0.89 0.74 0.81 0.78 0.75 0.80 0.76   
 
* The uncorrected sensitivity estimate is inflated due to the purposeful over-sampling of physician billing claims with a diagnosis of acute respiratory infection relative to claims without 
such a diagnosis (69;70). 
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Table 2. Sensitivity, specificity, and positive and negative predictive values of the RAMQ physician billing claims for identifying episodes of acute respiratory infection 
 
 RAMQ physician billing claims 
Prevalence per 1,000 
(95% CI) 
Sensitivity
1  
(95% CI) 
Specificity
1
  
(95% CI) 
PPV
2
 (95% CI) NPV
3
 (95% CI) 
All respiratory infections 67.3 (65.6, 69.0) 0.49 (0.45, 0.53) 0.99 (0.99, 1.00) 0.93  (0.91, 0.94) 0.93 (0.92, 0.94) 
All likely viral respiratory infections 16.4  (15.6, 17.3) 0.30 (0.26, 0.34) 1.00 (1.00, 1.00) 0.84 (0.81, 0.88) 0.97 (0.96, 0.97) 
Laryngitis / tracheitis 1.2  (0.9, 1.4) 0.20 (0.13, 0.30) 1.00 (1.00, 1.00) 1.00  (1.00, 1.00) 1.00  (0.99, 1.00) 
Common cold 1.4  (1.2, 1.7) 0.11 (0.08, 0.15) 1.00 (1.00, 1.00) 0.89  (0.82, 0.96) 0.99  (0.99, 0.99) 
Influenza 3.6  (3.2, 4.0) 0.45 (0.30, 0.60) 1.00 (1.00, 1.00) 0.66  (0.58, 0.74) 1.00  (1.00, 1.00) 
Unspecified acute upper 
respiratory infection 
10.2  (9.6, 10.9) 0.35 (0.29, 0.42) 1.00 (1.00, 1.00) 0.82  (0.77, 0.88) 0.98  (0.98, 0.99) 
All potentially bacterial respiratory 
infections 
50.9  (49.4, 52.3) 0.51 (0.47, 0.56) 0.99 (0.99, 0.99) 0.89  (0.87, 0.92) 0.95  (0.95, 0.96) 
Pharyngitis / tonsilitis 5.3 (4.9, 5.8) 0.42 (0.32, 0.53) 1.00 (1.00, 1.00) 0.87  (0.81, 0.93) 0.99  (0.99, 1.00) 
Otitis Media 8.6 (7.9, 9.2) 0.44 (0.35, 0.53) 1.00 (1.00, 1.00) 0.88  (0.82, 0.93) 0.99  (0.99, 0.99) 
Sinusitis 12.5 (11.7, 13.2) 0.46 (0.38, 0.53) 1.00 (1.00, 1.00) 0.90  (0.85, 0.95) 0.99  (0.98, 0.99) 
Acute bronchitis 19.5 (18.6, 20.4) 0.52 (0.46, 0.59) 0.99 (0.99, 0.99) 0.72  (0.67, 0.78) 0.99 (0.98, 0.99) 
Pneumonia 5.0 (4.5, 5.5) 0.38 (0.28, 0.47) 1.00 (1.00, 1.00) 0.91  (0.85, 0.97) 0.99 (0.99, 1.00) 
 
1 
Adjusted for over-sampling of physician billing claims with a diagnosis of acute respiratory infection relative to claims without such a diagnosis (69;70). 
2 
Positive predictive value. 
3 
Negative predictive value. 
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Table 3. Sensitivity, specificity, and positive and negative predictive values of the RAMQ physician billing claims database for identifying all acute respiratory infections 
combined, by study physician 
 
 RAMQ physician billing claims 
Study 
physician 
No. claims 
with a 
diagnosis of 
acute RI
1
 
No. 
claims 
Prevalence per 1,000  
(95% CI) 
Sensitivity
2  
(95% CI) 
Specificity
2
  
(95% CI) 
PPV
3
 (95% CI) NPV
4
 (95% CI) 
1 1,324 16,264 81.4 (77.1, 85.6) 0.85 (0.78, 0.91) 1.00 (0.99, 1.00) 0.96 (0.94, 0.98) 0.99 (0.98, 1.00) 
2 2,041 18,319 111.4 (106.9, 116.0) 0.39 (0.33, 0.44) 0.98 (0.98, 0.99) 0.89 (0.86, 0.92) 0.82 (0.78, 0.86) 
3 522 4,815 108.4 (99.6, 117.2) 0.42 (0.35, 0.49) 1.00 (0.99, 1.00) 0.97 (0.95, 1.00) 0.84 (0.80, 0.88) 
4 356 9,614 37.0 (33.3, 40.8) 0.34 (0.24, 0.47) 1.00 (1.00, 1.00) 0.98 (0.96, 1.00) 0.93 (0.90, 0.96) 
5 163 5,553 29.4 (24.9, 33.8) 0.37 (0.22, 0.56) 1.00 (0.99, 1.00) 0.89 (0.81, 0.97) 0.95 (0.92, 0.99) 
6 159 6,905 23.0 (19.5, 26.6) 0.57 (0.16, 0.90) 0.99 (0.99, 1.00) 0.77 (0.64, 0.90) 0.99 (0.98, 1.00) 
7 752 6,754 111.3 (103.8, 118.8) 0.72 (0.45, 0.89) 0.98 (0.96, 1.00) 0.82 (0.66, 0.98) 0.96 (0.92, 1.00) 
8 94 4,815 19.5 (15.6, 23.4) 1.00 (1.00, 1.00) 0.99 (0.99, 1.00) 0.70 (0.53, 0.87) 1.00 (1.00, 1.00) 
9 365 18,319 19.9 (17.9, 21.9) 0.19 (0.06, 0.47) 1.00 (0.99, 1.00) 0.97 (0.95, 1.00) 0.92 (0.84, 1.00) 
 
1 
RI: respiratory infection. 
2 
Adjusted for over-sampling of respiratory infections relative to other diagnoses (69;70). 
3 
Positive predictive value. 
4 
Negative predictive value. 
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Figure 1. Diagnoses from the sampled physician billing claims and corresponding patient medical records 
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729 patients 
made 3,526 visits 
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Chapter 5. Assessing the accuracy of syndrome definitions based on diagnoses in 
physician claims 
 
Preamble to Manuscript 2 
 
Findings from manuscript 1 provided encouraging preliminary evidence that ICD-9 coded 
diagnoses in RAMQ physician claims could be used to identify episodes of acute 
respiratory infection. These results also pointed to the presence of considerable 
variation between physicians in the accuracy of diagnostic coding and in the prevalence 
of acute respiratory infections. Previous validations of syndrome definitions based on 
ICD-9 coded diagnoses in administrative data were based on small convenience samples 
of one or a few healthcare sites (50;61-63;65); therefore their results likely did not 
reflect the true breath of syndrome prevalence and diagnostic coding accuracy. 
Therefore, a large representative sample of healthcare sites was needed to generate 
unbiased estimates of the accuracy of syndrome definitions based on diagnoses in 
administrative data.  
  
Previous studies of the accuracy of syndrome definitions based on diagnoses in 
administrative data focused exclusively on diagnoses from emergency departments 
(50;61-65). However, community-based clinics (as a group) offer broader population 
coverage and treat a larger volume of patients than emergency departments. Also, two 
studies suggested that diagnoses from community healthcare settings could detect 
seasonal influenza earlier than those from emergency departments (43;44). 
 
The purpose of the research described in manuscript 2 was to perform a large-scale, 
population-based validation of several syndrome definitions based on diagnoses in 
RAMQ physician claims from community healthcare settings. A province-wide random 
sample of physicians likely to provide first-contact care was drawn, and the accuracy of 
syndrome definitions based on diagnoses in their claims was evaluated against 
information in the corresponding medical chart.  
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ABSTRACT 
 
BACKGROUND: Community clinics offer potential for timelier outbreak detection and 
monitoring than emergency departments. However, the accuracy of syndrome 
definitions used in surveillance has never been evaluated in community settings. This 
study’s objective was to assess the accuracy of syndrome definitions based on diagnostic 
codes in physician claims for identifying 5 syndromes (fever, gastrointestinal, 
neurological, rash, and respiratory including influenza-like illness) in community clinics. 
METHODS: We selected a random sample of 3,600 community-based primary care 
physicians who practiced in the fee-for-service system in the province of Quebec, 
Canada in 2005-2007. We randomly selected 10 visits per physician from their claims, 
stratifying on syndrome type and presence, diagnosis, and month. Double-blinded chart 
reviews were conducted by telephone with consenting physicians to obtain information 
on patient diagnoses for each sampled visit. The sensitivity, specificity, and positive 
predictive value (PPV) of physician claims were estimated by comparison to chart 
review. 
RESULTS: 1,098 (30.5%) physicians completed the chart review. A chart entry on the 
date of the corresponding claim was found for 10,529 (95.9%) visits. The sensitivity of 
syndrome definitions based on diagnostic codes in physician claims was low, ranging 
from 0.11(fever) to 0.44 (respiratory), the specificity was high, and the PPV was 
moderate to high, ranging from 0.59 (fever) to 0.85 (respiratory). We found that rarely 
used diagnostic codes had a higher probability of being false-positive, and that more 
commonly used diagnostic codes had a higher PPV. 
CONCLUSIONS: Future research should identify physician, patient, and encounter 
characteristics associated with the accuracy of diagnostic codes in physician claims. This 
would enable public health to improve syndromic surveillance, either by focusing on 
physician claims whose diagnostic code is more likely to be accurate, or by using all 
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physician claims and weighting each according to the likelihood that its diagnostic code 
is accurate.  
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INTRODUCTION 
 
Syndromic surveillance is used widely by public health departments to detect and 
monitor unusual disease activity in the population by extracting nonspecific clinical data 
from information systems in clinical settings (24;25;132;133). Whereas much syndromic 
surveillance practice (24) and research (134) has focused on visits to emergency 
departments (ED), visits to community clinics offer another promising source of data. 
Syndromes followed in practice, such as influenza-like-illness (ILI), typically involve 
earlier, milder stages of disease, and most affected persons are likely to self-treat 
(28;135;136), at least initially, or present to walk-in clinics (135).  In fact, researchers 
have demonstrated that excess ILI activity can be detected earlier using data from clinics 
as compared to data from EDs (137-139). The accuracy of data from community clinics 
has not, however, been established.  
 
Many syndromic surveillance systems use International Classification of Disease , 9th 
revision (ICD-9) diagnostic codes in administrative databases to monitor syndrome 
occurrence (140). For this purpose, expert panels have generated groupings of ICD-9 
codes corresponding to conceptual syndrome definitions (66). Administrative databases 
offer great promise for population-based surveillance by providing access to diagnostic 
information from many sites, including community healthcare settings. However, unlike 
medical procedure codes, ICD-9 diagnostic codes are not usually linked to healthcare 
provider payment, and therefore are not audited by health administrative authorities. 
Because of this, variation in diagnostic coding between physicians and between 
institutions is expected. 
 
In a pilot study (141), we evaluated the accuracy of diagnostic codes in physician claims 
for identifying acute respiratory infections in nine Montreal-area physicians. We 
abstracted the diagnosis from the medical chart for the 3,526 visits made by 729 
sampled patients in 2002-2005, and compared the medical chart diagnosis to the ICD-9 
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code on the corresponding physician claim. For all acute respiratory infections 
combined, we found a sensitivity of 0.49, 95% CI (0.45, 0.53), and a positive predictive 
value (PPV) of 0.93, 95% CI (0.91, 0.94). These pilot study results are promising, but 
there is a need for a large-scale, population-based investigation of the accuracy of 
diagnostic codes used in syndromic surveillance. 
 
The objective of the present study was to assess the accuracy of syndrome definitions 
based on diagnostic codes from a representative sample of physician claims for 
identifying 5 syndromes (fever, gastrointestinal, neurological, rash, and respiratory 
including influenza-like illness (ILI)) in community healthcare settings. These syndromes 
were selected for their relevance to public health and the likelihood of being first 
detected among patients presenting to community healthcare settings. 
 
METHODS 
 
Context 
This study was conducted in the province of Quebec, Canada, where universal health 
coverage is provided through the provincial health insurance plan. Each Canadian 
province maintains a population-based registry of insured persons and claims for all 
physician visits remunerated on a fee-for-service basis. Physician claims include 
information on the diagnosis (ICD-9 coded), medical procedure, visit date, location, and 
cost of service. All claims also record unique physician and patient identifiers that can be 
used to create longitudinal histories of healthcare use. In the province of Quebec, 99% 
of residents have provincial health insurance and 85-95% of medical visits are 
remunerated on a fee-for-service basis (88). In 2006, there were more than 7.6 million 
inhabitants in Quebec (89), and 18,908 active registered physicians (90). The availability 
of diagnostic information for nearly all medical visits to Quebec physicians represents an 
invaluable opportunity for assessing the validity of using diagnostic codes in physician 
claims for population-based surveillance, including syndromic surveillance. 
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Study design and sampling 
The accuracy of diagnostic codes in physician claims for identifying syndromes was 
assessed by comparison to clinical information in the corresponding medical chart. To 
ensure representativeness, we used a population-based, 3-stage stratified random 
sample of 36,000 visits (Figure 1). In the first stage (Figure 1, Stage 1), the provincial 
health insurance agency identified all physicians who were eligible to be included in our 
study. To be eligible, physicians had to be a general practitioner, pediatrician, internist, 
geriatrician or general surgeon who practiced in the fee-for-service system in a private 
clinic, community health center, or hospital-based ambulatory care clinic during the 2-
year study period (October 1, 2005 to September 30, 2007). Internists and general 
surgeons were included in our sample because, especially in rural-remote and 
underserved areas, these physicians may provide first-contact care and act as patients’ 
family physician. From the 8,700 eligible physicians identified, the provincial health 
insurance agency selected a random sample of 3,600 (41.4%) physicians.  
 
In the second stage (Figure 1, Stage 2), to facilitate chart retrieval for review, the health 
insurance agency randomly selected one eligible community practice location for each 
physician. The health insurance agency then sent the research team an anonymized file 
containing all physician claims billed by the 3,600 physicians from their respective 
selected community practice location during the 2-year study period (Figure 2, Step 1).  
 
In the third stage (Figure 1, Stage 3), the research team randomly selected 5 syndrome-
positive visits, i.e., 1 visit for each of fever, gastrointestinal, neurological, rash, and 
respiratory syndrome (including ILI ), and 5 visits negative for all syndromes. Visits were 
classified as positive for a syndrome if a physician claim for the visit had an ICD-9 code 
that was part of the syndrome definition. Because syndromes have low population 
prevalence, to maximize data collection efficiency (70), syndrome-positive visits were 
over-sampled relative to syndrome-negative ones, so as to yield 1 syndrome-positive 
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visit per syndrome per physician and 5 syndrome-negative visits per physician.  When 
sampling syndrome-positive claims, to maximize the number of syndrome-positive ICD-9 
codes verified, we further stratified on ICD-9 code. Because two or more syndromes can 
occur concurrently in the same patient (61), syndrome-negative visits were negative for 
all syndromes. Syndrome-negative visits were also matched to syndrome-positive visits 
on calendar month to avoid bias due to syndrome seasonality. To avoid bias due to visits 
being clustered within patients, restriction was used to ensure that each patient was 
only sampled once. The list of 10 sampled visits was enumerated for each of the 3,600 
physicians, for a total of 36,000 visits. An anonymized unique identifier, the study 
number, was assigned to each sampled visit by the research team. The list of 36,000 
sampled visits was then sent to the health insurance agency (Figure 2, Step 2). 
 
Syndrome definitions 
We verified two sets of definitions for the 5 syndromes under study: the definitions 
developed and published by the US Centers for Disease Control and Prevention (CDC) in 
2003 (66), and used by the US Department of Defense’s (DoD) Electronic Surveillance 
System for Early Notification of Community-based Epidemics (ESSENCE), as well as the 
corresponding definitions in the University of Pittsburgh’s Real-time Outbreak and 
Disease Surveillance (RODS) system (61). For ILI, we used the large-group (sensitive) and 
small-group (specific) definitions developed for the DoD ESSENCE system (49). These 
definitions are similar to the consensus syndrome definitions being developed by 
representatives from the 10 syndromic surveillance systems in place in the US (142), 
which have not yet been mapped to ICD-9 codes. 
 
Physician recruitment 
To preserve physician and patient anonymity, the health insurance agency sent the list 
of 3,600 physicians and 36,000 visits sampled by the research team to the medical 
regulatory authority (Figure 2, Step 3). The medical regulatory authority has the legal 
right to access confidential physician and patient information, therefore the list it 
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received included physician names and mailing addresses, as well as patient names, 
insurance numbers, and dates of birth. The medical regulatory authority acted as a 
trusted third party and recruited physicians to the study on behalf of the research team; 
it also provided physicians with information on the 10 sampled visits (Figure 2, Step 4). 
Interested physicians mailed their written consent and contact information to the 
research team (Figure 2, Step 5). Non-responding physicians were sent up to five 
reminders. Physician recruitment began in September 2008 and ended in August 2009. 
To maximize participation, physicians were offered $50 compensation for their 
participation and a summary of study findings. 
 
Physician-facilitated medical chart review 
The medical regulatory authority sent each physician the list of 10 sampled visits (Figure 
2, Step 3). Lists sent to physicians included patients’ first and last names, date of birth, 
health insurance number, and date of the visit to be verified, as well as the study 
number for each visit. Because the lists sent to physicians contained both patient 
information and study numbers, it enabled physicians to retrieve the relevant medical 
charts, and researchers to link the information collected through chart review to the 
anonymized physician claims file. During the chart review, interviewers and physicians 
referred to each visit using only the study number and visit date, thereby preserving 
patient anonymity. 
 
Physician-facilitated medical chart reviews began in September 2008 and ended in 
December 2009. Using a previously published methodology (95), trained interviewers 
contacted consenting physicians by telephone to perform the chart review (Figure 2, 
Step 6). For each of the 10 sampled visits, the interviewer asked the physician to list all 
diagnoses. For each diagnosis corresponding to a syndrome definition, the interviewer 
asked the physician about the signs, symptoms, and key findings recorded in the medical 
chart, as well as the most likely etiology for the diagnosis (based solely on information 
available at the time of the visit).  
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Physician responses were entered directly into a database by the interviewer. Diagnoses 
were selected from a searchable list of diagnoses (mapped to ICD-9 codes) or, if the 
physician had recorded the ICD-9 code in the medical chart, the ICD-9 code was entered 
directly. For each syndrome-positive diagnosis, a list of syndrome-specific signs and 
symptoms was elicited, and the interviewer recorded whether the sign or symptom had 
been present, absent, or not recorded in the medical chart. Symptoms or signs not in the 
list and other key findings, such as epidemiologic links to other diagnosed cases or 
known outbreaks, were recorded as free text in separate fields. The data collection tool 
was translated to French for use with French-speaking physicians, and back-translated to 
English to ensure comparability of data collection.  
 
At the time of the chart review, the physician and the interviewer were both blinded to 
ICD-9 code in the physician claim and the syndrome-positive or syndrome-negative 
status of the claim. To minimize measurement error due to inter-rater differences, 
interviewers were trained to use the data collection tool. Inter-rater reliability was 
assessed at baseline by having interviewers perform 2 simulated physician interviews of 
10 visits each (for a total of 20 visits). To maintain data quality, interviewers underwent 
quality assurance monitoring every 3 months. Each assessment was comprised of 2 
simulated physician interviews of 10 visits each (for a total of 20 visits). Agreement 
between raters was measured using the intraclass correlation coefficient (ICC). 
 
Linkage of the medical chart review data to the physician claims data 
The database containing the medical chart review data was linked to the physician 
claims file using the study number, physician identifier, and visit date. In our pilot study 
(141), we found that the visit date in the chart sometimes differed slightly from the visit 
date on the claim. We considered the chart and the claim to refer to the same visit if the 
visit date in the chart was within 0 (identical date) to 3 days from the visit date in the 
claim. 
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Physician characteristics that may influence participation 
Physician gender, preferred language, specialty, practice setting, and geographic 
location were obtained from the health insurance agency. Physician year of licensure 
was obtained from the medical regulatory authority. The number of days worked per 
year was calculated as the number of days when at least one claim was submitted by the 
physician to the health insurance agency. The number of patients seen per day worked 
was calculated as the number of distinct patients for which one or more claim was 
submitted by the physician per day worked. The number and prevalence of syndrome-
positive visits were calculated for each physician using claims generated from the 
selected practice location during the 2-year study period. 
 
Statistical methods 
For each visit, we assessed if the ICD-9 code in the physician claim and the diagnosis in 
the corresponding medical chart agreed as to the presence of each of the 5 syndromes 
and ILI. For example, if the diagnosis in the claim was cough (786.2) and the diagnosis in 
the corresponding medical chart was acute bronchitis (466.0), then both the claim 
diagnosis and the chart diagnosis were positive for respiratory syndrome, therefore the 
claim was a true-positive for respiratory syndrome. If the diagnosis in the claim was 
cough (786.2) and the diagnoses in the chart were hypertension (401.9) and diabetes 
(250.0), then the claim diagnosis was positive for respiratory syndrome and the chart 
diagnoses were not, therefore the claim was a false-positive for respiratory syndrome. 
 
The negative predictive value (NPV) of a syndrome definition was estimated directly 
from the data for each of the 5 syndromes and ILI. Because we stratified syndrome-
positive visits by ICD-9 code, we had to use an adjustment based on Bayes Theorem (69) 
to estimate the PPV of each syndrome. The PPV was estimated as a weighted average of 
each ICD-9 code’s PPV, the weight being the number of visits with a given ICD-9 code 
divided by the total number of visits positive for that syndrome among participating 
physicians.  
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Because we verified more syndrome-positive visits than syndrome-negative ones, direct 
estimation of physician claims sensitivity and specificity using our data would lead to 
verification bias: sensitivity would be overestimated, and specificity underestimated 
(69). Because verified claims were randomly sampled within syndrome-positive and 
syndrome-negative strata, unbiased estimation of these parameters was achieved by re-
weighting for the verification fractions (69). The sensitivity and specificity of physician 
claims for identifying each syndrome was estimated from the PPV and NPV (96) using 
the correction for verification bias (69), re-weighting for the different sampling fractions. 
We estimated the 95% CI for the bias-corrected sensitivity and specificity using the 
methods described by Begg and Greenes (69). 
 
Ethics review 
The research protocol for this study was reviewed and approved by the McGill University 
Institutional Review Board, the Quebec privacy commission, the Quebec health 
insurance agency, and the Quebec medical regulatory authority. 
 
RESULTS 
 
Between October 1, 2005 and September 30, 2007, the 3,600 study physicians billed for 
over 20 million visits by 4.8 million patients (61% of the province’s population) from 
their randomly selected community practice.  
 
Physician participation 
Of 3,600 physicians contacted, 172 (4.8%) had an incorrect address on file with the 
health insurance agency, and 170 (4.7%) were discovered to be ineligible (recently 
deceased, retired, on sick/maternity leave, no longer practicing at the selected practice 
location). Of the 3,258 remaining physicians, 1,129 (34.7%) physicians consented to 
participate in the study, 218 (6.7%) refused, and 1,911 (58.7%) did not respond. Of the 
1,129 consenting physicians, 1,098 (97.3%) completed the physician-facilitated medical 
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chart review, and 31 (2.7%) were unreachable or withdrew consent prior to interview. 
Participating and non-participating physicians were similar on all measured variables 
except two (Table 1): as compared to non-participants, participants had been in practice 
longer and had worked more days during the study period. Syndrome prevalence was 
similar among participating and non-participating physicians, and ranged from 5 per 
1,000 visits for neurological syndrome and ILI small-group, to 126 per 1,000 visits for 
respiratory syndrome.  
 
Inter-rater agreement 
Agreement between raters was measured using simulated physician interviews shortly 
before the start of data collection and every 3 months thereafter. Agreement was 
perfect on all assessments (ICC=1.00). 
 
Date agreement between the claim and the medical chart  
Of the 10,980 visits selected for verification (10 visits per participating physician), 
physicians were able to access the corresponding medical chart for 10,669 (97.2%). The 
most common reasons for being unable to access the chart were inability to locate the 
medical chart (151 charts) and medical chart in storage with retrieval fee (140 charts). 
For 10,465 (98.1%) of the sampled visits, the visit date in the medical chart was identical 
to the visit date on the claim. Allowing for potential date transcription errors during 
billing, an additional 64 (0.6%) visits that had a date in the medical chart that was within 
1-3 days of the visit date on the claim were identified, for a total of 10,529 visits for 
which both the medical chart and the claim was available and the visit dates were in 
agreement (within the 3 day time window). 
 
Syndrome agreement between the claim ICD-9 code and the medical chart diagnosis 
Table 2 shows the accuracy of ICD-9 codes in physician claims for identifying syndromes, 
as compared to the medical chart. The sensitivity of ICD-9 codes in physician claims for 
identifying syndromes was low, ranging from 0.11, 95% CI (0.10, 0.13) for fever 
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syndrome to 0.44, 95% CI (0.41, 0.47) for respiratory syndrome. The PPV of ICD-9 codes 
in physician claims for identifying syndromes was moderate to high, ranging from 0.59, 
95% CI (0.55, 0.64) for fever syndrome to 0.85, 95% CI (0.83, 0.88) for respiratory 
syndrome. Both the specificity and NPV of ICD-9 codes in physician claims were near-
perfect for all syndromes studied. 
 
The additional file (excerpted in Table 3) shows the PPV of physician claims for 
identifying syndromes for each verified ICD-9 code individually. There was wide variation 
in PPV between different ICD-9 codes in a given syndrome. ICD-9 codes that were very 
rarely used by physicians, for example tularemia (ICD-9 code: 21.9), had a high 
probability of being false-positive, and therefore a very low PPV. ICD-9 codes that 
represent a common symptom, for example fever (ICD-9 code: 780.6), had a lower 
probability of being false-positive, and a higher PPV. ICD-9 codes that represent a 
common diagnosis, for example acute bronchitis (ICD-9 code: 466.0), had the lowest 
probability of being a false-positive, and the highest PPV. 
 
DISCUSSION 
 
This study was the first large-scale, population-based investigation of the accuracy of 
syndrome definitions based on diagnostic codes in physician claims from community 
healthcare settings. We found that the sensitivity of syndrome definitions based on 
diagnostic codes in physician claims for identifying syndromes was low, the PPV was 
moderate to high, and the specificity and NPV were near-perfect. Even though our 
sensitivity estimates were low for all syndromes definitions, these syndrome definitions 
may still be useful for monitoring syndrome occurrence when there are large numbers 
of cases (e.g., seasonal influenza). Respiratory syndrome had the highest prevalence and 
was the most accurately reported in physician claims. Unexpectedly, ILI small-group had 
the lowest PPV of all syndromes definitions studied, much lower than previously 
reported by others (49). The small-group definition of ILI is made up of only four ICD-9 
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codes: influenza with pneumonia (487.0), influenza with other respiratory 
manifestations (487.1), influenza with other manifestations (487.8), and acute upper 
respiratory infection, other multiple sites (465.8). Based on our interviews of over a 
thousand community physicians, we think that the poor accuracy of the ILI small-group 
definition reflects the common usage of the word ‘flu’ to describe a vague illness or a 
combination of non-specific symptoms. In addition to observing variation in physician 
claim accuracy between syndromes, we also found large variation in accuracy and 
prevalence between diagnostic codes within syndromes. Diagnostic codes with a very 
low prevalence were generally more likely to be false-positive; conversely, diagnostic 
codes with a higher prevalence were generally less likely to be false-positive, especially if 
they represented a diagnosis, as opposed to a symptom. This suggests that physicians 
are more likely to know the correct diagnostic code for a frequently diagnosed ailment, 
as compared to a rare one.  
 
Rigorous attempts to assess the accuracy of ICD-9 codes used in syndromic surveillance 
as compared to the medical chart have been few, and they have relied on small 
convenience samples of emergency departments. In one such study, the accuracy of 
ICD-9 codes in ED reports for identifying 3 syndromes (fever, gastrointestinal, and 
respiratory) was assessed as compared to hospital chart diagnoses in the context of the 
US DoD ESSENCE surveillance system (65). For greater data collection efficiency, 
syndrome-positive ED reports were over-sampled relative to syndrome-negative ones; 
however, analyses were not adjusted for this differential sampling strategy, resulting in 
verification bias (69), and leading to a large overestimation of sensitivity and 
underestimation of specificity. To illustrate, the proportion of fever-positive visits in the 
sample was 0.19, whereas the proportion of fever-positive visits in the population is 
approximately 0.01 (based on our study). The authors reported sensitivity of 0.69 and 
specificity of 0.95. However, adjusting for verification bias, the estimates would be 
approximately 0.09 for sensitivity and 1.00 for specificity, which is similar to our results. 
In another study, the accuracy of ICD-9 codes in ED reports for identifying 7 syndrome 
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definitions (botulinic, constitutional, gastrointestinal, hemorrhagic, neurological, rash, 
and respiratory) was assessed against hospital chart diagnoses in the context of the 
RODS surveillance system (61). To maximize the quantity of syndrome-positive ICD-9 
codes verified, the investigators selected a random sample of syndrome-positive visits 
from ED reports, stratified on syndrome-positive ICD-9 code, such that an equal number 
of syndrome-positive visits was sampled for each ICD-9 code in a syndrome. For 
example, fever (780.6) and bubonic plague (020.0), both corresponding to constitutional 
syndrome, contributed the same number of cases. However, the prevalence and 
accuracy of each ICD-9 code in a syndrome is different, and because the analyses were 
not adjusted for the uniform sampling strategy used, the reported estimates of 
sensitivity, specificity, PPV and NPV are biased. In a third study (62), the accuracy of ICD-
9 coded physician diagnoses from 9 hospital EDs for identifying ‘acute respiratory illness’ 
was assessed by comparison to medical chart review. A simple random sample was 
used; therefore the results were not subject to verification bias. The authors reported a 
sensitivity of 0.43, 95% CI (0.28-0.58) , which is almost identical to our sensitivity 
estimate for respiratory syndrome; their estimates of NPV and specificity were also 
similar to ours, but their PPV estimate of 0.45, 95% CI (0.29-0.61) is much lower than 
ours. 
 
Our study had several strengths and limitations. We used a large population-based 
random sample of all physicians working in the fee-for-service system in community 
healthcare settings in the province of Quebec in 2005-2007, thereby capturing potential 
ICD-9 coding differences between physicians, institutions, and regions. Not only did we 
estimate the accuracy of syndrome definitions, as others have done, but our study 
design enabled us to estimate the PPV for individual diagnostic codes within each 
syndrome definition. Matching syndrome-negative visits to syndrome-positive visit on 
calendar month ensured that our results were not affected by seasonal bias. Because 
two or more syndromes can occur concurrently in the same person (61), our 
requirement that syndrome-negative visits be negative for all 5 syndromes and ILI 
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ensured that we did not overestimate false-negatives and underestimate sensitivity and 
NPV. Our participation rate, though low, was consistent with that of other large 
population-based studies of Canadian physicians (143;144). Participating and non-
participating physicians were similar on nearly all measured variables. The physician 
participation rate was significantly lower among recently licensed physicians than among 
their more experienced counterparts; recently licensed physicians may have been less 
likely to participate in our study because they tend to experience greater practice 
mobility (145) and report more impediments to practice (146) than their more 
experienced counterparts. Unfortunately, the accuracy of very rare syndrome-positive 
ICD-9 codes, such as cutaneous and pulmonary anthrax (22.0 and 22.1), could not be 
estimated because, as expected, they were not present in any of the 1,098 participating 
physicians’ claims during the 2-year study period.  
 
CONCLUSIONS 
 
We found that diagnostic codes in physician claims from community healthcare settings 
have low sensitivity, moderate to high PPV, and near-perfect specificity and NPV for 
identifying 5 syndromes (fever, gastrointestinal, neurological, rash, and respiratory 
including ILI). Future research should evaluate the practical implications of our findings 
on decision-making in response to alerts from existing syndromic surveillance systems. 
Future research should also identify physician, patient, and encounter characteristics 
associated with better accuracy of diagnostic codes in physician claims. This would 
enable public health to improve syndromic surveillance, either by focusing on physician 
claims whose diagnostic code is more likely to be accurate, or by using all physician 
claims and weighting each according to the likelihood that its diagnostic code is 
accurate. We also estimated the prevalence and PPV of individual diagnostic codes 
within each syndrome. We found that rarely used diagnostic codes had a higher 
probability of being false-positive, and that more commonly used diagnostic codes had a 
higher PPV. These findings may be useful to the ongoing development of sensitive and 
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specific consensus syndrome definitions, as either a sensitive or a specific definition may 
be more useful depending on the surveillance objective. 
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Table 1. Characteristics of participating and non-participating physicians (N=3,258 eligible physicians) 
 
 Participating physicians (N=1,098) Non-participating physicians (N=2,160) 
Physician characteristics No. (%) No. (%) 
Gender:     
  Female 411 37.4 823 38.1 
  Male 687 62.6 1,337 61.9 
Preferred language:     
  French 1,006 91.6 1,937 89.7 
  English 92 8.4 223 10.3 
Specialty:     
  General practice 993 90.4 1,932 89.4 
  Internal medicine 13 1.2 41 1.9 
  Pediatrics 62 5.6 102 4.7 
  General surgery 30 2.7 85 3.9 
  Geriatrics 0 0 0 0 
Type of setting selected:
1
     
  Private clinic 1,060 96.5 2,044 94.6 
  Community health center 5 0.5 9 0.4 
  Hospital-based  
  ambulatory clinic 33 3.0 107 5.0 
Geographic location of selected 
setting:
1,3
     
   Urban 921 83.9 1,867 86.4 
   Rural 177 16.1 293 13.6 
 Mean SD Mean SD 
Years since licensure 24.2 9.7 22.3 10.5 
No. days worked per year
1
 157.0 55.0 143.2 59.8 
No. patients seen per day 
worked
1
 21.2 13.4 21.0 13.3 
Syndrome frequency based 
on claim ICD-9 code 
No. visits
1,2
 Prevalence 
per 1,000 visits
1
 
No. visits
1,2
 Prevalence 
per 1,000 visits
1
 
CDC and DoD-GEIS ESSENCE     
  Fever 80,884 11 160,821 12 
  Gastrointestinal 162,282 22 309,209 24 
  Neurological 40,236 5 73,810 6 
  Rash 126,900 17 224,370 17 
  Respiratory 911,924 125 1,643,240 126 
RODS         
  Fever 162,000 22 291,990 22 
  Gastrointestinal 146,355 20 283,578 22 
  Neurological 36,344 5 67,344 5 
  Rash 55,251 8 103,698 8 
  Respiratory 478,201 65 877,556 67 
Influenza-like illness         
  Large-group 622,046 85 1,129,782 87 
  Small-group 32,173 4 61,127 5 
1
As per our study design, for each physician, a single practice location was randomly selected to facilitate the validation 
process. The information in this table is based on claims generated from the selected practice location during the 2-year 
study period.  
2 
There were a total of 7,315,994 visits to the 1,098 participating physicians, and 13,010,410 visits to the 2,160 eligible 
non-participating physicians at the selected practice location during the 2-year study period. 
3
 We tested the statistical significance (at the p<0.05 level) of any differences between participating and non-participating 
physicians using a multivariate logistic regression model where the dependent variable was participation and the 
independent variables were all characteristics in Table 1. Due to overlap between CDC, RODS, and ILI syndrome 
definitions, to avoid collinearity, we used separate models for each set of syndrome definitions. As compared to non-
participating physicians, participating physicians had been in practice longer (odds ratio (OR)per 10 years since licensure, 1.15; 95% 
CI, 1.05-1.25), and had worked more days (ORper 50 days, 1.18; 95% CI, 1.09-1.28) during the 2-year study period.   
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Table 2. Accuracy of ICD-9 coded diagnoses in physician claims, as compared to ICD-9 coded diagnoses from 
physician-facilitated medical chart review, for identifying constitutional, gastrointestinal, neurological, rash, and 
respiratory syndrome, as well as influenza-like illness (ILI) (N=10,529 visits with matched claim-record pair) 
 
Syndrome 
definition 
No.  
visits in 
verified 
claims 
No.  
visits in 
verified 
charts 
Sensitivity  
(95% CI) 
Specificity  
(95% CI) 
PPV  
(95% CI) 
NPV  
(95% CI) 
CDC and DoD-
GEIS ESSENCE 
      
  Fever 601 656 0.11 (0.10, 0.13) 0.99 (0.99, 0.99) 0.59 (0.55, 0.64) 0.94 (0.93, 0.95) 
  Gastrointestinal 855 888 0.23 (0.20, 0.26) 0.99 (0.99, 0.99) 0.71 (0.66, 0.75) 0.94 (0.94, 0.95) 
  Neurological 971 693 0.17 (0.14, 0.21) 1.00 (1.00, 1.00) 0.67 (0.64, 0.70) 0.98 (0.98, 0.98) 
  Rash 897 905 0.20 (0.18, 0.23) 0.99 (0.99, 0.99) 0.66 (0.62, 0.70) 0.95 (0.95, 0.96) 
  Respiratory 1,049 1,779 0.44 (0.41, 0.47) 0.97 (0.96, 0.98) 0.85 (0.83, 0.88) 0.84 (0.83, 0.85) 
RODS       
  Fever 873 961 0.14 (0.12, 0.16) 0.99 (0.99, 0.99) 0.60 (0.56, 0.64) 0.91 (0.90, 0.92) 
  Gastrointestinal 703 834 0.20 (0.18, 0.23) 0.99 (0.99, 0.99) 0.68 (0.63, 0.73) 0.94 (0.94, 0.95) 
  Neurological 874 523 0.16 (0.13, 0.20) 1.00 (1.00, 1.00) 0.52 (0.48, 0.55) 0.99 (0.98, 0.99) 
  Rash 814 718 0.12 (0.10, 0.14) 1.00 (1.00, 1.00) 0.63 (0.59, 0.66) 0.96 (0.96, 0.97) 
  Respiratory 665 1,209 0.29 (0.26, 0.32) 0.98 (0.98, 0.98) 0.74 (0.70, 0.79) 0.87 (0.86, 0.88) 
Influenza-like 
illness 
      
  Large-group 653 1,232 0.38 (0.35, 0.41) 0.98 (0.98, 0.98) 0.77 (0.73, 0.81) 0.88 (0.87, 0.89) 
  Small-group 53 49 0.18 (0.12, 0.26) 1.00 (1.00, 1.00) 0.29 (0.16, 0.41) 0.99 (0.99, 0.99) 
PPV: positive predictive value. NPV: negative predictive value.
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Table 3. Example of diagnostic codes with the highest and lowest positive predictive value (excerpted from the 
Appendix) 
 
 
Example of diagnostic codes with the HIGHEST positive predictive value (PPV) 
 
Syndrome definition ICD-9 code Diagnostic label PPV (95% CI) 
CDC fever 
82.8 Tick-borne rickettsiosis not elsewhere classified 1.00 (1.00, 1.00) 
88.8 Other specified arthropod-borne diseases 1.00 (1.00, 1.00) 
CDC gastrointestinal 
7.1 Giardiasis 1.00 (1.00, 1.00) 
5.9 Food poisoning not otherwise specified 1.00 (1.00, 1.00) 
CDC neurological 
323.0 Encephalitis in viral disease classified elsewhere 1.00 (1.00, 1.00) 
784.3 Aphasia 1.00 (1.00, 1.00) 
CDC rash 
53.8 Herpes zoster with unspecified complication 1.00 (1.00, 1.00) 
695.2 Erythema nodosum 1.00 (1.00, 1.00) 
CDC respiratory 
33.0 Bordetella pertussis 1.00 (1.00, 1.00) 
462.9 Pharyngitis, acute not otherwise specified 1.00 (1.00, 1.00) 
ILI large-group 
487.0 Influenza with pneumonia 1.00 (1.00, 1.00) 
486.0 Pneumonia, organism not otherwise specified 1.00 (1.00, 1.00) 
 
Example of diagnostic codes with the LOWEST positive predictive value (PPV) 
 
Syndrome definition ICD-9 code Diagnostic label PPV (95% CI) 
CDC fever 
88.0 Bartonellosis 0.00 (0.00, 0.00) 
78.2 Sweating fever 0.00 (0.00, 0.00) 
CDC gastrointestinal 
555.0 Regional enteritis, small intestine 0.00 (0.00, 0.00) 
1.1 Cholera  due to Vibrio cholerae El Tor 0.00 (0.00, 0.00) 
CDC neurological 
323.2 Encephalitis in protozoal disease classified elsewhere 0.00 (0.00, 0.00) 
53.0 Herpes zoster with meningitis 0.00 (0.00, 0.00) 
CDC rash 
51.0 Cowpox 0.00 (0.00, 0.00) 
55.8 Measles complications not otherwise specified 0.00 (0.00, 0.00) 
CDC respiratory 
20.4 Secondary pneumonic plague 0.00 (0.00, 0.00) 
79.8 Hantavirus infection 0.00 (0.00, 0.00) 
ILI large-group 
490.0 Bronchitis not otherwise specified 0.00 (0.00, 0.00) 
465.8 Acute upper respiratory infection, other multiple sites 0.36 (0.08, 0.65) 
 
  
 101 
 
 
 
Figure 1. Population-based, 3-stage stratified random sample of visits to all community physicians in the 
province of Quebec 
  
 
8,700 eligible physicians 
Stage 1: simple random sample of 3,600 
(41.4%) eligible physicians 
 
3,600 sampled physicians 
Stage 2: simple random sample of 1 
eligible practice location per physician 
 
3,600 physician practice locations 
Stage 3: random sample of 10 visits per 
physician practice location:  
 5 visits negative for all syndromes 
 1 visit positive for each of the 5 
syndromes (fever, gastrointestinal, 
neurological, rash, and respiratory 
including influenza-like illness). 
 For each syndrome, the sample of 
syndrome-positive visits was further 
stratified by ICD-9 code. 
Exclusion was used to ensure each patient 
was sampled only once. 
Syndrome-negative visits were frequency-
matched on month to syndrome positive 
visits to avoid seasonal bias. 
 
36,000 visits to be verified 
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Figure 2. Overview of data collection 
* Physician sampling by the Quebec health insurance agency is described in Figure 1, Stages 1 and 2. 
** Visit sampling by the research team is described in Figure 1, Stage 3. 
  
 
Quebec 
health 
insurance 
agency 
 
McGill 
University 
research 
team 
 
 Physicians in 
community 
clinics 
 
Quebec 
medical 
regulatory 
authority 
Step 1: Health insurance 
agency sends anonymized 
physician claims from 3,600 
randomly-sampled 
physicians* to research 
team 
Step 4: Medical regulatory 
authority recruits physicians 
to study, sends info on 10 
sampled visits to each 
physician 
Step 5: 
Physicians 
provide written 
consent to 
research team 
Step 6: 
Physician-
facilitated 
medical chart 
review 
Step 3: Health insurance 
agency sends info on 
3,600 physicians and 
36,000 visits to medical 
regulatory authority 
Step 2: Research team 
samples 10 visits per 
physician** and sends them 
to health insurance agency 
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Appendix – Table 1. FEVER syndrome, CDC definition: positive predictive value of individual syndrome-
positive ICD-9 diagnostic codes  
ICD-9 code 
in claims* 
Text label for ICD-9 code 
No. visits 
in claims** 
No. visits 
in verified 
claims*** 
PPV 
95% CI 
Lower limit Upper limit 
2.0 TYPHOID FEVER 48 2 0.50 0.00 1.00 
2.1 PARATYPHOID FEVER A 5 2 0.00 0.00 0.00 
2.2 PARATYPHOID FEVER B 0 0 . . . 
2.3 PARATYPHOID FEVER C 1 1 0.00 0.00 0.00 
2.9 PARATYPHOID FEVER NOS 9 0 . . . 
3.1 SALMONELLA SEPTICEMIA 5 2 0.00 0.00 0.00 
20.2 PLAGUE, SEPTICEMIC 297 1 0.00 0.00 0.00 
20.8 OTHER TYPES OF PLAGUE 0 0 . . . 
20.9 PLAGUE NOS 1 0 . . . 
21.8 TULAREMIA NEC 0 0 . . . 
21.9 TULAREMIA NOS 2 2 0.00 0.00 0.00 
22.3 ANTHRAX, SEPTICEMIA 0 0 . . . 
22.8 ANTHRAX, OTHER SPECIFIED 0 0 . . . 
22.9 ANTHRAX, UNSPECIFIED 0 0 . . . 
23.0 BRUCELLA MELITENSIS 2 0 . . . 
23.1 BRUCELLA ABORTUS 0 0 . . . 
23.2 BRUCELLA SUIS 6 3 0.33 0.00 0.87 
23.3 BRUCELLA CANIS 0 0 . . . 
23.8 BRUCELLOSIS NEC 1 0 . . . 
23.9 BRUCELLOSIS, UNSPECIFIED 14 6 0.33 0.00 0.71 
24.9 GLANDERS 6 0 . . . 
25.9 MELOIDOSIS 10 0 . . . 
27.0 LISTERIOSIS 3 2 0.00 0.00 0.00 
34.1 SCARLET FEVER 2,552 42 0.81 0.69 0.93 
38.0 SEPTICEMIA STAPHYLOCOCCAL 5 4 0.25 0.00 0.67 
38.1 SEPTICEMIA STAPHYLOCOCCAL 0 0 . . . 
38.2 PNEUMOCOCCAL SEPTICEMIA 0 0 . . . 
38.3 ANAEROBES SEPTICEMIA 0 0 . . . 
38.4 GRAM-NEGATIVE SEPTICEMIA 22 5 0.20 0.00 0.55 
38.8 SEPTICEMIAS, OTHER SPECIF 0 0 . . . 
38.9 SEPTICEMIA, NOS 111 6 0.50 0.10 0.90 
54.5 HERPETIC SEPTICEMIA 2 1 0.00 0.00 0.00 
60.0 YELLOW FEVER, SYLVATIC 115 1 0.00 0.00 0.00 
60.1 YELLOW FEVER, URBAN 3 1 0.00 0.00 0.00 
60.9 YELLOW FEVER, UNSPEC 35 0 . . . 
66.0 PHLEBOTOMUS FEVER 5 0 . . . 
66.1 TICK-BORNE FEVER 0 0 . . . 
66.2 VENEZUELAN EQUINE FEVER 0 0 . . . 
66.3 MOSQUITO-BORNE FEVER NEC 0 0 . . . 
66.8 ARTHROPOD VIRUS NEC 0 0 . . . 
66.9 ARTHROPOD VIRUS NOS 306 1 0.00 0.00 0.00 
78.2 SWEATING FEVER 10 5 0.00 0.00 0.00 
79.8 VIRAL INFECTION OTHER S 154 4 0.00 0.00 0.00 
79.9 VIRAL INFECTIONS UNSPECIFIED 5,551 30 0.30 0.14 0.46 
80.9 LOUSE-BORNE TYPHUS 2 0 . . . 
81.0 MURINE TYPHUS 3 1 0.00 0.00 0.00 
81.1 BRILL'S DISEASE 0 0 . . . 
81.2 SCRUB TYPHUS 137 2 0.00 0.00 0.00 
81.9 TYPHUS NOS 0 0 . . . 
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Appendix – Table 1. FEVER syndrome, CDC definition: positive predictive value of individual syndrome-
positive ICD-9 diagnostic codes  
ICD-9 code 
in claims* 
Text label for ICD-9 code 
No. visits 
in claims** 
No. visits 
in verified 
claims*** 
PPV 
95% CI 
Lower limit Upper limit 
82.8 TICK-BORNE RICKETTS NEC 4 1 1.00 1.00 1.00 
82.9 TICK-BORNE RICKETTS NOS 9 4 0.00 0.00 0.00 
83.0 Q FEVER 56 0 . . . 
83.1 TRENCH FEVER 8 1 0.00 0.00 0.00 
83.2 RICKETTSIALPOX 2 2 0.00 0.00 0.00 
83.8 RICKETTSIOSES NEC 2 1 0.00 0.00 0.00 
83.9 RICKETTSIOSIS 2 1 0.00 0.00 0.00 
84.0 MALARIA, FALCIPARUM 46 5 0.20 0.00 0.55 
84.1 VIVAX MALARIA 4 2 0.00 0.00 0.00 
84.2 QUARTAN MALARIA 34 6 0.17 0.00 0.46 
84.3 OVALE MALARIA 9 0 . . . 
84.5 MIXED MALARIA 160 0 . . . 
84.6 MALARIA UNSPECIFIED 37 19 0.32 0.11 0.52 
86.2 CHAGA'S DISEASE WITHOUT 
MENTION OF ORG 2 2 0.00 0.00 0.00 
86.3 TRYPANOSOMIASIS, GAMBIAN 1 0 . . . 
86.4 TRYPANOSOMIASIS, RHODESIAN 0 0 . . . 
86.5 TRYPANOSOMIASIS, AFRICAN 0 0 . . . 
86.9 TRYPANOSOMIASIS, UNSPEC 19 1 0.00 0.00 0.00 
87.0 LOUSE-BORNE RELAPS FEVER 64 0 . . . 
87.1 TICK-BORNE RELAPS FEVER 5 0 . . . 
87.9 RELAPSING FEVER NOS 54 1 0.00 0.00 0.00 
88.0 BARTONELLOSIS 624 9 0.00 0.00 0.00 
88.8 OTHER ARTHROPOD-BORNE 2 1 1.00 1.00 1.00 
88.9 ARTHROPOD-BORNE DIS NOS 23 10 0.60 0.30 0.90 
100.8 LEPTOSPIROSIS, OTHER 0 0 . . . 
780.3 FEBRILE CONVULSIONS 653 19 0.63 0.41 0.85 
780.6 FEVER 20,028 150 0.58 0.50 0.66 
780.7 BACTEREMIA 49,102 232 0.65 0.59 0.71 
780.8 VIREMIA NOS 511 10 0.40 0.10 0.70 
Total   80,884 601 0.59 0.55 0.64 
*The Quebec provincial healthcare agency records ICD-9 diagnostic codes up to the first decimal position only. ICD-9 
codes that are in the syndrome definition but do not appear in this table were not used in any of the 7,315,994 visits billed 
by the 1,098 participating physicians during the 2-year study period. 
**Among the 7,315,994 visits to the 1,098 participating physicians during the 2-year study period. 
***Among the 10,529 visits for which both the physician claim and the medical chart were available for verification. 
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Appendix – Table 2. GASTROINTESTINAL syndrome, CDC definition: positive predictive value of individual 
syndrome-positive ICD-9 diagnostic codes 
ICD-9 code 
in claims* 
Text label for ICD-9 code 
No. visits 
in claims** 
No. visits 
in verified 
claims*** 
PPV 
95% CI 
Lower limit Upper limit 
1.0 CHOLERA D/T VIB CHOLERAE 13 10 0.00 0.00 0.00 
1.1 CHOLERA D/T VIB EL TOR 24 11 0.00 0.00 0.00 
1.9 CHOLERA NOS 21 6 0.17 0.00 0.46 
3.0 SALMONELLA GASTROENTERITI 266 3 0.67 0.13 1.00 
3.2 LOCAL SALMONELLA INF NOS 3 1 0.00 0.00 0.00 
3.8 SALMONELLA INFECTION NEC 0 0 . . . 
3.9 SALMONELLA INFECTION UNSP 30 12 0.75 0.51 1.00 
4.0 SHIGELLA DYSENTERIAE 64 0 . . . 
4.1 SHIGELLA FLEXNERI 0 0 . . . 
4.2 SHIGELLA BOYDII 0 0 . . . 
4.3 SHIGELLA SONNEI 2 2 0.00 0.00 0.00 
4.8 SHIGELLA INFECTIONS OTHER 43 0 . . . 
4.9 SHIGELLOSIS, UNSPECIFIED 4 1 1.00 1.00 1.00 
5.0 STAPH FOOD POISONING 3 0 . . . 
5.2 FOOD POIS D/T C. PERFRIN 102 1 0.00 0.00 0.00 
5.3 FOOD POIS: CLOSTRID NEC 343 1 0.00 0.00 0.00 
5.4 FOOD POIS: V. PARAHAEM 5 1 0.00 0.00 0.00 
5.8 FOOD POISONING, OTHER BAC 0 0 . . . 
5.9 FOOD POISONING      NOS 175 4 1.00 1.00 1.00 
6.0 AC AMEBIASIS W/O ABSCESS 9 3 0.33 0.00 0.87 
6.8 AMEBIC INFECTION NEC 0 0 . . . 
6.9 AMEBIASIS UNSPECIFIED 5 3 1.00 1.00 1.00 
7.0 BALANTIDIASIS 23 9 0.00 0.00 0.00 
7.1 GIARDIASIS 23 17 1.00 1.00 1.00 
7.2 COCCIDIOSIS 7 2 0.00 0.00 0.00 
7.3 INTEST TRICHOMONIASIS 0 0 . . . 
7.4 CRYPTOSPORIDOSIS 0 0 . . . 
7.5 CYCLOSPORIASIS 0 0 . . . 
7.8 PROTOZOAL INTEST DIS NEC 4 1 0.00 0.00 0.00 
7.9 PROTOZOAL INTEST DIS NOS 1 0 . . . 
8.0 E COLI ENTERITIS 4 3 0.33 0.00 0.87 
8.1 ARIZONA ENTERITIS 4 2 0.50 0.00 1.00 
8.2 AEROBACTER ENTERITIS 1 0 . . . 
8.3 PROTEUS ENTERITIS 0 0 . . . 
8.4 INTEST. INFECT BY OTHER B 10 4 0.25 0.00 0.67 
8.5 BACTERIAL ENTERITIS  NOS 24 0 . . . 
8.6 ENTERITIS VIRAL OTHER 11 5 0.60 0.17 1.00 
8.8 ENTERITIS VIRAL NOS 343 3 1.00 1.00 1.00 
9.0 ENTERITIS/COLITIS/GASTRO. 3,818 25 0.80 0.64 0.96 
9.1 COLITIS ENTERIT,GASTRO,IN 1,920 21 0.71 0.52 0.91 
9.2 DIARRHEA, INFECTIOUS  NOS 371 2 0.50 0.00 1.00 
9.3 DIARRHEA OF INFECT ORIG 342 4 0.50 0.01 0.99 
21.1 TULAREMIA, ENTERIC 0 0 . . . 
22.2 GASTROINTESTINAL ANTHRAX 22 6 0.33 0.00 0.71 
78.8 EPIDEMIC VOMITING SYND 204 4 0.00 0.00 0.00 
127.0 ASCARIASIS 9 9 0.89 0.68 1.00 
127.1 ANISAKIASIS 1 0 . . . 
127.3 STRONGYLOIDIASIS 0 0 . . . 
127.3 TRICHURIASIS 6 2 0.50 0.00 1.00 
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Appendix – Table 2. GASTROINTESTINAL syndrome, CDC definition: positive predictive value of individual 
syndrome-positive ICD-9 diagnostic codes 
ICD-9 code 
in claims* 
Text label for ICD-9 code 
No. visits 
in claims** 
No. visits 
in verified 
claims*** 
PPV 
95% CI 
Lower limit Upper limit 
127.4 ENTEROBIASIS 253 4 0.50 0.01 0.99 
127.5 CAPILLARIASIS 0 0 . . . 
127.6 TRICHOSTRONGYLIASIS 0 0 . . . 
127.7 INTEST HELMINTHIASIS NEC 0 0 . . . 
127.8 MIXED INTESTINE HELMINTH 0 0 . . . 
127.9 INTESTINAL HELMINTHIASIS, 251 3 1.00 1.00 1.00 
129.9 INTESTINAL PARASITISM UNS 86 1 1.00 1.00 1.00 
535.0 GASTRITIS, ACUTE 7,439 54 0.78 0.67 0.89 
535.4 GASTRITIS,OTH SPEC. 4,602 58 0.72 0.61 0.84 
535.5 GASTRITIS/DUODENITIS UNS 12,534 88 0.73 0.63 0.82 
535.6 DUODENITIS UNS 398 3 0.67 0.13 1.00 
536.2 VOMITING PERSISTENT 90 3 0.33 0.00 0.87 
555.0 ENTERITIS SMALL INTESTINE 759 16 0.00 0.00 0.00 
555.1 REG ENTERITIS, LG INTEST 1,332 9 0.11 0.00 0.32 
555.2 REG ENTERIT SM/LG INTEST 0 0 . . . 
558.2 GASTROENTERITIS/COLITIS, 0 0 . . . 
558.9 GASTROENTERITIS/COLITIS N 28,890 120 0.85 0.79 0.91 
567.0 PERITONITIS IN INFEC DIS 1 1 1.00 1.00 1.00 
567.1 PNEUMOCOCCAL PERITONITIS 2 1 0.00 0.00 0.00 
567.2 PERITONITIS SUPPURATIVE 8 5 0.20 0.00 0.55 
567.8 PERITONITIS, OTHER SPECIF 1 0 . . . 
567.9 PERITONITIS  NOS 43 0 . . . 
568.9 PERITONEAL DISORDER NOS 231 3 0.67 0.13 1.00 
569.9 INTESTINAL DISORDER  NOS 523 9 0.56 0.23 0.88 
578.0 HEMATEMESIS 102 3 0.67 0.13 1.00 
787.0 NAUSEA AND/OR VOMITING 4,882 76 0.63 0.52 0.74 
787.1 HEARTBURN/PYROSIS 572 8 0.50 0.15 0.85 
787.2 DYSPHAGIA 1,918 40 0.60 0.45 0.75 
787.3 FLATUL/ERUCTAT/GAS PAIN 434 8 0.50 0.15 0.85 
787.4 PERISTALSIS, VISIBLE 3 2 0.00 0.00 0.00 
787.9 DIARRHEA 2,787 14 0.79 0.57 1.00 
789.0 ABDOMINAL PAIN,UNSPECIF. 82,851 125 0.69 0.61 0.77 
789.6 ABDOMINAL TENDERNESS, UNS 0 0 . . . 
789.9 ABDOMEN/PELVIS SYMPTOMS O 3,030 23 0.22 0.05 0.39 
Total   162,282 855 0.71 0.66 0.75 
*The Quebec provincial healthcare agency records ICD-9 diagnostic codes up to the first decimal position only. ICD-9 
codes that are in the syndrome definition but do not appear in this table were not used in any of the 7,315,994 visits billed 
by the 1,098 participating physicians during the 2-year study period. 
**Among the 7,315,994 visits to the 1,098 participating physicians during the 2-year study period. 
***Among the 10,529 visits for which both the physician claim and the medical chart were available for verification. 
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Appendix – Table 3. NEUROLOGICAL syndrome, CDC definition: positive predictive value of individual 
syndrome-positive ICD-9 diagnostic codes 
ICD-9 code 
in claims* 
Text label for ICD-9 code 
No. visits 
in claims** 
No. visits 
in verified 
claims*** 
PPV 
95% CI 
Lower limit Upper limit 
3.2 SALMONELLA MENINGITIS 3 1 0.00 0.00 0.00 
36.0 MENINGITIS (MENINGOCOCCAL 3 2 0.50 0.00 1.00 
36.1 ENCEPHALITIS, MENINGOCOCCAL 8 5 0.60 0.17 1.00 
36.2 MENINGOCOCCEMIA INFECTION 23 2 0.00 0.00 0.00 
36.8 INFECTION, MENINGOCOCCAL NEC 0 0 . . . 
36.9 INFECTION, MENINGOCOCCAL NOS 0 0 . . . 
47.0 COXSACKIE DUE TO MENINGIT 10 6 0.00 0.00 0.00 
47.1 MENINGITIS D/T ECHO VIRUS 0 0 . . . 
47.8 MENINGITIS, VIRAL NEC 0 0 . . . 
47.9 MENINGITIS VIRAL NOS 10 5 0.60 0.17 1.00 
48.9 DIS ENTEROVIRAL OF CNS, NEC 3 0 . . . 
49.0 CHORIOMENINGITIS, LYMPHOCYTIC 328 3 0.00 0.00 0.00 
49.1 MENINGITIS, ADENOVIRUS 471 3 0.00 0.00 0.00 
49.8 ENCEPHALITIS VIRAL OTHER 0 0 . . . 
49.9 ENCEPHALITIS VIRAL NOS 58 1 0.00 0.00 0.00 
52.0 POSTVARICELLA ENCEPHALIT 0 0 . . . 
53.0 HERPES ZOSTER WITH MENINGITIS 396 13 0.00 0.00 0.00 
53.1 HERPES ZOSTER W UNSPED NER S 42 2 0.00 0.00 0.00 
54.3 HERPETIC MENINGOENCEPHALI 8 2 0.00 0.00 0.00 
54.7 HSV, MENINGITIS 16 8 0.13 0.00 0.35 
55.0 POSTMEASLES ENCEPHALITIS 10 1 0.00 0.00 0.00 
56.0 RUBELLA, WITH NEURO COMPLI 4 4 0.00 0.00 0.00 
61.9 DENGUE 2 0 . . . 
62.0 ENCEPHALITIS, JAPANESE 7 1 0.00 0.00 0.00 
62.1 ENCEPHALITIS, WESTERN EQUINE 0 0 . . . 
62.2 ENCEPHALITIS, EASTERN EQUINE 0 0 . . . 
62.3 ST.LOUIS ENCEPHALITIS 0 0 . . . 
62.4 ENCEPHALITIS, AUSTRALIAN 0 0 . . . 
62.5 ENCEPHALITIS, CALIFORNIA VIRUS 1 1 0.00 0.00 0.00 
62.8 ENCEPHALITIS, MOSQUITO-BORNE 
NEC 0 0 . . . 
62.9 ENCEPHALITIS, MOSQUITO-BORNE 
NOS 1 1 0.00 0.00 0.00 
63.0 ENCEPHALITIS, RUSSIAN SPRING-
SUMMER 1 0 . . . 
63.1 LOUPING ILL 0 0 . . . 
63.2 ENCEPHALITIS, CENTRAL 
EUROPEAN 0 0 . . . 
63.8 ENCEPHALITIS, VIRAL, TICK-BORNE 
NEC 0 0 . . . 
63.9 ENCEPHALITIS, TICK-BORNE VIRAL 
NOS 3 3 0.00 0.00 0.00 
64.9 ENCEPHALITIS ARTHPD-BORNE 
VIRAL NEC 7 0 . . . 
66.4 WEST NILE FEVER 0 0 . . . 
71.9 RABIES 7 0 . . . 
72.1 MUMPS MENINGITIS 7 4 0.00 0.00 0.00 
72.2 MUMPS ENCEPHALITIS 0 0 . . . 
84.9 MALARIA COMPLICATED NEC 16 1 0.00 0.00 0.00 
86.2 CHAGA'S DISEASE WITHOUT 2 2 0.00 0.00 0.00 
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Appendix – Table 3. NEUROLOGICAL syndrome, CDC definition: positive predictive value of individual 
syndrome-positive ICD-9 diagnostic codes 
ICD-9 code 
in claims* 
Text label for ICD-9 code 
No. visits 
in claims** 
No. visits 
in verified 
claims*** 
PPV 
95% CI 
Lower limit Upper limit 
MENTION OF ORG 
86.3 TRYPANOSOMIASIS, GAMBIAN 1 0 . . . 
86.4 TRYPANOSOMIASIS, RHODESIAN 0 0 . . . 
86.5 TRYPANOSOMIASIS, AFRICAN 0 0 . . . 
91.8 ACUTE SYPHIL MENINGITIS 4 2 0.00 0.00 0.00 
98.8 GONOCCOCAL, MENINGITIS 34 12 0.00 0.00 0.00 
100.8 LEPTOSPIRAL 
INFECTIONS,MENINGITIS (ASEPTIC) 0 0 . . . 
114.2 COCCIDIODAL MENINGITIS 0 0 . . . 
115.0 HISTOPLASMOSIS MENINGITIS 1 1 0.00 0.00 0.00 
115.1 HISTOPLASMA DUBOISII, 
MENINGITIS 0 0 . . . 
115.9 HISTOPLASMOSIS, UNSPEC, 
MENINGITIS 12 5 0.20 0.00 0.55 
117.5 CRYPTOCOCCOSIS 0 0 . . . 
130.0 TOXOPLASMOSIS, 
MENINGOENCEPHALITIS 0 0 . . . 
136.2 SPECIFIC INF BY FREE LIVING 
AMOEBA 0 0 . . . 
293.0 DELIRIUM, ACUTE 67 2 0.50 0.00 1.00 
293.1 CONFUSIONAL STATE(del subacute) 9 4 0.25 0.00 0.67 
307.8 TENSION HEADACHE 3,311 70 0.74 0.64 0.85 
320.0 HEMOPHILUS MENINGITIS 0 0 . . . 
320.1 MENINGITIS PNEUMOCOCCAL 0 0 . . . 
320.2 MENINGITIS, STREPTOCOCCAL 1 0 . . . 
320.3 MENINGITIS, STAPHYLOCOCCAL 0 0 . . . 
320.7 MENG, IN OTH BCTRL DISEASE CE 4 1 0.00 0.00 0.00 
320.8 BACTERIAL MENINGITIS  OTHER 0 0 . . . 
320.9 BACTERIAL MENINGITIS  NOS 6 6 0.00 0.00 0.00 
321.0 MENINGITIS, CRYPTOCOCCAL 0 0 . . . 
321.1 MENINGITIS IN OTH. FUNGAL 1 1 0.00 0.00 0.00 
321.2 Meningitis d/t viral diseases NEC 0 0 . . . 
321.3 MENINGITIS D/T TRYPANOSOMIASIS 2 1 0.00 0.00 0.00 
321.4 MENINGITIS IN SARCOIDOSIS 1 1 0.00 0.00 0.00 
321.8 MENG D/T OTH NONBACT 
ORGANISM CE 2 0 . . . 
322.0 MENINGITIS, NONPYOGENIC 18 5 0.20 0.00 0.55 
322.1 MENINGITIS, EOSINOPHILIC 0 0 . . . 
322.9 MENINGITIS  NOS 240 3 0.67 0.13 1.00 
323.0 ENCEPHALITIS IN VIRAL DISEASE 
CE 16 2 1.00 1.00 1.00 
323.1 ENCEPHALITIS IN RICKETTSIAL DIS 
CE 0 0 . . . 
323.2 ENCEPHALITIS IN PROTOZOAL DIS 
CE 18 12 0.00 0.00 0.00 
323.4 ENCEPHALITIS, OTH D/T INFECTION 
CE 4 1 1.00 1.00 1.00 
323.5 ENCEPHALITIS, POSTIMMUNIZATION 0 0 . . . 
323.6 ENCEPHALITIS POSTINFECTIO 0 0 . . . 
323.7 ENCEPHALITIS, TOXIC 1 1 0.00 0.00 0.00 
323.8 OTHER CAUSES OF ENCEPHALI 0 0 . . . 
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Appendix – Table 3. NEUROLOGICAL syndrome, CDC definition: positive predictive value of individual 
syndrome-positive ICD-9 diagnostic codes 
ICD-9 code 
in claims* 
Text label for ICD-9 code 
No. visits 
in claims** 
No. visits 
in verified 
claims*** 
PPV 
95% CI 
Lower limit Upper limit 
323.9 ENCEPHALITIS NOS 204 5 0.20 0.00 0.55 
348.3 ENCEPHALOPATHY NOS 175 3 0.33 0.00 0.87 
780.0 ALTERATION OF AWARENESS 1,603 47 0.02 0.00 0.06 
780.3 CONVULSIONS 653 19 0.53 0.30 0.75 
781.6 MENINGISMUS 21 11 0.18 0.00 0.41 
784.0 HEADACHE 32,290 683 0.73 0.70 0.76 
784.3 APHASIA 90 2 1.00 1.00 1.00 
Total   40,236 971 0.67 0.64 0.70 
*The Quebec provincial healthcare agency records ICD-9 diagnostic codes up to the first decimal position only. ICD-9 
codes that are in the syndrome definition but do not appear in this table were not used in any of the 7,315,994 visits billed 
by the 1,098 participating physicians during the 2-year study period. 
**Among the 7,315,994 visits to the 1,098 participating physicians during the 2-year study period. 
***Among the 10,529 visits for which both the physician claim and the medical chart were available for verification. 
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Appendix – Table 4. RASH syndrome, CDC definition: positive predictive value of individual syndrome-positive 
ICD-9 diagnostic codes 
ICD-9 code 
in claims* 
Text label for ICD-9 code 
No. visits 
in claims** 
No. visits 
in verified 
claims*** 
PPV 
95% CI 
Lower limit Upper limit 
26.0 SPIRILLARY FEVER 0 0 . . . 
26.1 STREPTOBACILLARY FEVER 1 1 0.00 0.00 0.00 
26.9 RAT-BITE FEVER UNSPECIFIED 6 3 0.00 0.00 0.00 
50.0 SMALL POX, VARIOLA MAJOR 3 3 0.00 0.00 0.00 
50.1 SMALL POX, ALASTRIM 0 0 . . . 
50.2 SMALL POX, MODIFIED 0 0 . . . 
50.9 SMALLPOX NOS 2 2 0.50 0.00 1.00 
51.0 COWPOX 3,730 20 0.00 0.00 0.00 
51.1 PSEUDOCOWPOX 42 0 . . . 
51.2 DERMATITIS PUSTULAR, CONT 44 1 1.00 1.00 1.00 
51.9 PARAVACCINIA NOS 30 1 1.00 1.00 1.00 
52.7 VARICELLA COMPLICAT NEC 0 0 . . . 
52.8 VARICELLA W/UNSPECIFIED C 0 0 . . . 
52.9 VARICELLA NOS 1,558 26 0.88 0.76 1.00 
53.2 HERPES ZOSTER DERMATITIS E 229 4 1.00 1.00 1.00 
53.7 HERPES ZOSTER WITH OTHER 
SPECIF COMPLIC 19 6 1.00 1.00 1.00 
53.8 H.Z. W/ UNSPEC. COMPLICATION 17 8 1.00 1.00 1.00 
53.9 HERPES ZOSTER NOS W/O COM 10,551 168 0.87 0.82 0.92 
54.0 ECZEMA HERPETICUM 708 13 0.62 0.35 0.88 
54.7 HERPES SIMPLEX W/OTH.SPEC 16 8 0.75 0.45 1.00 
54.8 HERPES SIMPLEX, W/UNS.COM 5 4 0.50 0.01 0.99 
54.9 HERPES SIMPLEX  NOS 8,763 153 0.66 0.59 0.74 
55.7 MEASLES COMPLICATION NEC 0 0 . . . 
55.8 MEASLES COMPLICATION NOS 141 4 0.00 0.00 0.00 
55.9 MEASLES UNCOMPLICATED 82 3 0.33 0.00 0.87 
56.7 RUBELLA COMPLICATION NEC 2 1 0.00 0.00 0.00 
56.8 RUBELLA COMPLICATION  NOS 0 0 . . . 
56.9 RUBELLA UNCOMPLICATED 172 1 0.00 0.00 0.00 
57.0 ERYTHEMIA INFECT.(5TH DIS 238 2 1.00 1.00 1.00 
57.8 EXANTHEMATA VIRAL OTHER S 619 9 0.56 0.23 0.88 
57.9 EXANTHEM VIRAL, UNSPECIFI 1,440 15 0.40 0.15 0.65 
74.3 HAND/FOOT AND MOUTH DISEA 49 1 1.00 1.00 1.00 
78.0 MOLLUSCUM CONTAGIOSUM 3,323 43 0.84 0.73 0.95 
82.0 ROCKY MOUNTAIN SPOTTED FE 2 2 0.50 0.00 1.00 
83.2 RICKETTSIALPOX 2 2 0.00 0.00 0.00 
692.9 DERMATITIS UNSPECIFIED CA 73,677 181 0.64 0.57 0.71 
695.0 ERYTHEMA TOXIC 53 3 0.67 0.13 1.00 
695.1 ERYTHEMA MULTIFORME 106 1 1.00 1.00 1.00 
695.2 ERYTHEMA NODOSUM 135 5 1.00 1.00 1.00 
695.3 ROSACEA 554 10 0.70 0.42 0.98 
695.4 LUPUS ERYTHEMATOSUS 540 9 0.56 0.23 0.88 
695.8 ERYTHEMATOUS CONDITIONS O 735 12 0.67 0.40 0.93 
695.9 ERYTHEMATOUS CONDITION  N 3,183 41 0.54 0.38 0.69 
782.1 RASH/OTHER NONSPEC SKIN E 16,123 131 0.74 0.67 0.82 
Total   126,900 897 0.66 0.62 0.70 
*The Quebec provincial healthcare agency records ICD-9 diagnostic codes up to the first decimal position only. ICD-9 
codes that are in the syndrome definition but do not appear in this table were not used in any of the 7,315,994 visits billed 
by the 1,098 participating physicians during the 2-year study period. 
**Among the 7,315,994 visits to the 1,098 participating physicians during the 2-year study period. 
***Among the 10,529 visits for which both the physician claim and the medical chart were available for verification. 
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Appendix – Table 5. RESPIRATORY syndrome, CDC definition: positive predictive value of individual 
syndrome-positive ICD-9 diagnostic codes 
ICD-9 code 
in claims* 
Text label for ICD-9 code 
No. visits 
in claims** 
No. visits 
in verified 
claims*** 
PPV 
95% CI 
Lower limit Upper limit 
3.2 SALMONELLA PNEUMONIA 3 1 0.00 0.00 0.00 
20.3 PRIMARY PNEUMONIC PLAGUE 0 0 . . . 
20.4 SECONDARY PNEUMON PLAGUE 7 3 0.00 0.00 0.00 
20.5 PNEUMONIC PLAGUE NOS 0 0 . . . 
21.2 PULMONARY TULAREMIA 0 0 . . . 
22.1 PULMONARY ANTHRAX 0 0 . . . 
31.0 MYCOBACTERIA, PULMONARY 7 3 0.33 0.00 0.87 
31.8 MYCOBACTERIAL DIS NEC 6 1 0.00 0.00 0.00 
31.9 MYCOBACTERIA DISEASES/UNS 15 5 0.20 0.00 0.55 
32.0 FAUCIAL DIPHTHERIA 52 0 . . . 
32.1 NASOPHARYNX DIPHTHERIA 8 5 0.60 0.17 1.00 
32.2 ANT NASAL DIPHTHERIA 7 2 0.00 0.00 0.00 
32.3 LARYNGEAL DIPHTHERIA 1 0 . . . 
32.8 DIPHTHERIA NEC 0 0 . . . 
32.9 DIPHTHERIA NOS 2 2 0.50 0.00 1.00 
33.0 BORDETELLA PERTUSSIS 39 9 1.00 1.00 1.00 
33.1 BORDETELLA PARAPERTUSSIS 0 0 . . . 
33.8 WHOOPING COUGH NEC 5 1 1.00 1.00 1.00 
33.9 WHOOPING COUGH(UNSPE.ORGA 325 0 . . . 
34.0 STREP SORE THROAT 735 2 1.00 1.00 1.00 
52.1 VARICELLA WITH PNEUMONIA 0 0 . . . 
55.1 POSTMEASLES PNEUMONIA 8 3 0.67 0.13 1.00 
55.2 POSTMEASLES OTITIS MEDIA 502 1 0.00 0.00 0.00 
73.0 ORNITHOSIS, WITH PNEUMONIA 0 0 . . . 
73.7 ORNITHOSIS, OTHER SPECIF 
COMPLIC 0 0 . . . 
73.8 ORNITHOSIS, UNSPECIFIED 
COMPLIC 0 0 . . . 
73.9 ORNITHOSIS, UNSPECIFIED 1 1 0.00 0.00 0.00 
75.9 MONONUCLEOSIS, INFECTIOUS 2,373 2 1.00 1.00 1.00 
79.0 ADENOVIRUS INFECT NOS 507 0 . . . 
79.1 ECHO VIRUS INFECT NOS 3 0 . . . 
79.2 COXSACKIE VIRUS 12 7 0.57 0.20 0.94 
79.3 RHINOVIRUS INFECT NOS 2 1 1.00 1.00 1.00 
79.6 RESPIRATORY SYNCYTIAL VIR 0 0 . . . 
79.8 HANTAVIRUS INFECTION 154 4 0.00 0.00 0.00 
98.6 GONOCCOCAL, INFECTION OF 
PHARYNX 4 1 1.00 1.00 1.00 
114.5 PULM COCCIDIOIDOMYCOS,UN 0 0 . . . 
114.9 COCCIDIOIDOMYCOSIS NOS 2 1 0.00 0.00 0.00 
115.0 HISTOPLASMA CAPSULATUM NOS 1 1 0.00 0.00 0.00 
115.1 HISTOPLASMA DUBOISII NOS 0 0 . . . 
115.9 HISTOPLASMOSIS UNS 12 5 0.20 0.00 0.55 
116.0 BLASTOMYCOSIS 5 1 0.00 0.00 0.00 
116.1 PARACOCCIDIOIDOMYCOSIS 2 2 0.00 0.00 0.00 
117.1 SPOROTRICHOSIS 1 1 0.00 0.00 0.00 
117.3 PULMONARY ASPERGILLOSIS 15 6 0.50 0.10 0.90 
117.5 CRYPTOCOCCOSIS 0 0 . . . 
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Appendix – Table 5. RESPIRATORY syndrome, CDC definition: positive predictive value of individual 
syndrome-positive ICD-9 diagnostic codes 
ICD-9 code 
in claims* 
Text label for ICD-9 code 
No. visits 
in claims** 
No. visits 
in verified 
claims*** 
PPV 
95% CI 
Lower limit Upper limit 
130.4 TOXOPLASMA PNEUMONITIS 0 0 . . . 
136.3 PNEUMOCYSTOSIS 1 0 . . . 
381.0 OTITIS MEDIA NONSUP ACUTE 9,398 16 0.94 0.82 1.00 
381.4 OTITIS MEDIA NONSUPPURATI 6,730 17 0.53 0.29 0.77 
381.5 EUSTACHIAN SALPINGITIS 144 0 . . . 
382.0 OM SUPPURATIVE & UNSPEC 6,326 17 0.88 0.73 1.00 
382.4 OM SUPPURATIVE NOS 154 0 . . . 
382.9 OTITIS MEDIA NOS 95,165 68 0.75 0.65 0.85 
460.0 NASOPHARYNGITIS, ACUTE 1 0 . . . 
460.9 NASOPHARYNGITIS, ACUTE NOS 20,179 11 1.00 1.00 1.00 
461.0 MAXILLARY SINUSITIS, ACUT 4,234 5 1.00 1.00 1.00 
461.1 SINUSITIS, FRONTAL-ACUTE 145 1 1.00 1.00 1.00 
461.2 SINUSITIS, ETHMOIDAL 43 7 0.57 0.20 0.94 
461.3 SINUSITIS,ACUTE SPHENOIDA 2 1 1.00 1.00 1.00 
461.8 SINUSITIS, ACUTE, OTHER 1,466 5 0.40 0.00 0.83 
461.9 SINUSITIS, ACUTE  NOS 39,976 57 0.91 0.84 0.99 
462.0 PHARYNGITIS, ACUTE 10 0 . . . 
462.9 PHARYNGITIS, ACUTE NOS 39,695 24 1.00 1.00 1.00 
463.0 TONSILLITIS, ACUTE 3 0 . . . 
463.9 TONSILLITIS, ACUTE NOS 32,676 16 0.94 0.82 1.00 
464.0 LARYNGITIS, ACUTE 12,319 27 0.81 0.67 0.96 
464.1 TRACHEITIS, ACUTE 9,716 13 0.92 0.78 1.00 
464.2 LARYNGOTRACHEITIS, ACUTE 1,214 1 1.00 1.00 1.00 
464.3 EPIGLOTTITIS, ACUTE 32 16 0.69 0.46 0.91 
464.4 CROUP 916 0 . . . 
464.5 SUPRAGLOTTIS, UNS 0 0 . . . 
465.0 LARYNGOPHARYNGITIS, ACUTE 4,679 3 0.67 0.13 1.00 
465.8 URI, OTHER MULT. SITES 3,809 11 0.91 0.74 1.00 
465.9 URI, ACUTE  NOS 223,128 84 0.90 0.84 0.97 
466.0 BRONCHITIS ACUTE 62,662 67 0.90 0.82 0.97 
466.1 BRONCHIOLITIS ACUTE 5,006 10 0.90 0.71 1.00 
478.9 RESPIRATORY TRACT DISEASE 85 0 . . . 
480.0 ADENOVIRAL PNEUMONIA 636 2 1.00 1.00 1.00 
480.1 PNEUMONIA,RESP.SYNCYTIAL 3 3 0.67 0.13 1.00 
480.2 PARINFLUENZA VIRAL PNEUM 1 0 . . . 
480.8 VIRAL PNEUMONIA NEC 1 1 1.00 1.00 1.00 
480.9 PNEUMONIA, VIRAL 1,044 0 . . . 
481.9 PNEUMOCOCCAL PNEUMONIA 837 1 1.00 1.00 1.00 
482.0 PNEUMONIA-KLEBSIELLA PNEU 311 0 . . . 
482.1 PNEUMONIA DUE TO PSEUDOMO 26 6 0.50 0.10 0.90 
482.2 H.INFLUENZAE PNEUMONIA 8 4 1.00 1.00 1.00 
482.3 STREPTOCOCCUS UNSPECIFIED 0 0 . . . 
482.4 STAPH PNEUMONIA NOS 0 0 . . . 
482.8 PNEUMONIA/ANAEROBES 25 4 1.00 1.00 1.00 
482.9 PNEUMONIA, BACTERIAL  NOS 2,915 2 0.50 0.00 1.00 
483.0 PNEUMONIA MYCOPLASMA 0 0 . . . 
483.1 PNEUMONIA DUE TO CHLAMYD 0 0 . . . 
483.8 PNEUMONIA DUE TO ORGANISM 
NEC 0 0 . . . 
484.1 PNEUM W CYTOMEG INCL DIS 10 4 0.50 0.01 0.99 
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Appendix – Table 5. RESPIRATORY syndrome, CDC definition: positive predictive value of individual 
syndrome-positive ICD-9 diagnostic codes 
ICD-9 code 
in claims* 
Text label for ICD-9 code 
No. visits 
in claims** 
No. visits 
in verified 
claims*** 
PPV 
95% CI 
Lower limit Upper limit 
484.3 PNEUMONIA IN WHOOP COUGH 0 0 . . . 
484.5 PNEUMONIA IN ANTHRAX 1 1 1.00 1.00 1.00 
484.6 PNEUMONIA IN ASPERGILLOSI 0 0 . . . 
484.7 PNEUM IN OTH SYS MYCOSES 0 0 . . . 
484.8 PNEUM IN INFECT DIS NEC 1 1 1.00 1.00 1.00 
485.9 BRONCHOPNEUMONIA ORGANISM 2,255 4 1.00 1.00 1.00 
486.0 PNEUMONIA, ORGANISM NOS 4 1 1.00 1.00 1.00 
486.9 PNEUMONIA, ORGANISM NOS 19,755 18 0.83 0.66 1.00 
487.0 INFLUENZA WITH PNEUMONIA 278 1 1.00 1.00 1.00 
487.1 INFLUENZA W/OTH. RESP. MA 28,029 41 0.88 0.78 0.98 
487.8 INFLUENZA W/OTHR MANIFEST 57 0 . . . 
490.0 BRONCHITIS NOS 7 1 0.00 0.00 0.00 
490.9 BRONCHITIS NOS 60,126 44 0.89 0.79 0.98 
493.0 ASTHMA, EXTRINSIC 3,265 10 0.90 0.71 1.00 
493.1 ASTHMA, INTRINSIC 25 9 1.00 1.00 1.00 
493.9 ASTHMA, UNSPEC 96,278 78 0.85 0.77 0.93 
511.0 PLEURISY W/O EFFUSION 139 1 . . . 
511.1 PLEURAL EFFUSION-VIRAL(NO 0 0 . . . 
511.8 HEMOTHORAX 9 6 0.67 0.29 1.00 
511.9 PLEURAL EFFUSION UNSPECIF 366 2 1.00 1.00 1.00 
513.0 ABSCESS LUNG 21 7 0.71 0.38 1.00 
513.1 ABSCESS OF MEDIASTINUM 1 1 0.00 0.00 0.00 
514.9 EDEMA PULMONARY 101 0 . . . 
518.0 PULMONARY COLLAPSE 143 2 0.50 0.00 1.00 
518.4 EDEMA LUNG ACUTE  NOS 246 1 0.00 0.00 0.00 
518.8 RESPIRATORY FAILURE, ACUTE 2,572 11 0.36 0.08 0.65 
519.2 MEDIASTINITIS 7 3 0.33 0.00 0.87 
519.3 MEDIASTINUM, DISEASES NEC 11 6 0.17 0.00 0.46 
769.9 RESPIRATORY DISTRESS SYND 24 1 0.00 0.00 0.00 
782.5 CYANOSIS 42 0 . . . 
784.1 PAIN IN THROAT 3,061 6 1.00 1.00 1.00 
786.0 RESPIRATORY ABNORMALITY 24,392 69 0.30 0.20 0.41 
786.1 STRIDOR 54 0 . . . 
786.2 COUGH 43,291 69 0.90 0.83 0.97 
786.3 HEMOPTYSIS 930 5 0.60 0.17 1.00 
786.5 CHEST PAIN, UNSPECIFIED 33,582 67 0.69 0.58 0.80 
786.7 ABNORMAL CHEST SOUNDS 30 0 . . . 
786.9 RESP SYS/CHEST SYMP NEC 2,204 7 0.57 0.20 0.94 
799.1 RESPIRATORY ARREST 70 2 0.50 0.00 1.00 
Total   911,924 1,050 0.85 0.83 0.88 
*The Quebec provincial healthcare agency records ICD-9 diagnostic codes up to the first decimal position only. ICD-9 
codes that are in the syndrome definition but do not appear in this table were not used in any of the 7,315,994 visits billed 
by the 1,098 participating physicians during the 2-year study period. 
**Among the 7,315,994 visits to the 1,098 participating physicians during the 2-year study period. 
***Among the 10,529 visits for which both the physician claim and the medical chart were available for verification. 
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Appendix – Table 6. FEVER syndrome, RODS definition: positive predictive value of individual syndrome-
positive ICD-9 diagnostic codes 
ICD-9 code 
in claims* 
Text label for ICD-9 code 
No. visits 
in claims** 
No. visits 
in verified 
claims*** 
PPV 
95% CI 
Lower limit Upper limit 
2.0 Typhoid/paratyphoid fever 48 2 0.50 0.00 1.00 
2.1 Paratyphoid fever a 5 2 0.00 0.00 0.00 
2.2 Paratyphoid fever b 0 0 . . . 
2.3 Paratyphoid fever c 1 1 0.00 0.00 0.00 
2.9 Paratyphoid fever nos 9 0 . . . 
20.0 Bubonic plague 1 1 0.00 0.00 0.00 
20.2 Septicemic plague 297 1 0.00 0.00 0.00 
20.8 Other specified types of plague 0 0 . . . 
20.9 Plague, unspecified 1 0 . . . 
21.0 Ulceroglandular tularemia 0 0 . . . 
21.3 Oculoglandular tularemia 0 0 . . . 
21.8 Other specified tularemia 0 0 . . . 
21.9 Unspecified tularemia 2 2 0.00 0.00 0.00 
22.3 Anthrax septicemia 0 0 . . . 
22.8 Other specified manifestations of 
anthrax 0 0 . . . 
22.9 Anthrax, unspecified 0 0 . . . 
23.0 Brucella melitensis 2 0 . . . 
23.1 Brucella abortus 0 0 . . . 
23.2 Brucella suis 6 3 0.33 0.00 0.87 
23.3 Brucella canis 0 0 . . . 
23.8 Other brucellosis 1 0 . . . 
23.9 Brucellosis, unspecified 14 6 0.33 0.00 0.71 
60.0 Sylvatic yellow fever 115 1 0.00 0.00 0.00 
60.1 Urban yellow fever 3 1 0.00 0.00 0.00 
60.9 Yellow fever, unspecified 35 0 . . . 
66.3 Mosquito-borne viral fever, 
Chikungunya 0 0 . . . 
73.7 Ornithosis with other specified 
complications 0 0 . . . 
73.8 Ornithosis with unspecified 
complication 0 0 . . . 
73.9 Ornithosis, unspecified 1 1 0.00 0.00 0.00 
75.0 Infectious mononucleosis 0 0 . . . 
78.3 Cat-scratch disease 14 4 0.00 0.00 0.00 
78.5 Cytomegaloviral disease 30 4 0.50 0.01 0.99 
79.0 Viral inf in oth dis/nos 507 0 . . . 
79.1 Echo virus infection in conditions 
classified elsewhere and of unspecified 
site 3 0 . . . 
79.2 Coxsackie virus infection in conditions 
classified elsewhere and of unspecified 
site 12 7 0.57 0.20 0.94 
79.9 Viral infection nos 5,551 30 0.33 0.16 0.50 
81.2 Scrub typhus 137 2 0.00 0.00 0.00 
130.7 Toxoplasmosis of other specified sites 0 0 . . . 
130.8 Multisystemic disseminated 
toxoplasmosis 0 0 . . . 
130.9 Toxoplasmosis, unspecified 5 4 0.50 0.01 0.99 
461.0 Acute maxillary sinusitis 4,234 5 0.40 0.00 0.83 
461.1 Acute frontal sinusitis 145 1 1.00 1.00 1.00 
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Appendix – Table 6. FEVER syndrome, RODS definition: positive predictive value of individual syndrome-
positive ICD-9 diagnostic codes 
ICD-9 code 
in claims* 
Text label for ICD-9 code 
No. visits 
in claims** 
No. visits 
in verified 
claims*** 
PPV 
95% CI 
Lower limit Upper limit 
461.2 Acute ethmoidal sinusitis 43 7 0.57 0.20 0.94 
461.3 Acute sphenoidal sinusitis 2 1 0.00 0.00 0.00 
461.8 Other acute sinusitis 1,466 5 0.40 0.00 0.83 
461.9 Acute sinusitis, unspecified 39,976 57 0.82 0.73 0.92 
464.0 Acute laryngitis 12,319 27 0.48 0.29 0.67 
464.5 Supraglottitis 0 0 . . . 
472.1 Chronic pharyngitis 466 4 0.00 0.00 0.00 
487.8 Influenza with other manifestations 57 0 . . . 
780.4 Dizziness and giddiness 23,611 257 0.35 0.30 0.41 
780.6 Fever 20,028 150 0.61 0.54 0.69 
780.7 Malaise and fatigue 49,102 232 0.66 0.60 0.72 
780.8 Hyperhidrosis 511 10 0.40 0.10 0.70 
780.9 Other general symptoms 2,004 29 0.21 0.06 0.35 
783.0 Anorexia 1,236 16 0.13 0.00 0.29 
Total   162,000 873 0.60 0.56 0.64 
*The Quebec provincial healthcare agency records ICD-9 diagnostic codes up to the first decimal position only. ICD-9 
codes that are in the syndrome definition but do not appear in this table were not used in any of the 7,315,994 visits billed 
by the 1,098 participating physicians during the 2-year study period. 
**Among the 7,315,994 visits to the 1,098 participating physicians during the 2-year study period. 
***Among the 10,529 visits for which both the physician claim and the medical chart were available for verification. 
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Appendix – Table 7. GASTROINTESTINAL syndrome, RODS definition: positive predictive value of individual 
syndrome-positive ICD-9 diagnostic codes 
ICD-9 code 
in claims* 
Text label for ICD-9 code 
No. visits 
in claims** 
No. visits 
in verified 
claims*** 
PPV 
95% CI 
Lower limit Upper limit 
1.0 Cholera due to Vibrio cholerae 13 10 0.00 0.00 0.00 
1.1 Cholera due to Vibrio cholerae el tor 24 11 0.00 0.00 0.00 
1.9 Cholera, unspecified 21 6 0.17 0.00 0.46 
3.0 Salmonella gastroenteritis 266 3 0.67 0.13 1.00 
4.0 Shigella dysenteriae 64 0 . . . 
4.1 Shigella flexneri 0 0 . . . 
4.2 Shigella boydii 0 0 . . . 
4.3 Shigella sonnei 2 2 0.00 0.00 0.00 
4.8 Other specified shigella infections 43 0 . . . 
4.9 Shigellosis, unspecified 4 1 1.00 1.00 1.00 
5.0 Staphylococcal food poisoning 3 0 . . . 
5.2 Food poisoning due to Clostridium 
perfringens (C. welchii) 102 1 0.00 0.00 0.00 
5.3 Food poisoning due to other clostridia 343 1 0.00 0.00 0.00 
5.4 Food poisoning due to vibrio 
parahaemolyticus 5 1 0.00 0.00 0.00 
5.8 Other bacterial food poisoning 0 0 . . . 
5.9 Food poisoning, unspecified 175 4 1.00 1.00 1.00 
6.0 Acute amebic dysentery without 
mention of abscess 9 3 0.33 0.00 0.87 
6.1 Chronic intestinal amebiasis without 
mention of abscess 7 2 0.00 0.00 0.00 
7.0 Balantidiasis 23 9 0.00 0.00 0.00 
7.1 GIardiasis 23 17 0.94 0.83 1.00 
7.2 Coccidiosis 7 2 0.00 0.00 0.00 
7.3 Intestinal trichomoniasis 0 0 . . . 
7.4 Cryptosporidiosis 0 0 . . . 
7.5 Cyclosporiasis 0 0 . . . 
7.8 Other specified protozoal intestinal 
diseases 4 1 0.00 0.00 0.00 
7.9 Unspecified protozoal intestinal disease 1 0 . . . 
8.0 Intestinal infection due to escherichia 
coli [e. Coli] 4 3 0.33 0.00 0.87 
8.1 Intestinal infection due to arizona group 
of paracolon bacilli 4 2 0.50 0.00 1.00 
8.2 Intestinal infection due to aerobacter 
aerogenes 1 0 . . . 
8.3 Intestinal infection due to proteus 
(mirabilis) (morganii) 0 0 . . . 
8.4 Intestinal infection due to other 
specified bacteria 10 4 0.00 0.00 0.00 
8.5 Bacterial enteritis nos 24 0 . . . 
8.6 Enteritis due to specified virus 11 5 0.60 0.17 1.00 
8.8 Intestinal infection due to other 
organism, not elsewhere classified 343 3 1.00 1.00 1.00 
9.0 Infectious colitis, enteritis, and 
gastroenteritis 3,818 25 0.76 0.59 0.93 
9.1 Colitis, enteritis, and gastroenteritis of 
presumed infectious origin 1,920 21 0.90 0.78 1.00 
9.2 Infectious diarrhea 371 2 0.50 0.00 1.00 
9.3 Diarrhea of presumed infectious origin 342 4 0.50 0.01 0.99 
21.1 Enteric tularemia 0 0 . . . 
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Appendix – Table 7. GASTROINTESTINAL syndrome, RODS definition: positive predictive value of individual 
syndrome-positive ICD-9 diagnostic codes 
ICD-9 code 
in claims* 
Text label for ICD-9 code 
No. visits 
in claims** 
No. visits 
in verified 
claims*** 
PPV 
95% CI 
Lower limit Upper limit 
22.2 GI anthrax 22 6 0.33 0.00 0.71 
32.8 Diphtheritic peritonitis 0 0 . . . 
535.0 Acute gastritis 7,439 54 0.67 0.54 0.79 
536.2 Persistent vomiting 90 3 0.33 0.00 0.87 
555.0 Regional enteritis of small intestine 759 16 0.44 0.19 0.68 
555.1 Regional enteritis of large intestine 1,332 9 0.78 0.51 1.00 
555.2 Regional enteritis of small intestine with 
large intestine 0 0 . . . 
555.9 Regional enteritis of unspecified site 6,993 95 0.88 0.82 0.95 
556.0 Ulcerative (chronic) enterocolitis 0 0 . . . 
556.1 Ulcerative (chronic) ileocolitis 0 0 . . . 
556.2 Ulcerative (chronic) proctitis 0 0 . . . 
556.3 Ulcerative (chronic) proctosigmoiditis 0 0 . . . 
556.4 Pseudopolyposis of colon 0 0 . . . 
556.5 Left-sided ulcerative (chronic) colitis 0 0 . . . 
556.6 Universal ulcerative (chronic) colitis 0 0 . . . 
556.8 Other ulcerative colitis 0 0 . . . 
556.9 Ulcerative colitis, unspecified 2,154 32 0.88 0.76 0.99 
558.0 Other and unspecified noninfectious 
gastroenteritis and colitis 0 0 . . . 
558.1 Gastroenteritis and colitis due to 
radiation 0 0 . . . 
558.2 Toxic gastroenteritis and colitis 0 0 . . . 
558.3 Allergic gastroenteritis and colitis 0 0 . . . 
558.9 Other and unspecified noninfectious 
gastroenteritis and colitis 28,890 120 0.86 0.80 0.92 
569.8 Ulceration of intestine 162 4 1.00 1.00 1.00 
787.0 Nausea and vomiting 4,882 76 0.62 0.51 0.73 
787.9 Diarrhea 2,787 14 0.50 0.24 0.76 
789.0 Abdominal pain 82,851 125 0.61 0.52 0.69 
789.4 Abdominal rigidity 7 6 0.33 0.00 0.71 
Total   146,355 703 0.68 0.63 0.73 
*The Quebec provincial healthcare agency records ICD-9 diagnostic codes up to the first decimal position only. ICD-9 
codes that are in the syndrome definition but do not appear in this table were not used in any of the 7,315,994 visits billed 
by the 1,098 participating physicians during the 2-year study period. 
**Among the 7,315,994 visits to the 1,098 participating physicians during the 2-year study period. 
***Among the 10,529 visits for which both the physician claim and the medical chart were available for verification. 
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Appendix – Table 8. NEUROLOGICAL syndrome, RODS definition: positive predictive value of individual 
syndrome-positive ICD-9 diagnostic codes 
ICD-9 code 
in claims* 
Text label for ICD-9 code 
No. visits 
in claims** 
No. visits 
in verified 
claims*** 
PPV 
95% CI 
Lower limit Upper limit 
13.0 Tuberculous meningitis 4 1 0.00 0.00 0.00 
13.6 Tuberculous encephalitis or myelitis 0 0 . . . 
13.8 Other specified tuberculosis of CNS 0 0 . . . 
13.9 Unspecified tuberculosis of CNS 0 0 . . . 
36.0 Meningococcal meningitis 3 2 0.50 0.00 1.00 
36.1 Meningococcal encephalitis 8 5 0.60 0.17 1.00 
36.2 Meningococcemia 23 2 0.00 0.00 0.00 
36.8 Meningococcal infect nec 0 0 . . . 
36.9 Meningococcal infect nos 0 0 . . . 
47.0 Coxsackie virus meningitis 10 6 0.00 0.00 0.00 
47.1 Echo virus meningitis 0 0 . . . 
47.8 Viral meningitis nec 0 0 . . . 
47.9 Viral meningitis nos 10 5 0.60 0.17 1.00 
48.0 Oth enteroviral cns dis 0 0 . . . 
49.0 Lymphocytic choriomeningitis 328 3 0.00 0.00 0.00 
49.1 Adenoviral meningitis 471 3 0.00 0.00 0.00 
49.8 Viral encephalitis nec 0 0 . . . 
49.9 Viral encephalitis nos 58 1 0.00 0.00 0.00 
52.0 Postvaricella encephalitis 0 0 . . . 
54.3 Herpetic meningoencephalitis 8 2 0.00 0.00 0.00 
54.7 Herpes simplex meningitis 16 8 0.00 0.00 0.00 
55.0 Postmeasles encephalitis 10 1 0.00 0.00 0.00 
56.0 Encephalomyelitis due to rubella 4 4 0.00 0.00 0.00 
62.0 Japanese encephalitis 7 1 0.00 0.00 0.00 
62.1 Western equine encephalitis 0 0 . . . 
62.2 Eastern equine encephalitis 0 0 . . . 
62.3 St. Louis encephalitis 0 0 . . . 
62.4 Australian encephalitis 0 0 . . . 
62.5 California virus encephalitis 1 1 0.00 0.00 0.00 
62.8 Other specified mosquito-borne viral 
encephalitis 0 0 . . . 
62.9 Mosquito-borne viral encephalitis, 
unspecified 1 1 0.00 0.00 0.00 
63.0 Russian spring-summer (taiga) 
encephalitis 1 0 . . . 
63.1 Louping ill 0 0 . . . 
63.2 Central European encephalitis 0 0 . . . 
63.8 Other specified tick-borne viral 
encephalitis 0 0 . . . 
63.9 Tick-borne viral encephalitis, 
unspecified 3 3 0.00 0.00 0.00 
64.0 Viral encephalitis arthropod nec 0 0 . . . 
66.2 Venezuelan equine fever (encephalitis) 0 0 . . . 
66.4 West Nile fever (encephalitis) 0 0 . . . 
71.0 Rabies 0 0 . . . 
72.2 Mumps encephalitis 0 0 . . . 
94.2 Syphilitic meningitis 10 5 0.00 0.00 0.00 
94.8 Syphilitic encephalitis 1 1 0.00 0.00 0.00 
100.8 Leptospiral meningitis 0 0 . . . 
114.2 Coccidioidal meningitis 0 0 . . . 
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Appendix – Table 8. NEUROLOGICAL syndrome, RODS definition: positive predictive value of individual 
syndrome-positive ICD-9 diagnostic codes 
ICD-9 code 
in claims* 
Text label for ICD-9 code 
No. visits 
in claims** 
No. visits 
in verified 
claims*** 
PPV 
95% CI 
Lower limit Upper limit 
115.0 Histoplasma capsulatum meningitis 1 1 0.00 0.00 0.00 
115.1 Histoplasma duboisii meningitis 0 0 . . . 
115.9 Histoplasmosis meningitis 12 5 0.20 0.00 0.55 
130.0 Meningoencephalitis due to 
toxoplasmosis 0 0 . . . 
293.0 Acute delirium 67 2 0.50 0.00 1.00 
293.1 Subacute delirium 9 4 0.25 0.00 0.67 
320.0 Hemophilus meningitis 0 0 . . . 
320.1 Pneumococcal meningitis 0 0 . . . 
320.2 Streptococcal meningitis 1 0 . . . 
320.3 Staphylococcal meningitis 0 0 . . . 
320.7 Meningitis in oth bact dis 4 1 0.00 0.00 0.00 
320.8 Bacterial meningitis nec 0 0 . . . 
320.9 Bacterial meningitis nos 6 6 0.00 0.00 0.00 
321.0 Cryptococcal meningitis 0 0 . . . 
321.1 Meningitis in oth fungal dis 1 1 0.00 0.00 0.00 
321.2 Meningitis in oth viral dis 0 0 . . . 
321.3 Trypanosomiasis meningitis 2 1 0.00 0.00 0.00 
321.8 Meningitis in oth nonbac dis 0 0 . . . 
322.0 Nonpyogenic meningitis 18 5 0.20 0.00 0.55 
322.1 Eosinophilic meningitis 0 0 . . . 
322.9 Meningitis nos 240 3 0.67 0.13 1.00 
323.0 Encephalitis in viral diseases classified 
elsewhere 16 2 1.00 1.00 1.00 
323.1 Encephalitis in rickettsial diseases 
classified elsewhere 0 0 . . . 
323.2 Encephalitis in protozoal diseases 
classified elsewhere 18 12 0.00 0.00 0.00 
323.4 Other encephalitis due to infection 
classified elsewhere 4 1 1.00 1.00 1.00 
323.5 Encephalitis following immunization 
procedures 0 0 . . . 
323.6 Postinfectious encephalitis 0 0 . . . 
323.7 Toxic encephalitis 1 1 0.00 0.00 0.00 
323.8 Other causes of encephalitis 0 0 . . . 
323.9 Unspecified cause of encephalitis 204 5 0.20 0.00 0.55 
331.8 Reye's syndrome 8 2 0.00 0.00 0.00 
348.3 Encephalopathy, unspecified 175 3 0.33 0.00 0.87 
780.0 Coma and stupor 1,603 47 0.02 0.00 0.06 
780.3 Convulsions 653 19 0.53 0.30 0.75 
781.6 Meningismus 21 11 0.18 0.00 0.41 
784.0 Headache 32,290 683 0.56 0.52 0.60 
989.7 Aflatoxin and other mycotoxin (food 
contaminants) 1 1 0.00 0.00 0.00 
998.0 Toxic effect of fish and shellfish 
(Saxitoxin) 10 3 0.00 0.00 0.00 
Total   36,342 874 0.52 0.48 0.55 
*The Quebec provincial healthcare agency records ICD-9 diagnostic codes up to the first decimal position only. ICD-9 
codes that are in the syndrome definition but do not appear in this table were not used in any of the 7,315,994 visits billed 
by the 1,098 participating physicians during the 2-year study period. 
**Among the 7,315,994 visits to the 1,098 participating physicians during the 2-year study period. 
***Among the 10,529 visits for which both the physician claim and the medical chart were available for verification.  
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Appendix – Table 9. RASH syndrome, RODS definition: positive predictive value of individual syndrome-
positive ICD-9 diagnostic codes 
ICD-9 code 
in claims* 
Text label for ICD-9 code 
No. visits 
in claims** 
No. visits 
in verified 
claims*** 
PPV 
95% CI 
Lower limit Upper limit 
20.1 Cellulocutaneous plague 6 2 0.00 0.00 0.00 
22.0 Cutaneous anthrax 9 6 0.00 0.00 0.00 
34.1 Scarlet fever 2,552 42 0.88 0.78 0.98 
40.8 Toxic shock syndrome 4 2 0.50 0.00 1.00 
50.0 Variola major 3 3 0.00 0.00 0.00 
50.1 Alastrim (Variola minor) 0 0 . . . 
50.2 Modified smallpox 0 0 . . . 
50.9 Smallpox, unspecified 2 2 0.50 0.00 1.00 
51.0 Cowpox 3,730 20 0.00 0.00 0.00 
51.1 Pseudocowpox 42 0 . . . 
51.2 Contagious pustular dermatitis 44 1 0.00 0.00 0.00 
51.9 Paravaccinia, unspecified 30 1 1.00 1.00 1.00 
52.0 Chickenpox 0 0 . . . 
52.7 Chickenpox with other specified 
complications 0 0 . . . 
52.8 Chickenpox with unspecified 
complication 0 0 . . . 
52.9 Varicella without mention of 
complication 1,558 26 0.88 0.76 1.00 
53.0 Herpes zoster with meningitis 396 13 0.92 0.78 1.00 
53.1 Herpes zoster with other nervous 
system complications 42 2 0.50 0.00 1.00 
53.2 Herpes zoster with ophthalmic 
complications 229 4 1.00 1.00 1.00 
53.7 Herpes zoster with other specified 
complications 19 6 1.00 1.00 1.00 
53.8 Herpes zoster with unspecified 
complication 17 8 1.00 1.00 1.00 
53.9 Herpes zoster without mention of 
complication 10,551 168 0.89 0.84 0.93 
54.0 Eczema herpeticum 708 13 0.46 0.19 0.73 
54.4 Herpes simplex with ophthalmic 
complications 7 5 0.40 0.00 0.83 
54.7 Herpes simplex with other specified 
complications 16 8 0.88 0.65 1.00 
54.8 Herpes simplex with unspecified 
complication 5 4 0.50 0.01 0.99 
54.9 Herpes simplex without mention of 
complication 8,763 153 0.65 0.57 0.72 
55.0 Measles 10 1 0.00 0.00 0.00 
55.7 Measles with other specified 
complications 0 0 . . . 
55.8 Measles with unspecified complication 141 4 0.00 0.00 0.00 
55.9 Measles without mention of 
complication 82 3 0.33 0.00 0.87 
56.0 Rubella 4 4 0.50 0.01 0.99 
56.7 Rubella with other specified 
complications 2 1 0.00 0.00 0.00 
56.8 Rubella with unspecified complications 0 0 . . . 
56.9 Rubella without mention of complication 172 1 0.00 0.00 0.00 
57.0 Erythema infectiosum [fifth disease] 238 2 1.00 1.00 1.00 
57.8 Other specified viral exanthemata 619 9 0.56 0.23 0.88 
57.9 Viral exanthem, unspecified 1,440 15 0.33 0.09 0.57 
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Appendix – Table 9. RASH syndrome, RODS definition: positive predictive value of individual syndrome-
positive ICD-9 diagnostic codes 
ICD-9 code 
in claims* 
Text label for ICD-9 code 
No. visits 
in claims** 
No. visits 
in verified 
claims*** 
PPV 
95% CI 
Lower limit Upper limit 
74.3 Hand, foot mouth dis 49 1 1.00 1.00 1.00 
80.0 Louse-borne (epidemic) typhus 0 0 . . . 
81.0 Murine (endemic) typhus 3 1 0.00 0.00 0.00 
81.9 Typhus, unspecified 0 0 . . . 
82.0 Spotted fevers (Rocky mountain spotted 
fever) 2 2 0.50 0.00 1.00 
82.1 Boutonneuse fever 14 2 0.00 0.00 0.00 
82.2 North asian tick fever 2 1 0.00 0.00 0.00 
82.3 Queensland tick typhus 3 2 0.00 0.00 0.00 
82.8 Tick-borne ricketts nec 4 1 1.00 1.00 1.00 
82.9 Tick-borne ricketts nos 9 4 0.00 0.00 0.00 
83.2 Rickettsialpox 2 2 0.00 0.00 0.00 
83.8 Rickettsioses nec 2 1 0.00 0.00 0.00 
83.9 Rickettsiosis nos 2 1 0.00 0.00 0.00 
91.3 Secondary syphilis skin 48 0 . . . 
115.1 Infection by Histoplasma duboisii 0 0 . . . 
287.0 Allergic purpura 66 2 1.00 1.00 1.00 
287.1 Qualitative platelet defects 56 2 0.00 0.00 0.00 
287.2 Other nonthrombocytopenic purpuras 389 11 0.36 0.08 0.65 
287.8 Other specified hemorrhagic conditions 2 2 0.00 0.00 0.00 
287.9 Unspecified hemorrhagic conditions 394 11 0.18 0.00 0.41 
684.0 Impetigo 0 0 . . . 
686.0 Pyoderma 752 13 0.15 0.00 0.35 
686.1 Pyogenic granuloma 433 6 0.00 0.00 0.00 
694.3 Impetigo herpetiformis 4 3 0.00 0.00 0.00 
695.0 Toxic erythema 53 3 0.67 0.13 1.00 
695.1 Erythema multiforme 106 1 1.00 1.00 1.00 
695.2 Erythema nodosum 135 5 1.00 1.00 1.00 
695.8 Other specified erythematous conditions 735 12 0.67 0.40 0.93 
695.9 Unspecified erythematous condition 3,183 41 0.29 0.15 0.43 
782.1 Rash and other nonspecific skin 
eruption 16,123 131 0.69 0.62 0.77 
782.7 Spontaneous ecchymoses 1,239 24 0.33 0.14 0.52 
Total   55,251 814 0.63 0.59 0.66 
*The Quebec provincial healthcare agency records ICD-9 diagnostic codes up to the first decimal position only. ICD-9 
codes that are in the syndrome definition but do not appear in this table were not used in any of the 7,315,994 visits billed 
by the 1,098 participating physicians during the 2-year study period. 
**Among the 7,315,994 visits to the 1,098 participating physicians during the 2-year study period. 
***Among the 10,529 visits for which both the physician claim and the medical chart were available for verification. 
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Appendix – Table 10. RESPIRATORY syndrome, RODS definition: positive predictive value of individual 
syndrome-positive ICD-9 diagnostic codes 
ICD-9 code 
in claims* 
Text label for ICD-9 code 
No. visits 
in claims** 
No. visits 
in verified 
claims*** 
PPV 
95% CI 
Lower limit Upper limit 
3.2 Salmonella pneumonia 3 1 0.00 0.00 0.00 
10.0 Primary tuberculous infection 2 1 1.00 1.00 1.00 
10.1 Tuberculous pleurisy in primary 
progressive tuberculosis 3 2 0.50 0.00 1.00 
10.8 Other primary progressive tuberculosis 1 1 0.00 0.00 0.00 
10.9 Primary tuberculous infection, 
unspecified type 16 6 0.33 0.00 0.71 
11.0 Tuberculosis of lung, infiltrative 29 8 0.38 0.04 0.71 
11.1 Tuberculosis of lung, nodular 20 8 0.13 0.00 0.35 
11.2 Tuberculosis of lung with cavitation 32 0 . . . 
11.3 Tuberculosis of bronchus 171 0 . . . 
11.4 Tuberculous fibrosis of lung 2 1 0.00 0.00 0.00 
11.5 Tuberculous bronchiectasis of lung 1 1 1.00 1.00 1.00 
11.6 Tuberculous pneumonia (any form) of 
lung 2 1 0.00 0.00 0.00 
11.7 Tuberculous pneumothorax of lung 7 2 0.00 0.00 0.00 
11.8 Other specified pulmonary tuberculosis 4 0 . . . 
11.9 Unspecified pulmonary tuberculosis 259 1 0.00 0.00 0.00 
20.0 Plague 1 1 1.00 1.00 1.00 
20.3 Primary pneumonic plague 0 0 . . . 
20.4 Secondary pneumonic plague 7 3 0.33 0.00 0.87 
20.5 Pneumonic plague, unspecified 0 0 . . . 
21.2 Pulmonary tularemia 0 0 . . . 
22.0 Anthrax 9 6 0.00 0.00 0.00 
22.1 Pulmonary anthrax 0 0 . . . 
24.0 Glanders 0 0 . . . 
25.0 Melioidosis 0 0 . . . 
32.0 Faucial diphtheria 52 0 . . . 
32.1 Nasopharyngeal diphtheria 8 5 0.40 0.00 0.83 
32.2 Anterior nasal diphtheria 7 2 0.00 0.00 0.00 
32.3 Laryngeal diphtheria 1 0 . . . 
32.8 Other specified diphtheria 0 0 . . . 
32.9 Diphtheria, unspecified 2 2 0.50 0.00 1.00 
33.0 Bordetella pertussis 39 9 1.00 1.00 1.00 
33.1 Bordetella parapertussis 0 0 . . . 
33.8 Whooping cough nec 5 1 1.00 1.00 1.00 
33.9 Whooping cough nos 325 0 . . . 
34.0 Strep sore throat 735 2 1.00 1.00 1.00 
52.1 Varicella (hemorrhagic) pneumonitis 0 0 . . . 
55.1 Postmeasles pneumonia 8 3 0.67 0.13 1.00 
73.0 Ornithosis (Psittacoisis) 0 0 . . . 
74.1 Epidemic pleurodynia 7 1 1.00 1.00 1.00 
79.0 Adenovirus infection in conditions 
classified elsewhere and of unspecified 
site 507 0 . . . 
79.3 Rhinovirus infection in conditions 
classified elsewhere and of unspecified 
site 2 1 0.00 0.00 0.00 
79.6 Resp syncytial virus (rsv) infection in 
conditions classified elsewhere and of 
unspecified site 0 0 . . . 
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Appendix – Table 10. RESPIRATORY syndrome, RODS definition: positive predictive value of individual 
syndrome-positive ICD-9 diagnostic codes 
ICD-9 code 
in claims* 
Text label for ICD-9 code 
No. visits 
in claims** 
No. visits 
in verified 
claims*** 
PPV 
95% CI 
Lower limit Upper limit 
79.8 Viral infection nec 154 4 0.00 0.00 0.00 
83.0 Q fever 56 0 . . . 
112.4 Candidiasis of lung 3 1 0.00 0.00 0.00 
114.0 Primary coccidioidomycosis 
(pulmonary) 0 0 . . . 
114.9 Coccidioidomycosis nos 2 1 0.00 0.00 0.00 
115.0 Infection by Histoplasma capsulatum 1 1 0.00 0.00 0.00 
115.1 Infection by Histoplasma duboisii 0 0 . . . 
115.9 Histoplasmosis, unspecified 12 5 0.20 0.00 0.55 
130.4 Pneumonitis due to toxoplasmosis 0 0 . . . 
136.3 Pneumocystosis 1 0 . . . 
460.0 Acute nasopharyngitis [common cold] 1 0 . . . 
462.0 Acute pharyngitis 10 0 . . . 
463.0 Acute tonsillitis 3 0 . . . 
464.0 Acute laryngitis 12,319 27 0.74 0.58 0.91 
464.1 Acute tracheitis 9,716 13 0.77 0.54 1.00 
464.2 Acute laryngotracheitis 1,214 1 1.00 1.00 1.00 
464.3 Acute epiglottitis 32 16 0.69 0.46 0.91 
464.4 Croup 916 0 . . . 
465.0 Acute laryngopharyngitis 4,679 3 0.67 0.13 1.00 
465.8 Acute upper Resp infections of other 
multiple sites 3,809 11 0.64 0.35 0.92 
465.9 Acute upper Resp infections of 
unspecified site 223,128 84 0.79 0.70 0.87 
466.0 Acute bronchitis 62,662 67 0.81 0.71 0.90 
466.1 Acute bronchiolitis 5,006 10 0.90 0.71 1.00 
480.0 Pneumonia due to adenovirus 636 2 0.00 0.00 0.00 
480.1 Pneumonia due to Resp syncytial virus 3 3 0.33 0.00 0.87 
480.2 Pneumonia due to parainfluenza virus 1 0 . . . 
480.8 Pneumonia due to other virus not 
elsewhere classified 1 1 1.00 1.00 1.00 
480.9 Viral pneumonia, unspecified 1,044 0 . . . 
481.0 Pneumococcal pneumonia 
[Streptococcus pneumoniae 
pneumonia] 0 0 . . . 
482.0 Pneumonia due to Klebsiella 
pneumoniae 311 0 . . . 
482.1 Pneumonia due to Pseudomonas 26 6 0.33 0.00 0.71 
482.2 Pneumonia due to Hemophilus 
influenzae [H. influenzae] 8 4 1.00 1.00 1.00 
482.3 Pneumonia due to Streptococcus 0 0 . . . 
482.4 Pneumonia due to Staphylococcus 0 0 . . . 
482.8 Pneumonia due to other specified 
bacteria 25 4 1.00 1.00 1.00 
482.9 Bacterial pneumonia, unspecified 2,915 2 0.50 0.00 1.00 
483.0 Pneumonia due to Mycoplasma 
pneumoniae 0 
0 
. . . 
483.1 Pneumonia due to Chlamydia 0 0 . . . 
483.8 Pneumonia due to other specified 
organism 0 
0 
. . . 
484.0 Pneumonia in infectious diseases 
classified elsewhere 6 3 0.33 0.00 0.87 
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Appendix – Table 10. RESPIRATORY syndrome, RODS definition: positive predictive value of individual 
syndrome-positive ICD-9 diagnostic codes 
ICD-9 code 
in claims* 
Text label for ICD-9 code 
No. visits 
in claims** 
No. visits 
in verified 
claims*** 
PPV 
95% CI 
Lower limit Upper limit 
484.1 Pneumonia in cytomegalic inclusion 
disease 10 4 0.50 0.01 0.99 
484.3 Pneumonia in whooping cough 0 0 . . . 
484.5 Pneumonia in anthrax 1 1 0.00 0.00 0.00 
484.6 Pneumonia in aspergillosis 0 0 . . . 
484.7 Pneumonia in other systemic mycoses 0 0 . . . 
484.8 Pneumonia in other infectious diseases 
classified elsewhere 1 1 0.00 0.00 0.00 
485.0 Bronchopneumonia, organism 
unspecified 0 0 . . . 
486.0 Pneumonia, organism unspecified 1 1 1.00 1.00 1.00 
487.0 Influenza with pneumonia 278 1 1.00 1.00 1.00 
487.1 Influenza with other Resp 
manifestations 28,029 41 0.76 0.62 0.89 
490.0 Bronchitis nos 2 1 0.00 0.00 0.00 
491.0 Chronic bronchitis 1,452 0 . . . 
491.1 Mucopurulent chronic bronchitis 90 0 . . . 
491.2 Obstructive chronic bronchitis 578 1 0.00 0.00 0.00 
491.8 Chronic bronchitis nec 795 3 0.67 0.13 1.00 
491.9 Chronic bronchitis nos 8,098 16 0.44 0.19 0.68 
507.0 Pneumonitis due to solids and liquids 24 11 0.45 0.16 0.75 
507.1 Pneumonitis due to inhalation of oils 
and essences 0 0 . . . 
507.8 Pneumonitis due to other solids and 
liquids 0 0 . . . 
511.0 Pleurisy 139 0 . . . 
511.1 Bact pleur/effus not tb 0 0 . . . 
511.8 Pleural effus nec not tb 9 6 0.67 0.29 1.00 
511.9 Pleural effusion nos 366 2 1.00 1.00 1.00 
513.0 Abscess of lung 21 7 0.71 0.38 1.00 
513.1 Abscess of mediastinum 1 1 0.00 0.00 0.00 
518.0 Pulmonary collapse 143 2 0.50 0.00 1.00 
518.4 Acute lung edema nos 246 1 0.00 0.00 0.00 
518.8 Other diseases of lung 2,572 11 0.36 0.08 0.65 
519.2 Mediastinitis 7 3 0.33 0.00 0.87 
784.1 Throat pain 3,061 6 1.00 1.00 1.00 
786.0 Dyspnea/Resp abn 24,392 69 0.28 0.17 0.38 
786.1 Stridor 54 0 . . . 
786.2 Cough 43,291 69 0.84 0.75 0.93 
786.5 Painful respiration 33,582 67 0.67 0.56 0.78 
795.3 Nonspecific positive findings for anthrax 
(Positive findings by nasal swab) 3 1 0.00 0.00 0.00 
V018 Contact or exposure to anthrax (Other 
communicable diseases) 2 1 0.00 0.00 0.00 
Total   478,215 665 0.74 0.70 0.79 
*The Quebec provincial healthcare agency records ICD-9 diagnostic codes up to the first decimal position only. ICD-9 
codes that are in the syndrome definition but do not appear in this table were not used in any of the 7,315,994 visits billed 
by the 1,098 participating physicians during the 2-year study period. 
**Among the 7,315,994 visits to the 1,098 participating physicians during the 2-year study period. 
***Among the 10,529 visits for which both the physician claim and the medical chart were available for verification. 
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Appendix – Table 11. INFLUENZA-LIKE ILLNESS, large-group definition: positive predictive value of individual 
syndrome-positive ICD-9 diagnostic codes 
ICD-9 code 
in claims* 
Text label for ICD-9 code 
No. visits 
in claims** 
No. visits 
in verified 
claims*** 
PPV 
95% CI 
Lower limit Upper limit 
79.9 VIRAL INFECTIONS UNSPECIFIED 5,551 30 0.63 0.46 0.81 
382.9 OTITIS MEDIA NOS 95,165 68 0.54 0.43 0.66 
460.0 NASOPHARYNGITIS, ACUTE 1 0 . . . 
460.9 NASOPHARYNGITIS, ACUTE NOS 20,179 11 0.82 0.59 1.05 
461.9 SINUSITIS, ACUTE  NOS 39,976 57 0.74 0.62 0.85 
465.8 URI, OTHER MULT. SITES 3,809 11 0.36 0.08 0.65 
465.9 URI, ACUTE  NOS 223,128 84 0.86 0.78 0.93 
466.0 BRONCHITIS ACUTE 62,662 67 0.85 0.77 0.94 
486.0 PNEUMONIA, ORGANISM NOS 4 1 1.00 1.00 1.00 
486.9 PNEUMONIA, ORGANISM NOS 19,755 18 0.39 0.16 0.61 
487.0 INFLUENZA WITH PNEUMONIA 278 1 1.00 1.00 1.00 
487.1 INFLUENZA W/OTH. RESP. MA 28,029 41 0.78 0.65 0.91 
487.8 INFLUENZA W/OTHR MANIFEST 57 0 . . . 
490.0 BRONCHITIS NOS 7 1 0.00 0.00 0.00 
490.9 BRONCHITIS NOS 60,126 44 0.86 0.76 0.97 
780.6 FEVER 20,028 150 0.77 0.71 0.84 
786.2 COUGH 43,291 69 0.81 0.72 0.90 
Total   622,046 653 0.77 0.73 0.81 
*The Quebec provincial healthcare agency records ICD-9 diagnostic codes up to the first decimal position only. ICD-9 
codes that are in the syndrome definition but do not appear in this table were not used in any of the 7,315,994 visits billed 
by the 1,098 participating physicians during the 2-year study period. 
**Among the 7,315,994 visits to the 1,098 participating physicians during the 2-year study period. 
***Among the 10,529 visits for which both the physician claim and the medical chart were available for verification. 
 
 
 
 
Appendix – Table 12. INFLUENZA-LIKE ILLNESS, small-group definition: positive predictive value of individual 
syndrome-positive ICD-9 diagnostic codes 
ICD-9 code 
in claims* 
Text label for ICD-9 code 
No. visits 
in claims** 
No. visits 
in verified 
claims*** 
PPV 
95% CI 
Lower limit Upper limit 
465.8 URI, OTHER MULT. SITES 3,809 11 0.09 0.00 0.26 
487.0 INFLUENZA WITH PNEUMONIA 278 1 0.00 0.00 0.00 
487.1 INFLUENZA W/OTH. RESP. MA 28,029 41 0.32 0.17 0.46 
487.8 INFLUENZA W/OTHR MANIFEST 57 0 . . . 
Total   32,173 53 0.29 0.16 0.41 
*The Quebec provincial healthcare agency records ICD-9 diagnostic codes up to the first decimal position only. ICD-9 
codes that are in the syndrome definition but do not appear in this table were not used in any of the 7,315,994 visits billed 
by the 1,098 participating physicians during the 2-year study period. 
**Among the 7,315,994 visits to the 1,098 participating physicians during the 2-year study period. 
***Among the 10,529 visits for which both the physician claim and the medical chart were available for verification. 
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Chapter 6. Predictors of accuracy of syndrome definitions based on diagnoses in 
physician claims 
 
Preamble to Manuscript 3 
 
Analyses for manuscript 2 revealed that, whereas the specificity and negative predictive 
value of syndrome definitions based on diagnoses in physician claims were extremely 
high, their sensitivity and positive predictive value could be improved. A potential 
method for improving the accuracy of syndrome definitions is to identify and take into 
account variables associated with syndrome definition accuracy. Our review of the 
literature suggested that this had only been attempted once in the context of syndromic 
surveillance. However, several studies in other fields, especially chronic diseases 
research, showed that the accuracy of case definitions based on diagnoses in 
administrative data was associated with covariates such as patient (34;75;76;78-82) and 
clinical encounter (67;74) characteristics, and could be improved by taking into account 
covariates (83-86). We hypothesized that several properties of surveillance data, 
including who generated them (i.e., healthcare provider characteristics), how the data 
were reported (i.e., reporting or billing system characteristics), who they describe (i.e., 
patient characteristics), and where and in what context they arose (i.e., clinical 
encounter characteristics), were likely to influence case definition accuracy.  
 
When the research protocol for this thesis was developed, the main goal of syndromic 
surveillance was the early detection of outbreaks, and the emphasis was on maximizing 
the sensitivity of surveillance systems, often at the expense of specificity and positive 
predictive value. This resulted in frequent false-alerts, and ultimately limited the 
usefulness of syndromic surveillance for early detection. Partly because of these 
limitations, syndromic surveillance systems are increasingly being used to monitor 
population health for situation awareness. The expanding goal of syndromic surveillance 
requires better positive predictive value and fewer false-positives. Therefore, for 
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manuscript 3, we attempted to identify covariates associated with the positive 
predictive value of syndrome definitions based on diagnoses in physician claims.   
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ABSTRACT 
 
BACKGROUND: Case definition accuracy is an important determinant of surveillance 
system usefulness. We assessed whether physician, billing, patient, and encounter 
characteristics are associated with the positive predictive value of case definitions for 5 
syndromes (fever, gastrointestinal, neurological, rash, and respiratory including 
influenza-like illness). 
 
METHODS: We sampled 4,330 syndrome-positive visits from the claims of 1,098 
randomly-selected physicians working in Quebec, Canada in 2005-2007. For each visit, 
we assessed whether the same syndrome was present in the medical chart through 
physician-facilitated chart review. We used multivariate logistic regression analyses to 
estimate the association between claim-chart agreement about the presence of a 
syndrome and physician, billing, patient, and encounter characteristics.  
 
RESULTS: The likelihood of the medical chart agreeing with the physician claim about the 
presence of a syndrome was higher when the treating physician had billed many visits 
for the same syndrome recently (ORper 5 years since licensure, 0.96; 95% CI, 0.92-1.00), had a 
lower workload (ORper 10 claims, 0.93; 95% CI, 0.90-0.97), and when the patient was 
younger (ORper 5 years of age, 0.96; 95% CI, 0.94-0.97), and less socially deprived (ORmost versus 
least deprived, 0.76; 95% CI, 0.60-0.95). 
 
CONCLUSION: Many predictors of syndrome definition accuracy identified are accessible 
to public health and other organizations that routinely perform syndromic surveillance. 
These predictors can be used to reduce the false-positive rate of syndromic surveillance 
systems, either by focusing on the data most likely to be accurate, or by adjusting the 
observed data for known biases in diagnosis reporting and performing surveillance using 
the adjusted values. 
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INTRODUCTION 
 
Syndromic surveillance systems were adopted rapidly in the wake of 9/11 amidst 
concerns of bioterrorism. The primary purpose of these systems was to detect disease 
outbreaks and bioterrorism events rapidly. To ensure that no outbreak would be missed, 
syndromic surveillance systems were initially designed to generate alerts at very low 
thresholds. A consequence of this design was high rates of false-positive alerts (36), 
which have limited syndromic surveillance systems’ ability to correctly identify 
outbreaks. Indeed, because of the prohibitive cost of investigating every alert, many 
public health practitioners have adopted a ‘wait-and-see’ response to alerts, thereby 
detracting from a main advantage of syndromic surveillance systems over traditional 
public health surveillance systems, namely the ability to provide a timelier portrait of 
population health. Attempts to reduce false-positive rates by improving statistical 
detection algorithms used in syndromic surveillance (37-39) have had limited success. 
 
Partly because of these limitations, the focus of syndromic surveillance has begun to 
shift away from outbreak detection towards population health monitoring or situation 
awareness (41;147). Syndromic surveillance systems are now being tailored to suit this 
novel use. Whereas outbreak detection sought to identify and alert on every suspicious 
increase in the incidence of cases, maintaining situation awareness entails gathering 
data about the current state of population health, analyzing and interpreting these data, 
and projecting the likely evolution of the current state (41). Accurate case definitions are 
critical for monitoring population health and maintaining situation awareness, but, to 
date, almost no attempts have been made to improve the accuracy of the case 
definitions used in syndromic surveillance (42-44). Identifying properties of surveillance 
data associated with higher positive predictive value (PPV) of case definitions used in 
syndromic surveillance will improve individual case detection and situation awareness, 
and will likely also lead to improved outbreak detection.  
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Several properties of surveillance data, such as who generated them (healthcare 
provider characteristics), how they were reported (reporting/billing system 
characteristics), who they describe (patient characteristics), and where and in what 
context they arose (clinical encounter characteristics), are likely to influence case 
definition accuracy. Characteristics of the healthcare provider that are associated with 
practice style or coding accuracy may influence the PPV of diagnostic data. For example, 
two studies have reported that greater experience was associated with lower diagnostic 
coding accuracy (45) and lower billing diagnosis accuracy (46). Reporting/billing 
practices, including who enters the diagnosis in the system and how the diagnosis is 
entered (e.g., direct entry of diagnostic codes, searchable list of diagnoses that the 
software then maps to codes, automated abstraction of the billing diagnosis from an 
electronic medical record) are likely to influence the PPV of the diagnostic data. The 
context for the clinical encounter, which influences how much time and what resources 
are available for reporting/billing, is also likely to impact diagnostic data accuracy. For 
example, higher physician workloads were associated with lower billing diagnosis 
accuracy in one study (46). Treating more complex patients likely requires more working 
memory and increases physician cognitive load (47), therefore diagnostic coding errors 
may be more likely to occur for complex patients. For this reason, indicators of patient 
complexity, such as age, comorbidity, socioeconomic status, and health services 
utilization(48), may impact the PPV of diagnostic data (67). 
 
The objective of the present study was to identify physician, billing, patient, and 
encounter characteristics associated with the PPV of syndrome definitions based on 
diagnoses in physician claims. Because of their public health importance, our study 
focused on the following 5 syndromes: fever, gastrointestinal, neurological, rash, and 
respiratory (66), including influenza-like illness (ILI)(49). 
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METHODS 
 
Context 
This study was conducted in the province of Quebec, Canada, where universal health 
coverage is provided through the provincial health insurance plan. Similar to health 
maintenance organizations and medical provider networks, each Canadian province 
maintains a population-based registry of insured persons and claims for all physician 
visits remunerated on a fee-for-service basis. The registrant database includes patient 
sex, date of birth, and postal code, enabling linkage to census information. Physician 
claims include information on the diagnosis, medical procedure, visit date, and location. 
All claims also record unique physician and patient identifiers that can be used to create 
longitudinal histories of healthcare use. In the province of Quebec, 99% of residents 
have provincial health insurance, and 85-95% of medical visits are remunerated on a fee-
for-service basis (148). In 2006, there were more than 7.6 million inhabitants in Quebec 
(89), and 18,908 active registered physicians (90). 
 
Study design and population 
In a prior study assessing the accuracy of syndrome definitions based on diagnoses in 
physician claims (71), we randomly selected a cohort of 3,600 physicians who were 
practicing in the fee-for-service system in the province of Quebec in 2005-2007, and 
who were likely to provide first-contact care. For each physician, we selected a stratified 
random sample of 5 visits with a syndrome-positive diagnosis in the claim (i.e., 1 visit for 
each of these 5 syndromes: fever, gastrointestinal, neurological, rash, and respiratory 
including ILI). Restriction was used to ensure that patients were only sampled once. The 
present study is based on the cohort of 1,098 physicians who consented to provide 
medical chart information (participation rate of  30.5%) and 4,330 of their visits with a 
syndrome-positive claim diagnosis (71).  
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Outcome measure 
For each visit with a syndrome-positive diagnosis in the physician claim, we assessed 
whether the same syndrome was documented in the medical chart. Medical chart data 
was retrieved using a previously described physician-facilitated chart review 
methodology (71). 
 
Potential predictors of the accuracy of syndrome definitions based on physician claim 
diagnoses 
 
Physician characteristics  
Physician gender  is associated with several practice style indicators, including physician-
patient communication (149-152), and it may be associated with billing diagnosis 
accuracy. Physician gender was obtained from the provincial health insurance agency. 
Physician language (French or English) likely affects communication with the patient, 
and may therefore impact billing diagnosis accuracy; physician language was obtained 
from the provincial health insurance agency. Year since licensure was calculated by 
subtracting the year of licensure, which was obtained from the provincial medical 
regulatory authority, from the year of the syndrome-positive visit. As compared to 
generalists, specialists see a narrower segment of the patient population for a subset of 
health conditions; therefore they likely use fewer diagnostic codes and may have better 
billing diagnosis accuracy. Physician specialty was obtained from the provincial health 
insurance agency.  
 
Billing practices  
Different billing softwares use different methods for entering diagnoses, which likely 
affect billing diagnosis accuracy. Billing software was obtained through a telephone 
interview with the physician (71). Who enters the diagnostic code in the claim was 
obtained through a telephone interview with the physician (71). We expect claim 
diagnosis accuracy to be highest when a physician does his own billing. Physicians’ 
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annual billing volume is an indicator of practice style. Annual billing volume was 
calculated as the number of distinct claims billed by a physician during the study year 
when the syndrome-positive visit occurred. The percent of visits with missing or 
unspecified diagnostic codes is expected to reflect attention to diagnostic coding. It was 
calculated as the total number of visits without any diagnostic code or with a diagnostic 
code of ‘V999’ (unspecified), multiplied by 100, and divided by the total number of visits 
billed by the physician during the study year when the syndrome-positive visit occurred. 
The number of distinct diagnostic codes used likely reflects the scope of health 
conditions treated by a physician, and physicians who see a narrower scope of health 
conditions may be more likely to remember and assign the correct diagnostic code for 
these conditions. It was calculated as the number of distinct diagnostic codes used 
among all claims billed during the study year when the syndrome-positive visit occurred. 
 
Patient characteristics 
Patient gender is expected to influence communication during the visit (149-152), and it 
may influence physician documentation of patient complaints. Patient gender was 
obtained from the registrant database. Greater patient complexity, by taxing limited 
physician resources, is expected to reduce physician billing diagnosis accuracy (67). 
Patient complexity is associated with patient age, comorbidity, and socioeconomic 
status (48). Patient age on October 1st of the study year when the visit took place was 
obtained from the provincial health services agency. For each patient, The Charlson 
Comorbidity Index (153) was computed using diagnoses in claims billed by all physicians 
seen (not only study physicians) during the year preceding the visit. Material and social 
deprivation indices developed by the Quebec National Public Health Institute (91;92), 
are associated with health services utilization (154-156), and therefore may influence 
billing diagnosis accuracy. The material deprivation index summarizes information on 
the proportion of persons who have no high school diploma, the proportion of persons 
employed, and the average income in the patient’s 6-digit postal code area of residence. 
The social deprivation index summarizes information on the proportion of single-parent 
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families, the proportion of persons living alone, and the proportion of persons 
separated, divorced, or widowed in the patient’s 6-digit postal code area of residence. 
For each patient, the material and social deprivation indices were calculated by the 
provincial health services agency using Statistics Canada’s 2006 census data. Health 
services utilization is expected to reflect patient complexity; it was calculated as the 
number of ambulatory care visits in the previous year. 
 
Encounter characteristics 
As reported in our previous study, different syndrome definitions have vastly different 
PPVs (71). Therefore syndrome type is likely to influence claim diagnosis accuracy. 
Different resources for physician billing are likely to be available depending on the type 
of clinic and geographic location of the clinic, which may influence claim diagnosis 
accuracy. The type of clinic was obtained from the physician claim and categorized as 
private clinic, community health center, or hospital ambulatory care clinic. The 
geographic location of the clinic was categorized as urban or rural based on the clinic’s 
6-digit postal code. Because the majority of physicians do not schedule appointments on 
the weekend, a medical encounter during the weekend is more likely to be a ‘walk-in’ 
visit for a specific acute or urgent health complaint, such as an infectious syndrome. For 
this reason, we expect syndromes to be more accurately reported in the physician claim 
for a weekend encounter, as opposed to a weekday encounter. The day of the week on 
which the encounter took place was derived from the encounter date in the physician 
claim. In our previous study, we found that infrequent claim diagnoses are more likely to 
be erroneous than frequent ones (71). Therefore, we expect that the more frequently a 
syndrome is diagnosed, the more accurate the claim diagnosis is. As an indicator of 
syndrome frequency, the number of visits for the same syndrome billed by the study 
physician in the previous 30 days was calculated from each physician’s claims. The 
occurrence of many syndromes undergoes seasonal variation, peaking in winter and 
plummeting in summer, therefore we expect that the season in which the encounter 
took place will influence the accuracy of claim diagnoses through a similar mechanism as 
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syndrome frequency. The season during which the encounter took place was derived 
from the encounter date in the physician claim. Higher physician workload may have a 
negative impact on record-keeping and billing practices, and may lead to poorer billing 
diagnosis accuracy. Workload was calculated as the number of physician claims on the 
day of the encounter, which reflects both the number of patients seen and the 
complexity of their care. Greater physician familiarity with a patient may increase the 
scope of health conditions discussed during the clinical encounter, thereby adding to the 
complexity of patient care. Therefore, the encounter is expected to be more focused, 
and claim diagnosis accuracy is expected to be better when physicians are not familiar 
with the patient. As an indicator of physician familiarity with the patient, we assessed 
whether or not the physician had treated the patient in the previous year, using the 
physicians’ claims. 
 
Statistical methods 
Multivariable logistic regression analyses for clustered data were performed using 
generalized estimating equations (GEE) to estimate the association between the 
presence or absence of the syndrome in the medical chart (binary dependent variable) 
for a given visit with a syndrome-positive diagnosis in the physician claim, and physician 
characteristics, billing practices, patient characteristics, and encounter characteristics 
(SAS Version 9.2, SAS Institute Inc., Cary, NC). The visit was the unit of analysis, and visits 
were clustered within study physicians (there was only 1 visit per patient). Based on the 
assumption that physician diagnostic coding and billing patterns may change over time, 
visits were ordered chronologically, and a first-order autoregressive correlation 
structure of residuals was used to account for clustering.  A 2-sided test with a p-value of 
0.05 was used to assess statistical significance. In the main analyses, physician time since 
licensure, billing characteristics, and patient age, health services utilization, and Charlson 
comorbidity index were modelled as continuous variables, assuming the linearity of their 
association with the logit of the probability of the presence or absence of the syndrome 
in the medical chart. In sensitivity analyses, to account for possibly non-linear 
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relationships, continuous variables were categorized into quartiles and modelled 
through three dummy indicators with the lowest quartile as the reference; we also 
tested the statistical significance of the quadratic component. 
 
Ethics review 
The research protocol for this study was reviewed and approved by the McGill University 
Institutional Review Board, the Quebec privacy commission, the Quebec health 
insurance agency, and the Quebec medical regulatory authority. 
 
RESULTS 
 
Of 4,330 visits with a syndrome-positive diagnosis in the physician claim, 2,967 (68.5%) 
also had a syndrome-positive diagnosis in the medical chart.  
 
Physician characteristics 
The accuracy of claim diagnoses decreased by 4% with every 5 additional years since 
medical licensure (ORper 5 years , 0.96; 95% CI, 0.92-1.00) (Table 1). Whereas an effect of 
4% may appear small, this is due to the scale used (i.e., per 5 years), and it implies a 20% 
difference between recently graduated physicians and those who have been in practice 
for 25 years, which was the average time elapsed since licensure among physicians in 
our sample. As compared to general practitioners, internists and general surgeons had 
41% poorer claim diagnosis accuracy (OR, 0.59; 95% CI, 0.35-0.98). Physician gender and 
language were not significantly associated with the PPV of syndrome definitions based 
on physician claim diagnoses. 
 
Billing practices 
Several billing softwares were significantly associated with claim diagnosis accuracy 
(Table 2). Purkinje billing software, which abstracted the billing diagnosis from the 
electronic medical record in an automated manner, had higher claim diagnosis accuracy 
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than Soft Informatique, which required manual input of the billing diagnosis (OR, 1.29; 
95% CI, 1.05-1.59). Surprisingly, who entered the ICD-9 diagnostic code on the billing 
claim was not significantly associated with claim diagnosis accuracy. Physician annual 
billing volume, proportion of visits billed with a missing or unspecified diagnostic code, 
and number of distinct diagnostic codes used were not significantly associated with 
claim diagnosis accuracy. 
 
Patient characteristics 
Claim diagnosis accuracy decreased by 4% with every additional 5 years of patient age 
(ORper 5 years, 0.96; 95% CI, 0.94-0.97), so that older patient had much poorer claim 
diagnosis accuracy than younger ones (Table 3). Whereas patient comorbidity, as 
measured by the Charlson Comorbidity Index, was significantly and negatively 
associated with claim diagnosis accuracy in bivariate analyses (ORper 1-point increase, 0.92; 
95% CI, 0.86-0.97), the association was no longer significant when the model was 
adjusted for patient age (ORper 1-point increase, 0.98; 95% CI, 0.92-1.05). Similarly, health 
services utilization in the previous year was significantly and negatively associated with 
claim diagnosis accuracy (ORper additional visit, 0.99; 95% CI, 0.98-0.99), but the association 
did not remain statistically significant in multivariate analyses. Patients in the highest 
quintile of social deprivation had significantly poorer claim diagnosis accuracy (ORmost 
versus least deprived, 0.76; 95% CI, 0.60-0.95), as compared to those in the least socially 
deprived quintile. Patient gender was not significantly associated with claim diagnosis 
accuracy. 
 
Encounter characteristics 
Gastrointestinal syndrome (OR, 1.72; 95% CI, 1.36-2.16), neurological syndrome (OR, 
1.38; 95% CI, 1.11-1.72), rash syndrome (OR, 1.89; 95% CI, 1.51-2.37), respiratory 
syndrome (OR, 1.66; 95% CI, 1.29-2.14), and ILI large-group (OR, 2.68; 95% CI, 2.06-
3.48), all had significantly higher claim diagnosis accuracy than fever syndrome (Table 4). 
With respect to physician workload, claim diagnosis accuracy decreased by 7% with 
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every 10 additional claims on the day of the encounter (ORper 10 claims, 0.93; 95% CI, 0.90-
0.97). Claim diagnosis accuracy improved by 5% with every 10 visits billed by the study 
physician for the same syndrome in the previous month (ORper 10 same-syndrome positive visits, 
1.05; 95% CI, 1.01-1.08). With respect to seasonality, claim diagnosis accuracy was 
significantly better in spring, as compared to winter (OR, 1.29; 95% CI, 1.07-1.57); this 
association seemed to be strongest for fever syndrome (Appendix 1). Type of clinic and 
geographic location of the clinic were not significantly associated with claim diagnosis 
accuracy. 
 
DISCUSSION 
 
To improve the accuracy of syndromic surveillance, we sought to identify physician, 
billing, patient, and encounter characteristics associated with the PPV of syndrome 
definitions based on diagnoses in physician claims. We identified several properties of 
surveillance data – healthcare provider, billing, patient, and encounter characteristics – 
associated with the PPV of syndrome definitions. Several of the predictors of syndrome 
definition accuracy that we identified (e.g., patient age, number of visits for the same 
syndrome in the last month) are readily accessible to public health departments and 
other organizations that routinely perform syndromic surveillance. These predictors can 
be used to reduce the false-positive rate of syndromic surveillance systems, either by 
focusing on the data most likely to be accurate, or by adjusting the observed data for 
known biases in diagnosis reporting and performing surveillance using the adjusted 
values.  
 
Specifically, we found that visits with a syndrome-positive diagnosis in physician claims 
were more likely to be confirmed as syndrome-positive by the medical chart when the 
physician was recently licensed. This finding is similar to those of other, general studies 
of billing diagnosis accuracy and physician practice experience (45;46). A potential 
explanation for this finding is that younger physicians may be more likely to follow 
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guidelines and give greater attention to billing, whereas more experienced physicians 
may be more likely to ‘code from memory’, which has been associated with more 
frequent diagnostic coding errors, as compared to coding from reference materials (45), 
Similar to another study (46), we found that physicians with a higher workload on the 
day of the encounter had lower billing diagnosis accuracy. We also found that claims for 
less complex patients (i.e., younger and less socially deprived patients) were more likely 
to be confirmed as syndrome-positive by the medical chart, as compared to those of 
more complex patients. Higher physician workload and greater patient complexity may 
increase demands on limited physician resources – taxing working memory and 
increasing cognitive load – thereby increasing the likelihood of physician errors, 
including errors in billing diagnosis. Additionally, we found that visits with a syndrome-
positive diagnosis in physician claims were more likely to be confirmed as syndrome-
positive by the medical chart when the physician had billed many visits for the same 
syndrome recently. This finding agrees with our previous finding (71) that commonly 
used diagnoses are more likely to be accurate than rarely used ones. The observation 
that billing diagnosis accuracy increases with repeated use can be explained by widely 
accepted theories on the effect of repetition on recall (157). 
 
We also found that billing software had a significant impact on the PPV of syndrome 
definitions based on diagnoses in physician claims: software that abstracted the billing 
diagnosis from the electronic medical record in an automated manner had higher claim 
diagnosis accuracy than software requiring the manual input of billing diagnoses. This 
finding has important implications for both clinical users and public health surveillance, 
given the ongoing transformation from a process where clinical practitioners manually 
submit case reports to a process where public health agencies automatically extract 
relevant data from clinical information systems. Indeed, the US federal government has 
allotted $39 billion to support the adoption and "meaningful use" of electronic health 
records, and software purchased using these funds must support automated submission 
of data to public health agencies for three public health uses, including syndromic 
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surveillance (158). This investment presents an opportunity to improve syndromic 
surveillance systems by having electronic health records capture and transmit 
information on highly influential predictors, such as indicators of patient complexity, to 
public health.  
 
Our study had several strengths. It was based on a large representative sample of 
physicians and patients. We had access to many physician, billing, patient, and 
encounter characteristics, which enabled us to perform a comprehensive assessment of 
the impact of a variety of factors on the accuracy of syndrome definitions. Whereas 
some of our findings are specific to our study population, most of our findings are likely 
to be generalizable to other jurisdictions across North America because of similar 
physician and patient populations. A limitation of our study was that the number of 
visits per syndrome was too small to identify predictors of syndrome definition accuracy 
for each syndrome individually. Whereas most of the predictors of syndrome definition 
accuracy that we identified would be expected to impact all syndrome definitions in a 
similar manner (e.g., physician workload, patient complexity), some predictors may have 
a greater or lesser impact on syndrome definition accuracy depending on the syndrome 
(e.g., season). 
 
In closing, we have demonstrated through a large random sample of physicians with 
chart validation that measurable elements of the medical visit determine the accuracy of 
a given syndrome report derived from physician claims. These elements include 
physician, billing, patient, and encounter characteristics, which public health 
departments can collect through surveillance and use to focus or adjust their analyses in 
order to enhance the accuracy of surveillance. The rich clinical data streams becoming 
accessible to public health should enable the implementation of surveillance strategies 
that incorporate our findings. As the volume and detail of clinical data continue to 
increase, future research should explore how public health can harness their full breadth 
to further enhance the accuracy of case detection.  
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Table 1. Physician characteristics associated with accuracy of syndrome definitions based on physician claims (OR>1.00 means the physician characteristic increased the 
PPV of the syndrome definition, OR<1.00 means the physician characteristic reduced the PPV) 
 
 No. visits with a syndrome-positive physician claim Bivariate regression analysis Multivariate regression 
analysis
1
 
Physician characteristics 
Syndrome-positive 
in the chart 
(N=2,967) 
Syndrome-negative 
in the chart 
(N=1,363) 
Total 
(N=4,330) 
OR 95% CI P value OR 95% CI P value 
 No. % No. % No. %       
Gender:             
   Female 1,164 39.2 523 38.4 1,687 39.0 Ref. Ref. Ref. Ref. Ref. Ref. 
   Male 1,803 60.8 840 61.6 2,643 61.0 0.97 (0.83, 1.12) 0.64 1.13 (0.96, 1.33) 0.13 
Preferred language:             
   French 2,743 92.5 1,253 91.9 3,996 92.3 Ref. Ref. Ref. Ref. Ref. Ref. 
   English 224 7.5 110 8.1 334 7.7 0.93 (0.69, 1.25) 0.63 0.94 (0.69, 1.26) 0.66 
Specialty:             
   General practice 2,721 91.7 1,246 91.4 3,967 91.6 Ref. Ref. Ref. Ref. Ref. Ref. 
   Pediatrics 203 6.8 75 5.5 278 6.4 1.24 (0.88, 1.77) 0.22 0.83 (0.57, 1.20) 0.33 
   Internal medicine or general surgery 43 1.5 42 3.1 85 2.0 0.46 (0.31, 0.69) <0.001 0.59 (0.35, 0.98) 0.04 
             
 Mean SD Mean SD Mean SD       
Years since licensure (per 5 years) 22.9  9.2 23.7  9.6 23.1  9.4 0.95 (0.92, 0.99) 0.02 0.96 (0.92, 1.00) 0.04 
 
1
 Multivariate analysis adjusted for all physician characteristics in Table 1, all patient characteristics in Table 3, and all encounter characteristics in Table 4. 
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Table 2. Billing characteristics associated with accuracy of syndrome definitions based on physician claims (OR>1.00 means the billing characteristic increased the PPV of the 
syndrome definition, OR<1.00 means the billing characteristic reduced the PPV) 
 
 No. visits with a syndrome-positive physician claim Bivariate regression analysis Multivariate regression 
analysis
1
 
Billing practices 
Syndrome-positive 
in the chart 
(N=2,967) 
Syndrome-negative 
in the chart 
(N=1,363) 
Total 
(N=4,330) 
OR 95% CI P value OR 95% CI P value 
 No. % No. % No. %       
Who entered the diagnostic code in the 
claim?             
   Physician 443 14.9 203 14.9 646 14.9 Ref. Ref. Ref. Ref. Ref. Ref. 
   Secretary or nurse 2,015 67.9 907 66.5 2,922 67.5 1.01 (0.82, 1.26) 0.91 0.93 (0.75, 1.15) 0.50 
   Off-site billing company or  
   RAMQ (i.e., paper billing) 509 17.2 253 18.6 762 17.6 0.92 (0.71, 1.19) 0.52 0.81 (0.62, 1.06) 0.12 
Billing software used:             
   Soft Informatique 715 24.4 342 25.4 1,057 24.8 Ref. Ref. Ref. Ref. Ref. Ref. 
   Purkinje 721 24.7 264 19.6 985 23.1 1.30 (1.07, 1.60) 0.01 1.29 (1.05, 1.59) 0.02 
   ADN Medical 405 13.9 166 12.3 571 13.4 1.16 (0.90, 1.49) 0.24 1.17 (0.91, 1.50) 0.23 
   Omni-Med.com Caduceus 250 8.6 124 9.2 374 8.8 0.96 (0.74, 1.25) 0.77 0.94 (0.72, 1.24) 0.67 
   Medicus MED-WIN 123 4.2 67 5.0 190 4.5 0.87 (0.65, 1.17) 0.36 0.87 (0.64, 1.17) 0.35 
   Facturation.net 73 2.5 64 4.8 137 3.2 0.55 (0.35, 0.86) 0.01 0.54 (0.34, 0.85) 0.01 
   ANDX Xclaim 61 2.1 40 3.0 115 2.7 0.73 (0.47, 1.14) 0.17 0.70 (0.42, 1.15) 0.16 
   CareOffice 85 2.9 30 2.2 103 2.4 1.36 (0.84, 2.18) 0.21 1.32 (0.76, 2.27) 0.32 
   Médifiche 75 2.6 28 2.1 101 2.4 1.28 (0.81, 2.02) 0.29 1.24 (0.77, 1.98) 0.38 
   Toubib 52 1.8 43 3.2 95 2.2 0.58 (0.32, 1.05) 0.07 0.53 (0.29, 0.97) 0.04 
   FMP 57 2.0 16 1.2 73 1.7 1.71 (0.92, 3.19) 0.09 1.74 (0.90, 3.34) 0.10 
   Médicalc Inc.
2
 49 1.7 19 1.4 68 1.6 1.23 (0.61, 2.47) 0.57 1.27 (0.62, 2.62) 0.51 
   Param 47 1.6 18 1.3 65 1.5 1.24 (0.67, 2.29) 0.49 1.19 (0.66, 2.17) 0.56 
   ACL Systèmes Santé 43 1.5 20 1.5 63 1.5 1.03 (0.58, 1.84) 0.92 1.06 (0.56, 2.02) 0.85 
   Factura-Med 43 1.5 17 1.3 60 1.4 1.20 (0.79, 1.84) 0.39 1.24 (0.81, 1.89) 0.32 
   FmedX MED-Office 39 1.3 18 1.3 57 1.3 1.04 (0.48, 2.25) 0.92 0.99 (0.46, 2.13) 0.98 
   Sys-Thèmes 24 0.8 9 0.7 33 0.8 1.27 (0.54, 3.00) 0.59 1.24 (0.55, 2.77) 0.61 
   Gestimed 12 0.4 14 1.0 26 0.6 0.41 (0.21, 0.81) 0.01 0.45 (0.25, 0.84) 0.01 
 
1
 Multivariate analysis adjusted for all billing practices in Table 2 and all physician characteristics in Table 1. 
2
 Software developed and used solely by their namesake off-site billing company. 
3
 Single-user billing software developed by individual physicians. 
4
 In the study year when the visit took place. The study spanned 2 years: October 1, 2005 to September 30, 2006, and October 1, 2006 to September 30, 2007. 
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Table 2 (continued). Billing characteristics associated with accuracy of syndrome definitions based on physician claims (OR>1.00 means the billing characteristic increased 
the PPV of the syndrome definition, OR<1.00 means the billing characteristic reduced the PPV) 
 
 No. visits with a syndrome-positive physician claim Bivariate regression analysis Multivariate regression 
analysis
1
 
Billing practices 
Syndrome-positive 
in the chart 
(N=2,967) 
Syndrome-negative 
in the chart 
(N=1,363) 
Total 
(N=4,330) 
OR 95% CI P value OR 95% CI P value 
 No. % No. % No. %       
Billing software used (continued):             
   Salus 10 0.3 10 0.7 20 0.5 0.48 (0.18, 1.32) 0.16 0.45 (0.14, 1.44) 0.18 
   Logimedic 7 0.2 8 0.6 15 0.4 0.41 (0.16, 1.05) 0.06 0.39 (0.15, 1.03) 0.06 
   Medi-Go 2 0.1 6 0.5 8 0.2 0.16 (0.02, 1.68) 0.13 0.15 (0.01, 1.72) 0.13 
   Services de facturations  
   médicales informatiques
2
 4 0.1 3 0.2 7 0.2 0.63 (0.40, 1.01) 0.06 0.65 (0.37, 1.16) 0.14 
   Other
3
 13 0.4 3 0.2 16 0.4 2.12 (0.71, 6.29) 0.18 1.94 (0.71, 5.28) 0.19 
   Unknown 15 0.5 17 1.3 32 0.8 0.41 (0.20, 0.86) 0.02 0.48 (0.24, 0.93) 0.03 
   RAMQ (i.e., paper billing) 42 1.4 17 1.2 59 1.4 1.18 (0.55, 2.57) 0.67 1.39 (0.63, 3.07) 0.41 
 Mean SD Mean SD Mean SD       
Annual billing volume (per 1,000 
claims)
4
 4,913 2,623 4,913 2,646 4,913  2,630  1.00 (0.97, 1.03) 0.94 1.00 (0.97, 1.04) 0.91 
Percent of visits with a missing or 
unspecified diagnostic code
4
 2.5  5.7  2.5  5.1  2.5 5.5  1.00 (0.99, 1.02) 0.91 1.01 (0.99, 1.02) 0.34 
No. distinct diagnostic codes used (per 
100 codes)
4
 228 88  227 97 228 91 1.01 (0.94, 1.10) 0.76 1.02 (0.92, 1.12) 0.75 
 
1
 Multivariate analysis adjusted for all billing practices in Table 2 and all physician characteristics in Table 1. 
2
 Software developed and used solely by their namesake off-site billing company. 
3
 Single-user billing software developed by individual physicians. 
4
 In the study year when the visit took place. The study spanned 2 years: October 1, 2005 to September 30, 2006, and October 1, 2006 to September 30, 2007. 
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Table 3. Patient characteristics associated with accuracy of syndrome definitions based on physician claims (OR>1.00 means the patient characteristic increased the PPV of 
the syndrome definition, OR<1.00 means the patient characteristic reduced the PPV) 
 
 No. visits with a syndrome-positive physician claim Bivariate regression analysis Multivariate regression 
analysis
1
 
Patient characteristics 
Syndrome-positive 
in the chart 
(N=2,967) 
Syndrome-negative 
in the chart 
(N=1,363) 
Total 
(N=4,330) 
OR 95% CI P value OR 95% CI P value 
Sex: No. % No. % No. %       
  Female 1,810 61.0 824 60.5 2,634 60.8 Ref. Ref. Ref. Ref. Ref. Ref. 
  Male 1,157 39.0 539 39.5 1,696 39.2 0.98 (0.86, 1.12) 0.75 0.89 (0.77, 1.03) 0.11 
Material deprivation index:
2
             
   1
st
 quintile (least deprived) 524 17.7 284 20.8 808 18.7 Ref. Ref. Ref. Ref. Ref. Ref. 
   2
nd
 quintile 584 19.7 270 19.8 854 19.7 1.16 (0.94, 1.42) 0.16 1.18 (0.95, 1.46) 0.14 
   3
rd
 quintile 604 20.4 243 17.8 847 19.6 1.33 (1.08, 1.64) 0.01 1.44 (1.15, 1.81) <0.01 
   4
th
 quintile 581 19.6 261 19.1 842 19.4 1.21 (0.98, 1.49) 0.07 1.25 (1.01, 1.55) 0.04 
   5
th
 quintile (most deprived) 545 18.4 255 18.7 800 18.5 1.16 (0.94, 1.43) 0.16 1.21 (0.97, 1.50) 0.09 
Social deprivation index:
2
             
   1
st
 quintile (least deprived) 611 20.6 251 18.4 862 19.9 Ref. Ref. Ref. Ref. Ref. Ref. 
   2
nd
 quintile 574 19.3 263 19.3 837 19.3 0.90 (0.73, 1.10) 0.30 0.91 (0.74, 1.13) 0.41 
   3
rd
 quintile 572 19.3 251 18.4 823 19.0 0.91 (0.74, 1.13) 0.41 0.97 (0.77, 1.21) 0.76 
   4
th
 quintile 554 18.7 261 19.1 815 18.8 0.87 (0.70, 1.07) 0.19 0.88 (0.70, 1.10) 0.26 
   5
th
 quintile (most deprived) 527 17.8 287 21.1 814 18.8 0.75 (0.61, 0.93) 0.01 0.76 (0.60, 0.95) 0.02 
Deprivation indices missing:             
   No 2,838 95.7 1,313 96.3 4,151 95.9 Ref. Ref. Ref. Ref. Ref. Ref. 
   Yes 129 4.3 50 3.7 179 4.1 1.04 (0.73, 1.49) 0.83 1.06 (0.68, 1.64) 0.81 
 Mean SD Mean SD Mean SD       
Age (per 5 years)
3
 36.4 24.9  43.2 24.0 38.5 24.8 0.95 (0.93, 0.96) <0.0001 0.96 (0.94, 0.97) <0.0001 
Health services utilization (no. 
ambulatory visits in the previous year)
4
 9.0 10.1  10.6 12.7 9.5 11.0 0.99 (0.98, 0.99) <0.0001 0.99 (0.99, 1.00) 0.08 
Charlson comorbidity index (per 1-point 
increase in score)
4
 0.38 0.98  0.49 1.17 0.42 1.04 0.92 (0.86, 0.97) <0.01 0.98 (0.92, 1.05) 0.58 
 
1
 Multivariate analysis adjusted for all patient characteristics in Table 3, all physician characteristics in Table 1, and all encounter characteristics in Table 4. 
2
 The material and social deprivation indices were calculated using Statistics Canada‟s 2006 census data. These indices were developed by the Quebec National Public Health 
Institute. The material deprivation index summarizes information on the proportion of persons who have no high school diploma, the proportion of persons employed, and the average 
income in the patient‟s 6-digit postal code area of residence. The social deprivation index summarizes information on the proportion of single-parent families, the proportion of persons 
living alone, and the proportion of persons separated, divorced, or widowed in the patient‟s 6-digit postal code area of residence.  
3
 On October 1
st
 of the study year when the visit took place. The study spanned 2 years: October 1, 2005 to September 30, 2006, and October 1, 2006 to September 30, 2007. 
4
 Based on all medical services claims billed by all Quebec physicians (not only the 3,600 study physicians) in the year prior to the date of the syndrome-positive visit.  
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Table 4. Encounter characteristics associated with accuracy of syndrome definitions based on physician claims (OR>1.00 means the encounter characteristic increased the 
PPV of the syndrome definition, OR<1.00 means the encounter characteristic reduced the PPV) 
 
 No. visits with a syndrome-positive physician claim 
Bivariate regression analysis 
Multivariate regression 
analysis
1
 
Encounter characteristics 
Syndrome-positive 
in the chart 
(N=2,967) 
Syndrome-negative 
in the chart 
(N=1,363) 
Total 
(N=4,330) 
OR 95% CI P value OR 95% CI P value 
 No. % No. % No. %       
Syndrome type:             
  Fever 371 12.5 230 16.9 601 13.9 Ref. Ref. Ref. Ref. Ref. Ref. 
  Gastrointestinal 572 19.3 283 20.8 855 19.8 1.57 (1.25, 1.97) <0.0001 1.72 (1.36, 2.16) <0.0001 
  Neurological 608 20.5 363 26.6 971 22.4 1.29 (1.05, 1.60) 0.02 1.38 (1.11, 1.72) <0.01 
  Rash 628 21.2 269 19.7 897 20.7 1.80 (1.44, 2.25) <0.0001 1.89 (1.51, 2.37) <0.0001 
  Respiratory 808 27.2 241 17.7 1049 24.2 1.72 (1.36, 2.17) <0.0001 1.66 (1.29, 2.14) <0.0001 
  ILI large-group 555 18.7 98 7.2 653 15.1 2.98 (2.32, 3.82) <0.0001 2.68 (2.06, 3.48) <0.0001 
Type of clinic:             
  Private clinic 2,916 98.3 1,320 96.9 4,236 97.8 Ref. Ref. Ref. Ref. Ref. Ref. 
  Community health center 10 0.3 8 0.6 18 0.4 0.58 (0.14, 2.35) 0.45 0.46 (0.11, 2.01) 0.30 
  Hospital-based ambulatory clinic 41 1.4 35 2.6 76 1.8 0.53 (0.30, 0.93) 0.03 0.75 (0.37, 1.53) 0.43 
Geographic location of clinic:             
   Urban 2,476 83.5 1,169 85.8 3,645 84.2 Ref. Ref. Ref. Ref. Ref. Ref. 
   Rural 491 16.6 194 14.2 685 15.8 1.20 (0.99, 1.46) 0.07 1.19 (0.98, 1.45) 0.08 
Physician familiarity with the patient 
(patient treated by the study physician 
in the previous year):             
   No 1,199 40.4 475 34.9 1,674 38.7 Ref. Ref. Ref. Ref. Ref. Ref. 
   Yes 1,768 59.6 888 65.1 2,656 61.3 0.79 (0.69, 0.91) <0.001 0.95 (0.82, 1.11) 0.53 
Day of the week:             
   Weekday 2,797 94.3 1,308 96.0 4,105 94.8 Ref. Ref. Ref. Ref. Ref. Ref. 
   Weekend 170 5.7 55 4.0 225 5.2 1.42 (1.03, 1.95) 0.03 1.28 (0.92, 1.77) 0.15 
Season:             
   Winter (12/22-03/20) 737 24.8 339 24.9 1,076 24.9 Ref. Ref. Ref. Ref. Ref. Ref. 
   Spring (03/21-06/20) 855 28.8 317 23.3 1,172 27.1 1.22 (1.02, 1.47) 0.03 1.29 (1.07, 1.57) 0.01 
   Summer (06/21-09/22) 645 21.7 351 25.8 996 23.0 0.84 (0.70, 1.01) 0.06 0.91 (0.75, 1.10) 0.33 
   Fall (09/23-12/21) 730 24.6 356 26.1 1,086 25.1 0.94 (0.79, 1.12) 0.48 0.97 (0.81, 1.17) 0.79 
 
1
 Multivariate analysis adjusted for all encounter characteristics in Table 4, all physician characteristics in Table 1, and all patient characteristics in Table 3. 
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Table 4 (continued). Encounter characteristics associated with accuracy of syndrome definitions based on physician claims (OR>1.00 means the encounter characteristic 
increased the PPV of the syndrome definition, OR<1.00 means the encounter characteristic reduced the PPV) 
 
 No. visits with a syndrome-positive physician claim 
Bivariate regression analysis 
Multivariate regression 
analysis
1
 
Encounter characteristics 
Syndrome-positive 
in the chart 
(N=2,967) 
Syndrome-negative 
in the chart 
(N=1,363) 
Total 
(N=4,330) 
OR 95% CI P value OR 95% CI P value 
 Mean SD Mean SD Mean SD       
No. syndrome-positive visits billed by 
the study physician in the previous 30 
days, for the same syndrome as the 
verified visit (per 10 visits) 4.1 6.7  4.2 6.2 4.2 6.6 1.08 (0.95, 1.23) 0.25 1.05 (1.01, 1.08) 0.01 
Physician workload: no. claims billed 
that day (per 10 claims) 35.1 17.4  36.5 21.0 35.5 18.6  0.96 (0.93, 1.00) 0.03 0.93 (0.90, 0.97) <0.001 
 
1
 Multivariate analysis adjusted for all encounter characteristics in Table 4, all physician characteristics in Table 1, and all patient characteristics in Table 3. 
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Appendix – Table 1. Physician characteristics associated with accuracy of syndrome definitions based on physician claims: results from bivariate regression analyses for 
each syndrome individually (OR>1.00 means the physician characteristic increased the PPV of the syndrome definition, OR<1.00 means the physician characteristic reduced the 
PPV) 
 
 Fever syndrome  
(N=601 visits) 
Gastrointestinal syndrome  
(N=855 visits) 
Neurological syndrome  
(N=971 visits) 
Rash syndrome  
(N=897 visits) 
Physician characteristics 
No. 
visits 
OR 95% CI 
P 
Value 
No. 
visits 
OR 95% CI 
P 
value 
No. 
visits 
OR 95% CI 
P 
Value 
No. 
visits 
OR 95% CI 
P 
value 
Gender:                 
  Female 249 Ref. Ref. Ref. 340 Ref. Ref. Ref. 371 Ref. Ref. Ref. 338 Ref. Ref. Ref. 
  Male 352 0.82 (0.60, 1.14) 0.25 515 0.83 (0.62, 1.11) 0.21 600 1.09 (0.83, 1.41) 0.54 559 1.37 (1.03, 1.84) 0.03 
Preferred language:                 
  French 548 Ref. Ref. Ref. 784 Ref. Ref. Ref. 901 Ref. Ref. Ref. 830 Ref. Ref. Ref. 
  English 53 0.59 (0.33, 1.05) 0.07 71 0.79 (0.48, 1.30) 0.35 70 1.13 (0.68, 1.86) 0.64 67 1.22 (0.70, 2.14) 0.48 
Specialty:                 
  General practice 539 Ref. Ref. Ref. 776 Ref. Ref. Ref. 899 Ref. Ref. Ref. 828 Ref. Ref. Ref. 
  Internal medicine 8 0.30 (0.06, 1.50) 0.14 12 0.18 (0.05, 0.68) 0.01 11 0.54 (0.16, 1.79) 0.31 8 0.72 (0.17, 3.02) 0.65 
  Pediatrics 51 1.51 (0.84, 2.73) 0.17 54 1.57 (0.84, 2.93) 0.16 56 1.00 (0.59, 1.75) 0.99 55 0.82 (0.46, 1.45) 0.49 
  General surgery 3 >999 infinity 0.98 13 0.34 (0.11, 1.06) 0.06 5 0.16 (0.02, 1.46) 0.10 6 0.22 (0.04, 1.18) 0.08 
Years since licensure (per 5 
years) 601 0.92 (0.84, 1.00) 0.05 855 0.91 (0.84, 0.98) 0.01 971 0.99 (0.92, 1.06) 0.76 897 0.97 (0.89, 1.04) 0.35 
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Appendix – Table 1 (continued). Physician characteristics associated with accuracy of syndrome definitions based on physician claims: results from bivariate regression 
analyses for each syndrome individually (OR>1.00 means the physician characteristic increased the PPV of the syndrome definition, OR<1.00 means the physician characteristic 
reduced the PPV) 
 
 Respiratory syndrome  
(N=1,049 visits) 
Influenza-like illness  
(N=653 visits) 
Physician characteristics 
No. 
visits 
OR 95% CI 
P 
Value 
No. 
visits 
OR 95% CI 
P 
value 
Gender:         
  Female 401 Ref. Ref. Ref. 255 Ref. Ref. Ref. 
  Male 648 0.72 (0.54, 0.98) 0.04 398 0.93 (0.64, 1.33) 0.67 
Preferred language:         
  French 973 Ref. Ref. Ref. 595 Ref. Ref. Ref. 
  English 76 0.85 (0.50, 1.44) 0.54 58 0.85 (0.47, 1.56) 0.61 
Specialty:         
  General practice 961 Ref. Ref. Ref. 575 Ref. Ref. Ref. 
  Internal medicine 11 3.16 (0.40, 24.83) 0.27 9 0.67 (0.17, 2.73) 0.58 
  Pediatrics 67 2.04 (1.00, 4.18) 0.05 65 1.49 (0.77, 2.87) 0.23 
  General surgery 10 0.32 (0.09, 1.10) 0.07 4 0.34 (0.05, 2.42) 0.28 
Years since licensure (per 5 
years) 1,049 0.93 (0.86, 1.01) 0.07 653 0.93 (0.84, 1.02) 0.12 
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Appendix - Table 2. Billing characteristics associated with accuracy of syndrome definitions based on physician claims: results from bivariate regression analyses for 
each syndrome individually (OR>1.00 means the billing characteristic increased the PPV of the syndrome definition, OR<1.00 means the billing characteristic reduced the PPV) 
 
 Fever syndrome  
(N=601 visits) 
Gastrointestinal syndrome  
(N=855 visits) 
Neurological syndrome  
(N=971 visits) 
Rash syndrome  
(N=897 visits) 
Billing practices 
No. 
visits 
OR 95% CI 
P 
Value 
No. 
visits 
OR 95% CI 
P 
value 
No. 
visits 
OR 95% CI 
P 
value 
No. 
visits 
OR 95% CI 
P 
value 
Who entered the diagnostic 
code in the claim?  
               
   Physician 95 Ref. Ref. Ref. 133 Ref. Ref. Ref. 137 Ref. Ref. Ref. 130 Ref. Ref. Ref. 
   Secretary or nurse 407 1.51 (0.96, 2.37) 0.07 571 1.21 (0.82, 1.78) 0.33 659 1.17 (0.80, 1.70) 0.42 614 0.78 (0.51, 1.20) 0.26 
   Off-site billing company or  
   RAMQ (i.e., paper billing) 99 1.34 (0.76, 2.35) 0.31 151 1.56 (0.96, 2.55) 0.08 175 0.87 (0.55, 1.36) 0.53 153 0.73 (0.44, 1.22) 0.23 
Billing software used:                 
   Soft Informatique 126 Ref. Ref. Ref. 217 Ref. Ref. Ref. 241 Ref. Ref. Ref. 216 Ref. Ref. Ref. 
   Purkinje 135 1.21 (0.74, 1.97) 0.45 197 0.81 (0.54, 1.22) 0.31 222 1.93 (1.30, 2.85) 0.001 206 1.10 (0.72, 1.67) 0.67 
   ADN Medical 80 0.97 (0.56, 1.71) 0.92 100 1.04 (0.62, 1.75) 0.88 128 1.05 (0.68, 1.63) 0.82 122 1.19 (0.73, 1.94) 0.50 
   Omni-Med.com Caduceus 55 0.98 (0.52, 1.85) 0.96 70 1.04 (0.58, 1.87) 0.89 82 0.66 (0.40, 1.10) 0.11 80 1.03 (0.59, 1.80) 0.93 
   Medicus MED-WIN 27 0.95 (0.41, 2.18) 0.90 41 0.52 (0.26, 1.02) 0.06 43 0.67 (0.35, 1.28) 0.22 37 0.65 (0.32, 1.32) 0.23 
   Facturation.net 24 0.36 (0.14, 0.94) 0.04 25 0.35 (0.15, 0.81) 0.01 29 0.43 (0.19, 0.94) 0.03 32 0.84 (0.38, 1.84) 0.66 
   ANDX Xclaim 21 0.54 (0.21, 1.40) 0.21 21 0.73 (0.29, 1.83) 0.50 22 0.70 (0.29, 1.67) 0.42 17 0.39 (0.15, 1.06) 0.06 
   CareOffice 20 0.72 (0.28, 1.86) 0.50 21 0.89 (0.35, 2.31) 0.82 23 1.31 (0.53, 3.20) 0.56 26 1.85 (0.67, 5.11) 0.24 
   Médifiche 14 3.23 (0.86, 12.13) 0.08 19 0.77 (0.29, 2.03) 0.59 24 0.98 (0.42, 2.29) 0.96 19 0.61 (0.23, 1.57) 0.30 
   Toubib 13 0.39 (0.12, 1.38) 0.13 21 0.60 (0.24, 1.48) 0.26 20 0.70 (0.28, 1.74) 0.44 18 0.35 (0.13, 0.93) 0.04 
   Other
2
 or unknown 86 1.35 (0.77, 2.35) 0.29 123 0.57 (0.36, 0.90) 0.02 137 1.01 (0.66, 1.55) 0.97 124 1.12 (0.69, 1.82) 0.65 
Annual billing volume (per 
1,000 claims)
1
 601 0.98 (0.92, 1.04) 0.44 855 0.97 (0.92, 1.02) 0.21 971 1.01 (0.96, 1.06) 0.85 897 1.02 (0.97, 1.08) 0.48 
Percent of visits with a 
missing or unspecified 
diagnostic code
1
 601 1.01 (0.98, 1.04) 0.39 855 0.99 (0.97, 1.02) 0.55 971 0.98 (0.96, 1.01) 0.13 897 1.02 (0.99, 1.05) 0.29 
No. distinct diagnostic codes 
used (per 100 codes)
1
 601 0.99 (0.84, 1.17) 0.93 855 1.01 (0.87, 1.18) 0.90 971 0.94 (0.81, 1.08) 0.35 897 1.03 (0.88, 1.20) 0.74 
 
1
 In the study year when the visit took place. The study spanned 2 years: October 1, 2005 to September 30, 2006, and October 1, 2006 to September 30, 2007. 
2
 The remaining billing softwares were aggregated under “other” because their numbers were too small to report individually in this analysis.  
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Appendix - Table 2 (continued). Billing characteristics associated with accuracy of syndrome definitions based on physician claims: results from bivariate regression 
analyses for each syndrome individually (OR>1.00 means the billing characteristic increased the PPV, OR<1.00 means the billing characteristic reduced the PPV) 
 
 Respiratory syndrome  
(N=1,049 visits) 
Influenza-like illness  
(N=653 visits) 
Billing practices 
No. 
visits 
OR 95% CI 
P 
value 
No. 
visits 
OR 95% CI 
P 
value 
Who entered the diagnostic 
code in the claim? 
        
   Physician 158 Ref. Ref. Ref. 116 Ref. Ref. Ref. 
   Secretary or nurse 702 0.75 (0.48, 1.15) 0.18 431 1.11 (0.69, 1.78) 0.66 
   Off-site billing company or  
   RAMQ (i.e., paper billing) 189 0.69 (0.41, 1.15) 0.16 106 0.93 (0.51, 1.68) 0.80 
Billing software used:         
   Soft Informatique 266 Ref. Ref. Ref. 132 Ref. Ref. Ref. 
   Purkinje 233 1.67 (1.11, 2.53) 0.02 139 1.65 (0.95, 2.87) 0.08 
   ADN Medical 144 1.83 (1.12, 3.00) 0.02 105 1.20 (0.68, 2.11) 0.54 
   Omni-Med.com Caduceus 91 1.25 (0.73, 2.15) 0.42 47 1.84 (0.81, 4.15) 0.14 
   Medicus MED-WIN 43 1.39 (0.66, 2.97) 0.39 38 1.22 (0.54, 2.74) 0.63 
   Facturation.net 28 1.27 (0.52, 2.10) 0.60 19 0.48 (0.18, 1.28) 0.14 
   ANDX Xclaim 25 2.22 (0.74, 6.67) 0.16 16 1.88 (0.51, 6.98) 0.34 
   CareOffice 28 1.06 (0.45, 2.50) 0.90 26 1.18 (0.46, 3.03) 0.73 
   Médifiche 29 2.64 (0.89, 7.84) 0.08 22 2.75 (0.77, 9.83) 0.12 
   Toubib 23 0.79 (0.32, 1.94) 0.61 11 4.34 (0.54, 35.06) 0.17 
   Other
2
 or unknown 139 1.60 (0.99, 2.61) 0.06 98 1.42 (0.78, 2.58) 0.25 
Annual billing volume (per 
1,000 claims)
1
 1,049 1.01 (0.96, 1.07) 0.63 653 1.03 (0.97, 1.10) 0.36 
Percent of visits with a 
missing or unspecified 
diagnostic code
1
 1,049 1.02 (0.99, 1.06) 0.17 653 1.00 (0.97, 1.03) 0.97 
No. distinct diagnostic codes 
used (per 100 codes)
1
 1,049 1.06 (0.91, 1.24) 0.47 653 1.38 (1.12, 1.70) <0.01 
 
1
 In the study year when the visit took place. The study spanned 2 years: October 1, 2005 to September 30, 2006, and October 1, 2006 to September 30, 2007. 
2
 The remaining billing softwares were aggregated under “other” because their numbers were too small to report individually in this analysis. 
 153 
 
Table 3. Patient characteristics associated with accuracy of syndrome definitions based on physician claims: results from bivariate regression analyses for each 
syndrome individually (OR>1.00 means the patient characteristic increased the PPV of the syndrome definition, OR<1.00 means the patient characteristic reduced the PPV) 
 
 Fever syndrome  
(N=601 visits) 
Gastrointestinal syndrome  
(N=855 visits) 
Neurological syndrome  
(N=971 visits) 
Rash syndrome  
(N=897 visits) 
Patient characteristics 
No. 
visits 
OR 95% CI 
P 
Value 
No. 
visits 
OR 95% CI 
P 
value 
No. 
visits 
OR 95% CI 
P 
value 
No. 
visits 
OR 95% CI 
P 
value 
Sex:                 
  Female 366 Ref. Ref. Ref. 529 Ref. Ref. Ref. 642 Ref. Ref. Ref. 534 Ref. Ref. Ref. 
  Male 235 1.10 (0.79, 1.53) 0.56 326 0.95 (0.71, 1.27) 0.73 329 0.72 (0.55, 0.94) 0.02 363 0.85 (0.64, 1.13) 0.26 
Material deprivation index:
1
 601 1.18 (1.05, 1.34) <0.01 855 1.06 (0.96, 1.17) 0.28 971 1.03 (0.94, 1.13) 0.55 897 1.08 (0.97, 1.20) 0.14 
   1
st
 quintile (least deprived) 107 Ref. Ref. Ref. 153 Ref. Ref. Ref. 177 Ref. Ref. Ref. 174 Ref. Ref. Ref. 
   2
nd
 quintile 121 1.39 (0.83, 2.35) 0.21 152 1.41 (0.89, 2.24) 0.14 183 1.19 (0.78, 1.81) 0.42 196 1.29 (0.83, 1.96) 0.25 
   3
rd
 quintile 129 1.53 (0.91, 2.56) 0.11 173 1.63 (1.04, 2.56) 0.03 196 1.52 (1.00, 2.31) 0.05 176 1.47 (0.94, 2.31) 0.09 
   4
th
 quintile 121 1.54 (0.91, 2.60) 0.11 171 1.64 (1.05, 2.58) 0.03 181 1.19 (0.78, 1.82) 0.41 170 1.36 (0.87, 2.14) 0.18 
   5
th
 quintile (most deprived) 92 2.26 (1.28, 4.00) 0.01 168 1.24 (0.79, 1.93) 0.35 203 1.16 (0.77, 1.75) 0.47 147 1.42 (0.88, 2.28) 0.15 
   Missing 31 2.78 (1.20, 6.48) 0.02 38 2.51 (1.11, 5.66) 0.03 31 0.96 (0.44, 2.06) 0.91 34 1.19 (0.54, 2.60) 0.67 
Social deprivation index:
1
 601 0.98 (0.87, 1.11) 0.79 855 0.94 (0.85, 1.04) 0.21 971 0.97 (0.88, 1.06) 0.52 897 0.95 (0.85, 1.05) 0.27 
   1
st
 quintile (least deprived) 106 Ref. Ref. Ref. 162 Ref. Ref. Ref. 192 Ref. Ref. Ref. 197 Ref. Ref. Ref. 
   2
nd
 quintile 131 0.87 (0.52, 1.46) 0.60 163 1.01 (0.64, 1.60) 0.97 197 1.11 (0.74, 1.67) 0.61 170 0.61 (0.39, 0.95) 0.03 
   3
rd
 quintile 117 0.97 (0.57, 1.64) 0.91 162 1.12 (0.70, 1.77) 0.64 202 1.16 (0.77, 1.74) 0.48 167 0.73 (0.46, 1.16) 0.19 
   4
th
 quintile 109 1.27 (0.74, 2.18) 0.39 163 0.70 (0.45, 1.10) 0.12 169 1.12 (0.74, 1.72) 0.59 164 0.61 (0.38, 0.96) 0.03 
   5
th
 quintile (most deprived) 107 0.75 (0.44, 1.29) 0.30 167 0.87 (0.56, 1.37) 0.55 180 0.86 (0.57, 1.29) 0.46 165 0.76 (0.48, 1.22) 0.25 
   Missing 31 1.81 (0.78, 4.20) 0.17 38 1.70 (0.75, 3.84) 0.20 31 0.83 (0.39, 1.78) 0.63 34 0.67 (0.31, 1.48) 0.33 
Age (per 5 years):
2
 601 0.99 (0.98, 1.00) <0.01 855 0.99 (0.98, 0.99) <0.01 971 0.99 (0.99, 1.00) 0.01 897 1.00 (0.99, 1.01) 0.93 
Healthcare services utilization 
(no. ambulatory visits in the 
previous year)
3
 601 0.99 (0.97, 1.01) 0.24 855 0.98 (0.97, 1.00) 0.01 971 1.00 (0.99, 1.01) 0.45 897 1.00 (0.98, 1.01) 0.50 
Charlson comorbidity index 
(per 1-point score increase)
3
 601 0.88 (0.75, 1.04) 0.13 855 0.86 (0.77, 0.97) <0.01 971 0.96 (0.83, 1.09) 0.50 897 0.96 (0.83, 1.11) 0.59 
 
1
 The material and social deprivation indices, developed by the Quebec National Public Health Institute, were calculated using Statistics Canada‟s 2006 census data.  
2
 On October 1
st
 of the study year when the visit took place. The study spanned 2 years: October 1, 2005 to September 30, 2006, and October 1, 2006 to September 30, 2007. 
3
 Based on all medical services claims billed by all Quebec physicians (not only the 3,600 study physicians) in the year prior to the date of the syndrome-positive visit. 
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Appendix - Table 3 (continued). Patient characteristics associated with accuracy of syndrome definitions based on physician claims: results from bivariate regression 
analyses for each syndrome individually (OR>1.00 means the patient characteristic increased the PPV, OR<1.00 means the patient characteristic reduced the PPV) 
 
 Respiratory syndrome  
(N=1,049 visits) 
Influenza-like illness  
(N=653 visits) 
Patient characteristics 
No. 
visits 
OR 95% CI 
P 
value 
No. 
visits 
OR 95% CI 
P 
value 
Sex:         
  Female 585 Ref. Ref. Ref. 371 Ref. Ref. Ref. 
  Male 464 1.00 (0.75, 1.33) 0.98 282 1.45 (1.01, 2.10) 0.05 
Material deprivation index:
1
 1,049 0.96 (0.87, 1.06) 0.43 653 1.18 (1.03, 1.34) 0.01 
   1
st
 quintile (least deprived) 204 Ref. Ref. Ref. 140 Ref. Ref. Ref. 
   2
nd
 quintile 213 0.88 (0.56, 1.38) 0.57 126 1.24 (0.73, 2.11) 0.43 
   3
rd
 quintile 180 1.17 (0.71, 1.93) 0.53 115 1.42 (0.82, 2.48) 0.21 
   4
th
 quintile 208 0.89 (0.57, 1.42) 0.63 130 1.67 (0.96, 2.89) 0.07 
   5
th
 quintile (most deprived) 196 0.81 (0.51, 1.27) 0.35 109 1.92 (1.06, 3.48) 0.03 
   Missing 48 0.76 (0.37, 1.56) 0.46 33 1.70 (0.69, 4.22) 0.25 
Social deprivation index:
1
 1,049 0.92 (0.83, 1.02) 0.13 653 0.94 (0.83, 1.07) 0.34 
   1
st
 quintile (least deprived) 215 Ref. Ref. Ref. 130 Ref. Ref. Ref. 
   2
nd
 quintile 184 1.22 (0.75, 1.99) 0.42 134 1.09 (0.62, 1.91) 0.78 
   3
rd
 quintile 184 0.89 (0.56, 1.41) 0.62 102 1.01 (0.55, 1.84) 0.99 
   4
th
 quintile 214 0.99 (0.63, 1.57) 0.98 133 1.17 (0.66, 2.08) 0.59 
   5
th
 quintile (most deprived) 204 0.74 (0.48, 1.16) 0.19 121 0.71 (0.41, 1.24) 0.23 
   Missing 48 0.77 (0.38, 1.58) 0.48 33 1.21 (0.48, 3.06) 0.68 
Age (per 5 years):
2
 1,049 0.98 (0.97, 0.98) <0.01 653 1.00 (0.99, 1.00) 0.14 
Healthcare services utilization 
(no. ambulatory visits in the 
previous year)
3
 1,049 0.97 (0.96, 0.98) <0.01 653 0.98 (0.96, 1.00) 0.02 
Charlson comorbidity index 
(per 1-point score increase)
3
 1,049 0.84 (0.74, 0.95) <0.01 653 0.96 (0.83, 1.12) 0.63 
 
1
 The material and social deprivation indices, developed by the Quebec National Public Health Institute, were calculated using Statistics Canada‟s 2006 census data.  
2
 On October 1
st
 of the study year when the visit took place. The study spanned 2 years: October 1, 2005 to September 30, 2006, and October 1, 2006 to September 30, 2007. 
3
 Based on all medical services claims billed by all Quebec physicians (not only the 3,600 study physicians) in the year prior to the date of the syndrome-positive visit. 
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Appendix - Table 4. Encounter characteristics associated with accuracy of syndrome definitions based on physician claims: results from bivariate regression analyses for 
each syndrome individually (OR>1.00 means the encounter characteristic increased the PPV, OR<1.00 means the encounter characteristic reduced the PPV) 
 
 Fever syndrome  
(N=601 visits) 
Gastrointestinal syndrome  
(N=855 visits) 
Neurological syndrome  
(N=971 visits) 
Rash syndrome  
(N=897 visits) 
Encounter characteristics 
No. 
visits 
OR 95% CI 
P 
Value 
No. 
visits 
OR 95% CI 
P 
value 
No. 
visits 
OR 95% CI 
P 
value 
No. 
visits 
OR 95% CI 
P 
value 
Type of clinic:                 
  Private clinic 587 Ref. Ref. Ref. 831 Ref. Ref. Ref. 952 Ref. Ref. Ref. 880 Ref. Ref. Ref. 
  Community health center 3 1.70 (0.15, 18.89) 0.66 2 0.27 (0.03, 3.02) 0.29 4 0.65 (0.09, 4.61) 0.66 4 0.15 (0.02, 1.40) 0.10 
  Hospital-based  
  ambulatory clinic 11 0.19 (0.04, 0.88) 0.03 31 0.50 (0.21, 1.18) 0.11 15 0.32 (0.11, 0.95) 0.04 13 0.70 (0.23, 2.15) 0.53 
Geographic location of clinic:                 
   Urban 514 Ref. Ref. Ref. 720 Ref. Ref. Ref. 818 Ref. Ref. Ref. 751 Ref. Ref. Ref. 
   Rural 87 1.09 (0.69, 1.72) 0.72 135 1.34 (0.90, 1.99) 0.15 153 1.39 (0.96, 2.00) 0.08 146 1.26 (0.85, 1.87) 0.26 
Patient treated by the study 
physician in the previous year:                 
   No 255 Ref. Ref. Ref. 307 Ref. Ref. Ref. 345 Ref. Ref. Ref. 371 Ref. Ref. Ref. 
   Yes 346 0.95 (0.69, 1.32) 0.77 548 0.80 (0.60, 1.08) 0.14 626 0.94 (0.72, 1.23) 0.67 526 0.83 (0.62, 1.11) 0.20 
Season:                 
   Winter (12/22-03/20) 153 Ref. Ref. Ref. 211 Ref. Ref. Ref. 228 Ref. Ref. Ref. 193 Ref. Ref. Ref. 
   Spring (03/21-06/20) 157 1.73 (1.10, 2.72) 0.02 230 1.02 (0.68, 1.53) 0.92 266 1.35 (0.94, 1.93) 0.11 261 1.41 (0.94, 2.12) 0.10 
   Summer (06/21-09/22) 152 0.94 (0.60, 1.47) 0.77 214 0.61 (0.41, 0.90) 0.01 219 1.52 (1.04, 2.22) 0.03 220 0.95 (0.64, 1.44) 0.84 
   Fall (09/23-12/21) 139 1.26 (0.79, 1.99) 0.33 200 0.79 (0.53, 1.19) 0.26 258 1.20 (0.84, 1.72) 0.32 223 1.13 (0.75, 1.71) 0.56 
Day of the week:                 
   Weekday 572 Ref. Ref. Ref. 805 Ref. Ref. Ref. 934 Ref. Ref. Ref. 849 Ref. Ref. Ref. 
   Weekend 29 1.70 (0.78, 3.72) 0.19 50 1.46 (0.78, 2.76) 0.24 37 1.39 (0.69, 2.80) 0.36 48 1.20 (0.63, 2.31) 0.58 
No. same-syndrome positive 
visits  billed by the study 
physician in the previous 30 
days (per 10 visits) 601 1.03 (0.98, 1.09) 0.23 855 1.04 (0.87, 1.25) 0.67 971 0.78 (0.54, 1.12) 0.17 897 0.96 (0.80, 1.15) 0.66 
Workload: no. claims billed 
that day (per 10 claims) 601 0.92 (0.84, 1.01) 0.08 855 0.99 (0.92, 1.07) 0.84 971 0.97 (0.90, 1.04) 0.41 897 0.92 (0.85, 0.99) 0.03 
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Appendix - Table 4 (continued). Encounter characteristics associated with accuracy of syndrome definitions based on physician claims: results from bivariate regression 
analyses for each syndrome individually (OR>1.00 means the encounter characteristic increased the PPV, OR<1.00 means the encounter characteristic reduced the PPV) 
 
 Respiratory syndrome  
(N=1,049 visits) 
Influenza-like illness  
(N=653 visits) 
Encounter characteristics 
No. 
visits 
OR 95% CI 
P 
value 
No. 
visits 
OR 95% CI 
P 
value 
Type of clinic:         
  Private clinic 1,026 Ref. Ref. Ref. 642 Ref. Ref. Ref. 
  Community health center 4 >999 infinity 0.98 3 >999 infinity 0.99 
  Hospital-based  
  ambulatory clinic 19 0.66 (0.24, 1.76) 0.41 8 0.33 (0.08, 1.32) 0.12 
Geographic location of clinic:         
   Urban 880 Ref. Ref. Ref. 560 Ref. Ref. Ref. 
   Rural 169 0.95 (0.65, 1.39) 0.79 93 0.69 (0.43, 1.11) 0.13 
Patient treated by the study 
physician in the previous year:         
   No 411 Ref. Ref. Ref. 295 Ref. Ref. Ref. 
   Yes 638 0.45 (0.33, 0.62) <0.01 358 0.81 (0.57, 1.17) 0.26 
Season:         
   Winter (12/22-03/20) 304 Ref. Ref. Ref. 184 Ref. Ref. Ref. 
   Spring (03/21-06/20) 268 1.17 (0.78, 1.75) 0.45 172 1.04 (0.63, 1.72) 0.87 
   Summer (06/21-09/22) 197 0.78 (0.52, 1.19) 0.25 125 0.65 (0.39, 1.09) 0.10 
   Fall (09/23-12/21) 280 0.83 (0.57, 1.22) 0.34 172 0.89 (0.55, 1.45) 0.63 
Day of the week:         
   Weekday 987 Ref. Ref. Ref. 606 Ref. Ref. Ref. 
   Weekend 62 1.86 (0.90, 3.83) 0.09 47 0.85 (0.44, 1.66) 0.64 
No. same-syndrome positive 
visits billed by the study 
physician in the previous 30 
days (per 10 visits) 1,049 1.06 (1.02, 1.10) <0.01 653 1.03 (0.99, 1.07) 0.13 
Workload: no. claims billed 
that day (per 10 claims) 1,049 0.95 (0.89, 1.02) 0.15 653 0.98 (0.90, 1.07) 0.63 
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Chapter 7. Discussion 
 
Monitoring infectious diseases is a continuously evolving challenge, and constant 
advances in surveillance methods and infrastructure are necessary to keep pace with 
rapidly evolving demands. Syndromic surveillance is a promising new surveillance 
methodology where health department staff, assisted by automated data acquisition 
and generation of statistical alerts, monitor human health indicators, including pre-
diagnostic and diagnostic data, in real-time or near real-time. This novel surveillance 
approach is used increasingly for detecting disease outbreaks rapidly (23), and, more 
recently, for ‘situation awareness’ or guiding efforts to control recognized public health 
threats in real-time (24). There are many syndromic surveillance systems in place 
throughout the world, and several of these systems use diagnoses captured from 
administrative databases. Because diagnoses in physician claims are generally not 
audited, variations in coding are expected. The influence of this variation on the 
accuracy of surveillance case definitions is not known. In practice, high false-positive 
rates undermine the usefulness of existing syndromic surveillance systems. Attempts to 
reduce the false-positive rate by improving statistical outbreak detection algorithms 
have had limited success. However, almost no effort has been made to reduce the false-
positive rate by improving the positive predictive value (PPV) of the case definitions, or 
syndromes, used in this type of surveillance. The objectives of this thesis were to 
evaluate the feasibility of identifying syndromes using diagnoses from physician claims, 
to assess the accuracy of syndromic surveillance case definitions based on diagnoses in 
physician claims, and to identify physician, billing, patient, and encounter characteristics 
associated with the positive predictive value of these case definitions, which may then 
be used to improve the accuracy of surveillance case definitions.  
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Summary of findings 
 
The goal of the first manuscript was to assess the feasibility of using diagnoses in 
physician billing claims to identify episodes of acute respiratory infections. We found 
that the positive predictive value of diagnoses in physician claims was high for all acute 
respiratory infections studied. However, for all but one acute respiratory infection (i.e., 
acute bronchitis), our sensitivity estimates were below 0.45. Even though we used a 
convenience sample of only 9 physicians, we found that the prevalence of acute 
respiratory infections in physician claims varied widely between physicians, and that the 
sensitivity and positive predictive value of physician claims for identifying acute 
respiratory infections also varied between physicians. This pilot work demonstrated the 
feasibility of using diagnoses from physician claims to identify episodes of acute 
respiratory infection, and generated estimates of sensitivity and positive predictive 
value that were crucial to planning and obtaining funding for the research described in 
manuscripts 2 and 3. 
 
The second manuscript reports the results of a full-scale, population-based validation of 
several syndromic surveillance case definitions based on diagnoses in physician billing 
claims from community-based physicians. We focused on 5 syndromes: fever, 
gastrointestinal, neurological, rash, and respiratory (including influenza-like illness), 
because of their public health importance and prevalence in community healthcare 
settings. We found that the sensitivity of the case definitions for these syndromes was 
low, the specificity and negative predictive value were very high, and the positive 
predictive value was moderate to high. We also estimated the prevalence and PPV of 
individual diagnostic codes within each syndrome. We found that rarely used diagnostic 
codes had a high probability of being false-positives, and that more commonly used 
diagnostic codes had a higher PPV. 
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The objective of the third manuscript – to identify predictors of the positive predictive 
value of syndrome definitions based on diagnoses in physician claims – reflects the 
expanding use of syndromic surveillance from outbreak detection to situation 
awareness, and explores one potential avenue for reducing frequent false-alerts in 
existing syndromic surveillance systems. We found that the positive predictive value of 
syndrome definitions was influenced by several properties of the data; information on 
these properties could easily be obtained by public health departments to improve case 
definition accuracy in syndromic surveillance. Agreement between the medical chart 
and the physician claim about the presence of a syndrome was higher when the treating 
physician had billed many visits for the same syndrome recently, had a lower workload 
on the day of the visit, and when the patient was younger and less socially deprived. We 
also found that syndrome-positive physician claims produced by billing software that 
abstracted the billing diagnosis from an electronic medical record in an automated 
manner were more likely to agree with the medical chart than claims produced by 
software that required manual input of billing diagnoses. 
 
Strengths and limitations 
 
This thesis research had several strengths, as well as some limitations. The research 
described in manuscript 1 was pilot work, and as such, it was limited by the small 
convenience sample used. The research in manuscripts 2 and 3 was based on a large 
stratified random sample of all physicians working in the fee-for-service system in 
community healthcare settings in the province of Quebec during a 2-year period. 
Although the participation rate was low, there were no significant differences between 
the participating and non-participating physicians on all measured variables, except that 
participating physicians had been in practice longer and had worked more days during 
the study period than non-participating physicians. In manuscript 3, we found that 
physician practice experience was significantly and negatively associated with the 
positive predictive value of syndrome definitions based on diagnoses in physician claims 
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– therefore the presence of more experienced physicians in our sample may have led to 
an underestimation of the positive predictive value. Based on our and another study’s 
(45) finding that diagnostic coding accuracy decreases with increasing experience, we 
hypothesize that other parameters (i.e., sensitivity, specificity, and negative predictive 
value) would also be underestimated. 
 
A major strength of our research was that our estimates of sensitivity and specificity in 
manuscripts 1 and 2 took into account the stratified sampling strategy used, and 
therefore did not suffer from verification bias. In other published validation studies  
(61;65;128), sensitivity was overestimated and specificity underestimated as a result of 
not correcting for the verification bias introduced by the sampling. 
 
Unlike other published validation studies of syndrome case definitions (61;65), our study 
design enabled us to estimate and report positive predictive value at the level of the 
individual ICD-9 diagnostic code. Unfortunately, we were not able to assess the accuracy 
of all the diagnostic codes in the syndrome case definitions, because some diagnostic 
codes were never used by the physicians in our sample (e.g., cutaneous and pulmonary 
anthrax; ICD-9 codes 22.0 and 22.1). Given our finding that infrequently used diagnostic 
codes had lower positive predictive value than frequently used ones, the absence of 
some diagnostic codes from our sample may have led to an overestimation of the 
positive predictive value of the case definition for the syndrome. 
 
When estimating the sensitivity, specificity, and positive and negative predictive values 
of syndrome definitions based on diagnoses in physician claims, we treated the 
physician-facilitated medical chart review as a gold standard. However, the physician-
facilitated medical chart review may not be a perfect gold standard. One solution that 
avoids considering either source of data a ‘gold standard’ is latent class analysis (159). 
But, with diffuse priors, latent class analysis would make the problem non-identifiable; 
the model would have more unknown parameters than degrees of freedom. Therefore, 
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informative prior distributions would need to be elicited on any two of the five unknown 
parameters (the sensitivity and specificity of the physician claims, the sensitivity and 
specificity of the chart review, and the syndrome prevalence) to obtain a meaningful 
solution. Eliciting informative priors would have been difficult because, as discussed in 
chapter 2, previously published estimates of the accuracy of syndrome definitions based 
on ICD-9 coded diagnoses vary widely due to methodological limitations and biases. 
 
Physician-facilitated chart reviews and physician claims may be conditionally dependent 
due to an unmeasured factor, other than true syndrome status. For example, it is 
possible that syndrome severity may affect both physician-facilitated chart reviews and 
physician claims, with more severe syndromes being more likely to be identified 
correctly from both sources. This unmeasured variable, shared by both sources of 
information, would cause the apparent correlation. Failure to account for conditional 
dependence between physician-facilitated chart reviews and physician claims may have 
overestimated the agreement between these two sources of information. In future 
research, the analyses presented in this thesis may be extended by modeling the 
conditional dependence between the two sources of information using random effects 
(160), such that the sensitivities and specificities of each source of information would be 
modelled as functions of a latent visit-specific random variable. 
 
Public health implications 
 
Implications for public health surveillance 
We found that diagnostic codes in physician claims from community healthcare settings 
have low sensitivity, moderate to high PPV, and near-perfect specificity and NPV for 
identifying 5 syndromes (fever, gastrointestinal, neurological, rash, and respiratory 
including influenza-like illness). Even though the sensitivity was below 0.45 for all 5 
syndrome definitions studied in this thesis, these syndrome definitions are likely to still 
be useful for surveillance when there are large numbers of cases (e.g., influenza-like 
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illness). More research is needed to identify how the relationship between syndrome 
sensitivity and prevalence influences the value of monitoring syndromes for different 
public health purposes.  
 
We also estimated the prevalence and positive predictive value of individual diagnostic 
codes within each syndrome. We found that rarely used diagnostic codes had a higher 
probability of being false-positive, and that more commonly used diagnostic codes had a 
higher positive predictive value. These findings may be useful to the ongoing 
development of sensitive and specific consensus syndrome definitions (142), as either a 
sensitive or a specific definition may be more useful depending on the surveillance 
objective. For example, if the objective is not to miss any case of a given syndrome or 
infection (e.g., anthrax), then the sensitive definition is the best suited one for that 
objective. In contrast, if the objective is situation awareness, then the specific definition 
may be more appropriate. 
 
We found that characteristics of the provider and the patient influenced the positive 
predictive value of syndrome definitions based on diagnoses in physician claims. Some 
of these predictors of accuracy (e.g., patient age) are readily available to public health 
departments. Public health departments can apply our findings to improve the positive 
predictive value of syndrome definitions, either by focusing on physician claims where 
diagnostic codes are more likely to be accurate (e.g., claims among children), or by using 
all physician claims and weighting each according to the likelihood that its diagnostic 
code is accurate (e.g., weighting by the positive predictive value of each ICD-9 code).  
 
Implications for physician billing 
Because of the many difficulties involved in obtaining population-level morbidity 
information, there is growing interest in making secondary use of ICD-9 coded diagnoses 
in physician claims from community healthcare settings for purposes beyond healthcare 
administration, including assessment of health outcomes (161) and clinical comorbidities 
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(153;162;163), and surveillance of chronic diseases (164;165), injury (166;167), and 
infectious syndromes (43;44;49;58-60). Furthermore, until electronic health records are 
implemented in every community-based clinic in a given healthcare jurisdiction, ICD-9 
coded diagnoses in physician claims represent a valuable source of information for use 
in reimbursement reform such as pay-for-performance physician reimbursement 
models. Indeed, ICD-9 coded diagnoses in physician claims have been used in 
combination with prescription claims and/or procedure codes to identify specific patient 
populations, such as patients with asthma (168;169), and to monitor clinical outcomes, 
such as asthma control (169). High diagnostic accuracy in physician claims is paramount 
if we are to use these data for public health monitoring or health research, or to assess 
physician performance.  
 
Many of the physicians who participated in our study told us that they would pay more 
attention to diagnostic coding if they knew that their codes were being used. Also, we 
and others (45) found that the accuracy of diagnostic coding decreased with experience. 
A potential explanation for this phenomena was suggested by a few participating and 
non-participating physicians, who told us that their attentiveness to diagnostic coding 
decreased over time, as they became increasingly aware that their choice of diagnostic 
codes generally had no impact on their reimbursement. One physician even told us that 
he had recently started using the code ‘V999’ (unspecified) for all patients seen on a 
walk-in basis. Based on these observations, interventions to prevent the loss of 
diagnostic coding accuracy over time in practice could be as simple as informing 
physicians that diagnostic codes on their claims are a widely used and valuable source of 
information for public health monitoring and health services research. Alternatively, if 
the healthcare agency (payer) wanted to insure high accuracy of diagnostic codes in 
physician claims – for example, to use in a pay-for-performance reimbursement model – 
the agency could enact mechanisms to 1) ask physicians to provide accurate diagnoses 
in their claims, and 2) audit diagnostic codes in physician claims. 
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Implications for the timely transmission of data from clinical to public health settings 
If diagnoses in physician claims are to be used for outbreak detection or situation 
awareness, their timeliness must be improved. In the fee-for-service system currently in 
place in the province of Quebec, physicians are reimbursed every 2 weeks. Because of 
this reimbursement schedule, many physicians cumulate their claims over the 2-week 
period then submit them to the payer before the deadline. In theory, the frequency of 
physician claim submission to the payer could be increased from once every 2 weeks to 
once a week (or even once a day) with only minor modifications to physician’s billing 
practices. 
 
In contrast, to enable real-time surveillance, substantial modifications to physician 
billing and reimbursement procedures would be required. One way to obtain physician 
claims data in real-time would be to implement an online adjudication system for 
physician claims, as is already in place for prescription claims. In such a system, the claim 
is submitted to the payer electronically, and the payer transmits its decision about the 
reimbursement of the claim in the same manner in just a few seconds. However, for the 
real-time submission of physician claims (i.e., during or immediately after the patient 
visit) to be feasible, the visit would most likely have to be documented using an 
electronic medical record, and the claim would have to be filled out and submitted in a 
mostly automated manner based on the information in the electronic medical record. 
 
Implications for the design and implementation of electronic medical records  
We found that billing software had a significant impact on the positive predictive value 
of syndrome definitions based on diagnoses in physician claims. Software that 
abstracted the billing diagnosis from the electronic medical record in an automated 
manner had higher claim diagnosis accuracy than software that required the manual 
input of billing diagnoses. This finding has important implications for both clinical users 
and public health surveillance, given the ongoing transformation of public health 
surveillance from a process where clinical practitioners manually submit case reports to 
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a process where public health agencies automatically extract relevant data from clinical 
information systems.  
 
The US federal government has allotted $39 billion to support the adoption and 
"meaningful use" of electronic health records, and software purchased using these funds 
must support automated submission of data to public health agencies for three public 
health uses, including syndromic surveillance (158). This investment presents an 
opportunity to improve syndromic surveillance systems by having electronic health 
records capture and transmit information on highly influential predictors, such as 
indicators of patient complexity, to public health. The rich clinical data streams 
becoming accessible to public health should enable the implementation of surveillance 
strategies that incorporate our findings. As the volume and detail of electronically-
available clinical data continue to increase, future research should explore how public 
health can harness their full breadth to further enhance the accuracy of case detection. 
 
Future research priorities 
 
Measuring the practical implications of our findings on the response to alerts 
Future research should evaluate the practical implications of our findings on decision-
making in response to alerts from existing syndromic surveillance systems. Using the 
sensitivity estimates we obtained, simulations should be used to evaluate the usefulness 
of different syndrome definitions as a function of syndrome prevalence. Such an 
evaluation would help determine whether some syndrome definitions, as they are 
currently formulated, are sufficiently sensitive for surveillance purposes. 
 
Modifying syndrome definitions to better suit surveillance objectives 
In this thesis, we estimated the agreement on the presence of a given syndrome 
between the diagnosis in the physician claim and the diagnosis in the chart. For 
example, if the diagnosis in the claim was headache (ICD-9 code: 784.0), which is 
 166 
 
included in the definition for neurological syndrome, we evaluated if the chart diagnosis 
was also included in the neurological syndrome definition. However, given that few 
‘headache’ diagnoses in physician claims would be expected to be associated with an 
infection, and given that ‘headache’ is highly prevalent in physician claims (i.e., its 
prevalence is several orders of magnitude higher than that of ‘meningitis’, for example), 
monitoring the incidence of ‘headache’ diagnoses in physician claims to detect 
neurological syndrome may yield a high rate of false-alerts.  
 
A potential avenue for improving the accuracy of syndrome case definitions would be to 
estimate, for each ICD-9 code in a syndrome case definition individually, the sensitivity, 
specificity, positive predictive value, and negative predictive value of that ICD-9 code for 
identifying true episodes of infection. To determine whether or not a visit involved a 
‘true’ episode of infection, we could use information such as the patient signs, 
symptoms, and other key findings we collected through physician-facilitated chart 
review (manuscript 2). Estimates of individual ICD-9 codes’ sensitivity, specificity, 
positive predictive value, and negative predictive value for identifying true episodes of 
infection could then be used to tailor syndrome definitions to match surveillance 
objectives. For example, the false-positive rate of the case definition for neurological 
syndrome could be reduced by weighting each individual ICD-9 code by its positive 
predictive value to identify true episodes of infection; as a result, visits with the ICD-9 
code for ‘headache’ would be given less weight than those with the diagnostic code for 
‘meningitis’, and the positive predictive value of the case definition for neurological 
syndrome would be improved. Similarly, if our surveillance objective was not to miss any 
case of hemorrhagic syndrome, then we could weight each visit by the sensitivity of its 
ICD-9 code for identifying true episodes of infection. As an alternative to weighting, we 
could establish a minimum threshold for the sensitivity, specificity, positive predictive 
value, and/or negative predictive value of individual ICD-9 codes, and exclude from the 
syndrome case definition any ICD-9 code whose accuracy is below the desired threshold. 
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Evaluating different methods of incorporating predictors of syndrome definition 
accuracy in surveillance analyses 
In this thesis, we propose two possible methods for incorporating predictors of 
syndrome definition accuracy in surveillance analyses. The first method is to use the 
predictors of syndrome definition accuracy to identify the subgroup of physician claims 
whose diagnosis is most likely to be a true-positive (i.e., with a positive predictive value 
above a certain threshold), and to apply detection algorithms to those claims only. The 
impact of using different thresholds of positive predictive value should be investigated. 
The other method is to use the predictors of syndrome definition accuracy to weight 
each physician claim by the likelihood that its diagnosis is a true-positive, and apply a 
detection algorithm to the weighted claims. Future research should compare the results 
obtained from these two methods, and evaluate their respective impact on decision-
making in response to alerts. 
 
Evaluating the impact of feeding syndromic surveillance information back to clinicians 
and healthcare administrators 
In addition to the obvious utility of syndromic surveillance for public health prevention 
and control, information generated by syndromic surveillance systems may also be 
useful to inform clinical decisions. Future research is needed to assess the impact of 
feeding back information, at the point of care, about local and regional syndrome 
incidence on the medical management of patients susceptible to and/or presenting with 
a complaint consistent with a prevalent syndrome. For example, given the high rates of 
inappropriate antibiotic prescribing for respiratory infections of likely viral etiology 
among primary care physicians (107;122;170;171), it would be interesting to measure 
the impact on antibiotic prescribing of providing primary care physicians with 
information about local respiratory syndrome incidence, and prevalence of etiological 
agents isolated from respiratory specimens. Furthermore, feeding back syndromic 
surveillance information derived from physician claims to physicians would likely 
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improve the quality of diagnoses in physician claims; as end-users of that information, 
physicians would be more likely to provide accurate claim diagnoses. 
 
The timely provision of up-to-date syndromic surveillance information may also be 
useful to plan healthcare delivery and improve healthcare resource allocation. For 
example, providing hospital administrators with a daily syndromic surveillance update, 
including local and regional trends in syndrome incidence as well as a detailed picture of 
syndrome-related healthcare services utilisation, may enable a systematic approach to 
planning healthcare staffing for emergency departments. 
 
Conclusions 
 
This was the first large-scale, population-based investigation of the accuracy of 
syndrome case definitions based on diagnoses in physician claims in community 
healthcare settings. We found that the sensitivity of syndrome case definitions based on 
diagnoses in physician claims was low, the positive predictive value was moderate to 
high, and the specificity and the negative predictive value were near-perfect. We 
identified several physician, billing, patient, and encounter characteristics associated 
with the positive predictive value of syndrome case definitions based on diagnoses in 
physician claims. Many of the predictors of syndrome case definition accuracy that we 
identified are readily accessible to public health departments and other organizations 
that routinely perform syndromic surveillance. These predictors could be used to reduce 
the false-positive rate of syndromic surveillance systems, either by focusing on the 
surveillance data most likely to be correct, or by adjusting the observed data for known 
biases in diagnostic coding and using the adjusted values to perform surveillance. 
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Introduction 
 
Recent events, including the emergence of severe acute respiratory syndrome (SARS), West Nile virus, 
and monkeypox, have resulted in the implementation of alternate methods of disease surveillance that 
can potentially identify clusters of cases before traditional methods. Some surveillance systems utilize 
International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) coded health 
information from physician visit records or emergency department discharge data (1). Other systems 
abstract data from emergency department logs, 911 calls, or nurse call line data through analysis of text 
or other developed coding systems (2). Such surveillance methods are often referred to as syndromic 
surveillance since they typically monitor the non-specific clinical information that may indicate a 
bioterrorism-associated disease before specific diagnoses are made. Syndromic surveillance systems often 
utilize data sources that already exist but have not been designed specifically for public health surveillance 
purposes. Two data sources that may be available to augment a public health agency’s surveillance 
activities are ICD-9-CM-coded discharge diagnoses for outpatient visits and emergency department visits. 
 
ICD-9-CM codes were developed to allow assignment of codes to diagnoses and procedures associated 
with hospital utilization in the United States and are often used for third-party insurance reimbursement 
purposes. ICD-9-CM codes have been monitored in several settings to support public health surveillance 
(3-6). Syndromic surveillance using ICD-9-CM-coded health information may be considered because the 
codes are readily available for use by health care systems, are used in multiple clinical settings (e.g., 
outpatient, inpatient, emergency departments), are often available electronically, and can be shared easily 
between different information systems. However, prior to implementing surveillance based on the use of 
ICD-9-CM-coded health information, public health agencies should evaluate their usefulness with regard to 
the goals of the surveillance system (7, 8). For example, there may be a substantial delay in ICD-9-CM 
code assignment or the availability of that information in an electronic health information system. Since 
timeliness is a critical requirement, use of ICD-9-CM-coded information that is not timely may not be 
appropriate. Additionally, nonspecific ICD-9-CM codes may be used in an outpatient setting yielding low 
specificity for the outcome of interest. There may be bias in the use of the codes by some data providers 
(e.g., using codes for greater severity of illness to justify patient treatment). Use of a limited number of 
ICD-9-CM codes to describe a clinical encounter may limit appropriate interpretation. However, given the 
widespread availability and use of ICD-9-CM codes, it is prudent to provide some guidance regarding their 
use and to encourage the evaluation of their use for syndromic surveillance. 
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Beginning in 1999 to support several enhanced syndromic surveillance activities associated with high-
profile community events (e.g., national political conventions), the Centers for Disease Control and 
Prevention (CDC) identified syndrome categories to be monitored that were indicative of the clinical 
presentations of several critical bioterrorism-associated conditions. The Department of Defense's ESSENCE 
program also developed broad syndrome groups using ICD-9-CM codes that approximate natural 
infectious disease outbreaks or bioterrorism. These syndrome groups are currently under routine 
surveillance at military medical treatment facilities (9). Other public health agencies have also developed 
syndrome-based definitions and code groupings specific to their data sources and surveillance goals. By 
combining our experiences, Department of Defense, CDC, and other investigators developed a suggested 
list of syndrome groups, definitions, and corresponding ICD-9-CM codes that can be used in syndromic 
surveillance programs. 
 
A multi-agency working group was established to identify and define candidate syndrome groups. Eleven 
syndromes and corresponding code sets were selected based on a systematic selection process (Table). 
Definitions for each syndrome group were created by consensus. Individual ICD-9-CM codes were selected 
as candidates for inclusion in defined syndrome groups after an exhaustive search through all possible 
codes (Appendix). The codes were divided into three categories based on overall association with a 
syndrome or specific disease and by observed frequency of code usage in three clinical data sources 
(representing discharge diagnoses for outpatient visits and emergency department visits). The following 
categories within syndrome groups were defined: 
 
Category 1 - Consists of codes that reflect general symptoms of the syndrome group and also 
include codes for the bioterrorism diseases of highest concern or those diseases highly 
approximating them. 
 
Category 2 - Consists of codes that might normally be placed in the syndrome group, but daily 
volume could overwhelm or otherwise detract from the signal generated from the Category 1 code 
set alone. 
 
Category 3 - Consists of specific diagnoses that fit into the syndrome category but occur 
infrequently or have very few counts. These codes may be excluded to simplify syndrome category 
code sets. 
 
The working group also assessed the trends over time, frequency of code use, and subsequent 
contribution of selected codes to background ‘noise’ of the ICD-9-CM-coded syndrome groups using two 
large medical data sets: DoD outpatient visits and civilian emergency department visits. This analysis is 
ongoing but emphasized the need to evaluate the performance of the code sets in each data source. 
 
These syndrome definitions and associated ICD-9-CM-coded syndrome groups can be used in syndromic 
surveillance systems to allow for comparability and evaluation among programs. However, analysis of the 
syndrome groups and subcategory distributions in individual data sources must be done as the frequency 
of code usage may vary by data source and will dictate which codes are best included for a particular 
surveillance program. Additional guidance from the working group will be forthcoming regarding statistical 
analysis methods that can be used to systematically choose ideal combinations of codes for syndrome 
groups. At this time, the working group wanted to share the syndrome groupings so that other public 
health agencies can have access to the results of their deliberations regarding defined syndrome 
groupings. 
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Table: Text-based Syndrome Case Definitions and Associated Category A Conditions 
 
Syndrome Definition Category 
A 
Condition 
Botulism-like ACUTE condition that may represent exposure to 
botulinum toxin 
ACUTE paralytic conditions consistent with botulism: 
cranial nerve VI (lateral rectus) palsy, ptosis, dilated 
pupils, decreased gag reflex, media rectus palsy. 
ACUTE descending motor paralysis (including 
muscles of respiration) 
ACUTE symptoms consistent with botulism: diplopia, 
dry mouth, dysphagia, difficulty focusing to a near 
point. 
Botulism 
Hemorrhagic 
Illness 
SPECIFIC diagnosis of any virus that causes viral 
hemorrhagic fever (VHF): yellow fever, dengue, Rift 
Valley fever, Crimean-Congo HF, Kyasanur Forest 
disease, Omsk HF, Hantaan, Junin, Machupo, Lassa, 
Marburg, Ebola 
ACUTE condition with multiple organ involvement 
that may be consistent with exposure to any virus 
that causes VHF 
 
ACUTE blood abnormalities consistent with VHF: 
leukopenia, neutropenia, thrombocytopenia, 
decreased clotting factors, albuminuria 
VHF  
Lymphadenitis ACUTE regional lymph node swelling and/ or 
infection (painful bubo- particularly in groin, axilla or 
neck) 
Plague 
(Bubonic) 
Localized 
Cutaneous 
Lesion 
SPECIFIC diagnosis of localized cutaneous lesion/ 
ulcer consistent with cutaneous anthrax or tularemia 
ACUTE localized edema and/ or cutaneous lesion/ 
vesicle, ulcer, eschar that may be consistent with 
cutaneous anthrax or tularemia 
INCLUDES insect bites 
EXCLUDES any lesion disseminated over the body or 
generalized rash 
EXCLUDES diabetic ulcer and ulcer associated with 
peripheral vascular disease 
Anthrax 
(cutaneous) 
Tularemia 
Gastrointestinal ACUTE infection of the upper and/ or lower 
gastrointestinal (GI) tract 
SPECIFIC diagnosis of acute GI distress such as 
Salmonella gastroenteritis 
ACUTE non-specific symptoms of GI distress such as 
nausea, vomiting, or diarrhea 
EXCLUDES any chronic conditions such as 
inflammatory bowel syndrome 
Anthrax 
(gastrointes
tinal) 
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Syndrome Definition Category 
A 
Condition 
Respiratory ACUTE infection of the upper and/ or lower 
respiratory tract (from the oropharynx to the lungs, 
includes otitis media) 
SPECIFIC diagnosis of acute respiratory tract 
infection (RTI) such as pneumonia due to 
parainfluenza virus 
ACUTE non-specific diagnosis of RTI such as 
sinusitis, pharyngitis, laryngitis 
ACUTE non-specific symptoms of RTI such as cough, 
stridor, shortness of breath, throat pain 
EXCLUDES chronic conditions such as chronic 
bronchitis, asthma without acute exacerbation, 
chronic sinusitis, allergic conditions (Note: INCLUDE 
acute exacerbation of chronic illnesses.) 
Anthrax 
(inhalationa
l) 
Tularemia 
Plague 
(pneumonic
) 
Neurological ACUTE neurological infection of the central nervous 
system (CNS) 
SPECIFIC diagnosis of acute CNS infection such as 
pneumoccocal meningitis, viral encephailitis 
ACUTE non-specific diagnosis of CNS infection such 
as meningitis not otherwise specified (NOS), 
encephailitis NOS, encephalopathy NOS 
ACUTE non-specific symptoms of CNS infection such 
as meningismus, delerium 
EXCLUDES any chronic, hereditary or degenerative 
conditions of the CNS such as obstructive 
hydrocephalus, Parkinson’s, Alzheimer’s 
Not 
applicable 
Rash ACUTE condition that may present as consistent with 
smallpox (macules, papules, vesicles predominantly 
of face/arms/legs) 
SPECIFIC diagnosis of acute rash such as chicken 
pox in person > XX years of age (base age cut-off 
on data interpretation) or smallpox 
ACUTE non-specific diagnosis of rash compatible 
with infectious disease, such as viral exanthem 
EXCLUDES allergic or inflammatory skin conditions 
such as contact or seborrheaic dermatitis, rosacea 
EXCLUDES rash NOS, rash due to poison ivy, 
sunburn, and eczema 
Smallpox 
Specific 
Infection 
ACUTE infection of known cause not covered in other 
syndrome groups, usually has more generalized 
symptoms (i.e., not just respiratory or 
gastrointestinal) 
INCLUDES septicemia from known bacteria 
INCLUDES other febrile illnesses such as scarlet 
fever 
Not 
applicable 
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Syndrome Definition Category 
A 
Condition 
Fever ACUTE potentially febrile illness of origin not 
specified 
INCLUDES fever and septicemia not otherwise 
specified 
INCLUDES unspecified viral illness even though 
unknown if fever is present 
 
EXCLUDE entry in this syndrome category if more 
specific diagnostic code is present allowing same 
patient visit to be categorized as respiratory, 
neurological or gastrointestinal illness syndrome  
Not 
applicable 
Severe Illness 
or Death 
potentially due 
to infectious 
disease 
ACUTE onset of shock or coma from potentially 
infectious causes 
EXCLUDES shock from trauma 
 
INCLUDES SUDDEN death, death in emergency 
room, intrauterine deaths, fetal death, spontaneous 
abortion, and still births 
EXCLUDES induced fetal abortions, deaths of 
unknown cause, and unattended deaths 
Not 
applicable 
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APPENDIX: ICD-9-CM CODES 
 
Fever ICD-9-CM Code List 
 
ICD9CM ICD9DESCR Consensus 
020.2 PLAGUE, SEPTICEMIC 1 
020.8 OTHER TYPES OF PLAGUE 1 
020.9 PLAGUE NOS 1 
021.8 TULAREMIA NEC 1 
021.9 TULAREMIA NOS 1 
022.3 ANTHRAX, SEPTICEMIA 1 
022.8 ANTHRAX, OTHER SPECIFIED 1 
022.9 ANTHRAX, UNSPECIFIED 1 
038.3 ANAEROBES SEPTICEMIA 1 
038.40 GRAM-NEGATIVE ORGANISM UN 1 
038.49 SEPTICEMIA,OTHER GRAM-NEG 1 
038.8 SEPTICEMIAS, OTHER SPECIF 1 
038.9 SEPTICEMIA, NOS 1 
079.89 VIRAL INFECTION OTHER S 1 
079.99 VIRAL INFECTIONS UNSPECIFIED 1 
780.31 FEBRILE CONVULSIONS 1 
780.6 FEVER 1 
790.7 BACTEREMIA 1 
790.8 VIREMIA NOS 1 
   
002.0 TYPHOID FEVER 3 
002.1 PARATYPHOID FEVER A 3 
002.2 PARATYPHOID FEVER B 3 
002.3 PARATYPHOID FEVER C 3 
002.9 PARATYPHOID FEVER NOS 3 
003.1 Salmonella septicemia 3 
023.0 BRUCELLA MELITENSIS 3 
023.1 BRUCELLA ABORTUS 3 
023.2 BRUCELLA SUIS 3 
023.3 BRUCELLA CANIS 3 
023.8 BRUCELLOSIS NEC 3 
023.9 BRUCELLOSIS, UNSPECIFIED 3 
024 GLANDERS 3 
025 MELOIDOSIS 3 
027.0 LISTERIOSIS 3 
034.1 SCARLET FEVER 3 
038.0 SEPTICEMIA STAPHYLOCOCCAL 3 
038.10 SEPTICEMIA STAPHYLOCOCCAL 3 
038.11 SEPTICEMIA STAPHYLOC. AUR 3 
038.19 SEPTICEMIA STAPHYLOCOCCAL 3 
038.2 PNEUMOCOCCAL SEPTICEMIA 3 
038.41 SEPTICEMIA, HEMOPHILUS INFLUENZAE 3 
038.42 SEPTICEMIA, E. COLI 3 
038.43 PSEUDOMONAS 3 
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Fever ICD-9-CM Code List, Cont’d 
 
038.44 SEPTICEMIA SERRATIA 3 
054.5 HERPETIC SEPTICEMIA 3 
060.0 YELLOW FEVER, SYLVATIC 3 
060.1 YELLOW FEVER, URBAN 3 
060.9 YELLOW FEVER, UNSPEC 3 
066.0 PHLEBOTOMUS FEVER 3 
066.1 TICK-BORNE FEVER 3 
066.2 VENEZUELAN EQUINE FEVER 3 
066.3 MOSQUITO-BORNE FEVER NEC 3 
066.8 ARTHROPOD VIRUS NEC 3 
066.9 ARTHROPOD VIRUS NOS 3 
078.2 SWEATING FEVER 3 
080 LOUSE-BORNE TYPHUS 3 
081.0 MURINE TYPHUS 3 
081.1 BRILL'S DISEASE 3 
081.2 SCRUB TYPHUS 3 
081.9 TYPHUS NOS 3 
082.8 TICK-BORNE RICKETTS NEC 3 
082.9 TICK-BORNE RICKETTS NOS 3 
083.0 Q FEVER 3 
083.1 TRENCH FEVER 3 
083.2 RICKETTSIALPOX 3 
083.8 RICKETTSIOSES NEC 3 
083.9 RICKETTSIOSIS 3 
084.0 MALARIA, FALCIPARUM 3 
084.1 VIVAX MALARIA 3 
084.2 QUARTAN MALARIA 3 
084.3 OVALE MALARIA 3 
084.5 MIXED MALARIA 3 
084.6 MALARIA UNSPECIFIED 3 
086.2 CHAGA'S DISEASE WITHOUT MENTION OF ORG 3 
086.3 TRYPANOSOMIASIS, GAMBIAN 3 
086.4 TRYPANOSOMIASIS, RHODESIAN 3 
086.5 TRYPANOSOMIASIS, AFRICAN 3 
086.9 TRYPANOSOMIASIS, UNSPEC 3 
087.0 LOUSE-BORNE RELAPS FEVER 3 
087.1 TICK-BORNE RELAPS FEVER 3 
087.9 RELAPSING FEVER NOS 3 
088.0 BARTONELLOSIS 3 
088.81 LYME DISEASE 3 
088.82 BABESIOSIS 3 
088.89 OTHER ARTHROPOD-BORNE 3 
088.9 ARTHROPOD-BORNE DIS NOS 3 
100.82 LEPTOSPIROSIS, OTHER 3 
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Hemr_ill ICD-9-CM Code List 
 
ICD9CM ICD9DESCR Consensus 
287.1 PLATELET DISORDER 1 
287.2 NONTHROMBOCYTOPENIC PURPU 1 
287.8 HEMORRHAGIC COND NEC 1 
287.9 HEMORRHAGIC CONDITIONS UN 1 
511.8 HEMOTHORAX 1 
790.01 HEMATOCRIT, PRECIPITOUS D 1 
790.92 ABNORMAL COAGULATION PROF 1 
   
286.9 COAGULATION DEFECTS-UNSPE 2 
287.3 THROMBOCYTOPENIA 2 
287.4 THROMBOCYTOPENIA SECONDAR 2 
287.5 THROMBOCYTOPENIA  UNSPEC. 2 
459.0 HEMORRHAGE  NOS 2 
578.0 HEMATEMESIS 2 
578.1 MELENA 2 
578.9 GASTROINTESTINAL HEMORRHA 2 
782.7 ECCHYMOSIS,SPONTANEOUS,NO 2 
784.7 EPISTAXIS 2 
784.8 HEMORRHAGE FROM THROAT 2 
786.3 HEMOPTYSIS 2 
   
061 DENGUE 3 
065.0 CRIMEAN HEMORRHAGIC FEV 3 
065.1 OMSK HEMORRHAGIC FEVER 3 
065.2 KYASANUR FOREST DISEASE 3 
065.3 TICK-BORNE HEM FEVER NEC 3 
065.4 MOSQUITO-BORNE HEM FEVER 3 
065.8 ARTHROPOD HEM FEVER NEC 3 
065.9 ARTHROPOD HEM FEVER NOS 3 
077.4 EPIDEM HEM CONJUNCTIVIT 3 
078.6 HEM NEPHROSONEPHRITIS 3 
078.7 ARENAVIRAL HEM FEVER 3 
084.8 BLACKWATER FEVER 3 
100.0 LEPTOSPIROSIS, ICTOHEMORRHAGICA 3 
283.11 HEMOLYTIC-UREMIC SYNDROME 3 
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Lesion ICD-9-CM Code List 
 
ICD9CM ICD9DESCR Consensus 
020.0 PLAGUE, BUBONIC 1 
020.1 CELLULOCUTANEOUS PLAGUE 1 
021.0 ULCEROGLANDUL TULAREMIA 1 
022.0 CUTANEOUS ANTHRAX 1 
680.0 CARBUNCLE FACE 1 
680.1 CARBUNCLE NECK 1 
680.2 CARBUNCLE TRUNK 1 
680.3 CARBUNCLE ARM 1 
680.4 CARBUNCLE HAND 1 
680.5 CARBUNCLE BUTTOCK 1 
680.6 CARBUNCLE LEG 1 
680.7 FURUNCLE FOOT, HEEL, TOE 1 
680.8 FURUNCLE HEAD/SCALP EXCEP 1 
707.11 ULCER OF THIGH 1 
707.12 ULCER OF CALF 1 
707.13 ULCER OF ANKLE 1 
707.14 ULCER OF HEEL AND MIDFOOT 1 
707.19 ULCER OF LOWER LIMB,OTHER 1 
   
680.9 BOIL  NOS 2 
681.00 CELLULITIS FINGER, NOS 2 
681.01 FELON 2 
681.02 ONYCHIA/PARONYCHIA OF FIN 2 
681.11 ONYCHIA/PARONYCHIA OF TOE 2 
681.9 CELLULITIS DIGIT, NOS 2 
682.0 CELLULITIS FACE 2 
682.1 CELLULITIS NECK 2 
682.2 CELLUL/ABSCESS-TRUNK/ABDO 2 
682.3 CELLULITIS/ABSCESS ARM 2 
682.4 CELLULITIS/ABSCESS HAND/W 2 
682.5 CELLULITIS BUTTOCK 2 
682.6 CELLULITIS LEG 2 
682.7 CELLULITIS FOOT 2 
682.8 ABSCESS/CELLULITIS-HEAD/S 2 
682.9 CELLULITIS  NOS 2 
707.10 ULCER OF LOWER LIMB, UNSP 2 
707.15 ULCER OF FOOT, OTHER PART 2 
   
027.1 ERYSIPELOTHRIX INFECTION 3 
054.6 HERPETIC WHITLOW 3 
081.2 SCRUB TYPHUS 3 
082.1 BOUTONNEUSE FEVER 3 
082.2 NORTH ASIAN TICK FEVER 3 
082.3 QUEENSLAND TICK TYPHUS 3 
085.1 LEISHMANIASIS, CUTANEOUS, URBAN 3 
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Lesion ICD-9-CM Code List, Cont’d 
 
085.2 LEISHMANIASIS, CUTANEOUS, ASIAN DESERT 3 
085.3 LEISHMANIASIS, ETHIOPIAN 3 
085.4 LEISHMANIASIS, CUTANEOUS AMERICAN 3 
085.5 LEISHMANIASIS, MUCOCUTANEOUS, AMERICAN 3 
086.2 CHAGA'S DISEASE WITHOUT MENTION OF ORG 3 
086.3 TRYPANOSOMIASIS, GAMBIAN 3 
086.5 TRYPANOSOMIASIS, AFRICAN 3 
091.2 SYPHILIS (PRIMARY NEC) 3 
103.0 PINTA, PRIMARY LESIONS 3 
103.9 PINTA, UNSPEC 3 
114.0 PRIMARY COCCIDIOIDOMYCOS 3 
117.1 SPOROTRICHOSIS 3 
911.4 Superficial inj/trunk, insect bite non-veno, no infect 3 
911.5 Superficial inj/trunk, insect bite non-veno, infection 3 
912.4 Superficial inj/shoulder/upper arm, insect bite non-veno, no infect 3 
912.5 Superficial inj/shoulder/upper arm, insect bite non-veno, infection 3 
913.4 Superficial inj/elbow,forearm,wrist, insect bite non-veno, no infect 3 
913.5 Superficial inj/elbow,forearm,wrist, insect bite non-veno, infection 3 
915.4 Superficial inj/finger(s), insect bite non-veno, no infect 3 
915.5 Superficial inj/finger(s) insect bite non-veno, infection 3 
916.4 Superficial inj/hip,thigh,leg,ankle, insect bite non-veno, no infect 3 
916.5 Superficial inj/hip,thigh,leg,ankle insect bite non-veno, infection 3 
917.4 Superficial inj/foot, toe(s), insect bite non-veno, no infect 3 
917.5 Superficial inj/foot, toe(s), insect bite non-veno, infection 3 
918 Superficial inj/eyelids, periocular area, insect bite  3 
919.4 Superficial inj/other,multiple,unspec insect bite non-veno, no infect 3 
919.5 Superficial inj/other, multiple, unspec insect bite non-veno, infection 3 
E906.4 Bite of non-venomous arthropod/insect bite NOS 3 
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Lymph ICD-9-CM Code List 
ICD9CM ICD9DESCR Consensus 
020.0 PLAGUE, BUBONIC 1 
021.0 ULCEROGLANDUL TULAREMIA 1 
021.3 TULAREMIA, OCULOGLANDULAR 1 
075 MONONUCLEOSIS, INFECTIOUS 1 
289.3 LYMPHADENITIS NOS 1 
683 ADENITIS, GANGRENOUS, ACU 1 
785.6 LYMPH NODE ENLARGEMENT 1 
   
026.0 SPIRILLARY FEVER 3 
027.2 PASTEURELLOSIS 3 
078.3 CAT-SCRATCH DISEASE 3 
081.2 SCRUB TYPHUS 3 
082.1 BOUTONNEUSE FEVER 3 
082.2 NORTH ASIAN TICK FEVER 3 
082.3 QUEENSLAND TICK TYPHUS 3 
083.2 RICKETTSIALPOX 3 
085.0 LEISHMANIASIS, VISCERAL 3 
086.2 CHAGA'S DISEASE WITHOUT MENTION OF ORG 3 
086.3 TRYPANOSOMIASIS, GAMBIAN 3 
086.5 TRYPANOSOMIASIS, AFRICAN 3 
088.0 BARTONELLOSIS 3 
091.4 SYPHILITIC ADENOPATHY 3 
099.0 CHANCROIOD 3 
099.1 LYMPHOGRANULOMA VENEREUM 3 
117.1 SPOROTRICHOSIS 3 
125.0 BANCROFTIAN FILARIASIS 3 
125.1 MALAYAN FILARIASIS 3 
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Bot_Like ICD-9-CM Code List 
 
ICD9CM ICD9DESCR Consensus 
005.1 BOTULISM 1 
344.04 QUADRIPLE/QUADRIPA.C5-C7 1 
344.09 QUADRIPLEGIA/QUADRIPARESI 1 
344.2 DIPLEGIA OF UPPER LIMBS 1 
344.89 PARALYTIC SYNDROME, OTHR 1 
344.9 PARALYSIS 1 
351.9 FACIAL NERVE DISORDER UNS 1 
352.6 CRANIAL NERVE PALSIES,MUL 1 
352.9 CRANIAL NERVE DISORDER, U 1 
357.0 GUILLAIN-BARRE SYNDROME 1 
368.2 DIPLOPIA 1 
374.30 PTOSIS OF EYELID, UNSPECI 1 
378.51 NERV PALSY 3RD OR OCULOMO, PARTIAL 1 
378.52 NERV PALSY 3RD OR OCULOMO, TOTAL 1 
378.53 NERV PALSY 4TH OR TROCHLEAR 1 
378.54 SIXTH OR ABDUCENS NERVE P 1 
378.55 RECTUS PALSY (MEDIAL) 1 
   
342.90 HEMIPLEGIA/HEMIPARESIS UN 2 
344.00 QUADRIPLEGIA, UNSPECIFIED 2 
344.1 PARAPLEGIA 2 
351.0 BELL'S PALSY 2 
351.8 NEURALGIA FACIAL 2 
358.0 MYASTHENIA GRAVIS 2 
368.8 VISUAL DISTURBANCES ;SPEC 2 
368.9 VISUAL DISTURBANCE UNSPEC 2 
784.3 APHASIA 2 
784.5 SPEECH DISTURBANCE 2 
787.2 DYSPHAGIA 2 
   
037 TETANUS 3 
350.8 TRIGEMINAL NERVE DISORDER, OTHER SPECIFIED 3 
350.9 TRIGEMINAL NERVE DISORDER, UNSPECIFIED 3 
352.0 OLFACTORY (1ST) CN DISORDERS 3 
352.1 GLOSSOPHARYNGEAL NEURALGI 3 
352.2 GLOSSOPHARYNGEAL, OTHER DISORDERS 3 
352.3 DISORD. PNEUMOGASTRIC 10T 3 
352.4 ACCESSORY (11TH) DISORDERS 3 
352.5 HYPOGLOSSAL NERVE (12TH) DISORDERS 3 
374.31 PARALYTIC PTOSIS 3 
378.50 PARALYTIC STRABISMUS, UNSPEC 3 
378.56 EXTERNAL OPTHALMOPLEGIA 3 
527.7 XEROSTOMIA (DRY MOUTH) 3 
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ICD9CM ICD9DESCR Consensus U or L 
005.89 FOOD POISONING, OTHER BAC 1 L 
005.9 FOOD POISONING      NOS 1 L 
008.49 INTEST. INFECT BY OTHER B 1 L 
008.5 BACTERIAL ENTERITIS  NOS 1 L 
008.69 ENTERITIS VIRAL OTHER 1 L 
008.8 ENTERITIS VIRAL NOS 1 L 
009.0 ENTERITIS/COLITIS/GASTRO. 1 L 
009.1 COLITIS ENTERIT,GASTRO,IN 1 L 
009.2 DIARRHEA, INFECTIOUS  NOS 1 L 
009.3 DIARRHEA OF INFECT ORIG 1 L 
022.2 GASTROINTESTINAL ANTHRAX 1 L 
078.82 EPIDEMIC VOMITING SYND 1 U 
535.00 GASTRITIS, ACUTE 1 U 
535.01 GASTRITIS, WITH HEMORRHAG 1 U 
535.40 GASTRITIS,W/O HEM. OTHER 1 U 
535.41 GASTRITIS,OTH SPEC. W/HEM 1 U 
535.50 GASTRITIS/GASTRODUOD. W/O 1 U 
535.51 ASTRITIS/DUODEN W/O HEMO 1 U 
535.60 DUODENITIS W/O HEMORRHAGE 1 U 
535.61 DUODENITIS W/ HEMORRHAGE 1 U 
536.2 VOMITING PERSISTENT 1 U 
555.0 ENTERITIS SMALL INTESTINE 1 L 
555.1 REG ENTERITIS, LG INTEST 1 L 
555.2 REG ENTERIT SM/LG INTEST 1 L 
558.2 GASTROENTERITIS/COLITIS, 1 L 
558.9 GASTROENTERITIS/COLITIS N 1 L 
569.9 INTESTINAL DISORDER  NOS 1 L 
787.01 NAUSEA WITH VOMITING 1 U 
787.02 NAUSEA ALONE 1 U 
787.03 VOMITING ALONE 1 U 
787.3 FLATUL/ERUCTAT/GAS PAIN 1 L 
787.91 DIARRHEA 1 L 
    
567.1 PNEUMOCOCCAL PERITONITIS 2 L 
567.2 PERITONITIS SUPPURATIVE 2 L 
567.8 PERITONITIS, OTHER SPECIF 2 L 
567.9 PERITONITIS  NOS 2 L 
568.9 PERITONEAL DISORDER NOS 2 L 
578.0 HEMATEMESIS 2 U 
787.1 HEARTBURN/PYROSIS 2 U 
787.2 DYSPHAGIA 2 U 
789.00 ABDOMINAL PAIN,UNSPECIF. 2 L 
789.01 ABDOMINAL PAIN,RIGHT UPPE 2 L 
789.02 ABDOMINAL PAIN,LEFT UPPER 2 L 
789.03 ABDOMINAL PAIN,RIGHT LOW 2 L 
789.04 ABDOMINAL PAIN,LEFT LOWER 2 L 
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789.05 ABDOMINAL PAIN,PERIUMBILI 2 L 
789.06 ABDOMINAL PAIN,EPIGASTRIC 2 L 
789.07 ABDOMINAL PAIN,GENERALIZE 2 L 
789.09 ABDOMINAL PAIN,OTHER SPEC 2 L 
789.60 ABDOMINAL TENDERNESS, UNS 2 L 
789.61 ABDOMINAL TENDERNESS,RUQ 2 L 
789.62 ABDOMINAL TENDERNESS,LUQ 2 L 
789.63 ABDOMINAL TENDERNESS.RLQ 2 L 
789.64 ABDOMINAL TENDERNESS,LLQ 2 L 
789.65 ABDOMINAL TENDERNESS PERI 2 L 
789.66 ABDOMINAL TENDERNESS EPIG 2 L 
789.67 ABDOMINAL TENDERNESS GENE 2 L 
789.69 ABDOMINAL TENDERNESS,OT S 2 L 
789.9 ABDOMEN/PELVIS SYMPTOMS O 2 L 
    
001.0 CHOLERA D/T VIB CHOLERAE 3 L 
001.1 CHOLERA D/T VIB EL TOR 3 L 
001.9 CHOLERA NOS 3 L 
003.0 SALMONELLA GASTROENTERITI 3 L 
003.20 LOCAL SALMONELLA INF NOS 3 L 
003.29 LOCAL SALMONELLA INF NEC 3 L 
003.8 SALMONELLA INFECTION NEC 3 L 
003.9 SALMONELLA INFECTION UNSP 3 L 
004.0 SHIGELLA DYSENTERIAE 3 L 
004.1 SHIGELLA FLEXNERI 3 L 
004.2 SHIGELLA BOYDII 3 L 
004.3 SHIGELLA SONNEI 3 L 
004.8 SHIGELLA INFECTIONS OTHER 3 L 
004.9 SHIGELLOSIS, UNSPECIFIED 3 L 
005.0 STAPH FOOD POISONING 3 U 
005.2 FOOD POIS D/T C. PERFRIN 3 L 
005.3 FOOD POIS: CLOSTRID NEC 3 L 
005.4 FOOD POIS: V. PARAHAEM 3 L 
005.81 FOOD POISON-VIBRIO VULNIF 3 L 
006.0 AC AMEBIASIS W/O ABSCESS 3 L 
006.8 AMEBIC INFECTION NEC 3 L 
006.9 AMEBIASIS UNSPECIFIED 3 L 
007.0 BALANTIDIASIS 3 L 
007.1 GIARDIASIS 3 L 
007.2 COCCIDIOSIS 3 L 
007.3 INTEST TRICHOMONIASIS 3 L 
007.4 CRYPTOSPORIDOSIS 3 L 
007.5 CYCLOSPORIASIS 3 L 
007.8 PROTOZOAL INTEST DIS NEC 3 L 
007.9 PROTOZOAL INTEST DIS NOS 3 L 
008.00 E.COLI,UNSP.(ESCHERICHIA 3 L 
008.01 ENTRPATHOGENIC E COLI 3 L 
008.02 ENTEROTOXIGENIC E COLI 3 L 
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008.03 ENTEROINVASIVE E COLI 3 L 
008.04 ENTEROHEMORRAGIE E COLI 3 L 
008.09 OTHER E COLI ENTERITIS 3 L 
008.1 ARIZONA ENTERITIS 3 L 
008.2 AEROBACTER ENTERITIS 3 L 
008.3 PROTEUS ENTERITIS 3 L 
008.41 STAPHYLOCOCC ENTERITIS 3 L 
008.43 CAMPYLOBACTER ENTERITIS 3 L 
008.44 YERSINIA ENTEROCOLITICA 3 L 
008.45 CLOSTRIDIUM DIFFICILE 3 L 
008.46 INTESTINAL INF.DUE TO ANA 3 L 
008.47 GRAM-NEG ENTERITIS NEC 3 L 
008.61 ENTERITIS D/T ROTAVIRUS 3 L 
008.62 ENTERITIS D/T ADENOVIRUS 3 L 
008.63 ENTERITIS D/T NORWALK VIRUS 3 L 
008.64 ENTERITIS D/T SMALL ROUND VIRUS NEC 3 L 
008.65 ENTERITIS D/T CALCIVIRUS 3 L 
008.66 ENTERITIS D/T ASTROVIRUS 3 L 
008.67 
ENTERITIS DUE TO ENTEROVIRUS NOT 
ELSEWHERE CLASSIFIED 
3 L 
021.1 TULAREMIA, ENTERIC 3 L 
127.0 ASCARIASIS 3 L 
127.1 ANISAKIASIS 3 L 
127.2 STRONGYLOIDIASIS 3 L 
127.3 TRICHURIASIS 3 L 
127.4 ENTEROBIASIS 3 L 
127.5 CAPILLARIASIS 3 L 
127.6 TRICHOSTRONGYLIASIS 3 L 
127.7 INTEST HELMINTHIASIS NEC 3 L 
127.8 MIXED INTESTINE HELMINTH 3 L 
127.9 INTESTINAL HELMINTHIASIS, 3 L 
129 INTESTINAL PARASITISM UNS 3 L 
567.0 PERITONITIS IN INFEC DIS 3 L 
787.4 PERISTALSIS, VISIBLE 3 L 
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ICD9CM ICD9DESCR Consensus Lower GI 
005.89 FOOD POISONING, OTHER BAC 1 L 
005.9 FOOD POISONING  NOS 1 L 
008.49 INTEST. INFECT BY OTHER B 1 L 
008.5 BACTERIAL ENTERITIS  NOS 1 L 
008.69 ENTERITIS VIRAL OTHER 1 L 
008.8 ENTERITIS VIRAL NOS 1 L 
009.0 ENTERITIS/COLITIS/GASTRO. 1 L 
009.1 COLITIS ENTERIT,GASTRO,IN 1 L 
009.2 DIARRHEA, INFECTIOUS  NOS 1 L 
009.3 DIARRHEA OF INFECT ORIG 1 L 
022.2 GASTROINTESTINAL ANTHRAX 1 L 
555.0 ENTERITIS SMALL INTESTINE 1 L 
555.1 REG ENTERITIS, LG INTEST 1 L 
555.2 REG ENTERIT SM/LG INTEST 1 L 
558.2 GASTROENTERITIS/COLITIS, 1 L 
558.9 GASTROENTERITIS/COLITIS N 1 L 
569.9 INTESTINAL DISORDER  NOS 1 L 
787.3 FLATUL/ERUCTAT/GAS PAIN 1 L 
787.91 DIARRHEA 1 L 
    
567.1 PNEUMOCOCCAL PERITONITIS 2 L 
567.2 PERITONITIS SUPPURATIVE 2 L 
567.8 PERITONITIS, OTHER SPECIF 2 L 
567.9 PERITONITIS  NOS 2 L 
568.9 PERITONEAL DISORDER NOS 2 L 
789.00 ABDOMINAL PAIN,UNSPECIF. 2 L 
789.01 ABDOMINAL PAIN,RIGHT UPPE 2 L 
789.02 ABDOMINAL PAIN,LEFT UPPER 2 L 
789.03 ABDOMINAL PAIN,RIGHT LOW 2 L 
789.04 ABDOMINAL PAIN,LEFT LOWER 2 L 
789.05 ABDOMINAL PAIN,PERIUMBILI 2 L 
789.06 ABDOMINAL PAIN,EPIGASTRIC 2 L 
789.07 ABDOMINAL PAIN,GENERALIZE 2 L 
789.09 ABDOMINAL PAIN,OTHER SPEC 2 L 
789.60 ABDOMINAL TENDERNESS, UNS 2 L 
789.61 ABDOMINAL TENDERNESS,RUQ 2 L 
789.62 ABDOMINAL TENDERNESS,LUQ 2 L 
789.63 ABDOMINAL TENDERNESS.RLQ 2 L 
789.64 ABDOMINAL TENDERNESS,LLQ 2 L 
789.65 ABDOMINAL TENDERNESS PERI 2 L 
789.66 ABDOMINAL TENDERNESS EPIG 2 L 
789.67 ABDOMINAL TENDERNESS GENE 2 L 
789.69 ABDOMINAL TENDERNESS,OT S 2 L 
789.9 ABDOMEN/PELVIS SYMPTOMS O 2 L 
    
001.0 CHOLERA D/T VIB CHOLERAE 3 L 
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001.1 CHOLERA D/T VIB EL TOR 3 L 
001.9 CHOLERA NOS 3 L 
003.0 SALMONELLA GASTROENTERITI 3 L 
003.20 LOCAL SALMONELLA INF NOS 3 L 
003.29 LOCAL SALMONELLA INF NEC 3 L 
003.8 SALMONELLA INFECTION NEC 3 L 
003.9 SALMONELLA INFECTION UNSP 3 L 
004.0 SHIGELLA DYSENTERIAE 3 L 
004.1 SHIGELLA FLEXNERI 3 L 
004.2 SHIGELLA BOYDII 3 L 
004.3 SHIGELLA SONNEI 3 L 
004.8 SHIGELLA INFECTIONS OTHER 3 L 
004.9 SHIGELLOSIS, UNSPECIFIED 3 L 
005.2 FOOD POIS D/T C. PERFRIN 3 L 
005.3 FOOD POIS: CLOSTRID NEC 3 L 
005.4 FOOD POIS: V. PARAHAEM 3 L 
005.81 FOOD POISON-VIBRIO VULNIF 3 L 
006.0 AC AMEBIASIS W/O ABSCESS 3 L 
006.8 AMEBIC INFECTION NEC 3 L 
006.9 AMEBIASIS UNSPECIFIED 3 L 
007.0 BALANTIDIASIS 3 L 
007.1 GIARDIASIS 3 L 
007.2 COCCIDIOSIS 3 L 
007.3 INTEST TRICHOMONIASIS 3 L 
007.4 CRYPTOSPORIDOSIS 3 L 
007.5 CYCLOSPORIASIS 3 L 
007.8 PROTOZOAL INTEST DIS NEC 3 L 
007.9 PROTOZOAL INTEST DIS NOS 3 L 
008.00 E.COLI,UNSP.(ESCHERICHIA 3 L 
008.01 ENTRPATHOGENIC E COLI 3 L 
008.02 ENTEROTOXIGENIC E COLI 3 L 
008.03 ENTEROINVASIVE E COLI 3 L 
008.04 ENTEROHEMORRAGIE E COLI 3 L 
008.09 OTHER E COLI ENTERITIS 3 L 
008.1 ARIZONA ENTERITIS 3 L 
008.2 AEROBACTER ENTERITIS 3 L 
008.3 PROTEUS ENTERITIS 3 L 
008.41 STAPHYLOCOCC ENTERITIS 3 L 
008.43 CAMPYLOBACTER ENTERITIS 3 L 
008.44 YERSINIA ENTEROCOLITICA 3 L 
008.45 CLOSTRIDIUM DIFFICILE 3 L 
008.46 INTESTINAL INF.DUE TO ANA 3 L 
008.47 GRAM-NEG ENTERITIS NEC 3 L 
008.61 ENTERITIS D/T ROTAVIRUS 3 L 
008.62 ENTERITIS D/T ADENOVIRUS 3 L 
008.63 ENTERITIS D/T NORWALK VIRUS 3 L 
008.64 ENTERITIS D/T SMALL ROUND VIRUS NEC 3 L 
008.65 ENTERITIS D/T CALCIVIRUS 3 L 
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008.66 ENTERITIS D/T ASTROVIRUS 3 L 
008.67 
ENTERITIS DUE TO ENTEROVIRUS NOT 
ELSEWHERE CLASSIFIED 
3 L 
021.1 TULAREMIA, ENTERIC 3 L 
127.0 ASCARIASIS 3 L 
127.1 ANISAKIASIS 3 L 
127.2 STRONGYLOIDIASIS 3 L 
127.3 TRICHURIASIS 3 L 
127.4 ENTEROBIASIS 3 L 
127.5 CAPILLARIASIS 3 L 
127.6 TRICHOSTRONGYLIASIS 3 L 
127.7 INTEST HELMINTHIASIS NEC 3 L 
127.8 MIXED INTESTINE HELMINTH 3 L 
127.9 INTESTINAL HELMINTHIASIS, 3 L 
129 INTESTINAL PARASITISM UNS 3 L 
567.0 PERITONITIS IN INFEC DIS 3 L 
787.4 PERISTALSIS, VISIBLE 3 L 
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ICD9CM ICD9DESCR Consensus Upper GI 
078.82 EPIDEMIC VOMITING SYND 1 U 
535.00 GASTRITIS, ACUTE 1 U 
535.01 GASTRITIS, WITH HEMORRHAG 1 U 
535.40 GASTRITIS,W/O HEM OTHER 1 U 
535.41 GASTRITIS,OTH SPEC W/HEM 1 U 
535.50 GASTRITIS/GASTRODUOD. W/O 1 U 
535.51 .ASTRITIS/DUODEN W/O HEMO 1 U 
535.60 DUODENITIS W/O HEMORRHAGE 1 U 
535.61 DUODENITIS W/ HEMORRHAGE 1 U 
536.2 VOMITING PERSISTENT 1 U 
787.01 NAUSEA WITH VOMITING 1 U 
787.02 NAUSEA ALONE 1 U 
787.03 VOMITING ALONE 1 U 
    
578.0 HEMATEMESIS 2 U 
787.1 HEARTBURN/PYROSIS 2 U 
787.2 DYSPHAGIA 2 U 
    
005.0 STAPH FOOD POISONING 3 U 
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047.8 MENINGITIS, VIRAL NEC 1 
047.9 MENINGITIS, VIRAL NOS 1 
048 DIS ENTEROVIRAL OF CNS, NEC 1 
049.0 CHORIOMENINGITIS, LYMPHOCYTIC 1 
049.9 ENCEPHALITIS VIRAL NOS 1 
320.9 BACTERIAL MENINGITIS NOS 1 
321.2 MENINGITIS D/T VIRAL DISEASES NEC 1 
322.0 MENINGITIS, NONPYOGENIC 1 
322.1 MENINGITIS, EOSINOPHILIC 1 
322.9 MENINGITIS NOS 1 
323.8 OTHER CAUSES OF ENCEPHALI 1 
323.9 ENCEPHALITIS NOS 1 
348.3 ENCEPHALOPATHY NOS 1 
781.6 MENINGISMUS 1 
   
293.0 DELIRIUM, ACUTE 2 
293.1 CONFUSIONAL STATE(DEL SUBACUTE)  2 
307.81 TENSION HEADACHE 2 
780.02 ALTERATION OF AWARENESS/T 2 
780.09 ALTERATION OF AWARENESS 2 
780.39 CONVULSIONS, OTHER 2 
784.0 HEADACHE 2 
784.3 APHASIA 2 
   
003.21 SALMONELLA MENINGITIS 3 
036.0 MENINGITIS (MENINGOCOCCAL) 3 
036.1 ENCEPHALITIS, MENINGOCCAL 3 
036.2 MENINGOCOCCEMIA INFECTION 3 
036.89 INFECTION, MENINGOCCAL NEC 3 
036.9 INFECTION, MENINGOCCAL NOS 3 
047.0 COXSACKIE DUE TO MENINGIT 3 
047.1 MENINGITIS D/T ECHO VIRUS 3 
049.1 MENINGITIS, ADENOVIRUS 3 
049.8 
OTHER SPECIFIED NON-ARTHORPOD-BORNE 
VIRAL DIS 
3 
052.0 POSTVARICELLA ENCEPHALIT 3 
053.0 HERPES ZOSTER WITH MENINGITIS 3 
053.10 HERPES ZOSTER W UNSPED NER S 3 
054.3 HERPETIC MENINGOENCEPHALI 3 
054.72 HSV, MENINGITIS 3 
055.0 POSTMEASLES ENCEPHALITIS 3 
056.00 RUBELLA, UNSPEC NEURO COMPLIC 3 
056.01 RUBELLA, ENCEPHALOMYELITIS 3 
056.09 RUBELLA, OTHER NEURO COMPLI 3 
061 DENGUE 3 
062.0 ENCEPHALITIS, JAPANESE 3 
062.1 ENCEPHALITIS, WESTERN EQUINE 3 
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062.2 ENCEPHALITIS, EASTERN EQUINE 3 
062.3 ST. LOUIS ENCEPHALITIS 3 
062.4 ENCEPHALITIS, AUSTRALIAN 3 
062.5 ENCEPHALITIS, CALIFORNIA VIRUS 3 
062.8 ENCEPHALITIS, MOSQUITO-BORNE NEC 3 
062.9 ENCEPHALITIS, MOSQUITO-BORNE NOS 3 
063.0 ENCEPHALITIS, RUSSIAN SPRING-SUMME 3 
063.1 LOUPING ILL 3 
063.2 ENCEPHALITIS, CENTRAL EUROPEAN 3 
063.8 ENCEPHALITIS, VIRAL, TICK-BORNE NEC 3 
063.9 ENCEPHALITIS, TICK-BORNE VIRAL NOS 3 
064 ENCEPHALITIS, ARTHPD-BORNE VIRAL NE 3 
066.4 WEST NILE FEVER 3 
071 RABIES 3 
072.1 MUMPS MENINGITIS 3 
072.2 MUMPS ENCEPHALITIS 3 
084.9 MALARIA COMPLICATED NEC 3 
086.2 CHAGA’S DISEASE W/O MENTION OF ORG 3 
086.3 TRYPANOSOMIASIS, GAMBIAN 3 
086.4 TRYPANOSOMIASIS, RHODESIAN 3 
086.5 TRYPANOSOMIASIS, AFRICAN 3 
091.81 ACUTE SYPHIL MENINGITIS 3 
098.82 GONOCCOCAL, MENINGITIS 3 
100.81 LEPTOSPIRAL INFECTION, MENG(ASEPTIC) 3 
114.2 COCCIDIODAL MENINGITIS 3 
115.01 HISTOPLASMOSIS MENINGITIS 3 
115.11 HISTOPLASMA DUBOISII, MENINGITIS 3 
115.91 HISTOPLASMOSIS, UNSPEC, MENINGITIS 3 
117.5 CRYPTOCOCCOSIS 3 
130.0 TOXOPLASMOSIS, MENINGOENCEPHALITIS 3 
136.2 SPECIFIC INF BY FREE LIVING AMOEBA 3 
320.0 HEMOPHILUS MENINGITIS 3 
320.1 MENINGITIS, PNEUMOCOCCAL 3 
320.2 MENINGITIS, STREPTOCOCCAL 3 
320.3 MENINGITIS, STAPHYLOCCAL 3 
320.7 MENG, IN OTH BCTRL DISEASE CE 3 
320.81 MENINGITIS, D/T ANAEROBIC BACTERIA 3 
320.82 MENINGITIS DUE TO GRAM-NE,  3 
320.89 MENINGITIS DUE TO OTHER S 3 
321 MENINGITIS, CRYPTOCCAL 3 
321.1 MENINGITIS IN OTH FUNGAL,  3 
321.3 MENINGITIS D/T TRYPANOSOMIASIS 3 
321.4 MENINGITIS IN SARCOIDOSIS 3 
321.8 MENG D/T OTH NONBACT ORGANISM CE 3 
323.0 ENCEPHALITIS IN VIRAL DISEASE CE 3 
323.1 ENCEPHALITIS IN RICKETTSIAL DIS CE 3 
323.2 ENCEPHALITIS IN PROTOZOAL DIS CE 3 
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323.4 ENCEPHALITIS, OTH D/T INFECTION CE 3 
323.5 ENCEPHALITIS, POSTIMMUNIZATION 3 
323.6 ENCEPHALITIS POSTINFECTIO 3 
323.7 ENCEPHALITIS, TOXIC 3 
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ICD9CM ICD9DESCR Consensus 
050.0 SMALL POX, VARIOLA MAJOR 1 
050.1 SMALL POX, ALASTRIM 1 
050.2 SMALL POX, MODIFIED 1 
050.9 SMALLPOX NOS 1 
051.0 COWPOX 1 
051.1 PSEUDOCOWPOX 1 
052.7 VARICELLA COMPLICAT NEC 1 
052.8 VARICELLA W/UNSPECIFIED C 1 
052.9 VARICELLA NOS 1 
057.8 EXANTHEMATA VIRAL OTHER S 1 
057.9 EXANTHEM VIRAL, UNSPECIFI 1 
695.0 ERYTHEMA TOXIC 1 
695.1 ERYTHEMA MULTIFORME 1 
695.2 ERYTHEMA NODOSUM 1 
695.89 ERYTHEMATOUS CONDITIONS O 1 
695.9 ERYTHEMATOUS CONDITION  N 1 
   
692.9 DERMATITIS UNSPECIFIED CA 2 
782.1 RASH/OTHER NONSPEC SKIN E 2 
   
026.0 SPIRILLARY FEVER 3 
026.1 STREPTOBACILLARY FEVER 3 
026.9 RAT-BITE FEVER UNSPECIFIED 3 
051.2 DERMATITIS PUSTULAR, CONT 3 
051.9 PARAVACCINIA NOS 3 
053.20 HERPES ZOSTER DERMATITIS E 3 
053.79 
HERPES ZOSTER WITH OTHER SPECIF 
COMPLIC 
3 
053.8 H.Z. W/ UNSPEC. COMPLICATION 3 
053.9 HERPES ZOSTER NOS W/O COM 3 
054.0 ECZEMA HERPETICUM 3 
054.79 HERPES SIMPLEX W/OTH.SPEC 3 
054.8 HERPES SIMPLEX, W/UNS.COM 3 
054.9 HERPES SIMPLEX  NOS 3 
055.79 MEASLES COMPLICATION NEC 3 
055.8 MEASLES COMPLICATION NOS 3 
055.9 MEASLES UNCOMPLICATED 3 
056.79 RUBELLA COMPLICATION NEC 3 
056.8 RUBELLA COMPLICATION  NOS 3 
056.9 RUBELLA UNCOMPLICATED 3 
057.0 ERYTHEMIA INFECT.(5TH DIS 3 
074.3 HAND/FOOT AND MOUTH DISEA 3 
078.0 MOLLUSCUM CONTAGIOSUM 3 
082.0 ROCKY MOUNTAIN SPOTTED FE 3 
083.2 RICKETTSIALPOX 3 
695.3 ROSACEA 3 
695.4 LUPUS ERYTHEMATOSUS 3 
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ICD9CM ICD9DESCR Consensus 
020.3 PRIMARY PNEUMONIC PLAGUE 1 
020.4 SECONDARY PNEUMON PLAGUE 1 
020.5 PNEUMONIC PLAGUE NOS 1 
021.2 PULMONARY TULAREMIA 1 
022.1 PULMONARY ANTHRAX 1 
460 NASOPHARYNGITIS, ACUTE 1 
462 PHARYNGITIS, ACUTE NOS 1 
463 TONSILLITIS, ACUTE 1 
464.00 LARYNGITIS, AC.W/O OBSTRU 1 
464.01 LARYNGITIS, AC.W/OBSTRUCT 1 
464.10 TRACHEITIS W/O OBSTRUCTIO 1 
464.11 AC TRACHEITIS W OBSTRUCT 1 
464.20 LARYNGOTRACHEITIS W/O OBS 1 
464.21 AC LARYNGOTRACH W OBSTR 1 
464.30 EPIGLOTTITIS ACUTE W/O OB 1 
464.31 AC EPIGLOTTITIS W OBSTR 1 
464.4 CROUP 1 
464.50 SUPRAGLOTTIS,UNS.W/O OBST 1 
464.51 SUPRAGLOTTIS,UNS.W/ OBST 1 
465.0 LARYNGOPHARYNGITIS, ACUTE 1 
465.8 URI, OTHER MULT. SITES 1 
465.9 URI, ACUTE  NOS 1 
466.0 BRONCHITIS ACUTE 1 
466.11 BRONCHIOLITIS ACUTE DUE T 1 
466.19 BRONCHIOLITIS DUE TO OT/I 1 
478.9 RESPIRATORY TRACT DISEASE 1 
480.8 VIRAL PNEUMONIA NEC 1 
480.9 PNEUMONIA, VIRAL 1 
482.9 PNEUMONIA, BACTERIAL  NOS 1 
483.8 PNEUMONIA D/T ORGANISM NEC 1 
484.5 PNEUMONIA IN ANTHRAX 1 
484.8 PNEUM IN INFECT DIS NEC 1 
485 BRONCHOPNEUMONIA ORGANISM 1 
486 PNEUMONIA, ORGANISM NOS 1 
490 BRONCHITIS NOS 1 
511.0 PLEURISY W/O EFFUSION 1 
511.1 PLEURAL EFFUSION-VIRAL(NO 1 
511.8 HEMOTHORAX 1 
513.0 ABSCESS LUNG 1 
513.1 ABSCESS OF MEDIASTINUM 1 
518.4 EDEMA LUNG ACUTE  NOS 1 
518.84 RESPIRATORY FAILURE,ACUTE 1 
519.2 MEDIASTINITIS 1 
519.3 MEDIASTINUM, DISEASES NEC 1 
769 RESPIRATORY DISTRESS SYND 1 
786.00 RESPIRATORY ABNORMALITY 1 
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786.06 TACHYPNEA 1 
786.1 STRIDOR 1 
786.2 COUGH 1 
786.3 HEMOPTYSIS 1 
786.52 PAINFUL RESPIRAT./PLEUROD 1 
799.1 RESPIRATORY ARREST 1 
   
075 MONONUCLEOSIS, INFECTIOUS 2 
381.00 OTITIS MEDIA NONSUP ACUTE 2 
381.01 OTITIS MEDIA SEROUS ACUTE 2 
381.03 OM, ACUTE SANGUINOS 2 
381.04 OM, ACUTE ALLERGIC SEROUS 2 
381.4 OTITIS MEDIA NONSUPPURATI 2 
381.50 EUSTACHIAN SALPINGITIS, U 2 
381.51 EUSTACHIAN SALPINGITIS AC 2 
382 OM SUPPURATIVE & UNSPEC 2 
382.0 OM, ACUTE SUPPURATIVE 2 
382.00 OTITIS MEDIA SUPP. ACUTE 2 
382.01 OTITIS MEDIA SUP.W/EARDRU 2 
382.02 OTITIS MEDIA SUPP.ACUTE I 2 
382.4 OM, SUPPURATIVE NOS 2 
382.9 OTITIS MEDIA NOS 2 
461.0 MAXILLARY SINUSITIS, ACUT 2 
461.1 SINUSITIS, FRONTAL-ACUTE 2 
461.2 SINUSITIS, ETHMOIDAL 2 
461.3 SINUSITIS,ACUTE SPHENOIDA 2 
461.8 SINUSITIS, ACUTE, OTHER 2 
461.9 SINUSITIS, ACUTE  NOS 2 
493.00 ASTHMA EXTRINSIC W/O STAT 2 
493.01 ASTHMA, EXTRINSIC W/ASTHM 2 
493.02 ASTHMA,EXTRINSIC W/AC.EXA 2 
493.10 ASTHMA, INTRINSIC W/O AST 2 
493.11 ASTHMA, INTRINSIC W/ASTHM 2 
493.12 ASTHMA INTRINSIC W/AC.EXA 2 
493.90 ASTHMA W/O STATUS ASTHMAT 2 
493.91 ASTHMA W/ STATUS ASTHMATI 2 
493.92 ASTHMA UNSPEC.W/AC.EXACER 2 
511.9 PLEURAL EFFUSION UNSPECIF 2 
514 EDEMA PULMONARY 2 
518.0 PULMONARY COLLAPSE 2 
518.81 RESPIRATORY FAILURE, ACUT 2 
518.82 PULMONARY INSUFFICIENCY 2 
782.5 CYANOSIS 2 
784.1 PAIN IN THROAT 2 
786.05 SHORTNESS OF BREATH 2 
786.07 WHEEZING 2 
786.09 DYSPNEA/RESP.ABNORMALITIE 2 
786.50 CHEST PAIN, UNSPECIFIED 2 
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786.51 PRECORDIAL PAIN 2 
786.59 CHEST PAIN, OTHER 2 
786.7 ABNORMAL CHEST SOUNDS 2 
786.9 RESP SYS/CHEST SYMP NEC 2 
   
003.22 SALMONELLA PNEUMONIA 3 
031.0 MYCOBACTERIA, PULMONARY 3 
031.8 MYCOBACTERIAL DIS NEC 3 
031.9 MYCOBACTERIA DISEASES/UNS 3 
032.0 FAUCIAL DIPHTHERIA 3 
032.1 NASOPHARYNX DIPHTHERIA 3 
032.2 ANT NASAL DIPHTHERIA 3 
032.3 LARYNGEAL DIPHTHERIA 3 
032.89 DIPHTHERIA NEC 3 
032.9 DIPHTHERIA NOS 3 
033.0 BORDETELLA PERTUSSIS 3 
033.1 BORDETELLA PARAPERTUSSIS 3 
033.8 WHOOPING COUGH NEC 3 
033.9 WHOOPING COUGH(UNSPE.ORGA 3 
034.0 STREP SORE THROAT 3 
052.1 VARICELLA WITH PNEUMONIA 3 
055.1 POSTMEASLES PNEUMONIA 3 
055.2 POSTMEASLES OTITIS MEDIA 3 
073.0 ORNITHOSIS, WITH PNEUMONIA 3 
073.7 ORNITHOSIS, OTHER SPECIF COMPLIC 3 
073.8 ORNITHOSIS, UNSPECIFIED COMPLIC 3 
073.9 ORNITHOSIS, UNSPECIFIED 3 
079.0 ADENOVIRUS INFECT NOS 3 
079.1 ECHO VIRUS INFECT NOS 3 
079.2 COXSACKIE VIRUS 3 
079.3 RHINOVIRUS INFECT NOS 3 
079.6 RESPIRATORY SYNCYTIAL VIR 3 
079.81 HANTAVIRUS INFECTION 3 
098.6 GONOCCOCAL, INFECTION OF PHARYNX 3 
114.5 PULM COCCIDIOIDOMYCOS,UN 3 
114.9 COCCIDIOIDOMYCOSIS NOS 3 
115.00 
HISTOPLASMOSIS, WITHOUT MENTION OF 
MANIFESTATION 
3 
115.05 HISTOPLASM CAPS PNEUMON 3 
115.09 HISTOPLASMA CAPSULAT NEC 3 
115.10 HISTOPLASMA DUBOISII NOS 3 
115.15 HISTOPLASMA DUBOISII PNEUMONIA 3 
115.90 HISTOPLASMOSIS,W/O MANIFE 3 
115.95 HISTOPLASMOSIS PNEUMONIA 3 
115.99 HISTOPLASMOSIS NEC 3 
116.0 BLASTOMYCOSIS 3 
116.1 PARACOCCIDIOIDOMYCOSIS 3 
117.1 SPOROTRICHOSIS 3 
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117.3 PULMONARY ASPERGILLOSIS 3 
117.5 CRYPTOCOCCOSIS 3 
130.4 TOXOPLASMA PNEUMONITIS 3 
136.3 PNEUMOCYSTOSIS 3 
480.0 ADENOVIRAL PNEUMONIA 3 
480.1 PNEUMONIA,RESP.SYNCYTIAL 3 
480.2 PARINFLUENZA VIRAL PNEUM 3 
481 PNEUMOCOCCAL PNEUMONIA (L 3 
482.0 PNEUMONIA-KLEBSIELLA PNEU 3 
482.1 PNEUMONIA DUE TO PSEUDOMO 3 
482.2 H.INFLUENZAE PNEUMONIA 3 
482.30 STREPTOCOCCUS UNSPECIFIED 3 
482.31 PNEUMONIA/STREPTOC GPA 3 
482.32 PHEUMONIA/STREPTO GPB 3 
482.39 PNEUMONIA/OTHER STREPTOC 3 
482.40 STAPH PNEUMONIA NOS 3 
482.41 PNEUMONIA, STAPHYLOCOC. A 3 
482.49 OTH STAPH PNEUMONIA 3 
482.81 PNEUMONIA/ANAEROBES 3 
482.82 PNEUMONIA/E COLI 3 
482.83 PNEUMONIA/OTHER GNEG BAC 3 
482.84 LEGIONNAIRES' DISEASE 3 
482.89 PNEUMONIA/OTHER SPEC BAC 3 
483.0 PNEUMONIA MYCOPLASMA 3 
483.1 PNEUMONIA DUE TO CHLAMYD 3 
484.1 PNEUM W CYTOMEG INCL DIS 3 
484.3 PNEUMONIA IN WHOOP COUGH 3 
484.6 PNEUMONIA IN ASPERGILLOSI 3 
484.7 PNEUM IN OTH SYS MYCOSES 3 
487.0 INFLUENZA WITH PNEUMONIA 3 
487.1 INFLUENZA W/OTH. RESP. MA 3 
487.8 INFLUENZA W/OTHR MANIFEST 3 
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780.01 COMA 1 
785.50 SHOCK (UNSPECIFIED) 1 
785.59 SHOCK, OTHER, W/O TRAUMA 1 
798.1 DEATH INSTANTANEOUS 1 
798.2 DEATH IN E.R. 1 
798.9 DEATH UNATTENDED 1 
799.9 MORTALITY, CAUSE UNKNOWN 1 
   
656.40 INTRAUTERINE DEATH, UNSPE 3 
656.41 INTRAUTERINE DEATH DEL.AN 3 
656.43 FETAL DEATH, ANTEPARTUM 3 
761.8 ABORTION OF FETUS, SPONTA 3 
768.0 FETAL DEATH 3 
779.9 STILLBIRTH 3 
798.0 SUDDEN INFANT DEATH SYND 3 
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Appendix A 
 
ICD-9 Codes for Selection of Potentially Positive Patients 
 
Syndrome ICD-9 ICD-9 Description 
Botulinic 045 Acute poliomyelitis 
Botulinic 005.1 Botulism 
Botulinic 045.0 Acute paralytic poliomyelitis specified as bulbar 
Botulinic 045.00 Acute paralytic poliomyelitis specified as bulbar, unspecified type of 
poliovirus 
Botulinic 045.01 Acute paralytic poliomyelitis specified as bulbar, poliovirus type i 
Botulinic 045.02 Acute paralytic poliomyelitis specified as bulbar, poliovirus type ii 
Botulinic 045.03 Acute paralytic poliomyelitis specified as bulbar, poliovirus type iii 
Botulinic 045.1 Acute poliomyelitis with other paralysis 
Botulinic 045.10 Acute poliomyelitis with other paralysis, unspecified type of poliovirus 
Botulinic 045.11 Acute poliomyelitis with other paralysis, poliovirus type i 
Botulinic 045.12 Acute poliomyelitis with other paralysis, poliovirus type ii 
Botulinic 045.13 Acute poliomyelitis with other paralysis, poliovirus type iii 
Botulinic 045.9 Acute poliomyelitis, unspecified 
Botulinic 045.90 Acute poliomyelitis, unspecified, poliovirus, unspecified type 
Botulinic 045.91 Acute poliomyelitis, unspecified, poliovirus type i 
Botulinic 045.92 Acute poliomyelitis, unspecified, poliovirus type ii 
Botulinic 045.93 Acute poliomyelitis, unspecified, poliovirus type iii 
Botulinic 344.1 Paraplegia nos 
Botulinic 344.2 Diplegia of upper limbs 
Botulinic 344.30 Monopleg low limb uns si 
Botulinic 344.31 Monopleg low limb dom si 
Botulinic 344.32 Monopleg low limb nondom 
Botulinic 344.40 Monopleg up limb uns si 
Botulinic 344.41 Monopleg up limb dom sit 
Botulinic 344.42 Monopleg up limb nondom 
Botulinic 344.89 Oth paralytic syndromes 
Botulinic 344.9 Paralysis nos 
Botulinic 350.8 Other specified trigeminal nerve disorder 
Botulinic 350.9 Trigeminal nerve dis nos 
Botulinic 351 Facial nerve disorders 
Botulinic 351.0 Bell's palsy 
Botulinic 351.1 Geniculate ganglionitis 
Botulinic 351.8 Other facial nerve disorders 
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Botulinic 351.9 Facial nerve disorder, unspecified 
Botulinic 352 Disorders of other cranial nerves 
Botulinic 352.0 Olfactory nerve disorder 
Botulinic 352.1 Glossopharyngeal neuralgia 
Botulinic 352.2 Other disorders of glossopharyngeal [9th nerve] 
Botulinic 352.3 Disorders of pneumogastric [10th nerve] 
Botulinic 352.4 Disorders of accessory [11th nerve] 
Botulinic 352.5 Disorders of hypoglossal [12th nerve] 
Botulinic 352.6 Multiple cranial nerve palsies 
Botulinic 352.9 Unspecified disorder of cranial nerves 
Botulinic 357 Acute infective polyneuritis 
Botulinic 358 Myoneural disorders 
Botulinic 358.0 Myasthenia gravis 
Botulinic 358.1 Myasthenic syndromes in diseases classified elsewhere  
Botulinic 358.2 Toxic myoneural disorders 
Botulinic 358.8 Other specified myoneural disorders 
Botulinic 358.9 Myoneural disorders, unspecified 
Botulinic 368.2 Diplopia 
Botulinic 368.8 Visual disturbances nec 
Botulinic 368.9 Visual disturbance nos 
Botulinic 374.3 Ptosis of eyelid 
Botulinic 374.30 Ptosis of eyelid nos 
Botulinic 374.31 Paralytic ptosis 
Botulinic 519.4 Disorders of diaphragm 
Botulinic 527.7 Disturbance of salivary secretion 
Botulinic 784.5 Speech disturbance nec 
Botulinic 787.2 Dysphagia 
Constitutional 002 Typhoid/paratyphoid fev 
Constitutional 002.0 Typhoid fever 
Constitutional 002.1 Paratyphoid fever a 
Constitutional 002.2 Paratyphoid fever b 
Constitutional 002.3 Paratyphoid fever c 
Constitutional 002.9 Paratyphoid fever nos 
Constitutional 020.0 Bubonic plague 
Constitutional 020.2 Septicemic plague 
Constitutional 020.8 Other specified types of plague 
Constitutional 020.9 Plague, unspecified  
Constitutional 021 Tularemia 
Constitutional 021.0 Ulceroglandular tularemia 
Constitutional 021.3 Oculoglandular tularemia 
Constitutional 021.8 Other specified tularemia 
Constitutional 021.9 Unspecified tularemia 
Constitutional 022.3 Anthrax septicemia 
Constitutional 022.8 Other specified manifestations of anthrax 
Constitutional 022.9 Anthrax, unspecified  
Constitutional 023 Brucellosis 
Constitutional 023.0 Brucella melitensis 
Constitutional 023.1 Brucella abortus 
Constitutional 023.2 Brucella suis 
Constitutional 023.3 Brucella canis 
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Constitutional 023.8 Other brucellosis 
Constitutional 023.9 Brucellosis, unspecified  
Constitutional 060 Yellow fever 
Constitutional 060.0 Sylvatic yellow fever 
Constitutional 060.1 Urban yellow fever 
Constitutional 060.9 Yellow fever, unspecified  
Constitutional 066.3 Mosquito-borne viral fever, Chikungunya  
Constitutional 073.7 Ornithosis with other specified complications 
Constitutional 073.8 Ornithosis with unspecified complication 
Constitutional 073.9 Ornithosis, unspecified  
Constitutional 075 Infectious mononucleosis 
Constitutional 078.3 Cat-scratch disease 
Constitutional 078.5 Cytomegaloviral disease 
Constitutional 079 Viral inf in oth dis/nos 
Constitutional 079.1 Echo virus infection in conditions classified elsewhere and of 
unspecified site 
Constitutional 079.2 Coxsackie virus infection in conditions classified elsewhere and of 
unspecified site 
Constitutional 079.9 Viral infection nos 
Constitutional 079.98 Chlamydial infect unspec 
Constitutional 079.99 Viral infection unspec 
Constitutional 081.2 Scrub typhus 
Constitutional 130.7 Toxoplasmosis of other specified sites 
Constitutional 130.8 Multisystemic disseminated toxoplasmosis 
Constitutional 130.9 Toxoplasmosis, unspecified 
Constitutional 461.0 Acute maxillary sinusitis 
Constitutional 461.1 Acute frontal sinusitis 
Constitutional 461.2 Acute ethmoidal sinusitis 
Constitutional 461.3 Acute sphenoidal sinusitis 
Constitutional 461.8 Other acute sinusitis 
Constitutional 461.9 Acute sinusitis, unspecified 
Constitutional 464.00 Acute laryngitis without mention of obstruction 
Constitutional 464.50 Supraglottitis, unspecified without mention of obstruction 
Constitutional 472.1 Chronic pharyngitis 
Constitutional 487.8 Influenza with other manifestations 
Constitutional 780.4 Dizziness and giddiness 
Constitutional 780.6 Fever 
Constitutional 780.7 Malaise and fatigue 
Constitutional 780.79 Other malaise and fatigue 
Constitutional 780.8 Hyperhidrosis 
Constitutional 780.9 Other general symptoms 
Constitutional 780.91 Fussy infant (baby) 
Constitutional 780.92 Excessive crying of infant (baby) 
Constitutional 780.99 Other general symptoms 
Constitutional 783.0 Anorexia 
Gastrointestinal 001 Cholera 
Gastrointestinal 001.0 Cholera due to Vibrio cholerae 
Gastrointestinal 001.1 Cholera due to Vibrio cholerae el tor 
Gastrointestinal 001.9 Cholera, unspecified  
Gastrointestinal 003.0 Salmonella gastroenteritis  
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Gastrointestinal 004 Shigellosis 
Gastrointestinal 004.0 Shigella dysenteriae 
Gastrointestinal 004.1 Shigella flexneri 
Gastrointestinal 004.2 Shigella boydii 
Gastrointestinal 004.3 Shigella sonnei 
Gastrointestinal 004.8 Other specified shigella infections 
Gastrointestinal 004.9 Shigellosis, unspecified  
Gastrointestinal 005 Other food poisoning (bacterial) 
Gastrointestinal 005.0 Staphylococcal food poisoning 
Gastrointestinal 005.2 Food poisoning due to Clostridium perfringens (C. welchii) 
Gastrointestinal 005.3 Food poisoning due to other clostridia 
Gastrointestinal 005.4 Food poisoning due to vibrio parahaemolyticus 
Gastrointestinal 005.8 Other bacterial food poisoning 
Gastrointestinal 005.81 Food pois-vibrio vulnif 
Gastrointestinal 005.89 Oth bacterial food pois 
Gastrointestinal 005.9 Food poisoning, unspecified 
Gastrointestinal 006.0 Acute amebic dysentery without mention of abscess 
Gastrointestinal 006.1 Chronic intestinal amebiasis without mention of abscess 
Gastrointestinal 007 Other protozoal intestinal diseases 
Gastrointestinal 007.0 Balantidiasis 
Gastrointestinal 007.1 Gastrointestinalardiasis 
Gastrointestinal 007.2 Coccidiosis 
Gastrointestinal 007.3 Intestinal trichomoniasis 
Gastrointestinal 007.4 Cryptosporidiosis 
Gastrointestinal 007.5 Cyclosporiasis 
Gastrointestinal 007.8 Other specified protozoal intestinal diseases 
Gastrointestinal 007.9 Unspecified protozoal intestinal disease 
Gastrointestinal 008 Intestinal infections due to other organisms 
Gastrointestinal 008.0 Intestinal infection due to escherichia coli [e. Coli] 
Gastrointestinal 008.00 Intestinal infection due to unspecified e. Coli 
Gastrointestinal 008.01 Intestinal infection due to enteropathogenic e. Coli 
Gastrointestinal 008.02 Intestinal infection due to enterotoxigenic e. Coli 
Gastrointestinal 008.03 Intestinal infection due to enteroinvasive e. Coli 
Gastrointestinal 008.04 Enterohemorrhagic E. coli (0157:H7) 
Gastrointestinal 008.09  Other intestinal e. Coli infections 
Gastrointestinal 008.1 Intestinal infection due to arizona group of paracolon bacilli 
Gastrointestinal 008.2 Intestinal infection due to aerobacter aerogenes 
Gastrointestinal 008.3 Intestinal infection due to proteus (mirabilis) (morganii) 
Gastrointestinal 008.4 Intestinal infection due to other specified bacteria 
Gastrointestinal 008.41 Intestinal infection due to staphylococcus 
Gastrointestinal 008.42 Intestinal infection due to pseudomonas 
Gastrointestinal 008.43 Intestinal infection due to campylobacter 
Gastrointestinal 008.44 Intestinal infection due to yersinia enterocolitica 
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Gastrointestinal 008.45 Intestinal infection due to clostridium difficile 
Gastrointestinal 008.46 Intestinal infection due to other anaerobes 
Gastrointestinal 008.47 Intestinal infection due to other gram-negative bacteria 
Gastrointestinal 008.49 Intestinal infection due to other specified bacteria 
Gastrointestinal 008.5 Bacterial enteritis nos 
Gastrointestinal 008.6 Enteritis due to specified virus 
Gastrointestinal 008.61 Enteritis due to rotavirus 
Gastrointestinal 008.62 Enteritis due to adenovirus 
Gastrointestinal 008.63 Enteritis due to norwalk virus 
Gastrointestinal 008.64 Enteritis due to other small round viruses [srv's] 
Gastrointestinal 008.65 Enteritis due to calcivirus 
Gastrointestinal 008.66 Enteritis due to astrovirus 
Gastrointestinal 008.67 Enteritis due to enterovirus nec 
Gastrointestinal 008.69 Enteritis due to other viral enteritis 
Gastrointestinal 008.8 Intestinal infection due to other organism, not elsewhere classified 
Gastrointestinal 009 Ill-defined intestinal infections 
Gastrointestinal 009.0 Infectious colitis, enteritis, and gastroenteritis 
Gastrointestinal 009.1 Colitis, enteritis, and gastroenteritis of presumed infectious origin 
Gastrointestinal 009.2 Infectious diarrhea 
Gastrointestinal 009.3 Diarrhea of presumed infectious origin 
Gastrointestinal 021.1 Enteric tularemia 
Gastrointestinal 022.2 Gastrointestinal anthrax 
Gastrointestinal 032.83 Diphtheritic peritonitis 
Gastrointestinal 535.00 Acute gastritis w/o hem 
Gastrointestinal 536.2 Persistent vomiting 
Gastrointestinal 555 Regional enteritis 
Gastrointestinal 555.0 Regional enteritis of small intestine 
Gastrointestinal 555.1 Regional enteritis of large intestine 
Gastrointestinal 555.2 Regional enteritis of small intestine with large intestine 
Gastrointestinal 555.9 Regional enteritis of unspecified site 
Gastrointestinal 556 Ulcerative colitis 
Gastrointestinal 556.0 Ulcerative (chronic) enterocolitis 
Gastrointestinal 556.1 Ulcerative (chronic) ileocolitis 
Gastrointestinal 556.2 Ulcerative (chronic) proctitis 
Gastrointestinal 556.3 Ulcerative (chronic) proctosigmoiditis 
Gastrointestinal 556.4 Pseudopolyposis of colon 
Gastrointestinal 556.5 Left-sided ulcerative (chronic) colitis 
Gastrointestinal 556.6 Universal ulcerative (chronic) colitis 
Gastrointestinal 556.8 Other ulcerative colitis 
Gastrointestinal 556.9 Ulcerative colitis, unspecified 
Gastrointestinal 558 Other and unspecified noninfectious gastroenteritis and colitis 
Gastrointestinal 558.1 Gastroenteritis and colitis due to radiation 
Gastrointestinal 558.2 Toxic gastroenteritis and colitis 
Gastrointestinal 558.3 Allergic gastroenteritis and colitis 
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Gastrointestinal 558.9 Other and unspecified noninfectious gastroenteritis and colitis 
Gastrointestinal 569.82  Ulceration of intestine 
Gastrointestinal 787.0 Nausea and vomiting 
Gastrointestinal 787.01 Nausea with vomiting 
Gastrointestinal 787.02 Nausea alone 
Gastrointestinal 787.03 Vomiting alone 
Gastrointestinal 787.91 Diarrhea 
Gastrointestinal 789.0 Abdominal pain 
Gastrointestinal 789.00 Abdominal pain, unspecified site 
Gastrointestinal 789.01 Abdominal pain, right upper quadrant 
Gastrointestinal 789.02 Abdominal pain, left upper quadrant 
Gastrointestinal 789.03 Abdominal pain, right lower quadrant 
Gastrointestinal 789.04 Abdominal pain, left lower quadrant 
Gastrointestinal 789.05 Abdominal pain, periumbilic 
Gastrointestinal 789.06 Abdominal pain, epigastric 
Gastrointestinal 789.07 Abdominal pain, generalized 
Gastrointestinal 789.09 Abdominal pain, other specified site; multiple sites 
Gastrointestinal 789.4 Abdominal rigidity 
Gastrointestinal 789.40 Abd rigidity unspe site 
Gastrointestinal 789.41 Abd rigidity rt up quad 
Gastrointestinal 789.42 Abd rigidity lt up quad 
Gastrointestinal 789.43 Abd rigidity rt low quad 
Gastrointestinal 789.44 Abd rigidity lt low quad 
Gastrointestinal 789.45 Abd rigidity periumbili 
Gastrointestinal 789.46 Abd rigidity epigastric 
Gastrointestinal 789.47 Abd rigidity generalized 
Gastrointestinal 789.49 Abd rigid oth spec site 
Hemorrhagic 065 Arthropod hemorrhag fev 
Hemorrhagic 065.0 Crimean hemorrhagic fev 
Hemorrhagic 065.1 Omsk hemorrhagic fever 
Hemorrhagic 065.2 Kyasanur forest disease 
Hemorrhagic 065.3 Tick-borne hem fever nec 
Hemorrhagic 065.4 Mosquito-borne hemorrhagic fever (Chikungunya hemorrhagic fever) 
Hemorrhagic 065.8 Other specified arthropod-borne hemorrhagic fever 
Hemorrhagic 065.9 Arthropod-borne hemorrhagic fever, unspecified  
Hemorrhagic 078.6 Hemorrhagic nephrosonephritis (Junin virus) 
Hemorrhagic 078.7 Arenaviral hemorrhagic fever (Korean) 
Hemorrhagic 459.0 Hemorrhage, unspecified 
Hemorrhagic 530.7 Gastroesophageal laceration-hemorrhage syndrome 
Hemorrhagic 530.82 Esophageal hemorrhage 
Hemorrhagic 531.0 Gastric ulcer- Acute with hemorrhage 
Hemorrhagic 531.00 Acute with hemorrhage- without mention of obstruction 
Hemorrhagic 531.01 Acute with hemorrhage- with obstruction 
Hemorrhagic 531.2 Gastric ulcer- Acute with hemorrhage and perforation 
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Hemorrhagic 531.20 Acute with hemorrhage and perforation- without mention of obstruction
Hemorrhagic 531.21 Acute with hemorrhage and perforation- with obstruction 
Hemorrhagic 531.4 Gastric ulcer- Chronic or unspecified with hemorrhage 
Hemorrhagic 531.40 Chronic or unspecified with hemorrhage- without mention of 
obstruction 
Hemorrhagic 531.41 Chronic or unspecified with hemorrhage- with obstruction 
Hemorrhagic 531.6 Gastric ulcer- Chronic or unspecified with hemorrhage and perforation 
Hemorrhagic 531.60 Chronic or unspecified with hemorrhage and perforation- without 
mention of obstruction 
Hemorrhagic 531.61 Chronic or unspecified with hemorrhage and perforation- with 
obstruction 
Hemorrhagic 532.0 Duodenal ulcer- Acute with hemorrhage 
Hemorrhagic 532.00 Acute with hemorrhage- without mention of obstruction 
Hemorrhagic 532.01 Acute with hemorrhage- with obstruction 
Hemorrhagic 532.2 Duodenal ulcer- Acute with hemorrhage and perforation 
Hemorrhagic 532.20 Acute with hemorrhage and perforation- without mention of obstruction
Hemorrhagic 532.21 Acute with hemorrhage and perforation- with obstruction 
Hemorrhagic 532.4 Duodenal ulcer- Chronic or unspecified with hemorrhage 
Hemorrhagic 532.40 Chronic or unspecified with hemorrhage- without mention of 
obstruction 
Hemorrhagic 532.41 Chronic or unspecified with hemorrhage- with obstruction 
Hemorrhagic 532.6 Duodenal ulcer- Chronic or unspecified with hemorrhage and 
perforation 
Hemorrhagic 532.60 Chronic or unspecified with hemorrhage and perforation- without 
mention of obstruction 
Hemorrhagic 532.61 Chronic or unspecified with hemorrhage and perforation- with 
obstruction 
Hemorrhagic 533.0 Peptic ulcer, site unspecified- Acute with hemorrhage 
Hemorrhagic 533.00 Acute with hemorrhage- without mention of obstruction 
Hemorrhagic 533.01 Acute with hemorrhage- with obstruction 
Hemorrhagic 533.2 Peptic ulcer, site unspecified- Acute with hemorrhage and perforation 
Hemorrhagic 533.20 Acute with hemorrhage and perforation- without mention of obstruction
Hemorrhagic 533.21 Acute with hemorrhage and perforation- with obstruction 
Hemorrhagic 533.4 Peptic ulcer, site unspecified- Chronic or unspecified with hemorrhage 
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Hemorrhagic 533.40 Chronic or unspecified with hemorrhage- without mention of 
obstruction 
Hemorrhagic 533.41 Chronic or unspecified with hemorrhage- with obstruction 
Hemorrhagic 533.6 Peptic ulcer, site unspecified- Chronic or unspecified with hemorrhage 
and perforation 
Hemorrhagic 533.60 Chronic or unspecified with hemorrhage and perforation- without 
mention of obstruction 
Hemorrhagic 533.61 Chronic or unspecified with hemorrhage and perforation- with 
obstruction 
Hemorrhagic 534.0 Gastrojejunal ulcer- Acute with hemorrhage 
Hemorrhagic 534.00 Acute with hemorrhage- without mention of obstruction 
Hemorrhagic 534.01 Acute with hemorrhage- with obstruction 
Hemorrhagic 534.2 Gastrojejunal ulcer- Acute with hemorrhage and perforation 
Hemorrhagic 534.20 Acute with hemorrhage and perforation- without mention of obstruction
Hemorrhagic 534.21 Acute with hemorrhage and perforation- with obstruction 
Hemorrhagic 534.4 Gastrojejunal ulcer- Chronic or unspecified with hemorrhage 
Hemorrhagic 534.40 Chronic or unspecified with hemorrhage- without mention of 
obstruction 
Hemorrhagic 534.41 Chronic or unspecified with hemorrhage- with obstruction 
Hemorrhagic 534.6 Gastrojejunal ulcer- Chronic or unspecified with hemorrhage and 
perforation 
Hemorrhagic 534.60 Chronic or unspecified with hemorrhage and perforation- without 
mention of obstruction 
Hemorrhagic 534.61 Chronic or unspecified with hemorrhage and perforation- with 
obstruction 
Hemorrhagic 535.01 Acute gastritis w hem 
Hemorrhagic 535.11 Atrophic gastritis- with hemorrhage 
Hemorrhagic 535.21 Gastric mucosal hypertrophy- with hemorrhage 
Hemorrhagic 535.31 Alcoholic gastritis- with hemorrhage 
Hemorrhagic 535.41 Oth spec gastrit w/ hem 
Hemorrhagic 535.51 Unspecified gastritis and gastroduodenitis- with hemorrhage 
Hemorrhagic 535.61 Duodenitis- with hemorrhage 
Hemorrhagic 537.83 Angiodysplasia of stomach and duodenum with hemorrhage 
Hemorrhagic 562.02 Diverticulosis of small intestine with hemorrhage 
Hemorrhagic 562.03 Diverticulitis of small intestine with hemorrhage 
Hemorrhagic 562.12 Diverticulosis of colon with hemorrhage 
Hemorrhagic 562.13 Diverticulitis of colon with hemorrhage 
Hemorrhagic 569.3 Hemorrhage of rectum and anus 
Hemorrhagic 569.85 Angiodysplasia of intestine with hemorrhage 
Hemorrhagic 578 Gastrointestinal hemorrhage 
Hemorrhagic 578.0 Hematemesis 
Hemorrhagic 578.1 Blood in stool 
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Hemorrhagic 578.9 Gastrointest hemorr nos 
Hemorrhagic 599.7 Hematuria 
Hemorrhagic 626.6 Metrorrhagia 
Hemorrhagic 626.8 Other disorders of menstruation and other abnormal bleeding from 
female genital tract 
Hemorrhagic 626.9 Unspecified disorders of menstruation and other abnormal bleeding 
from female genital tract 
Hemorrhagic 627.1 Postmenopausal bleeding 
Hemorrhagic 784.7 Epistaxis 
Hemorrhagic 784.8 Hemorrhage from throat 
Hemorrhagic 786.3 Hemoptysis 
Hemorrhagic 964.2 Poisoning by anticoagulants 
Hemorrhagic 998.11 Hemorrhage complicating a procedure 
Neurological 013 Tuberculosis of meninges and central nervous system 
Neurological 013.0 Tuberculous meningitis 
Neurological 013.00 Tuberculous meningitis, unspecified examination  
Neurological 013.01 Tuberculous meningitis, bacteriological or histological examination not 
done  
Neurological 013.02 Tuberculous meningitis, bacteriological or histological examination 
unknown (at present)  
Neurological 013.03 Tuberculous meningitis, tubercle bacilli found (in sputum) by 
microscopy  
Neurological 013.04 Tuberculous meningitis, tubercle bacilli not found (in sputum) by 
microscopy, but found by bacterial culture  
Neurological 013.05 Tuberculous meningitis, tubercle bacilli not found by bacteriological 
examination, but tuberculosis confirmed histologically  
Neurological 013.06 Tuberculous meningitis, tubercle bacilli not found by bacteriological or 
histological examination, but tuberculosis confirmed by other methods 
[inoculation of animals]  
Neurological 013.6 Tuberculous encephalitis or myelitis 
Neurological 013.60 Tuberculous encephalitis or myelitis, unspecified examination  
Neurological 013.61 Tuberculous encephalitis or myelitis, bacteriological or histological 
examination not done  
Neurological 013.62 Tuberculous encephalitis or myelitis, bacteriological or histological 
examination unknown (at present)  
Neurological 013.63 Tuberculous encephalitis or myelitis, tubercle bacilli found (in sputum) 
by microscopy  
Neurological 013.64 Tuberculous encephalitis or myelitis, tubercle bacilli not found (in 
sputum) by microscopy, but found by bacterial culture  
Neurological 013.65 Tuberculous encephalitis or myelitis, tubercle bacilli not found by 
bacteriological examination, but tuberculosis confirmed histologically  
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Neurological 013.66 Tuberculous encephalitis or myelitis, tubercle bacilli not found by 
bacteriological or histological examination, but tuberculosis confirmed 
by other methods [inoculation of animals]  
Neurological 013.8 Other specified tuberculosis of central nervous system 
Neurological 013.9 Unspecified tuberculosis of central nervous system 
Neurological 036 Meningococcal infection 
Neurological 036.0 Meningococcal meningitis 
Neurological 036.1 Meningococcal encephalitis 
Neurological 036.2 Meningococcemia 
Neurological 036.89 Meningococcal infect nec 
Neurological 036.9 Meningococcal infect nos 
Neurological 047 Enteroviral meningitis 
Neurological 047.0 Coxsackie virus mening 
Neurological 047.1 Echo virus meningitis 
Neurological 047.8 Viral meningitis nec 
Neurological 047.9 Viral meningitis nos 
Neurological 048 Oth enteroviral cns dis 
Neurological 049 Oth nonarthropod cns vir 
Neurological 049.0 Lymphocytic choriomening 
Neurological 049.1 Adenoviral meningitis 
Neurological 049.8 Viral encephalitis nec 
Neurological 049.9 Viral encephalitis nos 
Neurological 052.0 Postvaricella encephalitis 
Neurological 054.3 Herpetic meningoencephalitis 
Neurological 054.72 H simplex meningitis 
Neurological 055.0 Postmeasles encephalitis 
Neurological 056.01 Encephalomyelitis due to rubella 
Neurological 062 Mosquito-borne viral encephalitis 
Neurological 062.0 Japanese encephalitis 
Neurological 062.1 Western equine encephalitis 
Neurological 062.2 Eastern equine encephalitis 
Neurological 062.3 St. Louis encephalitis 
Neurological 062.4 Australian encephalitis 
Neurological 062.5 California virus encephalitis 
Neurological 062.8 Other specified mosquito-borne viral encephalitis 
Neurological 062.9 Mosquito-borne viral encephalitis, unspecified  
Neurological 063 Tick-borne viral encephalitis 
Neurological 063.0 Russian spring-summer (taiga) encephalitis 
Neurological 063.1 Louping ill 
Neurological 063.2 Central European encephalitis 
Neurological 063.8 Other specified tick-borne viral encephalitis 
Neurological 063.9 Tick-borne viral encephalitis, unspecified  
Neurological 064 Vir enceph arthropod nec 
Neurological 066.2 Venezuelan equine fever (encephalitis) 
Neurological 066.4 West Nile fever (encephalitis) 
Neurological 071 Rabies 
Neurological 072.2 Mumps encephalitis 
Neurological 094.2 Syphilitic meningitis 
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Neurological 94.81 Syphilitic encephalitis 
Neurological 100.81 Leptospiral meningitis 
Neurological 114.2 Coccidioidal meningitis 
Neurological 115.01 Histoplasma capsulatum meningitis 
Neurological 115.11 Histoplasma duboisii meningitis 
Neurological 115.91 Histoplasmosis meningitis 
Neurological 130.0 Meningoencephalitis due to toxoplasmosis 
Neurological 293.0 Acute delirium 
Neurological 293.1 Subacute delirium 
Neurological 320 Bacterial meningitis 
Neurological 320.0 Hemophilus meningitis 
Neurological 320.1 Pneumococcal meningitis 
Neurological 320.2 Streptococcal meningitis 
Neurological 320.3 Staphylococc meningitis 
Neurological 320.7 Mening in oth bact dis 
Neurological 320.8 Bacterial meningitis nec 
Neurological 320.81 Meningitis/anaerobic bac 
Neurological 320.82 Memingitis/gram-neg bact 
Neurological 320.89 Meningitis/bacteria nos 
Neurological 320.9 Bacterial meningitis nos 
Neurological 321 Oth organism meningitis 
Neurological 321.0 Cryptococcal meningitis 
Neurological 321.1 Mening in oth fungal dis 
Neurological 321.2 Mening in oth viral dis 
Neurological 321.3 Trypanosomiasis meningit 
Neurological 321.8 Mening in oth nonbac dis 
Neurological 322 Meningitis, unspecified 
Neurological 322.0 Nonpyogenic meningitis 
Neurological 322.1 Eosinophilic meningitis 
Neurological 322.9 Meningitis nos 
Neurological 323 Encephalitis, myelitis, and encephalomyelitis  
Neurological 323.0 Encephalitis in viral diseases classified elsewhere 
Neurological 323.1 Encephalitis in rickettsial diseases classified elsewhere 
Neurological 323.2 Encephalitis in protozoal diseases classified elsewhere 
Neurological 323.4 Other encephalitis due to infection classified elsewhere 
Neurological 323.5 Encephalitis following immunization procedures 
Neurological 323.6 Postinfectious encephalitis 
Neurological 323.7 Toxic encephalitis 
Neurological 323.8 Other causes of encephalitis 
Neurological 323.9 Unspecified cause of encephalitis 
Neurological 331.81 Reye's syndrome 
Neurological 348.3 Encephalopathy, unspecified  
Neurological 780.0 Coma and stupor 
Neurological 780.01 Coma 
Neurological 780.3 Convulsions 
Neurological 781.6 Meningismus 
Neurological 784.0 Headache 
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Neurological 989.7 Aflatoxin and other mycotoxin (food contaminents) 
Neurological 998.0 Toxic effect of fish and shellfish (Saxitoxin) 
Rash 020.1 Cellulocutaneous plague 
Rash 022.0 Cutaneous anthrax 
Rash 032.85 Cutaneous diphtheria 
Rash 034.1 Scarlet fever 
Rash 040.82 Toxic shock syndrome 
Rash 050 Smallpox 
Rash 050.0 Variola major 
Rash 050.1 Alastrim (Variola minor) 
Rash 050.2 Modified smallpox 
Rash 050.9 Smallpox, unspecified  
Rash 051 Cowpox and paravaccinia 
Rash 051.0 Cowpox 
Rash 051.1 Pseudocowpox 
Rash 051.2 Contagious pustular dermatitis 
Rash 051.9 Paravaccinia, unspecified  
Rash 052 Chickenpox 
Rash 052.7 Chickenpox with other specified complications 
Rash 052.8 Chickenpox with unspecified complication 
Rash 052.9 Varicella without mention of complication 
Rash 053 Herpes zoster 
Rash 053.0 Herpes zoster with meningitis 
Rash 053.1 Herpes zoster with other nervous system complications 
Rash 053.10 Herpes zoster with unspecified nervous system complication 
Rash 053.11 Geniculate herpes zoster 
Rash 053.19 Herpes zoster with other nervous system complications 
Rash 053.2 Herpes zoster with ophthalmic complications 
Rash 053.29 Herpes zoster with other ophthalmic complications 
Rash 053.7 Herpes zoster with other specified complications 
Rash 053.79 Herpes zoster with other specified complications 
Rash 053.8 Herpes zoster with unspecified complication 
Rash 053.9 Herpes zoster without mention of complication 
Rash 054 Herpes simplex 
Rash 054.0 Eczema herpeticum 
Rash 054.4 Herpes simplex with ophthalmic complications 
Rash 054.40 Herpes simplex with unspecified ophthalmic complication 
Rash 054.49 Herpes simplex with other ophthalmic complications 
Rash 054.7 Herpes simplex with other specified complications 
Rash 054.79 Herpes simplex with other specified complications 
Rash 054.8 Herpes simplex with unspecified complication 
Rash 054.9 Herpes simplex without mention of complication 
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Rash 055 Measles 
Rash 055.7 Measles with other specified complications 
Rash 055.79 Measles with other specified complications 
Rash 055.8 Measles with unspecified complication 
Rash 055.9 Measles without mention of complication 
Rash 056 Rubella 
Rash 056.0 Rubella with neurological complications 
Rash 056.00 Rubella with unspecified neurological complications 
Rash 056.09 Rubella with other neurological complications 
Rash 056.7 Rubella with other specified complications 
Rash 056.71 Arthritis due to rubella 
Rash 056.79 Rubella with other specified complications 
Rash 056.8 Rubella with unspecified complications 
Rash 056.9 Rubella without mention of complication 
Rash 057 Other viral exanthemata 
Rash 057.0 Erythema infectiosum [fifth disease] 
Rash 057.8 Other specified viral exanthemata 
Rash 057.9 Viral exanthem, unspecified  
Rash 074.3 Hand, foot mouth dis 
Rash 080 Louse-borne (epidemic) typhus 
Rash 081 Other typhus 
Rash 081.0 Murine (endemic) typhus 
Rash 081.9 Typhus, unspecified  
Rash 082 Tick-borne rickettsioses 
Rash 082.0 Spotted fevers (Rocky mountain spotted fever) 
Rash 082.1 Boutonneuse fever 
Rash 082.2 North asian tick fever 
Rash 082.3 Queensland tick typhus 
Rash 082.8 Tick-borne ricketts nec 
Rash 082.9 Tick-borne ricketts nos 
Rash 083.2 Rickettsialpox 
Rash 083.8 Rickettsioses nec 
Rash 083.9 Rickettsiosis nos 
Rash 091.3 Secondary syph skin 
Rash 115.1 Infection by Histoplasma duboisii 
Rash 115.10 Infection by Histoplasma duboisii, without mention of manifestation  
Rash 287 Purpura and other hemorrhagic conditions 
Rash 287.0 Allergic purpura 
Rash 287.1 Qualitative platelet defects 
Rash 287.2 Other nonthrombocytopenic purpuras 
Rash 287.8 Other specified hemorrhagic conditions 
Rash 287.9 Unspecified hemorrhagic conditions 
Rash 684 Impetigo 
Rash 686.0 Pyoderma 
Rash 686.00 Pyoderma nos 
Rash 686.01 Pyoderma gangrenosum 
Rash 686.09 Oth pyoderma skin/subcu 
Rash 686.1 Pyogenic granuloma 
Rash 694.3 Impetigo herpetiformis 
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Rash 695 Erythematous conditions 
Rash 695.0 Toxic erythema 
Rash 695.1 Erythema multiforme 
Rash 695.2 Erythema nodosum 
Rash 695.8 Other specified erythematous conditions 
Rash 695.81 Ritter's disease 
Rash 695.89 Other specified erythematous conditions 
Rash 695.9 Unspecified erythematous condition 
Rash 782.1 Rash and other nonspecific skin eruption 
Rash 782.7 Spontaneous ecchymoses 
Respiratory 003.22 Salmonella pneumonia 
Respiratory 010 Primary tuberculous infection 
Respiratory 010.0 Primary tuberculous infection 
Respiratory 010.00 Primary tuberculous infection, unspecified examination  
Respiratory 010.01 Primary tuberculous infection, bacteriological or histological 
examination not done  
Respiratory 010.02 Primary tuberculous infection, bacteriological or histological 
examination unknown (at present)  
Respiratory 010.03 Primary tuberculous infection, tubercle bacilli found (in sputum) by 
microscopy  
Respiratory 010.04 Primary tuberculous infection, tubercle bacilli not found (in sputum) by 
microscopy, but found by bacterial culture  
Respiratory 010.05 Primary tuberculous infection, tubercle bacilli not found by 
bacteriological examination, but tuberculosis confirmed histologically  
Respiratory 010.06 Primary tuberculous infection, tubercle bacilli not found by 
bacteriological or histological examination, but tuberculosis confirmed 
by other methods (inoculation of animals)  
Respiratory 010.1 Tuberculous pleurisy in primary progressive tuberculosis 
Respiratory 010.10 Tuberculous pleurisy in primary progressive tuberculosis, unspecified 
examination  
Respiratory 010.11 Tuberculous pleurisy in primary progressive tuberculosis, 
bacteriological or histological examination not done  
Respiratory 010.12 Tuberculous pleurisy in primary progressive tuberculosis, 
bacteriological or histological examination results unknown (at present) 
Respiratory 010.13 Tuberculous pleurisy in primary progressive tuberculosis, tubercle 
bacilli found (in sputum) by microscopy  
Respiratory 010.14 Tuberculous pleurisy in primary progressive tuberculosis, tubercle 
bacilli not found (in sputum) by microscopy, but found by bacterial 
culture  
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Respiratory 010.15 Tuberculous pleurisy in primary progressive tuberculosis, tubercle 
bacilli not found by bacteriological examination, but tuberculosis 
confirmed histologically  
Respiratory 010.16 Tuberculous pleurisy in primary progressive tuberculosis, tubercle 
bacilli not found by bacteriological or histological examination, but 
tuberculosis confirmed by other methods (inoculation of animals) 
Respiratory 010.8 Other primary progressive tuberculosis 
Respiratory 010.80 Other primary progressive tuberculosis, unspecified examination  
Respiratory 010.81 Other primary progressive tuberculosis, bacteriological or histological 
examination not done  
Respiratory 010.82 Other primary progressive tuberculosis, bacteriological or histological 
examination unknown (at present)  
Respiratory 010.83 Other primary progressive tuberculosis, tubercle bacilli found (in 
sputum) by microscopy  
Respiratory 010.84 Other primary progressive tuberculosis, tubercle bacilli not found (in 
sputum) by microscopy, but found by bacterial culture  
Respiratory 010.85 Other primary progressive tuberculosis, tubercle bacilli not found by 
bacteriological examination, but tuberculosis confirmed histologically  
Respiratory 010.86 Other primary progressive tuberculosis, tubercle bacilli not found by 
bacteriological or histological examination, but tuberculosis confirmed 
by other methods (inoculation of animals)  
Respiratory 010.9 Primary tuberculous infection, unspecified type  
Respiratory 010.90 Primary tuberculous infection, unspecified type, unspecified 
examination  
Respiratory 010.91 Primary tuberculous infection, unspecified type, bacteriological or 
histological examination not done  
Respiratory 010.92 Primary tuberculous infection, unspecified type, bacteriological or 
histological examination unknown (at present)  
Respiratory 010.93 Primary tuberculous infection, unspecified type, tubercle bacilli found 
(in sputum) by microscopy  
Respiratory 010.94 Primary tuberculous infection, unspecified type, tubercle bacilli not 
found (in sputum) by microscopy, but found by bacterial culture  
Respiratory 010.95 Primary tuberculous infection, unspecified type, tubercle bacilli not 
found by bacteriological examination, but tuberculosis confirmed 
histologically  
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Respiratory 010.96 Primary tuberculous infection, unspecified type, tubercle bacilli not 
found by bacteriological or histological examination, but tuberculosis 
confirmed by other methods (inoculation of animals) 
Respiratory 011 Pulmonary tuberculosis 
Respiratory 011.0 Tuberculosis of lung, infiltrative  
Respiratory 011.00 Tuberculosis of lung, infiltrative, unspecified examination  
Respiratory 011.01 Tuberculosis of lung, infiltrative, bacteriological or histological 
examination not done  
Respiratory 011.02 Tuberculosis of lung, infiltrative, bacteriological or histological 
examination unknown (at present)  
Respiratory 011.03 Tuberculosis of lung, infiltrative, tubercle bacilli found (in sputum) by 
microscopy  
Respiratory 011.04 Tuberculosis of lung, infiltrative, tubercle bacilli not found (in sputum) 
by microscopy, but found by bacterial culture  
Respiratory 011.05 Tuberculosis of lung, infiltrative, tubercle bacilli not found by 
bacteriological examination, but tuberculosis confirmed histologically  
Respiratory 011.06 Tuberculosis of lung, infiltrative, tubercle bacilli not found 
bacteriological or histological examination, but tuberculosis confirmed 
by other methods(inoculation of animals)  
Respiratory 011.1 Tuberculosis of lung, nodular  
Respiratory 011.10 Tuberculosis of lung, nodular, unspecified examination  
Respiratory 011.11 Tuberculosis of lung, nodular, bacteriological or histological 
examination not done  
Respiratory 011.12 Tuberculosis of lung, nodular, bacteriological or histological 
examination unknown (at present)  
Respiratory 011.13 Tuberculosis of lung, nodular, tubercle bacilli found (in sputum) by 
microscopy  
Respiratory 011.14 Tuberculosis of lung, nodular, tubercle bacilli not found (in sputum) by 
microscopy, but found by bacterial culture  
Respiratory 011.15 Tuberculosis of lung, nodular, tubercle bacilli not found by 
bacteriological examination, but tuberculosis confirmed histologically  
Respiratory 011.16 Tuberculosis of lung, nodular, tubercle bacilli not found by 
bacteriological or histological examination, but tuberculosis confirmed 
by other methods (inoculation of animals) 
Respiratory 011.2 Tuberculosis of lung with cavitation 
Respiratory 011.20 Tuberculosis of lung with cavitation, unspecified examination  
Respiratory 011.21 Tuberculosis of lung with cavitation, bacteriological or histological 
examination not done  
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Respiratory 011.22 Tuberculosis of lung with cavitation, bacteriological or histological 
examination unknown (at present)  
Respiratory 011.23 Tuberculosis of lung with cavitation, tubercle bacilli found (in sputum) 
by microscopy  
Respiratory 011.24 Tuberculosis of lung with cavitation, tubercle bacilli not found (in 
sputum) by microscopy, but found by bacterial culture  
Respiratory 011.25 Tuberculosis of lung with cavitation, tubercle bacilli not found by 
bacteriological examination, but tuberculosis confirmed histologically  
Respiratory 011.26 Tuberculosis of lung with cavitation, tubercle bacilli not found by 
bacteriological or histological examination, but tuberculosis confirmed 
by other methods (inoculation of animals) 
Respiratory 011.3 Tuberculosis of bronchus 
Respiratory 011.30 Tuberculosis of bronchus, unspecified examination  
Respiratory 011.31 Tuberculosis of bronchus, bacteriological or histological examination 
not done  
Respiratory 011.32 Tuberculosis of bronchus, bacteriological or histological examination 
unknown (at present)  
Respiratory 011.33 Tuberculosis of bronchus, tubercle bacilli found (in sputum) by 
microscopy  
Respiratory 011.34 Tuberculosis of bronchus, tubercle bacilli not found (in sputum) by 
microscopy, but found in bacterial culture  
Respiratory 011.35 Tuberculosis of bronchus, tubercle bacilli not found by bacteriological 
examination, but tuberculosis confirmed histologically  
Respiratory 011.36 Tuberculosis of bronchus, tubercle bacilli not found by bacteriological 
or histological examination, but tuberculosis confirmed by other 
methods (inoculation of animals) 
Respiratory 011.4 Tuberculous fibrosis of lung 
Respiratory 011.40 Tuberculous fibrosis of lung, unspecified examination  
Respiratory 011.41 Tuberculous fibrosis of lung, bacteriological or histological examination 
not done  
Respiratory 011.42 Tuberculous fibrosis of lung, bacteriological or histological examination 
unknown (at present)  
Respiratory 011.43 Tuberculous fibrosis of lung, tubercle bacilli found (in sputum) by 
microscopy  
Respiratory 011.44 Tuberculous fibrosis of lung, tubercle bacilli not found (in sputum) by 
microscopy, but found in bacterial culture  
Respiratory 011.45 Tuberculous fibrosis of lung, tubercle bacilli not found by 
bacteriological examination, but tuberculosis confirmed histologically  
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Respiratory 011.46 Tuberculous fibrosis of lung, tubercle bacilli not found by 
bacteriological or histological examination, but tuberculosis confirmed 
by other methods (inoculation of animals) 
Respiratory 011.5 Tuberculous bronchiectasis 
Respiratory 011.50 Tuberculous bronchiectasis, unspecified examination  
Respiratory 011.51 Tuberculous bronchiectasis, bacteriological or histological examination 
not done  
Respiratory 011.52 Tuberculous bronchiectasis, bacteriological or histological examination 
unknown (at present)  
Respiratory 011.53 Tuberculous bronchiectasis, tubercle bacilli found (in sputum) by 
microscopy  
Respiratory 011.54 Tuberculous bronchiectasis, tubercle bacilli not found (in sputum) by 
microscopy, but found by bacterial culture  
Respiratory 011.55 Tuberculous bronchiectasis, tubercle bacilli not found by 
bacteriological examination, but tuberculosis confirmed histologically  
Respiratory 011.56 Tuberculous bronchiectasis, tubercle bacilli not found by 
bacteriological or histological examination, but tuberculosis confirmed 
by other methods (inoculation of animals) 
Respiratory 011.6 Tuberculous pneumonia (any form) 
Respiratory 011.60 Tuberculous pneumonia (any form), unspecified examination  
Respiratory 011.61 Tuberculous pneumonia (any form), bacteriological or histological 
examination not done  
Respiratory 011.62 Tuberculous pneumonia (any form) bacteriological or histological 
examination unknown (at present) 
Respiratory 011.63 Tuberculous pneumonia (any form), tubercle bacilli found (in sputum) 
by microscopy  
Respiratory 011.64 Tuberculous pneumonia (any form), tubercle bacilli not found (in 
sputum) by microscopy, but found by bacterial culture  
Respiratory 011.65 Tuberculous pneumonia (any form), tubercle bacilli not found by 
bacteriological examination, but tuberculosis confirmed histologically  
Respiratory 011.66 Tuberculous pneumonia (any form), tubercle bacilli not found by 
bacteriological or histological examination, but tuberculosis confirmed 
by other methods (inoculation of animals)  
Respiratory 011.7 Tuberculous pneumothorax 
Respiratory 011.70 Tuberculous pneumothorax, unspecified examination  
Respiratory 011.71 Tuberculous pneumothorax, bacteriological or histological examination 
not done  
Respiratory 011.72 Tuberculous pneumothorax, bacteriological or histological examination 
unknown (at present)  
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Respiratory 011.73 Tuberculous pneumothorax, tubercle bacilli found (in sputum) by 
microscopy  
Respiratory 011.74 Tuberculous pneumothorax, tubercle bacilli not found (in sputum) by 
microscopy, but found by bacterial culture  
Respiratory 011.75 Tuberculous pneumothorax, tubercle bacilli not found by 
bacteriological examination, but tuberculosis confirmed histologically  
Respiratory 011.76 Tuberculous pneumothorax, tubercle bacilli not found by 
bacteriological or histological examination, but tuberculosis confirmed 
by other methods (inoculation of animals) 
Respiratory 011.8 Other specified pulmonary tuberculosis 
Respiratory 011.80 Other specified pulmonary tuberculosis, unspecified examination  
Respiratory 011.81 Other specified pulmonary tuberculosis, bacteriological or histological 
examination not done  
Respiratory 011.82 Other specified pulmonary tuberculosis, bacteriological or histological 
examination unknown (at present)  
Respiratory 011.83 Other specified pulmonary tuberculosis, tubercle bacilli found (in 
sputum) by microscopy  
Respiratory 011.84 Other specified pulmonary tuberculosis, tubercle bacilli not found (in 
sputum) by microscopy, but found by bacterial culture  
Respiratory 011.85 Other specified pulmonary tuberculosis, tubercle bacilli not found by 
bacteriological examination, but tuberculosis confirmed histologically  
Respiratory 011.86 Other specified pulmonary tuberculosis, tubercle bacilli not found by 
bacteriological or histological examination, but tuberculosis confirmed 
by other methods (inoculation of animals) 
Respiratory 011.9 Unspecified pulmonary tuberculosis 
Respiratory 011.90 Unspecified pulmonary tuberculosis, unspecified examination  
Respiratory 011.91 Unspecified pulmonary tuberculosis, bacteriological or histological 
examination not done  
Respiratory 011.92 Unspecified pulmonary tuberculosis, bacteriological or histological 
examination unknown (at present)  
Respiratory 011.93 Unspecified pulmonary tuberculosis, tubercle bacilli found (in sputum) 
by microscopy  
Respiratory 011.94 Unspecified pulmonary tuberculosis, tubercle bacilli not found (in 
sputum) by microscopy, but found by bacterial culture  
Respiratory 011.95 Unspecified pulmonary tuberculosis, tubercle bacilli not found by 
bacteriological examination, but tuberculosis confirmed histologically  
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Respiratory 011.96 Unspecified pulmonary tuberculosis, tubercle bacilli not found by 
bacteriological or histological examination, but tuberculosis confirmed 
by other methods (inoculation of animals) 
Respiratory 020 Plague 
Respiratory 020.3 Primary pneumonic plague 
Respiratory 020.4 Secondary pneumonic plague 
Respiratory 020.5 Pneumonic plague, unspecified  
Respiratory 021.2 Pulmonary tularemia 
Respiratory 022 Anthrax 
Respiratory 022.1 Pulmonary anthrax 
Respiratory 024 Glanders 
Respiratory 025 Melioidosis 
Respiratory 032 Diphtheria 
Respiratory 032.0 Faucial diphtheria 
Respiratory 032.1 Nasopharyngeal diphtheria 
Respiratory 032.2 Anterior nasal diphtheria 
Respiratory 032.3 Laryngeal diphtheria 
Respiratory 032.81 Conjunctival diphtheria 
Respiratory 032.82 Diphtheritic myocarditis 
Respiratory 032.84 Diphtheritic cystitis 
Respiratory 032.89 Other specified diphtheria 
Respiratory 032.9 Diphtheria, unspecified  
Respiratory 033 Whooping cough 
Respiratory 033.0 Bordetella pertussis 
Respiratory 033.1 Bordetella parapertussis 
Respiratory 033.8 Whooping cough nec 
Respiratory 033.9 Whooping cough nos 
Respiratory 034 Strep throat/scarlet fev 
Respiratory 034.0 Strep sore throat 
Respiratory 052.1 Varicella (hemorrhagic) pneumonitis 
Respiratory 055.1 Postmeasles pneumonia 
Respiratory 073 Ornithosis (Psittacoisis) 
Respiratory 073.0 Ornithosis with pneumonia 
Respiratory 074.1 Epidemic pleurodynia 
Respiratory 079.0 Adenovirus infection in conditions classified elsewhere and of 
unspecified site 
Respiratory 079.3 Rhinovirus infection in conditions classified elsewhere and of 
unspecified site 
Respiratory 079.6 Respiratory syncytial virus (rsv) infection in conditions classified 
elsewhere and of unspecified site 
Respiratory 079.8 Viral infection nec 
Respiratory 079.81 Hantavirus infection 
Respiratory 079.88 Oth spec chlamydial infe 
Respiratory 079.89 Oth spec viral infection 
Respiratory 083.0 Q fever  
Respiratory 112.4 Candidiasis of lung 
Respiratory 114.0 Primary coccidioidomycosis (pulmonary) 
Respiratory 114.9 Coccidioidomycosis nos 
Respiratory 115 Histoplasmosis 
Respiratory 115.0 Infection by Histoplasma capsulatum 
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Respiratory 115.00 Infection by Histoplasma capsulatum, without mention of manifestation 
Respiratory 115.02 Histoplasma capsulatum retinitis 
Respiratory 115.03 Histoplasma capsulatum pericarditis 
Respiratory 115.04 Histoplasma capsulatum endocarditis 
Respiratory 115.05 Histoplasma capsulatum pneumonia 
Respiratory 115.09 Infection by Histoplasma capsulatum, with mention of other 
manifestation  
Respiratory 115.12 Histoplasma duboisii retinitis 
Respiratory 115.13 Histoplasma duboisii pericarditis 
Respiratory 115.14 Histoplasma duboisii endocarditis 
Respiratory 115.15 Histoplasma duboisii pneumonia 
Respiratory 115.19 Infection by Histoplasma duboisii with mention of other manifestation 
Respiratory 115.9 Histoplasmosis, unspecified  
Respiratory 115.90 Histoplasmosis, unspecified without mention of manifestation  
Respiratory 115.92 Histoplasmosis retinitis 
Respiratory 115.93 Histoplasmosis pericarditis 
Respiratory 115.94 Histoplasmosis endocarditis 
Respiratory 115.95 Histoplasmosis pneumonia 
Respiratory 115.99 Histoplasmosis, unspecified with mention of other manifestation  
Respiratory 130.4 Pneumonitis due to toxoplasmosis 
Respiratory 136.3 Pneumocystosis 
Respiratory 460 Acute nasopharyngitis [common cold] 
Respiratory 462 Acute pharyngitis 
Respiratory 463 Acute tonsillitis 
Respiratory 464 Acute laryngitis and tracheitis 
Respiratory 464.0 Acute laryngitis 
Respiratory 464.1 Acute tracheitis 
Respiratory 464.10 Acute tracheitis without mention of obstruction 
Respiratory 464.11 Acute tracheitis with obstruction 
Respiratory 464.2 Acute laryngotracheitis 
Respiratory 464.20 Acute laryngotracheitis without mention of obstruction 
Respiratory 464.21 Acute laryngotracheitis with obstruction 
Respiratory 464.3 Acute epiglottitis 
Respiratory 464.30 Acute epiglottitis without mention of obstruction 
Respiratory 464.31 Acute epiglottitis with obstruction 
Respiratory 464.4 Croup 
Respiratory 465 Acute laryngopharyngitis 
Respiratory 465.0 Acute upper respiratory infections of multiple or unspecified sites 
Respiratory 465.8 Acute upper respiratory infections of other multiple sites 
Respiratory 465.9 Acute upper respiratory infections of unspecified site 
Respiratory 466 Acute bronchitis and bronchiolitis 
Respiratory 466.0 Acute bronchitis 
Respiratory 466.1 Acute bronchiolitis 
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Respiratory 466.11 Acute bronchiolitis due to respiratory syncytial virus (rsv) 
Respiratory 466.19 Acute bronchiolitis due to other infectious organisms 
Respiratory 480 Viral pneumonia 
Respiratory 480.0 Pneumonia due to adenovirus 
Respiratory 480.1 Pneumonia due to respiratory syncytial virus 
Respiratory 480.2 Pneumonia due to parainfluenza virus 
Respiratory 480.8 Pneumonia due to other virus not elsewhere classified 
Respiratory 480.9 Viral pneumonia, unspecified  
Respiratory 481 Pneumococcal pneumonia [Streptococcus pneumoniae pneumonia]  
Respiratory 482 Other bacterial pneumonia 
Respiratory 482.0 Pneumonia due to Klebsiella pneumoniae 
Respiratory 482.1 Pneumonia due to Pseudomonas 
Respiratory 482.2 Pneumonia due to Hemophilus influenzae [H. influenzae] 
Respiratory 482.3 Pneumonia due to Streptococcus 
Respiratory 482.30 Pneumonia due to Streptococcus, unspecified  
Respiratory 482.31 Pneumonia due to Streptococcus Group A 
Respiratory 482.32 Pneumonia due to Streptococcus Group B 
Respiratory 482.39 Pneumonia due to other Streptococcus 
Respiratory 482.4 Pneumonia due to Staphylococcus 
Respiratory 482.40 Pneumonia due to Staphylococcus, unspecified  
Respiratory 482.41 Pneumonia due to Staphylococcus aureus 
Respiratory 482.49 Other Staphylococcus pneumonia 
Respiratory 482.8 Pneumonia due to other specified bacteria 
Respiratory 482.81 Pneumonia due to anaerobes 
Respiratory 482.82 Pneumonia due to escherichia coli [E. coli] 
Respiratory 482.83 Pneumonia due to other gram-negative bacteria 
Respiratory 482.84 Legionnaires' disease 
Respiratory 482.89 Pneumonia due to other specified bacteria 
Respiratory 482.9 Bacterial pneumonia, unspecified  
Respiratory 483 Pneumonia due to other specified organism 
Respiratory 483.0 Pneumonia due to Mycoplasma pneumoniae 
Respiratory 483.1 Pneumonia due to Chlamydia 
Respiratory 483.8 Pneumonia due to other specified organism 
Respiratory 484 Pneumonia in infectious diseases classified elsewhere 
Respiratory 484.1 Pneumonia in cytomegalic inclusion disease 
Respiratory 484.3 Pneumonia in whooping cough 
Respiratory 484.5 Pneumonia in anthrax  
Respiratory 484.6 Pneumonia in aspergillosis 
Respiratory 484.7 Pneumonia in other systemic mycoses 
Respiratory 484.8 Pneumonia in other infectious diseases classified elsewhere 
Respiratory 485 Bronchopneumonia, organism unspecified   
Respiratory 486 Pneumonia, organism unspecified   
Respiratory 487 Influenza 
Respiratory 487.0 Influenza with pneumonia 
Respiratory 487.1 Influenza with other respiratory manifestations 
Respiratory 490 Bronchitis nos 
Respiratory 491 Chronic bronchitis 
Respiratory 491.0 Simple chr bronchitis 
Respiratory 491.1 Mucopurul chr bronchitis 
Respiratory 491.20 Obstr chr bronc wo exac 
Respiratory 491.21 Obstr chr bronc w/exac 
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Respiratory 491.8 Chronic bronchitis nec 
Respiratory 491.9 Chronic bronchitis nos 
Respiratory 507 Pneumonitis due to solids and liquids 
Respiratory 507.0 Pneumonitis due to inhalation of food or vomitus 
Respiratory 507.1 Pneumonitis due to inhalation of oils and essences 
Respiratory 507.8 Pneumonitis due to other solids and liquids 
Respiratory 511 Pleurisy 
Respiratory 511.0 Pleurisy w/o effus or tb 
Respiratory 511.1 Bact pleur/effus not tb 
Respiratory 511.8 Pleural effus nec not tb 
Respiratory 511.9 Pleural effusion nos 
Respiratory 513 Lung/mediastinum abscess 
Respiratory 513.0 Abscess of lung 
Respiratory 513.1 Abscess of mediastinum 
Respiratory 518 Other lung diseases 
Respiratory 518.0 Pulmonary collapse 
Respiratory 518.4 Acute lung edema nos 
Respiratory 518.8 Other diseases of lung 
Respiratory 518.81 Acute respiratory failur 
Respiratory 518.82 Other pulm insuff - nec 
Respiratory 518.84 Acute/chronic resp fail 
Respiratory 518.89 Othr lung disease nec 
Respiratory 519.2 Mediastinitis 
Respiratory 784.1 Throat pain 
Respiratory 786.0 Dyspnea/respiratory abn 
Respiratory 786.00 Respiratory abnorm nos 
Respiratory 786.05 Shortness of breath 
Respiratory 786.06 Tachypnea 
Respiratory 786.07 Wheezing 
Respiratory 786.09 Respiratory abnorm nec 
Respiratory 786.1 Stridor 
Respiratory 786.2 Cough 
Respiratory 786.52 Painful respiration 
Respiratory 795.31 Nonspecific positive findings for anthrax (Positive findings by nasal 
swab) 
Respiratory V01.81 Anthrax (Other communicable diseases) 
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APPENDIX B 
 
Classifying Patients into Syndromic Categories: 
Physician Instructions 
 
Contact Information: 
Wendy Chapman, PhD chapman@cbmi.pitt.edu   
John Dowling, M.D.  dowling@pitt.edu   
 
1. Overall Goal of Project 
Our goal is to detect outbreaks in their early stages – before the case has been culture-proven. 
Syndromic surveillance monitors patients based on the type of findings the patient presents with. 
We have designed seven syndromic categories we believe are useful to monitor. Because we 
monitor syndromes rather than diseases, the syndromic case definitions focus more on signs, 
symptoms, and findings consistent with relevant infectious diseases than on their etiology. To 
determine how well we can detect syndromic cases, we will compare our detection methods 
against a gold standard classification of patients made by physicians.  
 
2. Your Task 
Your task is to read the study patients’ ED reports and to classify the patients into relevant 
syndromic categories. Your classifications will comprise a gold standard set of patients for 
evaluation of biosurveillance techniques. We have provided you with ED reports for patients you 
are assigned (section 2.1) and a data collection form for recording your classifications (section 
2.2).  
 
2.1. ED Reports 
Every patient has been assigned a study ID that is printed in the top left-hand corner of the 
patient’s report(s). If a patient visit generated more than one ED report – which is often the case 
in the Presby ED – you need to read all the reports before determining your answers. You should 
use information from the patient’s entire ED record, including the past history, ED course, lab 
values, radiology findings, etc., to fill in the data collection form.  
 
2.2. Data Collection Forms 
For every patient you are assigned, fill in a single data collection form (Figure 1). If the patient 
meets the case definitions for any of the syndromes described on the form, check the box next to 
the syndrome and proceed to consider any case definitions nested under the syndrome. If you 
leave a box blank, it means the condition does not apply to that patient. 
 
You can use electronic or paper data collection forms, or you can use a combination of the two. 
If you are using the paper data collection form, write in the patient study ID and check all boxes 
that apply to that patient. If you are using the electronic form, you can open the form in 
Microsoft Access (as shown in Figure 1) and check all relevant boxes with your mouse. Be 
aware that Access will always open to the first record you completed. If you have already 
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completed some records, click the right-hand arrow with line (shown in Figure 1) to go to the last 
record you completed, then click the single right arrow to begin a new record. 
 
3. Syndromic Classifications  
On the data collection form you will check all of the acute syndromic case definitions met by the 
patient, where acute is defined as within the last 2 weeks. An acute syndromic presentation may 
be a new illness for the patient or could be acute exacerbation of a chronic problem (e.g., an 
acute asthma attack). A single patient can exhibit more than one syndrome, so mark all that 
apply.  
 
If you check a syndrome, also consider any other case definitions nested under that syndrome. 
For example, if you check Respiratory, you must also consider whether any of the patient’s 
respiratory symptoms are Lower respiratory and whether they are Explained by a non-
respiratory or non-infectious diagnosis. If you check the Lower respiratory box, you must 
determine whether there is Radiological evidence of an acute lower respiratory problem. 
 
3.1 Case Definitions 
 
1. Respiratory 
Signs, symptoms, or other evidence of an illness affecting the upper or lower respiratory tract, 
such as cough, decreased oxygen saturation, nasal congestion, sore throat, pneumonia, etc. 
 
1.1 Lower respiratory 
At least one of the patient’s respiratory conditions occurs in the lower respiratory tract 
(defined as below the larynx), such as shortness of breath, physical findings of pneumonia, 
pleuritic chest pain, hypoxia, etc. A cough can be considered either upper or lower 
respiratory, depending on the patient’s other characteristics. 
 
1.1.1 Radiological evidence of acute lower respiratory problem 
The report describes radiological evidence of an acute lower respiratory process, such 
as localized infiltrate, lobar mass, or widened mediastinum. 
 
1.2 Explained by a non-respiratory or non-infectious diagnosis 
Respiratory signs, symptoms, or findings are explained by a non-respiratory diagnosis, 
such as acute myocardial infarction, or a non-infectious diagnosis, such as congestive heart 
failure. 
 
2. Gastrointestinal 
Signs, symptoms, or other evidence of an illness affecting the gastrointestinal tract (defined as 
below and including the esophagus), such as nausea, vomiting, diarrhea, abdominal pain, or 
abdominal distension or swelling. 
 
2.1 Has diarrhea 
The patient has diarrhea. 
 
2.2 Explained by a non-GI or non-infectious diagnosis 
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Signs, symptoms, or findings of GI illness are explained by a non-GI diagnosis, such as 
liver disease with ascites, or a non-infectious diagnosis, such as reaction to medication or 
chemotherapy.  
 
 
3. Neurological 
Non-psychiatric signs, symptoms, or other evidence of an illness affecting the neurological 
system, such as headache, facial pain, seizure, syncope, ataxia, altered mental status, vertigo, or 
stiff neck.  
 
3.1 Meningoencephaltic 
Neurological signs and symptoms are consistent with meningitis, encephalitis or 
meningoencephalitis. 
 
4. Rash 
Any rash that is not eczematous (i.e., macular, papular, vesicular, pustular, or hemorrhagic) or an 
ulcer with eschar. 
 
5. Hemorrhagic 
Bleeding from any site except the central nervous system or into the conjunctiva  (e.g., bleeding 
from the lungs, GI tract, GU tract, nose, vagina, or skin). A patient bleeding from trauma or 
surgical incision should not be considered hemorrhagic. 
 
6. Botulinic 
Signs or symptoms consistent with a cranial nerve motor palsy (e.g., diplopia, blurred vision, 
mydriasis, ptosis, slurred speech, dysarthria, dysphagia, dry mouth) with or without symptoms or 
signs of a peripheral nerve motor palsy.  
 
7. Constitutional 
At least two non-localized (systemic) conditions, such as fever, chills, myalgia, weakness, 
fatigue, malaise, diaphoresis, non-cervical lymphadenopathy, anorexia, etc. Fever and chills can 
count as two separate conditions.  
 
8. Fever 
A measured temperature greater than 38.0 C (100.4 F) OR a report of recent fever or chills 
(report could come from the dictating physician, patient, family member, or referring institution).  
 
9. No fever information given 
The report does not provide the value of the patient’s temperature and does not describe whether 
the patient is febrile. (This should never be checked if Fever  is checked.) 
 
3.1.1 Multiple Syndromic Classifications 
Listed below are a few examples of cases that will require multiple syndromic classifications: 
• If a patient presents with a hemorrhagic rash, classify her as both Hemorrhagic and Rash 
• A patient with an upper respiratory infection, fever, and myalgia should be classified as 
Respiratory and Constitutional. You should also check the box for fever. 
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• If a patient has bloody stool, classify him as both GI and Hemorrhagic. 
• A patient with hemoptysis should be classified as Respiratory and Hemorrhagic. 
• A patient with hematemesis should be classified as GI and Hemorrhagic 
• If a patient has a headache, fever, and light-headedness, you should check Neurological 
(for the headache) and Constitutional. You should also check the box for fever. 
• A patient has a botulinic sign or symptom due to a neurological problem (e.g., slurred 
speech due to CVA), you should classify the patient as Botulinic (because he has at least 
one Botulinic symptom) and Neurological. 
• If a patient has an upper respiratory infection, fever, and chills, you should check 
Respiratory and Constitutional, because fever and chills can count as two separate 
conditions. You should also check the box for fever. 
 
 
3.1.2 Contradictory evidence in ED reports 
There may be contradictions among different reports for the same patient visit. We are relying on 
your judgment and intuition as a physician to determine the best answers in the face of confusing 
or contradictory evidence.  
 
If there is a conflict regarding the patient’s fever status, use this guideline: If a patient has no 
fever on exam and if there is a believable report of fever or chills in the recent history, the patient 
should be considered Febrile. If the report of fever or chills is questionable (e.g., conflict 
between resident’s and attending’s notes), the measured temperature on exam should take 
precedence (i.e., the patient should be considered not Febrile). 
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Accuracy of Physician Billing Claims for
Identifying Acute Respiratory Infections
in Primary Care
Genevie`ve Cadieux and Robyn Tamblyn
Objective. To assess the accuracy of physician billing claims for identifying acute
respiratory infections in primary care.
Study Setting. Nine primary care physician practices in Montreal, Canada (2002–
2005).
Study Design. A validation study was carried out to compare diagnoses in 3,526
physician billing claims with diagnoses documented in the corresponding patient med-
ical records.
Data Collection. In-office medical record abstraction.
Principal Findings. Claims had a high positive predictive value (PPV), negative pre-
dictive value, and specificity for identifying respiratory infections; however, their sen-
sitivity was below 50 percent. Large variation in sensitivity and PPV was observed
among physicians.
Conclusions. Because claims data are now routinely used to monitor antibiotic pre-
scribing in primary care, future research should determine if acute respiratory infection
diagnoses are missing from claims at random, or if bias is present.
Key Words. Validation studies, databases, health services, International Classifi-
cation of Diseases, respiratory tract infections
Several randomized, placebo-controlled trials of antibiotic use have shown
that antibiotics do not provide clinical benefit to children or adults with upper
respiratory tract infections (Hoaglund et al. 1950; Cronk et al. 1954; Howie and
Clark 1970; Stott and West 1976; Verheij, Hermans, and Mulder 1994; Kaiser
et al. 1996; Arroll 2005) and fail to prevent complicated bacterial
infections (Gadomski 1993; Heikkinen et al. 1995). Yet, 75 percent of oral
antibiotics prescribed to ambulatory patients are for pharyngitis, otitis media,
sinusitis, bronchitis, common cold, and unspecified upper respiratory tract
infection of likely viral etiology (McCaig and Hughes 1995), and 22–49 percent
are estimated to be unnecessary (Kozyrskyj et al. 2004; Cadieux et al. 2007).
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Inappropriate use of antibiotics for respiratory infections promotes antibiotic
resistance (Seppala et al. 1997; Austin, Kristinsson, and Anderson 1999;
Pihlajamaki et al. 2001), increases health services utilization and costs (Little
et al. 1997), and increases the risk of preventable drug-related adverse events
(Classen et al. 1991). To enable the development of effective interventions to
reduce inappropriate antibiotic use in primary care, determinants of inappro-
priate antibiotic prescribing and accurate methods for monitoring antibiotic use
need to be identified.
Monitoring antibiotic prescribing in primary care is challenging because
well-developed measures of antibiotic prescribing are scarce, often inaccurate,
and may not reflect real prescribing practices. Studies of antibiotic prescribing
in primary care have relied on physician self-reported prescribing (Mangione-
Smith et al. 1999; Nash et al. 2002; Steinman, Landefeld, and Gonzales 2003),
chart review or audit (Hueston, Jenkins, and Mainous 2000; Hutchinson et al.
2001; Mangione-Smith et al. 2002), or prescription claims (Mainous, Hueston,
and Clark 1996; Majeed and Moser 1999; Wang et al. 1999; Steinke et al.
2000; Gill and Roalfe 2001; Kozyrskyj et al. 2004; Cadieux et al. 2007). Self-
reported antibiotic prescribing was shown to underestimate actual antibiotic
prescribing by about 30 percent (Mangione-Smith et al. 2002), and the cost of
chart review is too high for wide-scale use. Prescription claims data avoid self-
report bias, do not require additional data collection, and because they involve
financial transactions, they are carefully audited by payers and have been
found to be highly accurate (Tamblyn et al. 1995). Owing to these advantages,
prescription claims are now used routinely to monitor antibiotic prescribing
for respiratory infections in primary care (Mainous, Hueston, and Clark 1996;
Majeed and Moser 1999; Wang et al. 1999; Steinke et al. 2000; Gill and Roalfe
2001; McCaig, Besser, and Hughes 2002; Kozyrskyj et al. 2004; Cadieux et al.
2007).
However, an important limitation of using prescription claims to mon-
itor antibiotic prescribing is that treatment indication is not recorded on pre-
scription claims. Treatment indication is required to determine the
appropriateness of antibiotic prescribing; therefore, it must be inferred from
other sources of information, such as physician billing claims for patient visits.
Address correspondence to Genevie`ve Cadieux, M.Sc., M.D.–Ph.D. Candidate, Clinical and
Health Informatics Research Group, McGill University, 1140 Pine Avenue West, Montreal QC
H3A 1A3, Canada; e-mail: genevieve.cadieux@mail.mcgill.ca. Robyn Tamblyn, Ph.D., Profes-
sor, is with the Department of Medicine and Department of Epidemiology, Biostatistics, and
Occupational Health, McGill University, Montreal, Canada.
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If prescription claims are to be used to monitor antibiotic prescribing, then the
accuracy of using diagnostic information in physician billing claims to infer
the indication for antibiotic treatment needs to be assessed.
Two previous studies have assessed the accuracy of physician billing
claims for identifying respiratory infection diagnoses, and both have shown
promising results. The first was a study of administrative claims data from
seven health insurance providers in Colorado, and it found that 79 percent of
bronchitis diagnoses and 83 percent of pharyngitis diagnoses in administrative
claims had a corresponding diagnosis in the written medical record (PPV;
Maselli and Gonzales 2001). However, this study did not investigate what
proportion of bronchitis and pharyngitis diagnoses documented in patient
medical records was accurately documented in physician billing claims (sen-
sitivity and specificity). The second study assessed the accuracy of Research
Patient Data Repository (RPDR) claims from nine primary care clinics in the
Brigham and Women’s Primary Care Practice-Based Research Network in
Boston and reported that 86 percent of respiratory infection diagnoses in
RPDR claims had a corresponding diagnosis in the electronic health record
(Linder et al. 2006). However, sensitivity and specificity estimates were not
corrected for the verification bias introduced by over-sampling claims with
a diagnosis of respiratory infection relative to claims without such a diagnosis
(i.e., the study design inflated the prevalence of respiratory infection in the
sample, relative to the true population prevalence; Begg and Greenes 1983;
Irwig et al. 1994).
The objective of this study was to assess the accuracy of physician billing
claims for identifying episodes of acute respiratory infection in primary care.
In particular, we sought to estimate the sensitivity, specificity, positive pre-
dictive value (PPV), and negative predictive value (NPV) of physician billing
claims.
METHODS
Study Design and Population
A validation study was carried out to assess the sensitivity, specificity, PPV, and
NPV of physician billing claims for identifying episodes of respiratory infection,
as compared with the patient medical record. The study population comprised
34 Montreal region family physicians and 17,002 of their patients who were
participating in the MOXXI electronic medication management trial (Tamblyn
et al. 2006) in 2002–2005. All patients participating in the MOXXI trial had
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previously consented to share their medical records and provincial health in-
surance (RAMQ) data with researchers. These data were available for a period
starting 1 year before patient enrollment date (2001 or later) until 2005, when the
present study was conducted. From the available physician billing claims, we
identified those with a diagnostic code (International Classification of Diseases,
9th Revision, or ICD-9) for laryngitis/tracheitis (464), common cold (460), in-
fluenza (480, 487), acute unspecified upper respiratory infection (465), pharyn-
gitis/tonsillitis (462, 463, 034), otitis media (381, 382), sinusitis (461), acute
bronchitis (466), or bacterial pneumonia (481–486); all decimal place suffixes of
these ICD-9 codes were included. We purposefully selected 10 physicians who
had been enrolled in the MOXXI trial for at least 2 years and had the most
MOXXI-consenting patients (and therefore also had the most physician billing
claims available for research purposes), and requested their consent.
Sample of Physician Billing Claims
Among the 10 physicians selected, we identified all MOXXI-consenting pa-
tients who had at least one physician billing claim with a diagnosis of acute
respiratory infection during the study period, and randomly sampled 635 of
those patients. We also identified all patients without any physician billing
claim with a diagnosis of acute respiratory infection during the study period,
and randomly sampled 94 of those patients. To improve the efficiency of data
collection, we over-sampled patients with at least one diagnosis of acute
respiratory infection, relative to those with no diagnosis of acute respiratory
infection (Begg and Greenes 1983; Irwig et al. 1994). For each of the 729
patients sampled, we identified all physician billing claims generated during
the study period (i.e., from 2001 or later, depending on the enrollment date,
until 2005) and validated each one against the paper-based patient medical
record. Information available in the physician billing claims included the
patient’s lifelong RAMQ personal identifier, physician license number, visit
date, and ICD-9 diagnostic code.
Medical Record Abstraction
Once the physician billing claims had been sampled, a list of sampled patients’
names and RAMQ personal identifiers was generated and sent to each con-
senting physician’s office. The selected patients’ paper-based medical records
were retrieved by the office staff and reviewed by one of the authors (G. C.).
For each sampled physician billing claim, the corresponding visit was
identified in the medical record, the date of the visit was recorded, and
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the presence or absence of all acute respiratory infections under study was
ascertained from the clinical notes. At the time of the medical record abstrac-
tion, the reviewer was blinded to the ICD-9 code in the corresponding
physician billing claim. Information abstracted from patient medical records
was entered directly in an electronic, structured chart abstraction form and
stored in an MS Access database, which had been prepopulated with partici-
pating physicians’ license numbers, sampled patients’ RAMQ identifiers, and
visit dates according to physician billing claims. Intra-rater reliability was
measured on 25 randomly selected visits that were reviewed a second time, and
the percent agreement between the first and second review was 100 percent.
Linkage of Physician Billing Claims and Data Abstracted from Medical Records
Data retrieved from patient medical records were linked directly to physician
billing claims using the patient lifelong RAMQ personal identifier, physician
license number, and visit date  1 day.
Analyses
For each type of acute respiratory infection under study, a 2  2 table of di-
agnoses abstracted from patient medical records versus diagnoses obtained
from the corresponding physician billing claims was generated using SAS sta-
tistical software (Version 9.3, SAS Institute Inc., Cary, NC). Information retrie-
ved from the patient medical record was treated as a gold standard. The
prevalence, PPV, and NPV of physician billing claims for identifying acute
respiratory infections were estimated. Sensitivity and specificity estimates were
corrected for the over-sampling of claims with a diagnosis of acute respiratory
infection relative to claims without such a diagnosis (Begg and Greenes 1983)
usingMSExcel 2003 (Version 5.1). To investigate between-physician variation in
physician billing claim diagnosis accuracy, these analyses were repeated for
each physician individually, combining all nine types of acute respiratory in-
fection under study (because each physician contributed too few of each type of
acute respiratory infection to analyze each type individually).
Because we sampled several claims (and medical record visits) per
patient, we conducted a sensitivity analysis to assess the effect of clustering of
claims within patients on our estimates of sensitivity, specificity, PPV, and NPV.
We did this by generating 100 random samples of one claim per patient
(n5 729 claims) from our total sample of 3,526 claims, and averaging the
estimates of sensitivity, specificity, PPV, and NPV over all 100 random samples,
which is similar to bootstrapping methodology (Efron and Tibshirani 1994).
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RESULTS
Ten physicians participating in the MOXXI trial were purposefully selected
for this study, and nine agreed to participate. Among these nine physicians’
patients enrolled in the MOXXI trial, we randomly selected 635 patients who
had at least one claim with a diagnosis of acute respiratory infection, and
94 patients without any claims with a diagnosis of acute respiratory infection.
These 729 patients made 3,526 visits to their respective MOXXI physicians
during the study period (duration of 1–5 years, depending on the date of
enrollment), for an average of 4.8 visits per patient. The medical records of all
729 sampled patients were abstracted, and written documentation for each
of the 3,526 visits identified from physician billing claims was found in
the corresponding patient’s medical record. In all, 1,173 (33.3 percent) of
sampled claims were positive for respiratory infection (Figure 1). Sixty-six
percent of sampled patients were women, and the mean age of sampled pa-
tients was 47.6 (SD 21.0, rangeo1–90 years). The characteristics of patients
enrolled in the MOXXI trial, as compared with those of the general popu-
lation, have been discussed previously (Bartlett et al. 2005).
The agreement between the diagnosis in the medical record and the
ICD-9 code in the physician billing claim is shown in Table 1, where
shaded areas indicate concordant diagnoses. For example, there were 63
physician billing claims with a diagnosis of laryngitis, and for all 63 claims, a
diagnosis of laryngitis was also documented in the medical record at the
corresponding date; however, an additional 16 diagnoses of laryngitis were
documented in medical records that were not documented in physician billing
claims. The overall percent agreement for the presence of any acute respi-
ratory infection was 72.5 percent, which is the sum of all diagnoses of respi-
ratory infection present in the physician billing claim and the corresponding
medical record (969) divided by the sum of all diagnoses of respiratory
infection documented in medical records (1,337).
The proportion of physician billing claims with a diagnosis of acute
respiratory infection confirmed in the patient medical record (PPV) was
0.93, 95 percent CI (0.91, 0.94), for all acute respiratory infection combined,
and 0.84, 95 percent CI (0.81, 0.88), for respiratory infections of likely viral
etiology (Table 2). The PPV for acute respiratory infections of potentially
bacterial etiology was 0.89, 95 percent CI (0.87, 0.92), and ranged from
0.72, 95 percent CI (0.67, 0.78), for acute bronchitis to 0.91, 95 percent CI
(0.85, 0.97), for bacterial pneumonia. Sensitivity of physician billing claims for
all acute respiratory infections combined was 0.49, 95 percent CI (0.45, 0.53).
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With the exception of influenza, sensitivity was markedly lower for viral re-
spiratory infections than for bacterial ones. Specificity was 0.99 or higher for
all types of acute respiratory infection studied.
The prevalence of acute respiratory infection diagnoses in physician
billing claims varied between physicians from 19.5 to 111.4 per 1,000 claims
(Table 3). Sensitivity and PPV varied between physicians from 1.00, 95 per-
cent CI (1.00, 1.00), to 0.19, 95 percent CI (0.06, 0.47), and from 0.98, 95
percent CI (0.96, 1.00), to 0.70, 95 percent CI (0.53, 0.87), respectively. The
accuracy of physician billing claims for identifying acute respiratory infections
did not appear to be higher among physicians who diagnosed more acute
respiratory infections.
Our sensitivity analysis using only one claim per patient yielded esti-
mates for sensitivity (0.55, 95 percent CI 0.45, 0.64), specificity (0.99, 95 per-
cent CI 0.99, 1.00), PPV (0.93, 95 percent CI 0.90, 0.96), and NPV (0.94, 95
percent CI 0.91, 0.97) that were similar to the estimates obtained when all
visits were used. The confidence intervals from the sensitivity analysis are
wider because the sample size is smaller: 729 claims (one per patient) were
729 patients
made 3,526 visits 
Number of visits with a diagnosis
of acute respiratory infection
Claims: 1,173
Charts:  1,254 
Number of visits without a diagnosis
of acute respiratory infection
Claims: 2,262
Charts:  2,192 
Pharyngitis
Claims: 107
Charts:  115 
Otitis media
Claims: 132
Charts:  149 
Sinusitis
Claims: 153
Charts:  184 
Bronchitis
Claims: 239
Charts:  216 
Pneumonia
Claims:  89
Charts: 107 
Acute URI
unspecified
Claims: 187
Charts:  207 
Common cold
Claims:  74
Charts: 102 
Laryngitis
Claims: 63
Charts:  79 
Influenza
Claims: 129
Charts:   95 
Figure 1: Diagnoses from the Sampled Physician Billing Claims and
Corresponding Patient Medical Records.
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used instead of all 3,526. This shows that the effect of within-patient clustering
of claims on sensitivity, specificity, PPV, and NPV estimates is small.
DISCUSSION
The PPV of physician billing claims was high for all types of acute respiratory
infection studied. Our study was the first to estimate the prevalence, sensitivity,
and specificity of physician billing claims for identifying chart-documented
acute respiratory infections in primary care. For all but one type of acute re-
spiratory infection investigated, our sensitivity estimates were below 0.50. Our
study was also the first to look at between-physician variation in physician billing
claim diagnosis accuracy. We found that prevalence of respiratory infections in
physician billing claims varied widely between primary care physicians. We
also observed large unexplained between-physician variation in sensitivity and
PPV of physician billing claims for identifying acute respiratory infections.
If physician billing claims had many false-positive diagnoses of respiratory
infection, they would not be a useful data source for monitoring antibiotic pre-
scribing. Therefore, a high PPV, or a high likelihood that diagnoses of respi-
ratory infection in physician billing claims are also present in the corresponding
patient medical record, provides support for using health administrative data for
monitoring antibiotic prescribing. For most of the acute respiratory infection
diagnoses investigated, our estimates of PPV were similar to those previously
reported in the literature (Maselli and Gonzales 2001; Linder et al. 2006).
However, our PPV estimate for influenza (0.66, 95 percent CI 0.58, 0.74) was
much higher than the 0.20 reported by Linder et al. (2006), but the latter was
aberrantly low as compared with other PPV estimates in the same study.
Previous studies have emphasized the high PPV of health administrative
data for identifying episodes of respiratory infection, but have overlooked the
importance of sensitivity (Maselli and Gonzales 2001; Linder et al. 2006). A
high sensitivity is desirable because it suggests that the data capture a majority of
visits for respiratory infections. A low sensitivity is problematic because it sug-
gests that several visits for respiratory infections are not documented in health
administrative data. Nondocumentation of visits for respiratory infections may
or may not be associated with antibiotic prescribing, which may result in bias
when using health administrative data to monitor antibiotic prescribing.
Our study estimated the sensitivity of physician billing claims for iden-
tifying acute respiratory infections. Our sensitivity estimates were below 0.50
for all types of acute respiratory infection studied except acute bronchitis, which
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raises concerns about the potential for bias. Whereas one previous study
estimated the sensitivity of claims for identifying respiratory infections (Linder et
al. 2006), the authors did not correct their sensitivity estimate for the verification
bias introduced by over-sampling claims with a diagnosis of acute respiratory
infection relative to claims without such a diagnosis (Begg and Greenes 1983;
Irwig et al. 1994); consequently, they greatly overestimated sensitivity. For ex-
ample, if we had not corrected our estimates for verification bias, our estimate of
the sensitivity of physician billing claims for identifying laryngitis would have
been 0.80, as compared with the corrected sensitivity estimate of 0.20.
We were first to investigate between-physician variation in physician bill-
ing claim diagnosis accuracy for acute respiratory infections. We found almost a
sixfold variation between physicians in the prevalence of acute respiratory in-
fections. We observed similar between-physician variation in the sensitivity and
PPV of physician billing claims for identifying acute respiratory infections. We
expected that claims submitted by physicians who diagnosed more acute respi-
ratory infections would be more accurate for identifying acute respiratory in-
fections, but we found that neither frequency nor prevalence of acute respiratory
infections seemed to be related to physician billing claim diagnosis accuracy.
This finding suggests that other factors are likely responsible for the observed
between-physician variation in physician billing claim diagnosis accuracy.
A limitation of our study is that medical records may not represent a true
gold standard for identifying acute respiratory infections diagnosed in primary
care. The use of a single rater was also a limitation of our study, and systematic
misclassification of acute respiratory infection diagnoses may have occurred as
a result. Another limitation of our study was its small convenience sample of
primary care physicians. Whereas physicians participating in the MOXXI
trial are generally similar to other eligible physicians in the Montreal region,
they tend to be younger than MOXXI nonparticipants. If physician billing
claim diagnosis accuracy is related to physician age or practice experience,
then our study results may not be applicable to older or more experienced
physicians. Also, the MOXXI trial involves physicians practicing in urban and
suburban areas, and our results may not be generalizable to physicians prac-
ticing in rural areas. Furthermore, patients enrolled in the MOXXI trial tend
to differ from nonparticipating patients in that they are generally older, with
more complex health status, and have more visits to the MOXXI physician
(Bartlett et al. 2005). Younger, healthier patients may be underrepresented in
our study sample. Future research should involve a large random sample of
primary care physician from both urban and rural areas, and a stratified ran-
dom sample of patients from each physician’s practice population.
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Because physician billing claims and prescription claims are now routinely
used to monitor antibiotic prescribing for acute respiratory infections in primary
care (Mainous, Hueston, and Clark 1996; Majeed and Moser 1999; Wang et al.
1999; Steinke et al. 2000; Gill and Roalfe 2001; Kozyrskyj et al. 2004; Cadieux et
al. 2007), it is important for future research to determine whether half of all acute
respiratory infections diagnoses are missing from physician billing claims at
random, or whether bias is present. If bias is present, future research should also
focus on identifying determinants of physician billing claim diagnosis accuracy,
so that appropriate corrections for the resulting bias can be developed and
applied when physician billing claims are used to infer treatment indication for
antibiotic prescribing. As suggested by the large between-physician variation
observed in this study, physician characteristics may be associated with phy-
sician billing claim diagnosis accuracy. The effect of physician characteristics, as
well as patient, encounter, practice, and billing characteristics, on physician
billing claim diagnosis accuracy should be assessed.
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Abstract
Background: Community clinics offer potential for timelier outbreak detection and monitoring than emergency
departments. However, the accuracy of syndrome definitions used in surveillance has never been evaluated in
community settings. This study’s objective was to assess the accuracy of syndrome definitions based on diagnostic
codes in physician claims for identifying 5 syndromes (fever, gastrointestinal, neurological, rash, and respiratory
including influenza-like illness) in community clinics.
Methods: We selected a random sample of 3,600 community-based primary care physicians who practiced in the
fee-for-service system in the province of Quebec, Canada in 2005-2007. We randomly selected 10 visits per
physician from their claims, stratifying on syndrome type and presence, diagnosis, and month. Double-blinded
chart reviews were conducted by telephone with consenting physicians to obtain information on patient
diagnoses for each sampled visit. The sensitivity, specificity, and positive predictive value (PPV) of physician claims
were estimated by comparison to chart review.
Results: 1,098 (30.5%) physicians completed the chart review. A chart entry on the date of the corresponding
claim was found for 10,529 (95.9%) visits. The sensitivity of syndrome definitions based on diagnostic codes in
physician claims was low, ranging from 0.11 (fever) to 0.44 (respiratory), the specificity was high, and the PPV was
moderate to high, ranging from 0.59 (fever) to 0.85 (respiratory). We found that rarely used diagnostic codes had a
higher probability of being false-positives, and that more commonly used diagnostic codes had a higher PPV.
Conclusions: Future research should identify physician, patient, and encounter characteristics associated with the
accuracy of diagnostic codes in physician claims. This would enable public health to improve syndromic
surveillance, either by focusing on physician claims whose diagnostic code is more likely to be accurate, or by
using all physician claims and weighing each according to the likelihood that its diagnostic code is accurate.
Background
Syndromic surveillance is used widely by public health
departments to detect and monitor unusual disease
activity in the population by extracting nonspecific clini-
cal data from information systems in clinical settings
[1-4]. Whereas much syndromic surveillance practice [3]
and research [5] has focused on visits to emergency
departments (ED), visits to community clinics offer
another promising source of data. Syndromes followed
in practice, such as influenza-like-illness (ILI), typically
involve earlier, milder stages of disease, and most
affected persons are likely to self-treat [6-8], at least
initially, or present to walk-in clinics [6]. In fact,
researchers have demonstrated that excess ILI activity
can be detected earlier using data from clinics as com-
pared to data from EDs [9-11]. The accuracy of diagnos-
tic data from community clinics has not, however, been
established.
Many syndromic surveillance systems use Interna-
tional Classification of Disease, 9th revision (ICD-9)
diagnostic codes in administrative databases to monitor
syndrome occurrence [12]. For this purpose, expert
panels have generated groupings of ICD-9 codes corre-
sponding to conceptual syndrome definitions [13].
Administrative databases offer great promise for popula-
tion-based surveillance by providing access to diagnostic
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information from many sites, including community
healthcare settings. However, unlike medical procedure
codes, ICD-9 diagnostic codes are not usually linked to
healthcare provider payment, and therefore are not
audited by health administrative authorities. Because of
this, variation in diagnostic coding between physicians
and between institutions is expected.
In a pilot study [14], we evaluated the accuracy of
diagnostic codes in physician claims for identifying
acute respiratory infections in nine Montreal-area com-
munity-based physicians. We abstracted the diagnosis
from the medical chart for the 3,526 visits made by 729
sampled patients in 2002-2005, and compared the medi-
cal chart diagnosis to the ICD-9 code on the corre-
sponding physician claim. For all acute respiratory
infections combined, we found a sensitivity of 0.49, 95%
CI (0.45, 0.53), and a positive predictive value (PPV) of
0.93, 95% CI (0.91, 0.94). These pilot study results are
promising, but there is a need for a large-scale, popula-
tion-based investigation of the accuracy of diagnostic
codes used in syndromic surveillance.
The objective of the present study was to assess the
accuracy of syndrome definitions based on diagnostic
codes from a representative sample of physician claims
for identifying 5 syndromes (fever, gastrointestinal, neu-
rological, rash, and respiratory, including influenza-like
illness (ILI)) in community healthcare settings. These
syndromes were selected for their relevance to public
health and the likelihood of being first detected among
patients presenting to community healthcare settings.
Methods
Context
This study was conducted in the province of Quebec,
Canada, where universal health coverage is provided
through the provincial health insurance plan. Each
Canadian province maintains a population-based registry
of insured persons and claims for all physician visits
remunerated on a fee-for-service basis. Physician claims
include information on the diagnosis (recorded as an
ICD-9 code), medical procedure, visit date, location, and
cost of service. All claims also record unique physician
and patient identifiers that can be used to create longi-
tudinal histories of healthcare use. In the province of
Quebec, 99% of residents have provincial health insur-
ance and 85-95% of medical visits are remunerated on a
fee-for-service basis [15]. In 2006, there were more than
7.6 million inhabitants in Quebec [16], and 18,908 active
registered physicians [17]. The availability of diagnostic
information for nearly all medical visits to Quebec phy-
sicians represents an invaluable opportunity for asses-
sing the validity of using diagnostic codes in physician
claims for population-based surveillance, including syn-
dromic surveillance.
Study design and sampling
The accuracy of diagnostic codes in physician claims for
identifying syndromes was assessed by comparison to
clinical information in the corresponding medical chart.
To ensure representativeness, we used a population-
based, 3-stage stratified random sample of 36,000 visits
(Figure 1). In the first stage (Figure 1 Stage 1), the pro-
vincial health insurance agency identified all physicians
who were eligible to be included in our study. To be eli-
gible, physicians had to be a general practitioner, pedia-
trician, internist, geriatrician or general surgeon who
practiced in the fee-for-service system in a private clinic,
community health center, or hospital-based ambulatory
care clinic during the 2-year study period (October 1,
2005 to September 30, 2007). Internists and general sur-
geons were included in our sample because, especially
in rural-remote and underserved areas, these physicians
may provide first-contact care and act as patients’ family
physician. From the 8,700 eligible physicians identified,
the provincial health insurance agency selected a ran-
dom sample of 3,600 (41.4%) physicians.
8,700 eligible physicians
Stage 1: simple random sample of 3,600 
(41.4%) eligible physicians
3,600 sampled physicians
Stage 2: simple random sample of 1 
eligible practice location per physician
3,600 physician practice locations
Stage 3: random sample of 10 visits per 
physician practice location:
? 5 visits negative for all syndromes
? 1 visit positive for each of the 5 
syndromes (fever, gastrointestinal, 
neurological, rash, and respiratory 
including influenza-like illness).
? For each syndrome, the sample of 
syndrome-positive visit was further 
stratified by ICD-9 code.
Exclusion was used to ensure each patient 
was sampled only once.
Syndrome-negative visits were frequency-
matched on month to syndrome positive 
visits to avoid seasonal bias.
36,000 visits to be verified
Figure 1 Population-based, 3-stage stratified random sample
of visits to all community physicians in the province of
Quebec.
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In the second stage (Figure 1 Stage 2), to facilitate
chart retrieval for review, the health insurance agency
randomly selected one eligible community practice loca-
tion for each physician. The health insurance agency
then sent the research team an anonymized file contain-
ing all physician claims billed by the 3,600 physicians
from their respective selected community practice loca-
tion during the 2-year study period (Figure 2 Step 1).
In the third stage (Figure 1 Stage 3), the research team
randomly selected 5 syndrome-positive visits, i.e., 1 visit
for each of fever, gastrointestinal, neurological, rash, and
respiratory syndrome (including ILI), and 5 visits nega-
tive for all syndromes. Visits were classified as positive
for a syndrome if a physician claim for the visit had an
ICD-9 code that was part of the syndrome definition.
Because syndromes have low population prevalence,
to maximize data collection efficiency [18], syndrome-
positive visits were over-sampled relative to syndrome-
negative ones, so as to yield 1 syndrome-positive visit per
syndrome per physician and 5 syndrome-negative visits
per physician. When sampling syndrome-positive claims,
to maximize the number of syndrome-positive ICD-9
codes verified, we further stratified on ICD-9 code.
Because two or more syndromes can occur concurrently
in the same patient [19], syndrome-negative visits were
negative for all syndromes. Syndrome-negative visits
were also matched to syndrome-positive visits on calen-
dar month to avoid bias due to syndrome seasonality. To
avoid bias due to visits being clustered within patients,
restriction was used to ensure that each patient was only
sampled once. The list of 10 sampled visits was enumer-
ated for each of the 3,600 physicians, for a total of 36,000
visits. An anonymized unique identifier, the study num-
ber, was assigned to each sampled visit by the research
team. The list of 36,000 sampled visits was then sent to
the health insurance agency (Figure 2 Step 2).
Syndrome definitions
We verified two sets of definitions for the 5 syndromes
under study: the definitions developed and published by
the US Centers for Disease Control and Prevention
(CDC) in 2003 [13], and used by the US Department of
Defense’s (DoD) Electronic Surveillance System for Early
Notification of Community-based Epidemics (ESSENCE),
as well as the corresponding definitions in the University
of Pittsburgh’s Real-time Outbreak and Disease Surveil-
lance (RODS) system [19]. For ILI, we used the large-
group (sensitive) and small-group (specific) definitions
developed for the DoD ESSENCE system [20]. These
definitions are similar to the consensus syndrome defini-
tions being developed by representatives from the
10 syndromic surveillance systems in place in the
US [21], which have not yet been mapped to ICD-9 codes.
Physician recruitment
To preserve physician and patient anonymity, the health
insurance agency sent the list of 3,600 physicians and
36,000 visits sampled by the research team to the medi-
cal regulatory authority (Figure 2 Step 3). The medical
regulatory authority has the legal right to access confi-
dential physician and patient information, therefore the
list it received included physician names and mailing
addresses, as well as patient names, insurance numbers,
and dates of birth. The medical regulatory authority
acted as a trusted third party and recruited physicians to
the study on behalf of the research team; it also pro-
vided physicians with information on the 10 sampled
visits (Figure 2 Step 4). Interested physicians mailed
their written consent and contact information to the
research team (Figure 2 Step 5). Non-responding physi-
cians were sent up to four reminders. Physician recruit-
ment began in September 2008 and ended in August
2009. To maximize participation, physicians were
offered $50 compensation for their participation and a
summary of study findings.
Physician-facilitated medical chart review
The medical regulatory authority sent each physician the
list of 10 sampled visits (Figure 2 Step 3). Lists sent to
physicians included patients’ first and last names, date
of birth, health insurance number, and date of the visit
to be verified, as well as the study number for each visit.
Because the lists sent to physicians contained both
patient information and study numbers, it enabled phy-
sicians to retrieve the relevant medical charts, and
researchers to link the information collected through
chart review to the anonymized physician claims file.
During the chart review, interviewers and physicians
 
Quebec 
health 
insurance 
agency 
 
McGill 
University 
research 
team 
 
 Physicians in 
community 
clinics 
 
Quebec 
medical 
regulatory 
authority 
Step 1: Health insurance 
agency sends anonymized 
physician claims from 3,600 
randomly-sampled physicians* 
to research team 
Step 4: Medical regulatory 
authority recruits physicians 
to study, sends info on 10 
sampled visits to each 
physician 
Step 5: 
Physicians 
provide written 
consent to 
research team 
Step 6: 
Physician-
facilitated 
medical chart
review 
Step 3: Health 
insurance agency 
sends info on 3,600 
physicians and 36,000 
visits to medical 
regulatory authority 
Step 2: Research team 
samples 10 visits per 
physician** and sends them 
to health insurance agency 
Figure 2 Overview of data collection * Physician sampling by the
Quebec health insurance agency is described in Figure 1, Stages 1
and 2. ** Visit sampling by the research team is described in Figure
1, Stage 3.
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referred to each visit using only the study number and
visit date, thereby preserving patient anonymity.
Physician-facilitated medical chart reviews began in
September 2008 and ended in December 2009. Using a
previously published methodology [22], trained inter-
viewers contacted consenting physicians by telephone to
perform the chart review (Figure 2 Step 6). For each of
the 10 sampled visits, the interviewer asked the physi-
cian to list all diagnoses. For each diagnosis correspond-
ing to a syndrome definition, the interviewer asked the
physician about the signs, symptoms, and key findings
recorded in the medical chart, as well as the most likely
etiology for the diagnosis (based solely on information
available at the time of the visit).
Physician responses were entered directly into a data-
base by the interviewer. Diagnoses were selected from a
searchable list of diagnoses (mapped to ICD-9 codes) or,
if the physician had recorded the ICD-9 code in the
medical chart, the ICD-9 code was entered directly. For
each syndrome-positive diagnosis, a list of syndrome-
specific signs and symptoms was elicited, and the inter-
viewer recorded whether the sign or symptom had been
present, absent, or not recorded in the medical chart.
Symptoms or signs not in the list and other key find-
ings, such as epidemiologic links to other diagnosed
cases or known outbreaks, were recorded as free text in
separate fields. The data collection tool was translated
to French for use with French-speaking physicians, and
back-translated to English to ensure comparability of
data collection.
At the time of chart review, the physician and inter-
viewer were both blinded to the ICD-9 code in the phy-
sician claim and the syndrome-positive or syndrome-
negative status of the claim. To minimize measurement
error due to inter-rater differences, interviewers were
trained to use the data collection tool. Inter-rater relia-
bility was assessed at baseline by having interviewers
perform 2 simulated physician interviews of 10 visits
each (for a total of 20 visits). To maintain data quality,
interviewers underwent quality assurance monitoring
every 3 months. Each assessment was comprised of 2
simulated physician interviews of 10 visits each (for a
total of 20 visits). Agreement between raters was mea-
sured using the intraclass correlation coefficient (ICC).
Linkage of the medical chart review data to the physician
claims data
The database containing the medical chart review data
was linked to the physician claims file using the study
number, physician identifier, and visit date. In our pilot
study [14], we found that the visit date in the chart
sometimes differed slightly from the visit date on the
claim. We considered the chart and the claim to refer to
the same visit if the visit date in the chart was within 0
(identical date) to 3 days from the visit date in the
claim.
Physician characteristics that may influence participation
Physician gender, preferred language (French or Eng-
lish), specialty, practice setting, and geographic location
were obtained from the health insurance agency. Physi-
cian year of licensure was obtained from the medical
regulatory authority. The number of days worked per
year was calculated as the number of days when at least
one claim was billed by the physician to the health
insurance agency. The number of patients seen per day
worked was calculated as the number of distinct patients
for which one or more claim was billed by the physician
per day worked. The number and prevalence of syn-
drome-positive visits were calculated for each physician
using claims billed from the selected practice location
during the 2-year study period.
Statistical methods
For each visit, we assessed if the ICD-9 code in the phy-
sician claim and the diagnosis in the corresponding
medical chart agreed as to the presence of each syn-
dromes and ILI. For example, if the diagnosis in the
claim was cough (786.2) and the diagnosis in the corre-
sponding medical chart was acute bronchitis (466.0),
then both the claim diagnosis and the chart diagnosis
were positive for respiratory syndrome, therefore the
claim was a true-positive for respiratory syndrome. If
the diagnosis in the claim was cough (786.2) and the
diagnoses in the chart were hypertension (401.9) and
diabetes (250.0), then the claim diagnosis was positive
for respiratory syndrome and the chart diagnoses were
not, therefore the claim was a false-positive for respira-
tory syndrome.
The negative predictive value (NPV) of each syndrome
definition was estimated directly from the data. Because
we stratified syndrome-positive visits by ICD-9 code, we
had to use an adjustment based on Bayes Theorem [23]
to estimate the PPV of each syndrome. The PPV was
estimated as a weighted average of each ICD-9 code’s
PPV, the weight being the number of visits with a given
ICD-9 code divided by the total number of visits posi-
tive for that syndrome among participating physicians.
Because we verified more syndrome-positive visits
than syndrome-negative ones, direct estimation of sensi-
tivity and specificity using our data would lead to verifi-
cation bias: sensitivity would be overestimated, and
specificity underestimated [23]. Because verified claims
were randomly sampled within syndrome-positive and
syndrome-negative strata, unbiased estimation of these
parameters was achieved by re-weighting for the verifi-
cation fractions [23]. The sensitivity and specificity of
physician claims for identifying each syndrome was
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estimated from the PPV and NPV [24] using the correc-
tion for verification bias [23], re-weighting for the differ-
ent sampling fractions. We estimated the 95% CI for the
bias-corrected sensitivity and specificity using the meth-
ods described by Begg and Greenes [23].
Ethics review
The research protocol for this study was reviewed and
approved by the McGill University Institutional Review
Board, the Quebec privacy commission (Commission
d’accès à l’information du Québec), the legal department
of the Quebec health insurance agency (Régie de l’assur-
ance maladie du Québec), and the Quebec medical reg-
ulatory authority (Collège des médecins du Québec).
Results
Between October 1, 2005 and September 30, 2007, the
3,600 study physicians billed for over 20 million visits
by 4.8 million patients (61% of the province’s popula-
tion) from their randomly selected community practice.
Physician participation
Of 3,600 physicians contacted, 172 (4.8%) had an incor-
rect address on file with the health insurance agency, and
170 (4.7%) were discovered to be ineligible (recently
deceased, retired, on sick/maternity leave, no longer
practicing at the selected practice location). Of the 3,258
remaining physicians, 1,129 (34.7%) physicians consented
to participate in the study, 218 (6.7%) refused, and 1,911
(58.7%) did not respond. Of the 1,129 consenting physi-
cians, 1,098 (97.3%) completed the physician-facilitated
medical chart review, and 31 (2.7%) were unreachable or
withdrew consent prior to interview. Participating and
non-participating physicians were similar on all measured
variables except two (Table 1): as compared to non-parti-
cipants, participants had been in practice longer and had
worked more days during the study period. Syndrome
prevalence was similar among participating and non-
participating physicians, and ranged from 5 per 1,000
visits for neurological syndrome and ILI small-group, to
126 per 1,000 visits for respiratory syndrome.
Inter-rater agreement
Agreement between raters was measured using simu-
lated physician interviews shortly before the start of data
collection and every 3 months thereafter. Agreement
was perfect on all assessments (ICC = 1.00).
Date agreement between the claim and the medical chart
Of the 10,980 visits selected for verification (10 visits
per participating physician), physicians were able to
access the corresponding medical chart for 10,669
(97.2%). The most common reasons for being unable to
access the chart were inability to locate the medical
chart (151 charts) and medical chart in storage with
retrieval fee (140 charts). For 10,465 (98.1%) of the
sampled visits, the visit date in the medical chart was
identical to the visit date on the claim. Allowing for
potential date transcription errors during billing, an
additional 64 (0.6%) visits with a date in the medical
chart that was within 1-3 days of the visit date on the
claim were identified, for a total of 10,529 visits for
which both the medical chart and the claim was avail-
able and the visit dates were in agreement (within the
3 day time window).
Syndrome agreement between the claim ICD-9 code and
the medical chart diagnosis
Table 2 shows the accuracy of ICD-9 codes in physician
claims for identifying syndromes, as compared to the
medical chart. The sensivity of ICD-9 codes in physician
claims for identifying syndromes was low, ranging from
0.11, 95% CI (0.10, 0.13) for fever syndrome to 0.44,
95% CI (0.41, 0.47) for respiratory syndrome. The PPV
of ICD-9 codes in physician claims for identifying syn-
dromes was moderate to high, ranging from 0.59, 95%
CI (0.55, 0.64) for fever syndrome to 0.85, 95% CI (0.83,
0.88) for respiratory syndrome. Both the specificity and
NPV of ICD-9 codes in physician claims were near-per-
fect for all syndromes studied.
Additional file 1 (excerpted in Table 3) shows the PPV
of physician claims for identifying syndromes for each
ICD-9 code individually. There was wide variation in
PPV between different ICD-9 codes in a given syn-
drome. ICD-9 codes that were very rarely used by physi-
cians, for example tularemia (ICD-9 code: 21.9), had a
high probability of being false-positives, and therefore a
very low PPV. ICD-9 codes for common symptoms, for
example fever (ICD-9 code: 780.6), had a lower prob-
ability of being false-positives, and a higher PPV. ICD-9
codes that represent common diagnoses, for example
acute bronchitis (ICD-9 code: 466.0), had the lowest
probability of being false-positives, and the highest PPV.
Discussion
This study was the first large-scale, population-based
investigation of the accuracy of syndrome definitions
based on diagnostic codes in physician claims from
community healthcare settings. We found that the sensi-
tivity of syndrome definitions based on diagnostic codes
in physician claims for identifying syndromes was low,
the PPV was moderate to high, and the specificity and
NPV were near-perfect. Even though our sensitivity esti-
mates were low for all syndromes definitions, these syn-
drome definitions may still be useful for monitoring
syndrome occurrence when there are large numbers of
cases (e.g., seasonal influenza). Respiratory syndrome
had the highest prevalence and was the most accurately
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Table 1 Characteristics of participating and non-participating physicians
Participating physicians (N = 1,098) Non-participating physicians (N = 2,160)
Physician characteristics No. (%) No. (%)
Gender:
Female 411 37.4 823 38.1
Male 687 62.6 1,337 61.9
Preferred language:
French 1,006 91.6 1,937 89.7
English 92 8.4 223 10.3
Specialty:
General practice 993 90.4 1,932 89.4
Internal medicine 13 1.2 41 1.9
Pediatrics 62 5.6 102 4.7
General surgery 30 2.7 85 3.9
Geriatrics 0 0 0 0
Type of setting selected:1
Private clinic 1,060 96.5 2,044 94.6
Community health center 5 0.5 9 0.4
Hospital-based
ambulatory clinic
33 3.0 107 5.0
Geographic location of selected setting:1,3
Urban 921 83.9 1,867 86.4
Rural 177 16.1 293 13.6
Mean SD Mean SD
Years since licensure 24.2 9.7 22.3 10.5
No. days worked per year1 157.0 55.0 143.2 59.8
No. patients seen per day worked1 21.2 13.4 21.0 13.3
Syndrome frequency based on claim ICD-9 code No. visits1,2 Prevalence
per 1,000 visits1
No. visits1,2 Prevalence
per 1,000 visits1
CDC and DoD ESSENCE4
Fever 80,884 11 160,821 12
Gastrointestinal 162,282 22 309,209 24
Neurological 40,236 5 73,810 6
Rash 126,900 17 224,370 17
Respiratory 911,924 125 1,643,240 126
RODS5
Fever 162,000 22 291,990 22
Gastrointestinal 146,355 20 283,578 22
Neurological 36,344 5 67,344 5
Rash 55,251 8 103,698 8
Respiratory 478,201 65 877,556 67
Influenza-like illness6
Large-group 622,046 85 1,129,782 87
Small-group 32,173 4 61,127 5
1 As per our study design, for each physician, a single practice location was randomly selected to facilitate the validation process. The information in this table is
based in claims generated from the selected practice location during the 2-year study period.
2 There were a total of 7,315,994 visits to the 1,098 participating physicians, and 13,010,410 visits to the 2,160 eligible non-participating physicians at the
selected practice location during the 2-year study period.
3 We tested the statistical significance (at the p < 0.05 level) of any differences between participating and non-participating physicians using a multivariate
logistic regression model where the dependent variable was participation and the independent variables were all characteristics in Table 1. Due to overlap
between CDC, RODS, and ILI syndrome definitions, to avoid collinearity, we used separate models for each set of syndrome definitions. As compared to non-
participating physicians, participating physicians had been in practice longer (odds ratio (OR)per 10 years since licensure, 1.15; 95% CI, 1.05-1.25), had worked more
days (ORper 50 days, 1.18; 95% CI, 1.09-1.28) during the 2-year study period.
4 Syndrome case definitions developed and published by the US Centers for Disease Control and Prevention (CDC) in 2003, and used by the US Department of
Defense’s Electronic Surveillance System for Early Notification of Community-based Epidemics (ESSENCE).
5 Syndrome case definitions developed in the context of the University of Pittsburgh’s Real-time Outbreak and Disease Surveillance (RODS) system.
6 Syndrome case definitions developed in the context of the US Department of Defense’s Electronic Surveillance System for Early Notification of Community-
based Epidemics (ESSENCE).
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reported in physician claims. Unexpectedly, ILI small-
group had the lowest PPV of all syndromes definitions
studied, much lower than previously reported by others
[20]. The small-group definition of ILI is made up of
only four ICD-9 codes: influenza with pneumonia
(487.0), influenza with other respiratory manifestations
(487.1), influenza with other manifestations (487.8), and
acute upper respiratory infection, other multiple sites
(465.8). Based on our interviews of over a thousand
community physicians, we think that the poor accuracy
of the ILI small-group definition reflects the common
usage of the word ‘flu’ to describe a vague illness or a
combination of non-specific symptoms. In addition to
observing variation in physician claim accuracy between
syndromes, we also found large variation in accuracy
and prevalence between diagnostic codes within syn-
dromes. Diagnostic codes with a very low prevalence
were generally more likely to be false-positives; conver-
sely, diagnostic codes with a higher prevalence were
generally less likely to be false-positives, especially if
they represented a diagnosis, as opposed to a symptom.
This suggests that physicians are more likely to know
the correct diagnostic code for a frequently diagnosed
ailment, as compared to a rare one.
Rigorous attempts to assess the accuracy of ICD-9
codes used in syndromic surveillance as compared to
the medical chart have been few, and they have relied
on small convenience samples of emergency depart-
ments. In one such study, the accuracy of ICD-9 codes
in ED reports for identifying 3 syndromes (fever, gastro-
intestinal, and respiratory) was assessed as compared to
hospital chart diagnoses in the context of the US DoD
ESSENCE surveillance system [25]. For greater data col-
lection efficiency, syndrome-positive ED reports were
over-sampled relative to syndrome-negative ones; how-
ever, analyses were not adjusted for this differential sam-
pling strategy, resulting in verification bias [23], and
leading to a large overestimation of sensivity and under-
estimation of specificity. To illustrate, the proportion of
fever-positive visits in the sample was 0.19, whereas the
proportion of fever-positive visits in the population is
approximately 0.01 (based on our study). The authors
reported a sensitivity of 0.69 and a specificity of 0.95.
However, adjusting for verification bias, the estimates
would be approximately 0.09 for sensivity and 1.00 for
specificity, which is similar to our results. In another
study, the accuracy of ICD-9 codes in ED reports for
identifying 7 syndrome definitions (botulinic, constitu-
tional, gastrointestinal, hemorrhagic, neurological, rash,
and respiratory) was assessed against hospital chart diag-
noses in the context of the RODS surveillance system [19].
To maximize the quantity of syndrome-positive ICD-9
codes verified, the investigators selected a random sample
of syndrome-positive visits from ED reports, stratified on
Table 2 Accuracy of ICD-9 coded diagnoses in physician claims, as compared to ICD-9 coded diagnoses from
physician-facilitated medical chart review, for identifying constitutional, gastrointestinal, neurological, rash, and
respiratory syndrome, as well as influenza-like illness (ILI) (N = 10,529 visits with matched claim-record pair)
Syndrome definition No.
visits in verified
claims
No.
visits in verified
charts
Sensivity (95%
CI)
Specificity (95%
CI)
PPV (95% CI) NPV (95% CI)
CDC and DoD
ESSENCE1
Fever 601 656 0.11 (0.10, 0.13) 0.99 (0.99, 0.99) 0.59 (0.55, 0.64) 0.94 (0.93, 0.95)
Gastrointestinal 855 888 0.23 (0.20, 0.26) 0.99 (0.99, 0.99) 0.71 (0.66, 0.75) 0.94 (0.94, 0.95)
Neurological 971 693 0.17 (0.14, 0.21) 1.00 (1.00, 1.00) 0.67 (0.64, 0.70) 0.98 (0.98, 0.98)
Rash 897 905 0.20 (0.18, 0.23) 0.99 (0.99, 0.99) 0.66 (0.62, 0.70) 0.95 (0.95, 0.96)
Respiratory 1,049 1,779 0.44 (0.41, 0.47) 0.97 (0.96, 0.98) 0.85 (0.83, 0.88) 0.84 (0.83, 0.85)
RODS2
Fever 873 961 0.14 (0.12, 0.16) 0.99 (0.99, 0.99) 0.60 (0.56, 0.64) 0.91 (0.90, 0.92)
Gastrointestinal 703 834 0.20 (0.18, 0.23) 0.99 (0.99, 0.99) 0.68 (0.63, 0.73) 0.94 (0.94, 0.95)
Neurological 874 523 0.16 (0.13, 0.20) 1.00 (1.00, 1.00) 0.52 (0.48, 0.55) 0.99 (0.98, 0.99)
Rash 814 718 0.12 (0.10, 0.14) 1.00 (1.00, 1.00) 0.63 (0.59, 0.66) 0.96 (0.96, 0.97)
Respiratory 665 1,209 0.29 (0.26, 0.32) 0.98 (0.98, 0.98) 0.74 (0.70, 0.79) 0.87 (0.86, 0.88)
Influenza-like illness3
Large-group 653 1,232 0.38 (0.35, 0.41) 0.98 (0.98, 0.98) 0.77 (0.73, 0.81) 0.88 (0.87, 0.89)
Small-group 53 49 0.18 (0.12, 0.26) 1.00 (1.00, 1.00) 0.29 (0.16, 0.41) 0.99 (0.99, 0.99)
1 Syndrome case definitions developed and published by the US Centers for Disease Control and Prevention (CDC) in 2003, and used by the US Department of
Defense’s Electronic Surveillance System for Early Notification of Community-based Epidemics (ESSENCE).
2 Syndrome case definitions developed in the context of the University of Pittsburgh’s Real-time Outbreak and Disease Surveillance (RODS) system.
3 Syndrome case definitions developed in the context of the US Department of Defense’s Electronic Surveillance System for Early Notification of Community-
based Epidemics (ESSENCE).
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syndrome-positive ICD-9 code, such that an equal number
of syndrome-positive visits was sampled for each ICD-9
code in a syndrome. For example, fever (780.6) and bubo-
nic plague (020.0), both corresponding to constitutional
syndrome, contributed the same number of cases. How-
ever, the prevalence and accuracy of each ICD-9 code in a
syndrome is different, and because the analyses were not
adjusted for the uniform sampling strategy used, the
reported estimates of sensitivity, specificity, PPV and NPV
are biased. In a third study [26], the accuracy of ICD-9
coded physician diagnoses from 9 hospital EDs for identi-
fying ‘acute respiratory illness’ was assessed by comparison
to medical chart review. A simple random sample was
used; therefore the results were not subject to verification
bias. The authors reported a sensitivity of 0.43, 95% CI
(0.28-0.58) for acute respiratory illness, which is almost
identical to our sensitivity estimate for respiratory syn-
drome; their estimates of NPV and specificity were also
similar to ours, but their PPV estimate of 0.45, 95% CI
(0.29-0.61) is much lower than ours.
Our study had several strengths and limitations. We
used a large population-based random sample of all phy-
sicians working in the fee-for-service system in commu-
nity healthcare settings in the province of Quebec in
2005-2007, thereby capturing potential ICD-9 coding dif-
ferences between physicians, institutions, and regions.
Not only did we estimate the accuracy of syndrome defi-
nitions, as others have done, but our study design
enabled us to estimate the PPV of individual diagnostic
codes within each syndrome definition. Matching syn-
drome-negative visits to syndrome-positive visit on calen-
dar month ensured that our results were not affected by
seasonal bias. Because two or more syndromes can occur
concurrently in the same person [19], our requirement
that syndrome-negative visits be negative for all syn-
dromes ensured that we did not overestimate false-
Table 3 Example of diagnostic codes with the highest and lowest positive predictive value (excerpted from additional
file 1)
Example of diagnostic codes with the HIGHEST positive predictive value (PPV)
Syndrome ICD-9 code Diagnostic label PPV (95% CI)
Fever1 82.8 Tick-borne rickettsiosis not elsewhere classified 1.00 (1.00, 1.00)
88.8 Other specified arthropod-borne diseases 1.00 (1.00, 1.00)
Gastrointestinal1 7.1 Giardiasis 1.00 (1.00, 1.00)
5.9 Food poisoning not otherwise specified 1.00 (1.00, 1.00)
Neurological1 323.0 Encephalitis in viral disease classified elsewhere 1.00 (1.00, 1.00)
784.3 Aphasia 1.00 (1.00, 1.00)
Rash1 53.8 Herpes zoster with unspecified complication 1.00 (1.00, 1.00)
695.2 Erythema nodosum 1.00 (1.00, 1.00)
Respiratory1 33.0 Bordetella pertussis 1.00 (1.00, 1.00)
462.9 Pharyngitis, acute not otherwise specified 1.00 (1.00, 1.00)
ILI large-group2 487.0 Influenza with pneumonia 1.00 (1.00, 1.00)
486.0 Pneumonia, organism not otherwise specified 1.00 (1.00, 1.00)
Example of diagnostic codes with the LOWEST positive predictive value (PPV)
Syndrome ICD-9 code Diagnostic label PPV (95% CI)
Fever1 88.0 Bartonellosis 0.00 (0.00, 0.00)
78.2 Sweating fever 0.00 (0.00, 0.00)
Gastrointestinal1 555.0 Regional enteritis, small intestine 0.00 (0.00, 0.00)
1.1 Cholera due to Vibrio cholerae El Tor 0.00 (0.00, 0.00)
Neurological1 323.2 Encephalitis in protozoal disease classified elsewhere 0.00 (0.00, 0.00)
53.0 Herpes zoster with meningitis 0.00 (0.00, 0.00)
Rash1 51.0 Cowpox 0.00 (0.00, 0.00)
55.8 Measles complications not otherwise specified 0.00 (0.00, 0.00)
Respiratory1 20.4 Secondary pneumonic plague 0.00 (0.00, 0.00)
79.8 Hantavirus infection 0.00 (0.00, 0.00)
ILI large-group2 490.0 Bronchitis not otherwise specified 0.00 (0.00, 0.00)
465.8 Acute upper respiratory infection, other multiple sites 0.36 (0.08, 0.65)
1 Syndrome case definitions developed and published by the US Centers for Disease Control and Prevention (CDC) in 2003, and used by the US Department of
Defense’s Electronic Surveillance System for Early Notification of Community-based Epidemics (ESSENCE).
2 Syndrome case definition developed in the context of the US Department of Defense’s Electronic Surveillance System for Early Notification of Community-based
Epidemics (ESSENCE).
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negatives and underestimate sensitivity and NPV. Our
participation rate, though low, was consistent with that
of other large population-based studies of Canadian
physicians [27,28]. Participating and non-participating
physicians were similar on nearly all measured variables.
The participation rate was significantly lower among
recently licensed physicians; recently licensed physicians
may have been less likely to participate in our study
because they tend to experience greater practice mobility
[29] and report more impediments to practice [30] than
their more experienced counterparts. Unfortunately, the
accuracy of very rare syndrome-positive ICD-9 codes,
such as cutaneous and pulmonary anthrax (22.0 and
22.1), could not be estimated because, as expected, they
were not present in any of the 1,098 participating physi-
cians’ claims during the 2-year study period.
Conclusions
We found that diagnostic codes in physician claims from
community healthcare settings have low sensitivity, mod-
erate to high PPV, and near-perfect specificity and NPV
for identifying 5 syndromes (fever, gastrointestinal, neuro-
logical, rash, and respiratory, including ILI). Future
research should evaluate the practical implications of our
findings on decision-making in response to alerts from
existing syndromic surveillance systems. Future research
should also identify physician, patient, and encounter
characteristics associated with better accuracy of diagnos-
tic codes in physician claims. This would enable public
health to improve syndromic surveillance, either by focus-
ing on physician claims whose diagnostic code is more
likely to be accurate, or by using all physician claims and
weighing each according to the likelihood that its diagnos-
tic code is accurate. We also estimated the prevalence and
PPV of individual diagnostic codes within each syndrome.
We found that rarely used diagnostic codes had a higher
probability of being false-positives, and that more
commonly used diagnostic codes had a higher PPV.
These findings may be useful to the ongoing development
of sensitive and specific consensus syndrome definitions,
as either a sensitive or a specific definition may be more
useful depending on the surveillance objective.
Additional material
Additional file 1: Positive predictive value of individual ICD-9 codes
within each syndrome case definition. For all 12 syndrome case
definitions investigated, the positive predictive value of diagnoses in
physician claims is provided for each individual ICD-9 code.
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